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   of	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VII	  	  	  	  AMINO	  ACID	  CODE	  
Amino	  acid	   	   	   Three	  letter	  symbol	   	   One	  letter	  symbol	  
alanine	  	   	   	   	   Ala	   	   	   	   A	  
arginine	  	   	   	   	   Arg	  	   	   	   	   R	  
asparagine	  	   	   	   	   Asn	  	   	   	   	   N	  
aspartate	  	   	   	   	   Asp	  	   	   	   	   D	  
cysteine	  	   	   	   	   Cys	  	   	   	   	   C	  
glutamate	  	   	   	   	   Glu	  	   	   	   	   E	  
glutamine	   	   	   	   Gln	  	   	   	   	   Q	  
glycine	  	   	   	   	   Gly	  	   	   	   	   G	  
histidine	   	   	   	   His	   	   	   	   H	  
isoleucine	   	   	   	   Ile	   	   	   	   I	  
leucine	  	   	   	   	   Leu	  	   	   	   	   L	  
lysine	  	   	   	   	   	   Lys	  	   	   	   	   K	  
methionine	  	   	   	   	   Met	  	   	   	   	   M	  
phenylalanine	  	   	   	   Phe	   	   	   	   F	  
proline	  	   	   	   	   Pro	   	   	   	   P	  
serine	   	   	   	   	   Ser	   	   	   	   S	  
threonine	   	   	   	   Thr	   	   	   	   T	  
tryptophan	   	   	   	   Trp	   	   	   	   W	  
tyrosine	   	   	   	   Tyr	   	   	   	   Y	  
valine	   	   	   	   	  	  	  	   Val	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   V	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VIII	  	  	  	  	  Summary	  
Parkinson’s	   Disease	   (PD)	   is	   the	   second	  most	   common	   neurodegenerative	   disorder	  
after	  Alzheimer’s	  and	  old	  age	   is	  the	  strongest	  risk	  factor	  for	  developing	  PD.	  PD	  has	  
traditionally	   been	   seen	   as	   a	  motor	   disorder,	   but	   its	   non-­‐motor	   symptoms	   such	   as	  
dysautonomia,	   sensory	   dysfunction,	   sleeping	   problems	   and	   neuropsychiatric	  
features	   equally	   add	   to	   the	   disease	   burden.	   There	   is	   no	   cure	   for	   PD	   and	   this	   is	  
probably	   a	   reflection	   of	   our	   poor	   understanding	   of	   the	   disease	   pathogenesis.	  One	  
way	  of	   tackling	   this	   is	   to	   focus	  on	   the	  small,	  but	   significant	  number	  of	  PD	  patients	  
with	   a	   family	   history	   compatible	   with	  Mendelian	   autosomal	   inheritance	   (10-­‐15%).	  
Hereditary	  and	  sporadic	  PD	  share	  important	  clinical	  and	  neuropathological	  features,	  
and	   there	   is	   reasonable	   hope	   that	   dissecting	   molecular	   pathways	   of	   PD	   gene	  
products	   will	   have	   more	   general	   implications	   for	   the	   pathophysiology	   of	   PD	  
associated	  neurodegeneration	  and	  help	  device	  new	  treatment	  strategies.	  
Mutations	   in	   the	   FBXO7	   gene	   have	   recently	   been	   shown	   to	   cause	   an	   autosomal	  
recessive	   early	   onset	   Parkinsonian-­‐pyramidal	   syndrome	   and	   FBXO7	   has	   been	  
designated	   as	   PARK	   15	   (Di	   Fonzo	   et	   al.,	   2009).	   FBXO7	   is	   a	   member	   of	   the	   F-­‐box	  
protein	  family,	  which	  functions	  as	  the	  variable	  subunit	  of	  Skp1-­‐Cullin1-­‐F-­‐box	  protein	  
(SCF)	   E3	   ubiquitin	   ligase	   complexes	   and	   as	   such	   dictate	   substrate	   specificity.	   The	  
canonical	   outcome	   of	   ubiquitylation	   is	   proteasomal	   degradation	   and	   my	   working	  
hypothesis	   is	   that	  FBXO7	  may	  be	   involved	   in	  protein	  quality	  control	   in	   the	  brain.	  A	  
perturbation	  thereof	  may	  be	  a	  first	  step	  towards	  FBXO7	  dependent	  disease.	  
At	   the	   time	  of	   starting	  with	  my	  PhD	  project,	   little	  was	  known	  about	   the	  molecular	  
function	   of	   FBXO7	   and	   how	   mutations	   in	   FBXO7	   result	   in	   neurodegeneration.	   In	  
order	  to	  learn	  more	  and	  dissect	  the	  signalling	  pathway	  of	  FBXO7	  I	  have	  used	  tagged	  
stable	   overexpression	   cell	   lines	   of	   the	   FBXO7	   wildtype	   as	   well	   as	   human	   disease	  
mutant	   proteins	   for	   tag-­‐pulldowns	   followed	   by	   mass-­‐spectrometry	   to	   identify	  
interacting	  partners	  and	  possible	  substrates.	  With	  this	  approach	  I	  have	  been	  able	  to	  
confirm	  the	  interaction	  between	  FBXO7	  and	  its	  core	  SCF	  E3	  ligase	  partners	  as	  well	  as	  
some	  of	  the	  previously	  reported	  interacting	  partners.	  I	  have	  been	  able	  to	  show	  that	  
not	   only	   the	   FBXO7	   wildytpe	   protein,	   but	   also	   all	   of	   the	   so	   far	   reported	   human	  
disease	  mutants	  are	  able	  to	  assemble	  into	  an	  SCF	  complex.	  Hence,	  my	  fist	  conclusion	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is	  that	  the	  human	  disease	  mutants	  do	  not	  exert	  their	  pathogenicity	  by	  SCF	  complex	  
disruption.	  	  
Next,	   a	   knock-­‐in	   (KI)	   mouse	   model	   of	   one	   of	   the	   pathogenic	   FBXO7	   mutations	  
(R378G)	  was	  generated	  and	  evaluated	  by	  molecular	  and	  biochemical	  approaches	  as	  
well	   as	   motor	   and	   behaviour	   phenotyping.	   In	   particular,	   I	   have	   used	   the	   Fbxo7	  
mouse	  model	  for	  extensive	  proteomic	  screens	  to	  identify	  wildtype	  (wt)	  and	  KI	  Fbxo7	  
interactors:	  endogenous	  Fbxo7	  immunoprecipitations	  from	  mouse	  brain	  lysates	  and	  
subsequent	   fingerprint	   mass-­‐spectrometry;	   differential	   whole	   proteome:	   ex	   vivo	  
differential	   dimethyl	   labelling	   of	   wt	   and	   KI	   brain	   samples,	   and	   Fbxo7-­‐dependent	  
ubiquitinome	   analysis:	   quantitative	   di-­‐GLY	   capture	   proteomics	   combining	   in	   vivo	  
SILAC	  labelling	  with	  antibody-­‐based	  affinity	  enrichment	  of	  “di-­‐GLY	  remnant	  motifs”-­‐	  
containing	   peptides	   prior	   to	   proteomic	   profiling	   of	   the	  wild-­‐type	   in	   comparison	   to	  
the	  homozygous	  R379G	  Fbxo7	  KI	  ubiquitinome	   in	  MEF	   lysates.	  The	  di-­‐GLY	  remnant	  
motif	   is	   the	  signature	  peptide	  of	  ubiquitinylated	  protein	  sites	  at	  peptide	   level	  after	  
tryptic	  digestions.	  Some	  of	  my	  findings	  are:	  
• For	  the	  first	  time	  I	  show	  that	  endogenous	  Fbxo7	  actually	  assembles	  into	  an	  Skp1-­‐
Cullin1-­‐Fbxo7	  complex	  and	  that	  the	  pathogenic	  R378G	  does	  not	  disrupt	  SCFFbxo7-­‐KI	  
complex	  formation	  in	  vivo.	  This	  is	  true	  for	  the	  Fbxo7	  KI	  mouse	  model,	  but	  also	  for	  
patient	  derived	  immortalized	  cell	  lines	  carrying	  the	  R378G	  FBXO7	  mutation.	  	  
• Endogenous	   Fbxo7	   interacts	   with	   the	   Sumo	   E3	   ligase	   complex	   RanBP2/	  
RanGAP1*Sumo1/Ubc9	  complex.	  
• In	   the	  differential	  enrichment	  of	  ubiquitylated	  protein	   species	   in	  SILAC	   labelled	  
wild-­‐type	  and	  homozygous	  R379G	  Fbxo7	  KI	  MEFs,	  I	  have	  clearly	  identifies	  2	  highly	  
conserved	   lysine	   residues,	   which	   are	   conserved	   amongst	   VDAC	   1,	   2,	   and	   3	   in	  
mouse	   as	  well	   as	   human	   homologous,	   to	   be	   preferentially	   ubiquitinylated	   in	   a	  
Fbxo7	   wild-­‐type	   background	   (in	   collaboration	   with	   Dr.	   Patrick	   Pedrioli,	   MRC	  
Programme	  leader).	  	  
• There	   is	   a	   significant	   difference	   in	   motor	   performance	   between	   wildtype	   and	  
homozygous	  R379G	  KI	  Fbxo7	  mice	  at	  10	  months	  of	  age	  (in	  collaboration	  with	  Dr.	  
Steve	  Martin,	  Neuroscience	  Division,	  Dundee).	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• Furthermore,	   I	   have	   successfully	   set	   up	   an	   in	   vitro	   FBXO7	   dependent	  
ubiquitinylation	  assays.	  
	   	  
	  
	  
	   19	  
1 	  Introduction	  
	  
1.1 	  Parkinson’s	  Disease	  	  
 Historical	  perspective	  1.1.1
It	   was	   the	   English	   physician	   James	   Parkinson	   who	   first	   captured	   the	   clinical	  
symptoms	   of	   Parkinson’s	   disease	   (PD)	   by	   describing	   6	   cases	   in	   his	   famous	  
monograph	  “An	  Essay	  on	  the	  Shaking	  Palsy”	  published	  in	  1817(Parkinson,	  2002):	  
Involuntary	  tremulous	  motion,	  with	   lessened	  muscular	  power,	   in	  parts	  not	   in	  action	  
and	  even	  when	  supported;	  with	  a	  propensity	  to	  bend	  the	  trunk	  forward,	  and	  to	  pass	  
from	  a	  walking	  to	  a	  running	  pace:	  the	  senses	  and	  intellects	  being	  uninjured.	  
Apparently,	   James	  Parkinson	  did	  not	  have	  the	  opportunity	  to	  examine	  the	  patients	  
he	  described	  or	  else	  he	  would	  have	  noticed	  that	  muscle	  power	  was	   in	  fact	  normal.	  
Also,	   today	   we	   appreciate	   that	   senses	   and	   intellect	   may	   be	   affected	   in	   PD.	   The	  
French	  neurologist	  Jean-­‐Martin	  Charcot	  subsequently	  named	  the	  illness	  after	  James	  
Parkinson	  (in	  1879)	  and	  also	  added	  the	  description	  of	  increased	  “rigid”	  muscle	  tone	  
to	   the	   syndrome.	   James	   Parkinson	   speculated	   that	   the	   “supposed	   proximate	  
cause…was	  a	  disease	  state	  of	  the	  medulla	  spinalis”	  (medulla	  spinalis	  =	  spinal	  cord).	  It	  
was	   in	   the	   early	   20th	   century	   that	   the	   substantia	   nigra	   in	   the	  midbrain	  was	   firmly	  
established	   at	   the	   primary	   site	   of	   pathology,	   and	   characteristic	   intraneuronal	  
inclusions	  had	  already	  been	  described	  by	   Lewy	   in	  1912(Greenfield	   and	  Bosanquet,	  
1953;	  Hassler,	  1937; Lewy,	  1912).	  Subsequently,	  the	  neurotransmitter	  dopamine	  
was	   found	   to	   be	   present	   in	   the	   brain	   and	   “concerned	   with	   the	   function	   of	   the	  
striatum	   and	   thus	   with	   the	   control	   of	   movement(Bertler	   and	   Rosengren,	   1959)”.	  
These	   discoveries	   form	   basis	   for	   the	   hypothesis	   of	   dopaminergic	   loss	   in	   the	  
pathogenesis	   of	   PD	   and	   the	   rational	   for	   alleviating	   symptoms	   with	   levodopa	   and	  
dopamine-­‐based	  therapies.	  	  
 Etiological	  classification	  of	  Parkinsonian	  syndromes	  1.1.2
PD	   is	   characterized	  by	  paucity	  and	  slowness	  of	  movement	  accompanied	  by	  muscle	  
stiffness	   and	   resistance	   to	   passive	  movement	   and	   as	   such	   is	   the	   prototype	   of	   the	  
akinetic-­‐rigid	  syndromes.	  The	  clinical	  signs	  and	  symptoms	  of	  Parkinsonism	  can	  occur	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in	  different	  settings,	  and	  the	  current	  classification	  aims	  to	  stratify	  patients	  according	  
to	   the	   underlying	   aetiology.	   This	   is	   important	   for	   clinical	   practice	   –	   especially	   for	  
prognosis	  and	  management	  –	  but	  also	  for	  basic	  and	  clinical	  research	  into	  molecular	  
pathways,	  treatments	  or	  biomarkers	  for	  the	  disease.	  For	  example,	  age	  of	  symptom	  
onset	  and	  distinguishing	  whether	  pure	  Parkinsonism	  or	  Parkinsonism	  with	  additional	  
clinical	  signs	  and	  symptoms	  points	  to	  a	  hereditary	  cause	  in	  the	  former	  and	  helps	  to	  
distinguish	  idiopathic	  Parkinsonism	  from	  the	  so	  called	  Parkinsonism-­‐Plus	  syndromes.	  
A	   variety	   of	   drugs,	   in	   particular	   neuroleptic	   antipsychotic	   medications,	   and	   other	  
underlying	  conditions	  may	  cause	  secondary	  Parkinsonism:	  
• Idiopathic	  Lewy	  body	  Parkinsonism:	  70%	  of	  all	  patients	  	  
• Familial	  PD:	  There	  is	  a	  positive	  family	  history	  in	  about	  10%	  of	  cases;	  this	  can	  be	  
with	  autosomal	  recessive	  or	  autosomal	  dominant	  inheritance	  pattern.	  
• Parkinson-­‐plus	   syndromes:	   examples	   include	   Multiple	   Systems	   Atrophy,	  
Progressive	   supranucelar	   palsy,	   Corticobasal	   degeneration,	   and	   Lewy	   body	  
dementia.	  	  
• Secondary	   PD:	   examples	   include	   drug-­‐	   or	   toxin	   induced,	   PD	   in	   the	   context	   of	  
infection,	   deranged	   metabolism,	   trauma,	   cerebrovascular	   disease,	   or	   Wilson’s	  
disease.	  	  
 Clinical	  features	  1.1.3
Idiopathic	   PD	   is	   characterized	   by	   the	   gradual	   onset	   and	   progression	   of	   tremor,	  
rigidity,	  akinesia	  and	  impairment	  of	  posture	  and	  locomotion	  in	  conjunction	  with	  non-­‐
motor	   symptoms.	   The	   onset	   of	   motor	   symptoms	   is	   unilateral	   with	   progressive	  
persistent	  asymmetry	  throughout	  the	  disease	  course.	  There	  is	  a	  good	  and	  sustained	  
response	   to	   levodopa	   and	   eventually	   levodopa-­‐induced	   dyskinesias.	   Idiopathic	   PD	  
would	  be	  excluded	  if	  there	  was	  no	  response	  to	  levodopa,	  if	  a	  positive	  family	  history	  
of	   PD	   was	   present	   and	   if	   dementia,	   postural	   imbalance	   and	   falls,	   as	   well	   as	  
dysautonomia	  were	  prominent	   features	  during	   the	  early	   stages	  of	   the	   illness.	  Also	  
idiopathic	  PD	  would	  be	  excluded	   if	  eye	  movement	  abnormalities,	  and	  pyramidal	  or	  
cerebellar	  signs	  were	  present.	  However,	  the	  gold	  standard	  for	  the	  diagnosis	  of	  PD	  is	  
its	   distinct	   neuropathology	   with	   degeneration	   of	   pigmented	   brainstem	   nuclei	   –	  
including	   the	  dopaminergic	   substantia	  nigra	  pars	   compacta	  –	  with	   the	  presence	  of	  
Lewy	  bodies	  in	  remaining	  nerve	  cells.	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 Epidemiology	  and	  risk	  factors	  1.1.4
PD	  is	  a	  common	  and	  often	  disabling	  disease,	  which	  affects	  mainly	  people	  of	  middle	  
and	  old	  age	  and	  occurs	  worldwide.	  	  About	  1%	  of	  people	  older	  than	  60	  years	  of	  age	  or	  
3	   in	   1000	   of	   the	   general	   population	   are	   affected	   PD,	   and	   its	   crude	   incidence	   is	  
between	  5-­‐20	  new	  cases	  per	  year	  for	  every	  100	  000	  of	  the	  population	  (de	  Lau	  and	  
Breteler,	  2006).	  Given	  the	  demographic	  trends	  –	  ageing	  in	  the	  developed	  and	  ageing	  
plus	   growing	   in	   the	   developing	   world	   –	   the	   prevalence	   of	   PD	   and	   associated	  
socioeconomic	  burden	  are	  expected	  to	  rise	  exponentially(Dorsey	  et	  al.,	  2007).	  Most	  
studies	   report	  men	   to	   be	   slightly	  more	   often	   affected	   than	   females.	   Pesticide	   and	  
other	   toxin	   exposure	   have	   been	   postulated	   to	   increase	   the	   risk	   of	   developing	  
PD(Massano	   and	   Bhatia,	   2012).	   Likewise,	   there	  may	   be	   protective	   factors	   and	   the	  
most	   robust	   association	   exists	   for	   smoking	   (Morens	   et	   al.,	   1995).	   However,	   the	  
strongest	  risk	  factors	  for	  developing	  PD	  are	  old	  age	  and	  a	  positive	  family	  history.	  
 Monogenetic	  forms	  of	  Parkinsonism	  1.1.5
Heredibility	  in	  PD	  has	  been	  acknowledged	  for	  more	  than	  100	  years.	  The	  British	  
neurologist	  William	  Gowers	  noted	  already	  in	  1902	  that	  15%	  of	  his	  patients	  stated	  a	  
positive	  family	  history	  of	  PD(Bhatia,	  2012).	  Although	  historically	  a	  number	  of	  large	  
PD	  families	  exhibiting	  autosomal-­‐dominant	  inheritance	  were	  known,	  it	  was	  not	  until	  
1996/1997	  that	  the	  first	  PARK	  gene	  (PARK	  to	  denote	  the	  putative	  link	  to	  PD)	  was	  
mapped	  and	  identified	  to	  indisputably	  demonstrate	  heredibility	  in	  PD(Duvoisin,	  
1996;	  Polymeropoulos	  et	  al.,	  1996;	  Polymeropoulos	  et	  al.,	  1997).	  Since	  then,	  28	  
distinct	  chromosomal	  regions	  have	  been	  linked	  to	  PD,	  but	  only	  6	  of	  these	  regions	  
contain	  genes	  with	  mutations	  that	  conclusively	  cause	  monogenetic	  disease(Klein	  and	  
Westenberger,	  2012):	  SNCA,	  LRRK2,	  PARKIN,	  PINK1,	  DJ-­‐1,	  ATP13A2.	  Although	  
altogether	  mutations	  in	  these	  6	  genes	  only	  account	  for	  3-­‐5%	  of	  all	  PD	  patients,	  a	  lot	  
of	  research	  focuses	  on	  mapping	  the	  pathways	  in	  which	  the	  aberrated	  gene	  products	  
function	  and	  whether	  they	  intersect	  with	  the	  reasonable	  expectation	  to	  draw	  more	  
general	  conclusions	  for	  the	  molecular	  basis	  of	  PD	  associated	  neurodegeneration.	  
Table	  1-­‐1	  gives	  an	  up	  to	  date	  overview	  of	  the	  chromosomal	  regions	  with	  a	  putative	  
link	  to	  PD	  according	  to	  the	  current	  genetic	  classification	  of	  PD.
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Table	  1-­‐1	  Overview	  of	  PD	  associated	  chromosomal	  regions:	  PARK	  loci	  
PARK	  	   Gene	  locus	   Gene	  	   Inheritance	   Onset	   Comments	   Pathology	  
PARK1	   4q21-­‐22	   SNCA	  	   AD	   EO	   Confirmed	   Lewy	  bodies,	  atypical	  in	  
some	  cases	  (MSA	  like)	  
PARK2	   6q25.2-­‐q27	   PARKIN	  	   AR	   EO	   Confirmed	   In	  general	  no	  Lewy	  bodies	  
PARK3	   2q13	   Unknown	   AD	   Classical	  PD	   Unconfirmed	  since	  1998	   	  
PARK4	   4q21-­‐q23	   SNCA	  	   AD	   EO	   Erroneous	  locus	  /	  same	  as	  PARK1	   	  
PARK5	   4q13	   UCHL1	   AD	   EO	   Unconfirmed	  since	  1998	   	  
PARK6	   1q35-­‐p36	   PINK1	   AR	   EO	   Confirmed	  
So	  far	  only	  one	  brain	  for	  
autopsy	  (Lewy	  bodies)	  
PARK7	   1p36	   DJ-­‐1	   AR	   EO	   Confirmed	   Unknown	  
PARK8	   12q12	   LRRK2	   AD	   Classical	  PD	   Confirmed;	  pathogenic	  mutations	  as	  well	  as	  risk	  variants	  
Heterogenous,	  typical	  
Lewy	  bodies	  in	  most	  
cases	  
PARK9	   1p36	   ATP13A2	   AR	   Complex	  PD	  with	  EO	   Confirmed	  
So	  far	  only	  one	  brain	  for	  
autopsy	  (ceroid	  
lipofuscinosis)	  
PARK10	   1p32	   Unknown	   Risk	  factor	   	   Confirmed	  susceptibility	  locus	   	  
PARK11	   2q36-­‐27	   Unknown	   AD	   Late	  onset	  PD	   Unconfirmed	   	  
PARK12	   Xq21-­‐p25	   Unknown	   Risk	  factor	   	   Confirmed	  susceptibility	  locus	   	  
PARK13	   2p12	   HTRA2	   AD	  or	  risk	  factor	   Classical	  PD	   Unconfirmed	   	  
PARK14	   22q13.1	   PLA2G6	   AR	   EO	  plus	  dystonia	  	   Confirmed	   Typical	  Lewy	  bodies,	  iron	  
accummulation	  
PARK15	   22q12-­‐q13	   FBXO7	   AR	   Complex	  PD	  with	  EO	   Confirmed	   Unknown	  
PARK16	   1q32	   Unknown	   Risk	  factor	   Classical	  PD	   Confirmed	  susceptibility	  locus	   	  
PARK17	   16q11.2	   VPS35	   AD	   Classical	  PD	   Confirmed	   Unknown	  
PARK18	   3q11.2	   EIF4G1	   AD	   Classical	   Unconfirmed,	  likely	  not	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Up	  to	  date	  list	  of	  PARK	  loci	  (modified	  according	  to(Klein	  and	  Westenberger,	  2012)):	  The	  current	  genetic	  PD	  nomenclature	  denotes	  specific	  genetic	  regions	  with	  a	  putative	  link	  to	  PD	  as	  
“PARK	  loci”	  and	  numbers	  them	  in	  chronological	  order	  of	  their	  discovery.	  It	  is	  neither	  comprehensive	  as	  there	  are	  other	  confirmed	  genes	  with	  a	  link	  to	  PD	  not	  listed	  amongst	  the	  PARK	  
loci	  as	  well	  as	  erroneous	  –	  PARK	  4	  was	  designated	  as	  a	  novel	  loci	  but	  eventually	  found	  to	  be	  identical	  with	  PARK1.	  Some	  of	  the	  have	  been	  identified	  by	  genetic	  linkage	  analysis	  in	  large	  
families,	  others	  by	  candidate	  gene	  approaches	  or	  genome	  wide	  association	  studies.	  EO	  –	  early	  onset,	  AR	  –	  autosomal	  recessive,	  AD	  –	  autosomal	  dominant.	  Pathology	  has	  only	  been	  
reported	  for	  confirmed	  monogenetic	  Parkinsonism.
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 Autosomal	  dominant	  PD	  1.1.6
Mutations	   in	   the	  α-­‐synuclein	   gene	   (SNCA)	   and	   in	   leucin-­‐rich	   repeat	   kinase	   2	   (LRRK2)	  
cause	  autosomal	  dominant	  forms	  of	  PD.	  	  
• α-­‐synuclein	   mutations	   are	   rare	   and	   include	   point	   mutations	   (PARK1)	   and	   whole-­‐
locus	   multiplications	   (PARK4)(Chartier-­‐Harlin	   et	   al.,	   2004;	   Polymeropoulos	   et	   al.,	  
1997;	  Singleton	  et	  al.,	  2003).	  The	  seminal	  discovery	  of	   the	  A53T	  point	  mutation	   in	  
the	  α-­‐synuclein	  gene	  was	  made	  in	  one	  of	  2	  large	  related	  kindreds	  from	  Itlay	  with	  41	  
affected	  people	  over	  four	  generations(Polymeropoulos	  et	  al.,	  1997).	  The	  same	  point	  
mutation	  has	  so	  far	  been	  found	   in	  8	  Greek,	  2	  Korean,	  and	  1	  Swedish	  families(Klein	  
and	  Westenberger,	  2012).	  Two	  further	  missense	  mutations	  in	  α-­‐synuclein	  have	  been	  
reported	   in	   single	   families	   from	  Germany	   (A30P)	   and	   from	   Spain	   (E46K)(Klein	   and	  
Westenberger,	   2012).	   Duplications	   have	   been	   found	   in	   13	   PD	   families	   and	   4	   in	  
sporadic	   disease;	   whereas	   triplications	   of	   α-­‐synuclein	   have	   been	   detected	   in	   3	  
independent	   families(Klein	   and	   Westenberger,	   2012).	   Clinically,	   patients	   with	   α-­‐
synuclein	   mutations	   tend	   to	   have	   early-­‐onset	   PD	   (<50years)	   and	   rapid	   disease	  
progression.	  The	  associated	  clinical	   spectrum	   is	  broad	   ranging	   from	  classical	  PD	   to	  
Parkinson-­‐plus	   syndromes	  and	  penetrance	   tends	   to	  be	  high	  and	  brain	  pathology	   is	  
characterized	   by	   abundant	   α-­‐synuclein-­‐positive	   neuronal	   inclusions.	   The	  
physiological	   function	   of	   the	  α-­‐synuclein	   protein	   remains	   unknown,	   but	   a	   role	   in	  
lipid	   membranes	   and	   their	   stabilization	   has	   been	   suggested(Bhatia,	   2012).	  
Interestingly,	  abnormal	  filamentous	  aggregates	  of	  misfolded	  α-­‐synuclein	  protein	  are	  
a	  major	  component	  of	  Lewy	  bodies	   in	  sporadic	  PD(Jellinger,	  2003;	  Spillantini	  et	  al.,	  
1997).	  	  
• LRRK2	  (PARK8)	  mutations	   in	  PD	  families	  were	  first	  discovered	   in	  2004;	  and	  are	  the	  
most	  common	  cause	  of	  autosomal	  dominant	  PD	  explaining	  10%	  of	  cases	  (Di	  Fonzo	  et	  
al.,	   2006;	   Paisan-­‐Ruiz	   et	   al.,	   2004;	   Zimprich	   et	   al.,	   2004).	   The	   LRRK2	   gene	   has	   51	  
exons	   and	   encodes	   a	   large	   protein	   (>250kDa),	   called	   lrrk2	   or	   dardarin.	   Over	   50	  
variants	   have	   been	   identified	   in	   LRRK2	   so	   far,	   but	   only	   some	   of	   them	   can	   be	  
considered	  clearly	  pathogenic.	  Amongst	  them	  is	  the	  G2019S	  mutation,	  which	  has	  an	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incomplete,	  age-­‐related	  penetrance	  (ranging	  from	  20%	  to70%	  by	  80	  years	  of	  age	  in	  
differed	   studies)	   and	   can	   thus	   be	   found	   in	   familial	   as	   well	   as	   seemingly	   sporadic	  
disease.	  The	  G2019S	  mutation	  is	  very	  common	  with	  a	  frequency	  of	  2%	  of	  in	  general	  
North	   American	   clinical	   populations	   and	   British	   Parkinson’s	   Disease	   Brain	   Bank	  
specimens	   and	   particularly	   frequent	   in	   Ashkenazy	   Jewish,	   Portuguese,	   and	   North	  
African	   Arabian	   PD	   patients	   even	   in	   the	   absence	   of	   a	   clear	   family	  
history(review:(Hardy	  et	  al.,	  2006)).	  In	  general,	  the	  clinical	  characteristics	  of	  patients	  
with	  LRRK2	  gene	  mutations	  	  -­‐	  in	  particular	  those	  with	  the	  common	  G2019S	  mutation	  
–	   are	   very	   similar	   to	   those	   of	   idiopathic	   PD.	   Nigrostriatal	   cell	   loss	   and	   gliosis	   are	  
common	   findings	   in	   patients	   with	   LRRK2	  mutations,	   and	  most	   of	   them	   also	   have	  
Lewy	  bodies.	  However,	  there	  are	  also	  cases	  with	  no	  Lewy	  bodies,	  where	  only	  tau-­‐	  or	  
ubiquitin	   positive	   inclusions	   are	   observed(Zimprich	   et	   al.,	   2004).	   The	   lrrk2	   protein	  
contains	   a	   GTPase	   and	   kinase	   enzymatic	   domains	   and	   at	   least	   2	   protein-­‐protein	  
interaction	  domains.	   The	   common	  G2019S	  mutation	   lies	  within	   the	  kinase	  domain	  
and	  results	  in	  a	  small	  increase	  in	  kinase	  activity	  in	  vitro(Nichols	  et	  al.,	  2010).	  Despite	  
extensive	  efforts	   the	  physiological	   function	  of	   lrrk2	   remains	  unknown	  and	   to	  date,	  
no	  in	  vivo	  substrates	  of	  its	  kinase	  domain	  has	  been	  identified.	  	  
 Autosomal	  recessive	  PD	  1.1.7
Mutations	   in	   PARKIN	   (PARK2),	   PINK1	   (PARK6),	   and	   DJ1	   (PARK7)	   cause	   autosomal	  
recessive	  forms	  of	  PD.	  Furthermore,	  mutations	  in	  ATP13A2	  (PARK9),	  PLA2G6	  (PARK14),	  
and	  FBXO7	  (PARK15),	  cause	  more	  rare	  forms	  of	  recessive	  disease	  with	  usually	  very	  early	  
onset	  (<30	  years	  of	  age)	  and	  complex	  phenotype(Kitada	  et	  al.,	  1998;	  Paisan-­‐Ruiz	  et	  al.,	  
2009;	  Ramirez	  et	  al.,	  2006;	  Shojaee	  et	  al.,	  2008;	  Valente	  et	  al.,	  2004).	  	  
• Parkin	  mutations	  (PARK2)	  are	  a	  common	  cause	  of	  autosomal	  recessive	  parkinsonism	  
with	  early	  onset.	  Various	  point	  mutations	  as	  well	  as	   large	  genomic	  rearrangements	  
resulting	   in	   exon	   deletions	   and	   multiplications	   have	   been	   detected	   in	   the	  
homozygeous	  as	  well	  as	  compound	  heterozygeous	  state.	  About	  half	  of	  the	  reported	  
changes	  affect	  the	  region	  that	  encodes	  the	  UBL	  domain	  (459/887),	  amongst	  them	  is	  
the	  most	  frequent	  of	  all	  PARKIN	  mutation:	  deletion	  of	  exon	  3	  (88/887,	  in	  17	  different	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screens).	  The	  second	  most	  common	  mutation	  (c.C924T)	  lies	  outwith	  the	  UBL	  domain	  
in	  RING1	  of	  the	  protein.	  Additionally,	  there	  are	  numerous	  reports	  of	  cases	  with	  only	  
a	  single	  mutation	  with	  then	  apparent	  autosomal	  dominant	  inheritance(Farrer	  et	  al.,	  
2001;	  Hardy	  et	  al.,	   2006).	  Parkin	  mutations	  explain	  up	   to	  half	  of	   the	   familial	   cases	  
with	  autosomal	  recessive	  inheritance	  and	  early	  disease	  onset	  (<45	  years	  of	  age),	  and	  
in	   about	   15%	   of	   the	   sporadic	   cases	   with	   early	   disease	   onset	   (<45	   years	   of	  
age)(Periquet	   et	   al.,	   2003).	   	   The	   clinical	   phenotype	   associated	   with	   PARKIN	  
mutations	   is	   characterized	   by	   Parkinsonism	   of	   early	   onset,	   good	   and	   prolonged	  
response	  to	  levodopa,	  and	  in	  general	  no	  profound	  cognitive	  or	  autonomic	  declines.	  
Late	   onset	   cases	   have	   been	   reported	   but	   not	   systematically	   screened	   for.	   The	  
pathology	  associated	  with	  Parkin	  has	  only	  been	  studied	  in	  a	  small	  number	  of	  cases	  
and	  has	  usually	  been	  regarded	  as	  a	  severe	  nigropathy	  –	  neuronal	  cell	  loss	  and	  gliosis	  
in	   the	   substantia	   nigra	   –	   with	   lewy	   bodies	   present	   only	   in	   a	   minority	   of	  
patients(Doherty	  and	  Hardy,	  2013;	  Hattori	  et	  al.,	  2000).	  Parkin	  encodes	  for	  a	  465	  AA	  
protein	  with	   a	  modular	   architecture	   comprising	   a	   carboxy-­‐terminal	   domain	  with	   3	  
RING	  (really	  interesting	  new	  gene)	  domains,	  one	  IBR	  (in	  between	  ring)	  domain	  and	  a	  
aminoterminal	   ubiquitin	   like	   (UBL)	   domain(Wauer	   and	   Komander,	   2013).	   As	   such	  
Parkin	  may	  physiologically	  function	  as	  an	  E3	  ligase	  with	  the	  ability	  to	  control	  protein	  
turnover	   via	   polyubiquitin	   chain	   addition.	   However,	   pathological	   substrates	  
responsible	  for	  neuronal	  death	  have	  yet	  to	  be	  identified	  in	  vivo.	  
• PINK1	   (PARK6)	   mutations	   are	   the	   second	   most	   common	   cause	   for	   autosomal	  
recessive	   PD	   with	   early	   onset	   with	   variable	   frequency	   between	   1%	   and	   9%	  
depending	  on	  which	  population	   is	   examined(Klein	  and	  Westenberger,	   2012).	  Most	  
patients	   carry	   homozygeous	   point	   mutations	   –	   so	   far	   60	   different	   missense	   and	  
nonsense	  mutations	   in	   >170	   patients-­‐	   	   but	   also	   a	   number	   of	   single	   heterozygous	  
mutations	  as	  well	  as	  genomic	  rearrangements	  have	  been	  found.	  Clinically,	  patients	  
resemble	   parkin	   cases,	   and	  with	   regards	   to	   PINK1	   related	   pathology,	   it	   has	   to	   be	  
noted	  that	  so	  far	  only	  one	  case	  with	  nigrostriatal	  neuronal	  loss	  and	  gliosis	  with	  only	  
a	   few	   Lewy	   bodies	   and	   Lewy	   dendrites	   identified(Samaranch	   et	   al.,	   2010).	   PINK	  
1encodes	   for	   a	   protein	   called	   phosphatase	   and	   tensin	   homolog	   (PTEN)-­‐induced,	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putative	   kinase	   1	   with	   581	   AA.	   It	   consists	   of	   an	   aminoterminal	   mitochondrial	  
targeting	  motif,	  a	  conserved	  serine-­‐threonine	  kinase	  domain	  and	  a	  carboxy-­‐terminal	  
autoregulatory	   domain.	   The	   majority	   of	   mutations	   are	   loss-­‐of-­‐function	   mutations	  
affecting	   the	   kinase	   domain.	   It	   is	   now	   assumed	   that	   PINK1	   and	   Parkin	   share	   a	  
mechanistic	  pathway	  in	  the	  pathogenesis	  of	  PD.	  	  
• DJ-­‐1	   (PARK7)	   mutations	   account	   for	   1%	   to	   2%	   of	   early-­‐onset	   familial	   PD	   with	  
autosomal	   recessive	   inheritance(Pankratz	   et	   al.,	   2006).	   About	   10	   different	   point	  
mutations	  and	  exonic	  deletions	  have	  been	  described,	  mostly	  in	  the	  homozygeous	  or	  
compound	  heterozygeous	  state.	  	  Overall,	  DJ-­‐1	  associated	  disease	  resembles	  that	  of	  
the	   other	   early	   onset	   autosomal	   recessive	   syndromes	   caused	   by	   PINK1	   and	  
PARKIN(Hardy	  et	  al.,	  2006).	  DJ-­‐1	  codes	   for	  a	  uniquitously	  expressed	  protein	  of	  189	  
AA	  that	  may	  function	  as	  a	  cellular	  sensor	  for	  oxidative	  stress.	  Mutant	  DJ-­‐1	  proteins	  
are	   frequently	   misfolded,	   unstable,	   and	   readily	   degraded	   by	   the	  
proteasome(Anderson	  and	  Daggett,	  2008).	  	  
• ATP13A2	  (PARK9)	  mutations	  cause	  a	  rare	  early	  onset	  and	  rapidly	  progressive	  atypical	  
PD	  syndrome	  that	  is	  also	  called	  Kufor-­‐Rabek	  disease	  after	  the	  region	  in	  Jordan	  where	  
it	  was	  first	  described.	  Less	  than	  10	  families	  with	  PARK9	  disease	  have	  been	  described	  
so	   far	  and	  all	   affected	  cases	  present	  early	   (around	  15	  years	  of	  age)	  with	   levodopa	  
responsive	  parkinsonism	  with	  additional	  spasticity,	  supranuclear	  upgaze	  paresis	  and	  
dementia.	  There	  may	  be	  brain	  atrophy,	  and	  in	  at	  least	  2	  cases	  iron	  deposition	  in	  the	  
basal	  ganglia	  has	  been	  described(Behrens	  et	  al.,	  2010;	  Schneider	  et	  al.,	  2010).	  The	  
associated	   pathology	   is	   still	   unknown.	   ATP13A2	   encodes	   a	   large	   protein	   with	  
putative	   ATP-­‐ase	   activity	   in	   the	   lysosomal	   membrane	   with	   10	   transmembrane	  
domains(Ramirez	   et	   al.,	   2006).	   Its	   function	   is	   unknown,	   but	   its	   transcript	   is	   highy	  
expressed	   in	   the	   substantia	   nigra,	   and	   it	   appears	   to	   be	   upregulated	   in	   idiopathic	  
PD(Ramirez	  et	  al.,	  2006).	  	  
• FBXO7	   mutations	   (PARK15)	   are	   associated	   with	   an	   early	   onset	   pyramidal-­‐
parkinsonian	   syndrome.	   3	   different	   homozygeous	   and	   compound	   heterozygeous	  
mutations	  have	  been	  identified	  so	  far	  in	  only	  a	  handful	  of	  families	  worldwide.	  FBXO7	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encodes	   for	   a	   subunit	   of	   an	   E3	   ubiquitin	   ligase	   and	   may	   as	   such	   be	   involved	   in	  
protein	  quality	  control.	  FBXO7	  will	  be	  discussed	  in	  great	  detail	  in	  section	  1.3.	  
There	  are	  a	  number	  of	  other	   genes	  with	  a	   link	   to	   familial	   PD.	  Amongst	   the	  ones	  with	  
PARK	   designation	   are	   UCHL1	   (PARK5),	   GYGYF2	   (PARK11),	   and	   OMI/HTRA2	   (PARK13).	  	  
Additionaly,	   mutations	   in	   synphilin-­‐1,	   NR4A2/Nurr1,	   POLG,	   mortalin,	   and	   PARL	   are	  
considered	   to	   contribute	   to	   the	   pool	   of	   very	   rare	   causes	   of	   familial	   PD(Klein	   and	  
Westenberger,	   2012).	   UCHL	   (ubiquitin	   carboxy-­‐terminal	   hydrolase	   L1)	   is	   a	   neuronal	  
protein	  and	  has	  been	  suggested	  to	  binds	  and	  stabilize	  neuronal	  monoubiquitin.	  It	  is	  also	  
found	   to	   be	   a	   component	   of	   Lewy	  bodies(Osaka	   et	   al.,	   2003).	   	   Also,	  mutations	   in	   the	  
GBA	  gene	  encoding	   for	   the	   lysosomal	  enzyme	  geta-­‐glucocerebrosidase	   is	  a	   recognized	  
risk	  factor	  for	  PD.	  Pathogenic	  loss-­‐of-­‐function	  mutations	  can	  cause	  Gaucher	  disease	  with	  
dysfunction	   of	   liver,	   blood,	   bone	   marrow,	   spleen,	   lung,	   and	   the	   central	   nervous	  
system(Klein	  and	  Westenberger,	  2012).	  
1.2 The	  Ubiquitin	  system	  
 Posttranslational	  modifications	  and	  cellular	  signaling	  1.2.1
The	   complexity	   and	   diversity	   of	   all	   the	   proteins	   in	   a	   living	   organism	   can	   be	   greatly	  
increased	  by	  the	  covalent	  attachment	  of	  posttranslational	  modifications	  (PTMs).	  PTM	  is	  
a	   swift	   way	   to	   alter	   activation	   status,	   turn	   over,	   subcellular	   localization,	   interacting	  
partners	  or	  even	  conformational	  change	  of	  a	  protein	   to	  allow	  prompt	  adjustment	  and	  
response	  to	  internal	  and	  external	  stimuli(Deribe	  et	  al.,	  2010).	  Important	  representatives	  
of	  PTMs	  are	  protein	  phosphorylation	  and	  protein	  ubiquitination.	  Together,	  they	  govern	  
most	  aspects	  of	  a	  living	  cell,	  but	  disturbances	  in	  their	  control	  mechanism	  can	  also	  have	  
detrimental	  consequences	  and	  be	  linked	  to	  cancerogeneis	  and	  numerous	  other	  diseases	  
and	   make	   a	   perfect	   target	   for	   research	   into	   understanding	   human	   diseases	   and	  
developing	  therapies(Cohen	  and	  Tcherpakov,	  2010).	  
 Ubiquitin	  1.2.2
Aaron	  Ciechanover,	  Avram	  Hershko	  and	  Irwin	  Rose	  were	  awarded	  the	  Nobel	  Prize	  in	  
Chemistry	  in	  2004	  for	  their	  discovery	  of	  the	  ubiquitin	  proteasom	  pathway(Ciechanover,	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2005;	  Hershko,	  2005;	  Rose,	  2005).	  Ubiquitin	  is	  a	  small,	  highly	  conserved	  -­‐	  76	  amino	  acids	  
-­‐	  polypeptide	  of	  about	  8500	  Da	  –	  and	  is	  encoded	  by	  4	  different	  genes	  in	  mammals:	  the	  
UBB	  and	  UBC	  genes	  encode	  polyubiquitin	  precursors,	  while	  UBA52	  and	  UBA80	  encode	  
single	  copy	  ubiquitin	  in	  fusion	  with	  ribosomal	  proteins(Redman	  and	  Rechsteiner,	  1989).	  
In	  the	  end,	  these	  precursors	  are	  then	  cleaved	  to	  release	  identical	  monomeric	  ubiquitin	  
units.	  Ubiquitin	  is	  characterized	  by	  seven	  Lysine	  residues	  at	  positions	  K6,	  K11,	  K27,	  K29,	  
K33,	  K48,	  and	  K68;	  and	  these	  Lysines	  as	  well	  as	  the	  Methionine	  at	  position	  1	  can	  be	  
involved	  in	  colalent	  linkages	  either	  between	  ubiquitin	  and	  its	  target	  proteins	  or	  the	  
formation	  of	  ubiquitin	  polymers	  (Figure	  1).	  It	  should	  be	  noted	  that	  there	  are	  many	  
ubiquitin-­‐like	  proteins	  that	  also	  serve	  as	  posttranslational	  modifiers.	  Despite	  limited	  
sequence	  homology	  of	  some	  of	  these	  proteins	  with	  ubiquitin,	  they	  display	  structural	  
homology	  and	  undergo	  an	  analogues	  enzymatic	  cascade	  in	  order	  to	  be	  transferred	  to	  a	  





Figure	  1:	  Structure	  of	  Ubiquitin	  
Ribbon	  representation	  of	  ubiquitin	  indicating	  the	  C-­‐terminal	  tail	  and	  showing	  the	  seven	  Lysine	  residues	  
(K6,	  11,	  27,	  29,	  33,	  48,	  and	  63)	  in	  green	  and	  the	  Methionine	  at	  position	  1	  in	  blue.	  These	  residues	  are	  used	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RGG	  motif	  at	  its	  C-­‐terminal	  end	  is	  important	  for	  MS/MS	  detection	  of	  ubiquitylated	  species	  and	  this	  will	  be	  
discussed	  in	  more	  detail	  in	  5.1.	  
	  
 The	  Ubiquitinylation	  Cascade	  1.2.3
Ubiquitin	   is	   covalently	   attached	   to	   other	   proteins	   in	   a	   cascade	   of	   events	   called	  
ubiquitination	  (Figure	  2).	  In	  the	  first	  instance,	  ubiquitin	  is	  activated	  by	  the	  formation	  of	  a	  
thioester	   bond	   between	   its	   C-­‐terminal	   carboxylate	   group	   and	   either	   the	   thiol	   or	  
sulhydryl	  group	  of	  a	  cysteine	  residue	  of	  an	  E1	  activating	  enzyme.	  Second,	  the	  ubiquitin	  is	  
then	   transferred	   to	   the	  active	   site	   cysteine	  of	  an	  E2	  congugating	  enzyme.	   In	   the	   third	  
step,	   the	   E2	   conjugating	   enzyme	   interacts	  with	   an	   E3	   ligase	   in	   order	   to	   attach	   the	   C-­‐
terminal	   glycine	  of	  ubiquitin	   to	   the	  ε-­‐amino	  group	  of	   a	   lysine	  of	   its	   target	  protein.	  By	  
attaching	  one	  ubiquitin	  moiety	  to	  a	  substrate	  lysine,	  the	  outcome	  is	  monoubiquitylation.	  
Multiple	   lysine	   residues	   of	   a	   particular	   substrate	   can	   be	   modified	   during	   multi-­‐
monoubiquitylation.	  If,	  however,	  the	  N-­‐terminal	  Methionine	  or	  any	  of	  the	  seven	  Lysine	  
residues	   of	   an	   ubiquitin	   molecule	   that	   is	   attached	   to	   a	   substrate	   becomes	   modified,	  
polymeric	  ubiquitin	  chains	  are	  being	  formed.	  These	  can	  vary	  in	  length	  -­‐	  from	  2	  to	  about	  
10	  moieties	   –	   and	   also	   differ	   in	   architecture,	   depending	   on	   the	   linkage	   between	   the	  
ubiquitin	   molecules.	   It	   is	   the	   topology,	   mode	   of	   linkage,	   and	   number	   of	   ubiquitin	  
monomers	  or	  polymers	  attached	  that	  encode	  quite	  versatile	  information	  about	  the	  fate	  
of	  a	  protein	  undergoing	  ubiquitylation	  (Figure	  3).	  The	  outcome	  of	  ubiquitylation	  will	  be	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Figure	  2:	  The	  ubiquitin	  conjugating	  system	  and	  functional	  outcomes	  
The	  ubiquitination	  of	  target	  protein	  is	  a	  three-­‐step	  enzymatic	  reaction:	  Activated	  ubiquitin	  is	  transferred	  
to	  the	  E2	  conjugating	  enzyme.	  The	  E2∼Ubiquitin	  then	  interacts	  with	  the	  E3	  ligase	  resulting	  in	  the	  covalent	  
attachment	  of	  Ubiquitin	  to	  its	  target	  protein.	  Monoubiquitinated	  proteins	  can	  either	  dissociate	  from	  the	  
ubiquitination	  machinery	  or	  can	  undergo	  multiple	  rounds	  of	  ubiquitination	  with	  the	  effect	  of	  multi-­‐
monoubiquitin	  or	  polyubiquitin	  chain	  attachment.	  K48-­‐polyubiquitination	  usually	  directs	  targets	  towards	  
degradation	  by	  the	  ubiquitin	  proteasome	  pathway,	  whereas	  monoubiquitination	  and	  other	  ubiquitin	  





Figure	  3:	  Different	  ubiquitin	  topologies	  
Depending	  on	  number	  and	  linkage	  type,	  the	  outcome	  of	  ubiquitylation	  can	  be	  mono-­‐,	  multimono-­‐	  and	  
polyubiquitylation.	  Polyubiquitylation	  can	  result	  in	  homogtypic	  (polymers	  of	  the	  same	  linkage)	  or	  
heterotypic	  ubiquitin	  chains	  and	  the	  examples	  of	  either	  type	  on	  the	  right	  illustrate	  the	  difference	  in	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1.2.3.1 The	  Ubiquitin	  activating	  enzyme	  
The	   first	   step	   in	   the	   ubiquitinylation	   cascade	   is	   catalysed	   by	   the	   ubiquitin	   activating	  
enzyme	  E1.	  The	  human	  genome	  encodes	  2	  E1s;	   the	  UBE1	  and	  UBE1L2	  genes(Pelzer	  et	  
al.,	  2007;	  Pickart,	  2001).	  Interestingly,	  mutations	  in	  the	  UBE1	  gene	  have	  been	  associated	  
with	  a	  lethal	  infantile	  form	  of	  spinal	  muscular	  atrophy,	  a	  neuromuscular	  disorder	  that	  is	  






Figure	  4:	  Ubiquitin	  activation	  
Ubiquitin	  activation	  by	  E1	  +	  ATP	  to	  form	  E1-­‐thioester	  
	  
1.2.3.2 The	  Ubiquitin	  Conjugating	  Enzyme	  
The	  ubiquitin	  is	  then	  transferred	  from	  the	  E1	  enzyme	  to	  the	  E2	  conjugating	  enzyme	  by	  
means	   of	   yet	   another	   thiol	   beyond	   between	   a	   cysteine	   residue	   of	   the	   E2	   and	  
Ubiquitin(Figure	  5).	  There	  are	  at	  least	  38	  ubiquitin	  conjugating	  enymes	  in	  humans	  and	  at	  
least	   one	   is	   associated	   with	   Mendalian	   disease:	   mutations	   in	   the	   UBE2A	   gene	   are	  
associated	   with	   a	   X-­‐linked	   syndromic	   mental	   retardation(Budny	   et	   al.,	   2010).	   The	  
specificity	   in	   terms	  of	   the	  outcome	  of	  ubiquitylation	  –	  number	  of	   ubiquitin	  molecules	  
attached	   and	   type	   of	   linkage	   –	   can	   either	   be	   attributed	   to	   the	   E2	   alone,	   the	   E3,	   or	   a	  
particular	   E3-­‐substrate	   complex.	   An	   example	   of	   an	   E2	   enzyme	   being	   the	   critical	  
determand	  of	  the	  outcome	  of	  ubiquitylation	  is	  the	  E2	  UBE2W:	  the	  E3	  enzymes	  BRCA-­‐1-­‐
BARD1	   and	   CHIP	   catalyze	   monoubiquitylation	   if	   UBE2W	   is	   the	   corresponding	   E2,	   but	  
produce	   ubiquitin	   chains	   with	   the	   unspecific	   UBE2D	   E2(Christensen	   et	   al.,	   2007;	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one	  of	  the	  2	  E1	  enzymes	  and	  a	  single	  E2	  can	  function	  together	  with	  several	  different	  E3s	  
(Ye	  and	  Rape,	  2009).	  
	  
Figure	  5:	  The	  Ubiquitin	  conjugating	  enzyme	  
Formation	  of	  a	  thiol	  bond	  between	  the	  acceptor	  Cysteine	  residue	  of	  the	  E2	  and	  ubiquitin	  
	  
1.2.3.3 The	  Ubiquitin	  Ligating	  Enzyme	  
E3	   ubiquitin	   ligases	   are	   involved	   in	   the	   final	   step	   of	   the	   ubiquitylation	   cascade,	  when	  
ubiquitin	  is	  transferred	  to	  a	  substrate.	  There	  are	  2	  major	  classes	  of	  E3	  ubiquitin	  ligases	  
defined	  by	  the	  presence	  of	  a	  RING	  (really	   interesting	  new	  gene)	  or	  HECT	  (homology	  to	  
E6AP	  carboxyl	  terminus)	  domain(Deshaies	  and	  Joazeiro,	  2009;	  Rotin	  and	  Kumar,	  2009).	  
HECT-­‐type	  E3	  enzymes	  form	  an	  obligatory	  thioester	  intermediate	  with	  ubiquitin,	  wheras	  
RING-­‐type	   E3	   ligases	   lack	   cathalytic	   cysteines	   and	   mediate	   the	   direct	   transfer	   of	  
ubiquitin	   to	   a	   substrate	   (Figure	  6)(Deshaies	   and	   Joazeiro,	   2009;	  Metzger	   et	   al.,	   2012).	  
More	  recently,	  another	  distict	  type	  of	  E3	  ligases	  has	  been	  discovered:	  RING-­‐in-­‐between-­‐
RING	  E3	  ligases,	  which	  are	  hybrids	  in	  terms	  of	  how	  the	  ubiquitin	  is	  transferred	  from	  the	  
E2	  onto	  a	  substrate(Wenzel	  et	  al.,	  2011).	  It	  is	  estimated	  that	  there	  are	  over	  600	  human	  
genes	  that	  encode	  E3	  ligases,	  of	  which	  the	  vast	  majority	  belongs	  to	  the	  class	  of	  RING	  E3	  
ligases(Li	  et	  al.,	  2008).	  Many	  E3	  ligases	  are	  involved	  in	  disease,	  which	  has	  raised	  interest	  
in	   exploiting	   them	   as	   therapeutic	   targets(Kirkin	   and	   Dikic,	   2011;	   Lipkowitz	   and	  
Weissman,	  2011).	  FBXO7	  as	  part	  of	  an	  E3	  RING	  complex,	  PARKIN	  as	  a	  RING-­‐in-­‐between-­‐
RING	   E3	   ligase,	   and	   HECT2	   as	   a	   HECT	   E3	   ligase	   are	   all	   examples	   of	   E3	   ligases	   being	  
involved	  in	  monogenetic	  Mendelian	  neurodegenerative	  diseases:	  the	  former	  2	  in	  PD	  and	  
the	   latter	   in	   an	  Angelman	   syndrome	   like	  neurodevelopmental	   disorder(Harlalka	  et	   al.,	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Figure	  6:	  The	  2	  main	  classes	  of	  Ubiquitin	  ligating	  enzymes:	  RING	  and	  HECT	  E3	  ligases	  
RING	  E3	   ligases	   do	  not	   posses	   a	   catalytically	   active	   cysteine	   residue	   and	   facilitate	   the	  
direct	   transfer	  pf	  ubiquitin	  to	  the	  ε-­‐amine	  group	  of	  a	  substrate	   lysine.	  HECT	  E3	   ligases	  
posses	   an	   active	   site	   cysteine	   group	  which	   serves	   as	   an	   acceptor	   site	   for	   ubiquitin	   by	  
means	  of	  an	  intermediate	  thiolester.	  The	  ubiquitin	  is	  then	  transferred	  from	  the	  HECT	  E3	  
ligase	  to	  the	  ε-­‐amine	  group	  of	  a	  substrate	  lysine.	  
 Outcome	  of	  ubiquitylation	  depending	  on	  topology	  1.2.4
Ubiquitinylated	   proteins	   are	   recognized	   by	   at	   least	   20	   specialized	   ubiquitin-­‐binding	  
domains,	  which	  help	  decoding	  and	  translating	  the	  various	  ubiquitylation	  signals(Hurley	  
et	   al.,	   2006).	  Ubiquitinylation	   had	   first	   been	   discovered	   and	   studied	   in	   the	   context	   of	  
proteasomal	  degradation(Hershko	  and	  Ciechanover,	  1998).	  This	  is	  mostly	  the	  case	  when	  
the	  ubiquitin	   signal	   is	   encoded	  as	  K48	  polyubiquitin	   chains(Chau	  et	  al.,	   1989;	  Hershko	  
and	  Ciechanover,	   1998).	  However,	   it	   has	   recently	   been	   found,	   that	   even	  K48	   linkages	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while	  K63	  and	  K11	  linked	  chgains	  as	  well	  as	  to	  a	  lesser	  extend	  K29-­‐linked	  chains	  can	  also	  
contribute	   to	   protesomal	   degradation(Flick	   et	   al.,	   2006;	   Komander,	   2009).	   In	   cells,	   all	  
possible	   linkages	   of	   ubiquitin	   chains	   have	   been	   detected	   and	   at	   least	   for	   some	   –	  
monoubiquitylation	   and	   K11,	   K48,	   K63	   linkges	   -­‐	   distinct	   cellular	   outcomes	   have	   been	  
ascertained.	  For	  other	  chain	   types	   -­‐	  K6,	  K27,	  K29,	  or	  K33	  –	  a	  clear	  pattern	   in	   terms	  of	  
downstream	  effects	  has	  not	  been	  established	  as	  yet(Komander	  and	  Rape,	  2012).	  	  
Mono-­‐	   and	   multimonoubiquitylation	   are	   involved	   in	   receptor	   trafficking	   and	   DNA	  
damage	   response	   pathways.	   Fanconi	   anaemia	   is	   a	   rare,	   heterogeneous	   chromosomal	  
instability	   syndrome,	   which	   predisposes	   affected	   individuals	   to	   cancer.	   The	   Fanconi	  
pathway	   contains	   a	   multiprotein	   core	   complex	   that	   functions	   as	   an	   E3	   ligase	   to	  
monoubiquitylate	   the	   heterodimeric	   FANCD2	   /	   FANCI	   complex	   with	   subsequent	  
initiation	   of	   replicative	   DNA	   crosslink	   repair(Moldovan	   and	   D'Andrea,	   2009).	   In	   this	  
context,	  monoubiquitylation	   is	   considered	   the	   signal	   for	   translocating	   the	   complex	   to	  
the	   nucleus	   and	   linking	   it	   to	   the	  BRCA1	   repair	  machinery.	   This	   is	   deficient	   in	   patients	  
with	   Fanconi	   anaemia.	   Multimonoubiquitylation	   is	   involved	   in	   cell-­‐surface	   receptor’s	  
lysosomal	  degradation	  and	  recycling	  by	  means	  of	  the	  ESCRT	  (endosomal	  sorting	  complex	  
required	   for	   transport)	   machinery(Haglund	   et	   al.,	   2003a;	   Haglund	   et	   al.,	   2003b).	   K11	  
linked	   chains	   are	   involved	   in	   endoplasmatic	   reticulum	   associated	   degradation	   (ERAD)	  
and	   cell	   cycle	   regulation;	   K48	   linkages	   mostly	   in	   proteasomal	   degradation,	   and	   K63	  
linked	  polyubiquitinylation	  plays	  a	  rold	  in	  signalling,	  trafficking,	  as	  well	  as	  DNA	  damage	  
response	  reviewed	  in:	  (Komander	  and	  Rape,	  2012).	  	  
Ubiquitination	   is	   reversible	   and	   the	   cleavage	   of	   ubiquitin	   from	   proteins	  
(“deubiquitination”)	   is	   catalyzed	   by	   deubiquitinases	   or	   DUBs.	   Proteins	   that	   posses	   an	  
ubiquitin-­‐binding	  domain	  or	  ubiquitin-­‐like	  domain	  further	  add	  to	  the	  complexity	  of	  the	  
ubiquitination	   machinery	   by	   influencing	   the	   fate	   of	   ubiquitinated	   proteins	   via	  
noncovalent	  interactions	  with	  ubiquitin(Grabbe	  and	  Dikic,	  2009).	  	  
 The	  Ubiquitin	  system	  and	  human	  disease	  1.2.5
It	  has	  become	  increasingly	  evident	  that	  altered	  functions	  of	  components	  of	  the	  ubiquitin	  
system	   play	   an	   important	   role	   in	   human	   diseases.	   Hence,	   the	   ubiquitin	   proteasome	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system	  is	  subject	  of	  intense	  drug	  discovery	  programmes	  and	  harbours	  huge	  potential	  for	  
devising	   new	   treatments	   in	   cancer,	   but	   possibly	   also	   in	   neurodegenerative	  
diseases(Cohen	  and	  Tcherpakov,	  2010;	  Kessler,	  2013;	  Nalepa	  et	  al.,	  2006).	  Altered	  gene	  
expression	   and	   mutations	   have	   been	   identified	   in	   proteins	   functioning	   as	   tumor	  
suppressors	  such	  as	  F-­‐box	  protein	  FBW7	  or	  the	  E3	  ligase	  von	  Hippel	  Lindau	  (VHL	  gene)	  
with	  an	  heightened	  risk	  for	  cancer	  in	  general	  in	  the	  former	  and	  increased	  susceptibility	  
to	   pheochromocytoma	   in	   the	   latter(Latif	   et	   al.,	   1993;	   Welcker	   and	   Clurman,	   2008).	  	  
Oncogenes	  such	  as	  MDM2	  –	  encoding	  an	  E3	  ligases	  -­‐	  or	  SKP2	  –	  a	  F-­‐box	  protein	  -­‐	  can	  also	  
be	  found	  to	  be	  dysregulated	  in	  cancer	  and	  thereby	  ineffectively	  promote	  degradation	  of	  
proteins	   that	  negatively	   regulate	   cell	   division	   (p53	  and	  p27)(for	   review	   see:(Nalepa	  et	  
al.,	  2006)).	  Mutations	   in	  the	  DUB	  CLYD	  (USP4)	  cause	  rare	  forms	  of	  cancer	  arising	  from	  
skin	   appendages(Bignell	   et	   al.,	   2000).	   The	   breast	   cancer	   type	   1	   susceptibity	   protein	  
(BRCA1)	   has	   E3	   ligase	   activity	   and	   is	   involved	   in	  DNA	   repair	   and	   genome	   integrity(for	  
review	  see:(Nalepa	  et	  al.,	  2006)).	  	  
There	  are	  many	  examples	  of	  neurodegenerative	  diseases	  that	  are	  linked	  with	  mutations	  
in	  the	  ubiquitin	  proteasome	  system:	  Mutations	  in	  the	  E3	  ligase	  PARKIN	  are	  frequently	  
associated	  with	  early	  onset	  PD	  and	  had	  first	  been	  described	  in	  1998	  (see:	  1.1.7	  and	  
(Kitada	  et	  al.,	  1998)).	  The	  UCHL1	  gene	  encodes	  for	  a	  ubiquitin	  C-­‐terminal	  hydrolase	  has	  
at	  least	  been	  implicated	  in	  one	  German	  family	  with	  early	  onset	  PD,	  but	  so	  far	  has	  not	  
been	  replicated	  in	  other	  affected	  individuals(Leroy	  et	  al.,	  1998).	  Interestingly,	  
homozygeous	  UCHL1	  mutations	  that	  are	  predicted	  to	  affect	  the	  function	  of	  the	  ubiquitin	  
binding	  domain	  have	  recently	  been	  found	  in	  a	  Turkish	  family	  with	  childhood	  onset	  
neurodegeneration	  with	  optic	  atrophy	  but	  no	  parkinsonism(Bilguvar	  et	  al.,	  2013).	  
Muations	  in	  the	  F-­‐box	  protein	  FBXO7	  –	  subject	  of	  this	  thesis	  –	  are	  also	  associated	  with	  
early	  onset	  complex	  Parkinsonism	  (see:	  1.1.7	  and	  (Shojaee	  et	  al.,	  2008).	  Angelman’s	  
syndrome	  is	  a	  complex	  neurodevelopmental	  disorder	  that	  can	  be	  caused	  by	  various	  
genetic	  mechanisms	  and	  a	  subset	  of	  cases	  is	  caused	  by	  mutations	  in	  the	  E3	  ligase	  E6-­‐AP	  
(UBE3A)(Malzac	  et	  al.,	  1998).	  Another	  mental	  retardation	  syndrome	  is	  caused	  by	  
mutations	  in	  the	  E3	  ligase	  HUWE1(Froyen	  et	  al.,	  2008;	  Parsons	  et	  al.,	  2009).	  Additionally,	  
pathogenic	  polyglutamine	  expansions	  in	  ATXN3,	  which	  encodes	  a	  protein	  ATAXIN	  that	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has	  deubiquitinase	  activity,	  causes	  autosomal	  dominant	  Spinocerebellar	  
Ataxia(Kawaguchi	  et	  al.,	  1994).	  It	  has	  also	  been	  suggested	  that	  pathogenic	  expansions	  in	  
the	  ATXN3	  gene	  may	  be	  associated	  with	  PD	  depending	  on	  ethnic	  background	  based	  on	  
one	  reported	  family	  of	  African	  descent(Gwinn-­‐Hardy	  et	  al.,	  2001).	  All	  this	  only	  illustrates	  
how	  important	  the	  ubiquitin	  system	  is	  and	  how	  fine	  a	  balance	  it	  keeps	  between	  health	  
and	  disease.	  
1.3 	  	  FBXO7	  
 Clinical	  spectrum	  of	  FBXO7	  associated	  PD	  1.3.1
Mutations	   in	   the	   FBXO7	   gene	   were	   first	   shown	   to	   cause	   an	   autosomal	   recessive	  
Parkinsonian-­‐Pyramidal	   syndrome	   with	   early	   onset	   in	   2008:	   Shojaee	   and	   colleagues	  
reported	  homozygeous	  FBXO7	  missense	  mutations	  (p.R378G)	  in	  a	  large	  consanguineous	  
family	  from	  Iran	  that	  cosegregated	  with	  the	  disease	  in	  11	  affected	  family	  members	  over	  
2	   generations(Shojaee	   et	   al.,	   2008).	   Subsequently,	   one	   Italian	   and	   one	   Dutch	   family	  
(each	  with	  2	  affected	  siblings)	  associated	  with	  homozygeous	  nonsense	  mutations	  in	  the	  
former	   (p.R498G)	   and	   compound	   heterozygeous	  mutations	   in	   the	   FBXO7	   gene	   in	   the	  
latter	  have	  been	  identified(p.T22M	  and	  IVS7+1g/t)(Di Fonzo	  et	  al.,	  2009).	  Additionally,	  
a	   family	   from	   Pakistan	   and	   one	   from	   southeast	   Turkey	   each	   with	   homozygeous	  
nonsense	  mutations	  (p.R498X)	  have	  been	  found(Paisan-Ruiz	  et	  al.,	  2010).	  Clinically,	  all	  
affected	   individuals	   from	   the	   Iranian	   index	   family	   presented	   with	   equinovarus	   foot	  
deformities	   since	   childhood.	   All	   exhibited	   pyramidal	   tract	   abnormalities	  mainly	   of	   the	  
lower	  limbs	  (or	  spastic	  paraparesis)	  including	  spacticity,	  brisk	  deep	  tendon	  reflexes,	  and	  
positive	  Babinski	  signs.	  No	  cerebellar	  nor	  supranuclear	  gaze	  abnormalities,	  as	  well	  as	  no	  
dementia	  were	  reported.	  Onset	  of	  the	  pyramidal	  symptoms	  was	  always	  before	  the	  third	  
decade	   of	   life.	   3	   of	   the	   10	   living	   affected	   family	   members	   developed	   extrapyramidal	  
Parkinsonian	  symptoms	  5-­‐20	  years	  after	   the	  appearance	  of	   the	  pyramidal	  signs.	  There	  
was	   sustained	   levodopa	   responsiveness	   over	   at	   least	   4	   years	   in	   the	   only	   patient	  with	  
extrapyramidal	   symptoms	   that	   was	   aminable	   for	   treatment.	   Structural	   imaging	   was	  
unremarkable	   in	   the	   3	   patients	   with	   Parkinsonism.	   All	   other	   family	  members	   did	   not	  
show	  any	   abnormal	   neurological	   signs	   or	   symptoms(Shojaee	   et	   al.,	   2008).	   The	   clinical	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description	   for	   2	   out	   of	   4	   affected	   sibelings	   from	   the	   Italian	   family	   (p.R498X)	   states	  
equinovarus	   foot	   deformities	   in	   one	   case	   and	   a	   combination	   of	   pyramidal	   and	  
parkinsonian	  features	  from	  the	  age	  of	  10	  in	  the	  sister	  and	  13	  from	  the	  brother	  onwards.	  
Additionally,	  there	  were	  dystonic	  symptoms,	  eye	  movement	  abnormalities	  and	  possibly	  
cerebellar	  signs.	  The	  2	  Dutch	  sibelings	  (compound	  heterozygous	  mutations)	  developed	  
symptoms	  at	  the	  age	  of	  18	  (sister)	  and	  19	  (brother).	  There	  was	  no	  dystonia,	  though.	  All	  
4	   patients	   reported	   by	   Di	   Fonzo	   and	   colleagues	   had	   in	   common	   that	   there	   was	   no	  
dementia	  and	  that	  structural	  imaging	  of	  the	  brain	  was	  unremarkable.	  A	  DaTSCAN-­‐Spect	  
(assessing	  biochemical	   integrity	  of	  presynaptic	  dopaminergic	  neurotransmitter	  system)	  
was	   performed	   only	   in	   1	   of	   the	   Dutch	   sibelings	   and	   was	   abnormal.	   There	   was	   also	  
levodopa	  responsiveness	  as	  well	  as	   levodopa-­‐induced	  side	  effects	  –	  dyskinesias,	  motor	  
fluctuations	  and	  behavioural	  disturbances	  –	  in	  all	  4	  patients(Di Fonzo	  et	  al.,	  2009).	  The	  
family	   from	  Pakistan	   (p.R498X)	   includes	  3	  affected	   individuals	  over	  3	  generations	  with	  
symptom	   onset	   between	   17	   and	   22	   years	   of	   age.	   They	   all	   display	   a	   combination	   of	  
pyramidal	   and	   parkinsonian	   signs	   and	   symptoms	   and	   have	   a	   marked	   response	   to	  
levodopa	   including	   the	   usual	   levodopa-­‐induced	   side	   effects.	   Additionally,	   there	   was	  
cognitive	  decline	  and	  some	  behavioural	  /	  psyichiatric	  deaftures	  in	  all	  3,	  dysarthria	  in	  all	  
3,	  cataracts	  in	  2,	  and	  cervical	  dystonia	  in	  1.	  Structural	  imaging	  of	  the	  brain	  was	  normal	  in	  
1	  and	  showed	  general	  atrophy	  in	  the	  other	  2.	  Symptom	  duration	  was	  about	  20	  years	  at	  
the	   time	   of	   the	   report.	   There	   was	   one	   affected	  member	   with	   homozygeous	   p.R498X	  
FBXO7	  mutations	   in	   the	  Turkish	   family.	  He	  developed	   symptoms	  at	   the	  age	  of	  17	  and	  
died	   10	   years	   later	   due	   to	   aspiration.	   He	   also	   had	   a	   combination	   of	   pyramidal	   and	  
parkinsonian	   signs,	   mild	   eye	   movement	   abnormalities	   and	   no	   cognitive	   symptoms.	  
Structural	   brain	   imaging	   was	   normal	   and	   there	   was	   leavodopa	   responsiveness	   and	  
induction	  of	  side	  effects(Paisan-Ruiz	  et	  al.,	  2010).	  	  
In	   summary,	   the	   core	   features	   of	   FBXO7	   associated	   disease	   are	   a	   combination	   of	  
progressive	   parkinsonism	   and	   pyramidal	   tract	   signs	   with	   early	   onset	   (range	   10	   to	   22	  
years	   of	   age).	   Additional	   features	   may	   include	   supranuclear	   eye	   movement	  
abnormalities,	   dystonia,	   cognitive	   decline,	   incontinence	   and	   dysarthria	   /	   dysphagia.	  
Generally,	  there	  is	  levodopa	  responsiveness	  and	  suseptability	  to	  levodopa-­‐induced	  side	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effects.	   Also	   structural	   imaging	   of	   the	   brain	   is	   normal	   or	   shows	   general	   atrophy.	  
Functional	   imaging	   suggests	   that	   there	   is	   a	   defect	   in	   the	   presynaptic	   dopaminergic	  
neurotransmitter	   system.	   To	   date,	   there	   is	   no	   autopsy	   report	   available	   as	   yet.	   Thus,	  
parkinsonism	   is	   cleary	   a	   core	   feature	   of	   FBXO7	   associated	   disease	   justifying	   it’s	  
designation	  as	  a	  PARK	  gene	  –	  but	  the	  associated	  phenotype	  is	  cleary	  more	  complex	  than	  
the	   pure	   Parkinsonism	   seen	   in	   other	   autosomal	   recessive	   PARK	   genes	   such	   as	   PINK1,	  
PARKIN	  or	  DJ-­‐1.	  	  
 FBXO7	   gene	   mutations	   in	   diease	   families	   and	   polymorphisms	   across	  1.3.2
populations	  
In	   the	   FBXO7	   index	   family	   the	   associated	   disease	  was	   first	   linked	   to	   chromosome	   22	  
before	  direct	  sequencing	  of	  candidate	  genes	  revealed	  mutations	   in	  FBXO7	  gene	  as	  the	  
culprit(Shojaee	  et	  al.,	  2008).	  The	  mutant	  allele	  (p.R378G)	  was	  not	  found	  in	  800	  control	  
individuals	  –	  600	  of	  them	  were	  unrelated	  healthy	  controls	  over	  the	  age	  of	  60	  and	  200	  
were	   unrelated	   Iranian	   PD	   patients(Shojaee	   et	   al.,	   2008).	   The	   truncating	   mutation	  
(p.R498X,	  c.C1492T)	  was	  not	  found	  in	  364	  chromosomes	  tested	  from	  the	  Italian	  general	  
population	  and	  of	  the	  2	  alterations	  that	  constitute	  the	  compound	  heterozygous	  FBXO7	  
mutation	   in	   the	  Dutch	   family,	   the	  splice	   site	  mutation	   IVS7+1G/T	  was	  not	   seen	   in	  300	  
and	   the	   c.C65T	   (P.T22M)	  was	  not	   found	   in	  348	   chromosomes	   from	   the	  general	  Dutch	  
population(Di	  Fonzo	  et	  al.,	  2009).	  	  More	  systematic	  screens	  have	  looked	  at	  populations	  
in	  China,	  Taiwan	  and	  the	  South	  of	  Spain(Gomez-­‐Garre	  et	  al.,	  2013;	  Lin	  et	  al.,	  2013;	  Luo	  
et	   al.,	   2010):	   none	  of	   the	   known	  disease	   causing	   Fbxo7	  mutations	  were	   found	   in	   135	  
Chinese	  early-­‐onset	   (<	  40	  years	  of	  age)	  PD	  patients	  and	  200	  controls,	  448	  PD	  patients	  
(mean	   age	   of	   symptom	   onset	   57.4	   years	   of	   age)	   and	   452	   age-­‐matched	   controls	   from	  
Taiwan,	  nor	  338	  PD	  patients	  and	  330	  unrelated	  controls	  from	  Southern	  Spain	  Table	  1-­‐2).	  
All	   together	   variants	   in	   the	   FBXO7	   gene	   in	   heterozygosis	   were	   only	   found	   in	   a	   small	  
proportion	  of	  subjects	  and	  probably	  don’t	  have	  a	  significant	  impact	  in	  the	  etiology	  of	  PD	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individuals	   Controls	  
Iranian	   family	  
(Shojaee	   et	   al.,	  
2008)	  
p.R378G	  /	  	  
missense	  mutation	   c.C1132G	   Hom	  
11	  in	  2	  
generations	   800	  
Dutch	   family	   (Di 
Fonzo	   et	   al.,	  
2009)	  
p.T22M	  /	  	  
missense	  mutation	  
(isoform	  1	  only)	  
c.C65T	   compound	  het	  
2	  in	  1	  
generation	   348	  
IVS7+1G/T	  /	  disrupts	  
mRNA	  splicing	  	   Splice	  site	  
compound	  
het	   	   300	  
Italian	   family	   (Di 
Fonzo	   et	   al.,	  
2009)	  
p.R498X	  /	  	  
nonsense	   c.C1492T	   hom	  
2	  in	  1	  
generation	   364	  
Turkish	   family	  
(Paisan-­‐Ruiz	   et	  
al.,	  2010)	  
p.R498X	  /	  	  
nonsense	   c.C1492T	   hom	  
1	  in	  1	  




p.R498X	  /	  	  
nonsense	   c.C1492T	   hom	  
3	  in	  3	  
generations	   N/A	  
Table	  1-­‐2	  Pathogenic	  FBXO7	  mutations	  
List	  of	  pathogenic	  FBXO7	  gene	  mutations	  that	  have	  been	  identified	  so	  far	  in	  a	  small	  number	  of	  families	  
from	  different	  ethnicities,	  associated	  amino	  acid	  change	  and	  number	  of	  affected	  individuals	  per	  family	  
and	  population	  matched	  controls.	  Mutations	  in	  FBXO7	  with	  reference	  to	  GenBank	  accession	  number	  
NP_036311.3	  [Homo	  sapiens].	  
 FBXO7:	  transcripts	  and	  protein	  1.3.3
1.3.3.1 FBXO7	  transcripts	  
The	  FBXO7	  gene	  is	  located	  on	  the	  long	  arm	  of	  chromosome	  22	  (22q12-­‐q13)	  where	  also	  
one	  of	  the	  other	  rare	  autosomal	  recessive	  PARK	  genes	  is	  located	  (PARK14/PLA2G6).	  It	  is	  
composed	   of	   9	   exons	   and	   spans	   a	   genomic	   region	   of	   about	   24	   kilobases.	   Alternative	  
splicing	   at	   the	  5’	   end	   is	   expected	   to	   yield	  3	   complete	  protein	   coding	   FBXO7	   isoforms,	  
which	  are	  annotated	  by	  NCBI:	  (NM_001033024.1,	  NM_001257990.1,	  NM_012179.3)(Di 
Fonzo	   et	   al.,	   2009).	   By	   convention,	   FBXO7	   gene	   variants	   and	   mutations	   are	   named	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after	  the	  longest	  mRNA	  transcript:	  isoform	  1(GenBank	  accession	  numbers	  NM_012179.3	  
for	   the	   transcript	   and	  NP_036311.3	   for	   the	   protein).	  One	   of	   the	   pathogenic	  missense	  
mutations	   (p.T22M)	  only	  affects	   the	   longer	   isoform	  1	  and	   leaves	  any	   shorter	   isoforms	  
unaltered.	  The	  splice	  site	  mutation	  (IVS7	  +	  1G/T)	  is	  expected	  to	  disrupt	  mRNA	  splicing	  as	  
it	  removes	  an	  invariable	  splicing	  donor	  of	  intron	  7(Di Fonzo	  et	  al.,	  2009).	  
 FBXO7	  belongs	  to	  the	  family	  of	  F-­‐box	  proteins	  1.3.4
FBXO7	  belongs	  to	  the	  family	  of	  F-­‐box	  proteins.	  F-­‐box	  proteins	  are	  characterized	  by	  the	  
presence	  of	  a	  F-­‐box	  domain,	  which	  mediates	  binding	  to	  SKP1	  and	  subsequent	  assembly	  
into	  Skp1-Cullin1-F-box-protein-Rbx1 (SCF) ubiquitin E3 ligase complexes(Zheng et al., 
2002). F-box proteins usually form the variable substrate recognizing subunit of SCF 
ubiquitin E3 ligases of the RING type (1.2.3.3) with the canonical outcome of ubiquitin-
mediated proteolysis(Ho et al., 2006; Skaar et al., 2013). However, functioning within the 
ubiquitin-proteasome-pathway is not a necessary or at least not exclusive function of F-
box proteins, and there are ample examples in the literature(Hermand, 2006; Jonkers 
and Rep, 2009; Nelson et al., 2013). F-box proteins are a divers group of proteins and 
can be further classified into 3 subfamilies depending on the presence of additional 
domains other than the F-box: FBXW with an additional WD40 domain, FBXL with a 
leucin-rich-repeat domain and F-box only proteins(FBXO)(Jin et al., 2004). More 
recently, it has become clear that some members of the FBXO family actually do have 
additional domains hence calling them ‘F-box proteins with other domains’ is more 
appropriate than ‘F-box only proteins ’(Skaar et al., 2013). In humans, there are about 70 
F-box proteins; 12 of them are members of the FBXW, 21 of the FBXL, and 36 of the 
FBXO family(Skaar et al., 2009a). However, if	   an	   F-­‐box	   protein	   functions	   as	   an	   E3	  
ubiquitin	   ligase,	   it	   requires	  assembly	   into	  an	  SCF	  complex	  as	   the	  substrate	  recognizing	  
subunit.	   It	   then	   plays	   its	   part	   in	   the concerted action of ubiquitin-activating (E1), 
ubiquitin-conjugating (E2) and ubiquitin-ligating (E3) enzymes with the outcome of 
ubiquitylation and subsequent proteasomal degradation of its substrates.  
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Figure	  7:	  The	  SCF	  E3	  ubiquitin	  ligase	  complex	  and	  proteasomal	  degradation	  
Cullin	  1	  (Cul1)	  serves	  as	  a	  scaffold	  bringing	  the	  E2	  conjugating	  enzyme	  via	  RBX1	  at	  its	  carboxy-­‐terminal	  
end	  in	  proximity	  to	  its	  target	  by	  recruiting	  the	  F-­‐box	  protein	  via	  SKP1	  to	  its	  amino-­‐terminal	  end.	  Substrate	  
specificity	  is	  hence	  dictated	  by	  the	  F-­‐box	  protein;	  and	  the	  modular	  assembly	  of	  SCF	  complexes	  allows	  
ubiquitinylation	  of	  many	  different	  substrates	  depending	  on	  which	  F-­‐box	  protein	  participates.	  The	  E2	  
transfers	  ubiquitin	  to	  the	  target	  for	  ubiquitin-­‐mediated	  degradation	  by	  the	  26S	  proteasome(Zheng	  et	  al.,	  
2002).	  	  
	  
1.3.4.1 Protein	  and	  domain	  architecture	  of	  FBXO7	  
There	  are	  at	  least	  3	  Fbxo7	  isoforms	  with	  differing	  N-­‐terminal	  domains	  and	  consisting	  of	  
between	  408	  and	  522	  AA(Di Fonzo	  et	  al.,	  2009).	  Only	  the	  longer	  isoform	  1	  contains	  an	  
additional	  N-­‐terminal	  Ubiquitin-­‐like	  domain	  (UBL;	  AA	  1-­‐78);	  otherwise	  there	  are	  the	  F-­‐
box	  domain	  for	  binding	  to	  SKP1	  (AA	  329-­‐379),	   the	  FBXO7	  and	  PI31	   interacting	  domain	  
(FP,	  AA	  180-­‐324),	   a	  Cdk6-­‐interacting	  motif,	   and	  a	  C-­‐terminal,	  most	   likely	  unstructured	  
proline-­‐rich-­‐region	   (PRR,	   AA	   423-­‐522),	   which	   are	   shared	   by	   all	   3	   isoforms	   (Figure	   8).	  
There	  is	  no	  structural	  information	  available	  on	  FBXO7	  as	  yet;	  the	  crystal	  structure	  of	  the	  
FP	  domain	  of	  PI31	  has	  been	  solved,	  and	  the	  corresponding	  FBXO7	  domain	  is	  on	  its	  way	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Figure	  8:	  The	  human	  FBXO7	  protein,	  domain	  arichtecture	  and	  pathogenic	  mutations	  
Schematic	  representation	  of	  the	  FBXO7	  transcripts	  (NM_001033024.1,	  NM_001257990.1,	  NM_012179.3)	  
with	  functional	  domains	  and	  position	  of	  all	  so	  far	  reported	  pathogenic	  FBXO7	  mutations.	  By	  convention,	  
FBXO7	  gene	  variants	  and	  mutations	  are	  named	  after	  the	  longest	  mRNA	  transcript:	  isoform	  1(GenBank	  
accession	  numbers	  NM_012179.3).	  UBL	  (Ubiquitin-­‐like	  domain,	  AA	  1-­‐78),	  FP	  (FBXO7	  and	  PI31	  interacting	  
domain,	  AA	  180-­‐324),	  F-­‐box	  (AA	  329-­‐379)	  and	  proline-­‐rich-­‐region	  (PRR,	  AA	  423-­‐522).	  	  
	  
 Putative	  function	  and	  reported	  interacting	  partners	  of	  FBXO7	  1.3.5
FBXO7	   was	   identified	   as	   a	   member	   of	   the	   F-­‐box	   protein	   family	   in	   the	   context	   of	  
systematic	  screening	  for	  other	  SKP1	  binding	  poteins	  after	  the	  initial	  discovery	  of	  the	  first	  
F-­‐box	   protein,	   cyclin	   F,	   in	   1999(Cenciarelli	   et	   al.,	   1999;	   Winston	   et	   al.,	   1999).	   While	  
FBXO7	  had	  been	  the	  subjects	  of	  only	  a	  few	  publications	  before	  its	  link	  to	  human	  disease	  
in	  2008	  /	  2009,	  this	  has	  changed	  in	  recent	  times,	  at	  least	  in	  terms	  of	  number	  of	  citations	  
and	  related	  publications.	  	  
1.3.5.1 FBXO7	  and	  its	  link	  to	  the	  ubiquitin-­‐proteasome	  system	  
The	   first	   reported	   substrate	   of	   FBXO7	   /	   SCFFbxo7	   was	   HURP	   (Hepatoma	   up-­‐regulated	  
protein)(Hsu	  et	  al.,	  2004).	  It	  was	  shown	  that	  HURP	  is	  a	  mitotic	  phophoprotein,	  which	  co-­‐
immunoprecipitates	   specifically	   with	   tagged	   FBXO7,	   but	   not	   with	   several	   other	   F-­‐box	  
proteins.	   Endogenous	   Cullin1	   and	   endogenous	   SKP1	   were	   also	   shown	   to	   co-­‐
immunopreicipitate	  with	  overexpressed	  FBXO7.	  The	  binding	  site	  for	  HURP	  was	  mapped	  
to	   the	   C-­‐terminal	   proline	   rich	   region	   of	   FBXO7	   and	   binding	   was	   dependent	   on	   HURP	  
phosphorylation	   as	   a	   phosphomutant,	   in	  which	   all	   9	   previously	  mapped	   cdk1-­‐cyclinB-­‐
mediated	   phosphosites	   of	   HURP	  were	  mutated	   to	   Alanine,	   abolished	   this	   interaction.	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Furthermore,	   HURP	   expression	   levels	   stabilized	   in	   the	   presence	   of	   proteasomal	  
inhibition	  and	  higher	  molecular	  weight	  species	  of	  tagged	  HURP	  co-­‐immunoprecipitated	  
with	   tagged	   Ubiquitin	   in	   Hek	   293	   cells.	   Also,	   knockdown	   of	   Fbxo7	   was	   suggested	   to	  
stabilize	  endogenous	  HURP.	   In	  summary,	  HURP	  was	  proposed	  to	  be	  the	  first	   identified	  
FBXO7	   substrate,	   which	   requires	   cdk1-­‐cyclinB-­‐mediated	   phosphorylation	   for	   its	  
recognition.	   It	   was	   initially	   identified	   as	   a	   putative	   oncogene	   in	   hepatocellular	  
carcinoma.	  Whether	   it	   is	   physiological	   substrate	   of	   FBXO7	   and	   its	   role	   –	   if	   at	   all	   –	   in	  
FBXO7	  mediated	  pathology	  is	  unknown.	  	  
FBXO7	  has	  further	  been	  suggested	  to	  be	  involved	  in	  the	  ubiquitinylation	  of	  the	  cellular	  
inhibitor	  of	  apoptosis	  (cIAP1)	  and	  TNF	  receptor	  associated	  factor	  2	  (TRAF2)(Kuiken	  et	  al.,	  
2012):	  First,	  FBXO7	  was	  identified	  as	  a	  negative	  regulator	  of	  NFκB	  signalling	  in	  a	  siRNA	  
screen	  amongst	  E3	  conjugating	  and	  deconjugating	  enzymes.	  This	  was	   linked	   to	  FBXO7	  
function	  within	  a	  SCFFBXO7	  E3	  ubiquitin	  complex	  as	  overexpression	  of	  the	  FBXO7	  wt,	  but	  
not	   a	   F-­‐box	   motif-­‐deficient	   mutant	   (predicted	   to	   disrupt	   SCF	   complex	   formation)	  
diminished	   the	   activity	   of	   a	   NFκB	   luciferase	   assay	   in	   U2OS	   cells.	   Subsequently,	   the	  
interaction	  between	  overexpressed	  FBXO7	  and	  either	  cIAP1	  or	  TRAF2	  was	  investigated	  
as	   both	   proteins	   associate	   with	   activated	   TNF-­‐α	   receptor	   1	   complex	   (TNFR1)	   -­‐	   cIAP1	  
being	   recruited	   via	   TRAF2	   -­‐	   and	   hence	   find	   there	   place	   in	   the	   complicated	   NFκB	  
signalling	  cascade(Wertz	  and	  Dixit,	  2010).	  Also,	  cIAP1	  had	  previously	  been	  reported	  to	  
interact	  with	  FBXO7	  in	  co-­‐expression	  experiments(Chang	  et	  al.,	  2006).	  It	  was	  shown	  that	  
co-­‐expressed	  FBXO7	  -­‐wt	  as	  well	  as	  mutant	  -­‐	  and	  cIAP1	  coimmunoprecipiate,	  but	  that	  the	  
wt	  associates	  with	  higher	  molecular	  weight,	  ubiquitin-­‐modfied	  species	  of	  cIAP1	  whereas	  
the	  mutant	  doesn’t.	  Similarly,	  overexpression	  experiments	  demonstrated	  an	  interaction	  
between	  TRAF	  2	  and	  the	  wt	  as	  well	  as	  the	  mutant	  FBXO7.	  When	  tagged	  TRAF2,	  ubiquitin	  
with	   either	   wt	   or	   mutant	   FBXO7	   were	   co-­‐transfected,	   an	   increase	   in	   TRAF2	  
ubiquitylation	   in	   the	  wt,	   but	  not	   the	  mutant	   FBXO7	  was	  demonstrated.	  Hence,	   it	  was	  
concluded	   that	   FBXO7	   ubiquitylates	   cIAP1	   and	   TRAF2.	   NFκB	   signalling	   is	   involved	   in	  
many	   pathologies	   and	   a	   link	   to	   FBXO7-­‐associated	   neurodegeneration	   is	   an	   intriguing	  
hypothesis	  warranting	  further	  investigation.	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1.3.5.2 Cyclin	  D	  and	  FBXO7:	  potential	  involvement	  in	  the	  cell	  cycle	  
The	   first	   physical	   interaction	   at	   endogenous	   levels	   was	   shown	   between	   FBXO7	   and	  
cyclin	   D	   in	   U2OS	   cells(Laman	   et	   al.,	   2005).	   It	   was	   also	   shown	   that	   coexpressed	   Flag-­‐
FBXO7	   and	   T7-­‐RBX1	   into	   U2Os	   cells	   interacted	   with	   each	   other	   and	   also	   with	  
endogenous	  Skp1	  in	  support	  of	  SCFFBXO7	  complex	  formation	  in	  vivo.	  FBXO7	  was	  thus	  seen	  
in	  the	  context	  of	  cell	  cycle	  regulation.	  The	  same	  authors	  further	  speculated	  that	  FBXO7	  
might	   have	   oncogenic	   potential.	   This	   was	   based	   on	   the	   observation	   that	   exogenous	  
overexpression	   of	   FBXO7	   in	   mouse	   fibroblasts	   was	   associated	   with	   cellular	  
transformation	   and	   tumour	   formation	   in	   nude	   mice,	   and	   also	   that	   certain	   tumour	  
biospsie	  of	  human	  lung	  and	  colon	  cancer	  were	  positive	  for	  FBXO7	  while	  it	  was	  absent	  in	  
corresponding	  normal	  tissues(Laman,	  2006; Laman	  et	  al.,	  2005).	  
1.3.5.3 FBXO7	  and	  PI31:	  proteasomal	  pathways	  
As	   a	  member	   of	   the	   F-­‐box	   family	   and	   supported	   by	   previous	   reports	   on	   its	   potential	  
involvement	   in	   ubiquitylation	   of	   other	   proteins,	   FBXO7	  may	   play	   a	   critical	   role	   in	   the	  
ubiquitin-­‐proteasome	   pathway.	   Further	   evidence	   that	   places	   FBXO7	   in	   the	   context	   of	  
proteasmal	   pathways	   comes	   from	   its	   domain	   architecture:	   the	  presence	  of	   a	   putative	  
UBL	  and	  FP	  domain.	  Isoform	  1	  of	  FBXO7	  has	  been	  suggested	  to	  contain	  a	  UBL	  domain,	  
although	  no	  function	  has	  been	  reported	  with	  it	  as	  yet.	  PI31	  on	  the	  other	  hand	  has	  been	  
found	  to	  share	  sequence	  homology	   in	  a	  region	  of	  about	  150	  AA	  with	  FBXO7	  with	  24%	  
identity	   and	   45%	   similarity	   (FBXO7:	   AA	   180-­‐324	   and	   PI31:	   AA	   1-­‐151).	   As	   this	   region	  
mediates	  binding	  between	  the	  2	  proteins,	  it	  has	  been	  termed	  FP	  domain	  (for	  FBXO7	  and	  
PI31	  dimerization	  domain).	   Its	  crystal	  structure	  has	  been	  solved	  for	  PI31	  and	  reveals	  a	  
globular	  domain	  with	  an	  unusal	  α/β fold(Kirk	  et	  al.,	  2008).	  What	  the	  in	  vivo	  function	  of	  
the	   interaction	   between	   FBXO7	   and	   PI31	   may	   be	   is	   unclear.	   However,	   studies	   in	  
Drosophila	   demonstrate	   a	   functional	   relationship	   of	   their	   orthologues	   DmNutcracker	  
and	  DmPI31	  in	  a	  proteasomal	  regulatory	  complex	  involved	  in	  non-­‐lethal	  caspase	  activity	  
in	   the	   final	   step	   of	   spermatogenesis,	   a	   cellular	   remodelling	   process	   that	   eliminates	  
excess	   organelles	   and	   cytoplasm(Bader	   et	   al.,	   2011).	   Binding	   via	   the	   FP	   domain	   was	  
conserved,	  and	  this	  interaction	  was	  indispensable	  for	  DmPI31	  stability:	  in	  the	  absence	  of	  
Nutcracker	  or	  a	  mutant	  deficient	  of	  binding,	  DmPI31	  levels	  were	  greatly	  reduced	  –	  the	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opposite	  of	  what	  one	  would	  expect	  if	  DmPI31	  was	  a	  substrate	  of	  SCFFBXO7	  proteasomal	  
degradation.	   Also,	   C-­‐terminal	   cleaved	   forms	   of	   DmPI31	   appeared	   in	   the	   Nutcracker	  
deficient	  and	  mutant	   forms.	  Ultimatively,	   the	  conclusion	  was	   that	  Nucracker	   functions	  
through	   DmPI31	   stabilization	   of	   especially	   the	   C-­‐terminal	   end	   of	   DmPI31	   to	   promote	  
caspase	  activation	  and	  sperm	  differentiation.	  Contrary	  to	  the	  original	  characterization	  of	  
PI31	  as	  a	  proteasomal	  inhibitor,	  DmPI31	  was	  found	  to	  have	  activating	  effects	  in	  vivo	  and	  
a	   C-­‐terminal	   HbYX	   motif	   was	   thought	   to	   be	   important	   in	   this	   context.	   This	   motif	  
resembles	   the	   proteasome-­‐interacting,	   gate-­‐opening	   domains	   of	   the	   proteasome-­‐
regulatory	   ATPases,	   which	   are	   proteasome	   activators.	   In	   DmPI31	   the	   HbYX	   motif	   is	  
located	   within	   in	   the	   C-­‐terminal	   end	   that	   is	   stabilizes	   via	   its	   interaction	   with	   FBXO7.	  
Understanding	   the	   FBXO7	   /	   PI31	   interaction	   as	   a	  mechanism	   to	   regulate	   proteasomal	  
activity	   is	   very	   interesting	   for	   formulating	   hypothesis	   of	   how	   FBXO7	  mutations	   cause	  
human	  pathology.	  Abnormal	  protein	  aggregation	  is	  a	  key	  feature	  of	  neurodegenerative	  
diseases	   including	   PD	   and	   the	   ubiquitin	   proteasome	   system	   has	   been	   implicated	   in	  
disease	   pathogenesis	   by	   failing	   to	   clear	   potentially	   neurotoxic	   molecules(Ebrahimi-­‐
Fakhari	  et	  al.,	  2012;	  Ross	  and	  Poirier,	  2004).	  
1.3.5.4 FBXO7	  and	  possible	  links	  to	  PD/PARK	  associated	  pathways	  in	  mitophay	  
So	  far	  the	  mitochondrial	  damage	  repair	  pathway	  has	  been	  implicated	  as	  a	  theme	  in	  the	  
pathogenesis	   of	   several	   monogenetic	   PD	   genes.	   In	   fact,	   there	   is	   now	   compelling	  
evidence	  that	  at	  least	  2	  of	  the	  autosomal	  recessive	  PD	  gene	  products	  –	  PINK1	  and	  PAKIN	  
-­‐	   act	   in	   the	   same	   pathway	   involved	   in	   mitochondrial	   quality	   control:	   In	   genetic	  
Drosophila	   models,	   DmPINK1	   as	   well	   as	   DmPARKIN	   knockout	   flies	   display	   similar	  
phenotypes	   with	   reduced	   longevity,	   degeneration	   within	   the	   dopaminergic	   system,	  
motor	  deficits,	  and	  male	  sterility	  as	  well	  as	  mitochondrial	  dysfunction	  in	  particular	  in	  the	  
former	  Clark,	  2006	  #160}(Park	  et	  al.,	  2006).	  Furthermore,	  the	  double-­‐knock	  out	  of	  both	  
genes	  presents	  with	  a	   very	   similar	  phenotype	  and	  overexpressing	  either	   fly	  or	  human	  
PARKIN	  was	  able	  to	  rescue	  the	  PINK	  null	  phenotype,	  but	  not	  vice	  versa	  and	  hence,	  that	  
both	  gene	  products	  act	   in	  series	  with	  PARKIN	  downstream	  of	  PINK1(Yang	  et	  al.,	  2006).	  
Further	   studies	   in	   mammalian	   cells	   have	   shown	   that	   PINK1	   senses	   depolarized	   /	  
damaged	  mitochondria,	  and	  recruits	  and	  activates	  PARKIN,	  which	  functions	  as	  a	  RING-­‐
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IBR-­‐RING	   E3	   ubiquitin	   ligase,	   to	   ubiquitinylate	   proteins	   in	   the	   outer	   mitochondrial	  
membrane(Chan	  et	  al.,	  2011;	  Chen	  and	  Dorn,	  2013;	  Narendra	  et	  al.,	  2010;	  Poole	  et	  al.,	  
2010;	  Sarraf	  et	  al.,	  2013;	  Seibler	  et	  al.,	  2011;	  Tanaka	  et	  al.,	  2010).	  The	  end	  result	  is	  then	  
selective	  autophagy	  of	  damaged	  mitochondria	  called	  mitophagy.	  	  
More	  recently,	  FBXO7	  has	  been	  implicated	  to	  interact	  with	  PARKIN	  as	  well	  as	  PINK1	  and	  
also	   be	   involved	   in	   mitophagy(Burchell	   et	   al.,	   2013).	   In	   analogy	   to	   the	   genetic	  
drosophila	  studies	  that	  eluded	  the	  functional	  dependency	  of	  PINK1	  and	  PARKIN,	  ectopic	  
expression	   of	   FBXO7	   was	   shown	   to	   be	   able	   to	   rescue	   the	   PARKIN	   locomotor	   and	  
mitochondrial	  phenotype.	  This	  was	  not	  achieved	  when	  any	  of	  the	  disease	  mutants	  was	  
expressed	   instead,	   possibly	   suggesting	   a	   pathomechanistic	   clue.	   As	   before	   shown	   by	  
Bader	  et	  al.	  knockdown	  of	  the	  FBXO7	  ortholog	  DmNutcracker	  resulted	  in	  male	  sterility	  
with	  no	  other	  overlap	  with	  the	  PD	  phenotypes	  of	  PINK1	  and	  PARK	  knockdown(Bader	  et	  
al.,	   2011),	  which	   could	   not	   be	   rescued	   by	   ectopic	   FBXO7	   expression	  which	   led	   to	   the	  
authors’	  conclusion	  that	  DmNutcracker	   is	  not	  a	  functional	  homolog	  of	  FBXO7(Burchell	  
et	  al.,	  2013).	  Furthermore	  a	  direct	  physical	  interaction	  between	  FBXO7	  and	  PARKIN	  was	  
demonstrated	   in	   coimmunoprecipitations	   assays	   in	   double	   overexpression	   cell	   culture	  
systems	   and	   also	   for	   endogenous	   FBXO7	  with	   overexpressed	   PARKIN	   in	  HEK293	   cells.	  
The	   site	   of	   interaction	   was	  mapped	   to	   the	   N-­‐terminal	   end	   of	   FBXO7	   (AA1-­‐88)	   which	  
includes	  its	  UBL	  domain	  and	  which	  is	  only	  present	  in	  the	  longer	  isoform	  1	  of	  FBXO7.	  	  
With	  regards	  to	  genetic	  Drosophila	  studies	  aiming	  to	  elucidate	  the	  interaction	  between	  
FBXO7	  and	  PINK1,	  it	  was	  shown	  that	  FBXO7	  was	  unable	  to	  rescue	  the	  PINK1	  knockdown	  
phenotype.	   However,	   the	   fact	   that	   FBXO7	   overexpression	   enhanced	   the	   “rough	   eye”	  
phenotype	  that	   is	  seen	  with	  PINK1	  overexpression	  was	  seen	  as	  a	  potential	  genetic	   link	  
between	   the	   2	   nonetheless.	   In	   fact,	   FBXO7	   overexpression	   was	   unable	   to	   rescue	   the	  
phenotype	  of	  the	  double	  knockout	  PINK1/PARKIN,	  which	  was	  interpretated	  that	  PINK1	  
activity	  was	  required	  for	  proper	  FBXO7	  functioning(Burchell	  et	  al.,	  2013).	  Please	  refer	  
to	   the	   schematics	   and	   table	   below	   for	   a	   summary	   of	   the	   insight	   into	   genetic	   links	  
between	  PINK1,	  PARKIN	  and	  FBXO7	  that	  has	  been	  gained	  from	  Drosophila	  melanogaster	  
studies	  (Figure	  10,	  Figure	  9,Table	  1-­‐2).	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PD	  locus	   Gene	   Inheritance	   Fly	  homolog	   Fly	  homolog	  	  
PARK2	   PARKIN	   AR	   DmPARKIN	  /	  CG10523	   42%	  	  identidity	  
50%	  similarity	  
PARK6	   PINK1	   AR	   DmPINK1	  /	  CG4523	   32%	  identity	  50%	  similarity	  
PARK15	   FBXO7	   AR	   Dmnutcracker*	  /	  CG10855 28%	  identity	  45%	  similarity	  
Table	  1-­‐3	  Drosophila	  homologs	  of	  the	  PARK	  genes	  PINK1,	  PARKIN	  and	  FBXO7	  
Fly	  homologs	  are	  referenced	  according	  to	  Flybase(Marygold	  et	  al.,	  2013).	  With	  regards	  to	  FBXO7	  (*),	  
DmNutcracker	  may	  not	  be	  a	  functional	  ortholog,	  as	  it	  does	  not	  cause	  a	  neurodegenerative	  /	  locomotor	  
phenotype	  as	  for	  example	  PINK1	  and	  PARKIN.	  Nutcracker	  and	  FBXO7	  share	  the	  F-­‐box	  and	  FP	  domain,	  but	  
Nutcracker	  lacks	  the	  C-­‐terminal	  Proline	  rich	  region	  of	  FBXO7.	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Figure	  9	  Genetic	  insights	  from	  Drosophila	  studies	  into	  PD	  pathways	  
Summary	  of	  the	  effects	  of	  genetype	  (gene	  knock-­‐out:	  red	  cross;	  or	  transgenic	  expression:	  coloured	  boxes)	  
on	  phenotype	  (wt:	  no	  difference	  to	  wildtype;	  red	  tick:	  abnormality	  present)	  in	  Drosophila	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Figure	  10	  Genetic	  drosophila	  model	  of	  PINK1,	  PARKIN	  and	  FBXO7	  interaction	  
PINK1	  and	  PARKIN	  loss	  of	  function	  mutations	  each	  cause	  a	  similar	  neurodegenerative	  phenotype.	  PARKIN	  
overexpression	  can	  rescue	  the	  PINK1	  phenotype,	  but	  not	  vice	  versa.	  FBXO7	  loss	  of	  function	  mutations	  do	  
not	  result	  in	  a	  neurodegenerative	  phenotype,	  but	  FBXO7	  overexpression	  rescues	  the	  PARKIN	  knockout	  
phenotype,	  but	  not	  the	  double	  knockout	  of	  PINK1	  and	  PARKIN	  together.	  
	  
2 Materials	  &	  Methods	  
2.1 Materials	  
 Commercial	  reagents	  2.1.1
Acetone,	   ethanol,	   formic	   acid,	   glycerol,	   glycine,	   4-­‐(2-­‐Hydroxyethyl)piperazine-­‐1-­‐
ethanesulfonic	   acid	   (Hepes),	   isopropanol,	   methanol,	   2-­‐mercaptoethanol,	  
orthophosphoric	   acid,	   potassium	   chloride,	   sodium	   chloride,	   sodium	  
ethylenediaminetetraacetic	   acid	   (EDTA),	   magnesium	   acetate,	   sodium	   ethylene	   glycol	  
tetraacetic	   acid	   (EGTA),	   sodium	   fluoride,	   sodium	   β-­‐glycerophosphate,	   sodium	  
orthovanadate,	  pentobarbital,	  puromycin,	  adenosine	  5’-­‐triphosphate	  sodium	  salt	  (ATP),	  
anti-­‐HA-­‐agarose,	   ammonium	   bicarbonate,	   ammonium	   persulphate	   (APS),	   ampicillin,	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doxorubicin,	   dimethyl	   pimelimidate	   (DMP),	   dimethyl	   sulphoxide	   (DMSO),	   hydrogen	  
peroxide,	   iodoacetamide,	  MISSION™	  shRNAs,	  phenylmethanesulphonylfluoride	  (PMSF),	  
Ponceau	   S,	   sodium	   dodecyl	   sulphate	   (SDS),	   sodium	   tetraborate,	   N,	   N,	   N’,	   N’-­‐
Tetramethylethylenediamine	   (TEMED),	   triethylammonium	   bicarbonate,	   Nonidet	   P40,	  
Triton-­‐X-­‐100	   and	   Tween-­‐20	   were	   from	   Sigma-­‐Aldrich	   (Poole,	   UK).	   	   Sucrose	   and	  
Tris(hydroxymethyl)methylamine	   (Tris)	   were	   from	   BDH	   (Lutterworth,	   UK).	   Cellophane	  
films,	  i-­‐Script	  Kit,	  SsoFast™	  EvaGreen®	  Supermix,	  polymerase	  chain	  reaction	  (PCR)	  plates	  
and	   Precision	   Plus	   protein	   markers	   were	   from	   BioRad	   (Herts,	   UK).	   3-­‐[(3-­‐
Cholamidopropyl)dimethylammonio]-­‐1-­‐propanesulfonate	  (CHAPS)	  was	  from	  Calbiochem	  
(Merck	   Biosciences,	   Nottingham,	   UK).	   Insulin-­‐like	   growth	   factor	   (IGF1)	   was	   from	   Cell	  
Signaling	  Technology	   (New	  England	  Biolabs,	  Herts,	  UK).	  Polybrene	  was	   from	  SantaCruz	  
Biotechnology	  (Heidelberg,	  Germany).	  Cell	  culture	  dishes	  and	  flasks,	  cryovials	  and	  Spin-­‐X	  
columns	  were	  from	  Corning	  (NY,	  USA).	  Cell	  scrapers	  were	  from	  Costar	  (Cambridge,	  USA).	  
40%	   (w/v)	   29:1	   Acrylamide:Bis-­‐Acrylamide	   solution	   was	   from	   Flowgen	   Bioscience	  
(Nottingham,	   UK).	   Protein	   A-­‐agarose,	   Protein	   G-­‐sepharose,	   Glutathione-­‐sepharose,	  
Enhanced	   chemiluminescence	   (ECL)	   kit,	   Hyperfilm	   MP,	   Protran	   nitrocellulose	  
membrane,	  P81	  paper,	  3mm	  chromatography	  paper	  and	  [γ32P]-­‐labelled	  ATP	  were	  from	  
GE	   Healthcare	   (Piscataway,	   USA).	   Cell	   dissociation	   buffer,	   Dulbecco’s	   modified	   eagle	  
medium	  (DMEM),	  RPMI-­‐1640	  medium,	  Phosphate	  buffered	  saline	  (PBS),	  Trypsin/EDTA,	  
L-­‐glutamine,	   Lipofectamine	   2000,	   non-­‐essential	   amino	   acids,	   sodium	   pyruvate,	  
antibiotic/antimycotic,	  NuPAGE	  Novex	  SDS	  Bis-­‐Tris	  gels,	  NuPAGE	  MOPS	  running	  buffer,	  
NuPAGE	  reducing	  agent,	  NuPAGE	  LDS	  sample	  buffer	  and	  primers	  were	  from	  Invitrogen	  
(Paisley,	   UK).	   Photographic	   developer	   (LX24)	   and	   liquid	   fixer	   (FX40)	  were	   from	   Kodak	  
(Liverpool,	  UK).	  X-­‐ray	  films	  were	  from	  Konica	  (Japan).	  Polyethylenimine	  (PEI)	  was	  from	  
Polysciences	   (Warrington,	   PA).	   Skimmed	   milk	   (Marvel)	   was	   from	   Premier	   Beverages	  
(Stafford,	  UK).	  Plasmid	  Maxiprep	  and	  RNeasy	  kits	  were	  from	  Qiagen	  Ltd	  (Crawley,	  UK).	  
Acetonitrile	   (HPLC	   grade)	   was	   from	   Rathburn	   Chemicals	   (Walkerburn,	   UK).	   Protease	  
inhibitor	   cocktail	   was	   from	   Roche	   (Lewes,	   UK).	   Horseradish	   peroxidase	   (HRP)-­‐	   and	  
Alexafluor-­‐conjugated	  secondary	  antibodies,	  Bradford	  reagent	  and	  Fetal	  Bovine	  Serum	  
(FBS)	  were	  from	  Thermo-­‐scientific	  (Essex,	  UK).	  CellTiter	  96®	  AQueous	  One	  Solution	  Cell	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Proliferation	   Assay	   (MTS)	   and	   trypsin	   (mass	   spectrometry	   grade)	  were	   from	   Promega	  
(Southhampton,	  UK).	  Matrigel™	  invasion	  chambers	  were	  from	  BD	  Biosciences	  #354483	  
(Oxford,	   UK).	   Reastain	   Quick-­‐Diff	   kit	   was	   from	   Reagena	   (Finland).	   InstantBlue	   protein	  
staining	  solution	  was	  from	  Expedeon	  (Harston,	  UK).	  
 Tissue	  culture	  reagents	  2.1.2
6 well plates, cell culture dishes and cryovials were from Corning Incorporated 
(NY, USA). Cell scrapers were from Costar (Cambridge, USA). Dulbecco’s 
modified eagle medium (DMEM), Opti-MEM reduced serum media, Foetal bovine 
serum (FBS), tissue culture grade Dulbecco’s phosphate buffered serum (PBS), 
Trypsin/EDTA solution, L-glutamine, non-essential amino acids, vitamins, sodium 
pyruvate and antibiotic/antimycotic were from GIBCO (Paisley, UK). 
Polyethylenimine (PEI) was from Polysciences (Warrington, PA). 
Penicillin/streptomycin solution, hygromycin, tetracycline, blasticidin, Zeocin, 
Lipfectamine 2000 were from Invitrogen. Dialysed Foetal Calf Serum (FCS) and 
DMEM w/o Arg, Lys and Met were from Biowest. Following unlabeled and 
isotopically labeled amino acids were purchased for SILAC experiments; L-
arginine and L-lysine (Sigma–Aldrich) for R0K0 (light); L-arginine-HCl (U-13C6) 
and L-lysine-2HCl (4,4,5,5,D4) for R6K4 (medium); and L-arginine-HCl (U-13C6, 
15N4) and 13C-Llysine-2HCl (U-13C6, 15N2) for R10K8 (heavy) (Cambridge 
Isotope Laboratory). Polybrene, puromycin, and the MISSION™shRNA and 
siRNA constructs were from Sigma-Aldrich. The following chemicals used to 
induce mitochondrial depolarization were purchased from SIGMA: Oligomycin, 
Antimycin, Valinomycin, FCCP, CCCP, Dopamine, 6-OHDA, MPP+Iodide, 
Rotenone, Ionomycin, 3-N- Propionic acid, L-BSO (L-Buthionine Sulfoxime), 
H202, Diamide, Doxorubicin. Phenformin (SIGMA) and Deferiprone (SIGMA). 
 In-­‐house	  reagents	  2.1.3
Luria	   Bertani	   (LB)	   broth	   and	   LB	   agar	   plates	   supplemented	   with	   200	  µg/mL	   ampicillin	  
were	   from	  media	   kitchen.	  Primers were synthesised by the University of Dundee 
oligonucleotide synthesis service. Bacterial culture medium Luria Bertani (LB) 
broth and LB agar plates were provided by the University of Dundee media 
kitchen facility. The Protein Production Team at Division of Signal Transduction 
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and Therapy (DSTT) expressed and purified all proteins used in any of the in 
vitro ubiquitinylation assays. 	  	  
 Antibodies	  2.1.4
In-­‐house	   antibodies	   (Table	   2-­‐1)were	   raised	   in	   sheep	   and	   affinity	   purified	   on	   the	  
appropriate	  antigen	  by	  the	  DSTT.	  In-­‐house	  antibodies	  were	  used	  at	  1	  µg/mL	  in	  5%	  (w/v)	  
skimmed	  milk	  in	  TBST.	  Commercial	  antibodies	  (Table	  2-­‐2)were	  used	  at	  1:1000	  dilutions.	  
The	  α-­‐UBC9	  antibody	  was	  a	  gift	  from	  Professor	  Ron	  Hay	  (University	  of	  Dundee).	  
Antibody	   Immunogen	   DU	   Sheep	  	   Bleed	  
FBXO7	   GST-­‐	  human	  full	  lenth	  FBXO7	  	   34108	   S916C	   3rd	  	  
FBXO7	   GST-­‐	  human	  full	  lenth	  FBXO7	  	   34108	   S038D	   3rd,	  4th	  
FBXO7	   GST-­‐	  mouse	  full	  lenth	  FBXO7	  	   34179	   S917D	   3rd	  	  
PI31	   GST-­‐	  human	  full	  length	  PI31	   34918	   S194D	   3rd	  
SKP1	  A	   GST	  –	  SKP11	   22343	   S408D	   2nd	  
RanBP2	   GST	  –	  RanBP2	  (2553-­‐2838)	   41169	   S363D	   3rd,	  4th	  
NogoB	   GST	  –	  human	  full	  length	  NogoB	   92	   S845A	   3rd	  
GFP	  tag	   GST	  –	  GFP	  (2-­‐238)	   1574	   S268B	   1st	  
Table	  2-­‐1:	  In	  house	  DSTT	  produced	  antibodies	  
Antibody	   Company	   Catalog	  #	   Host	   Dilution	  
Flag	   Sigma-­‐Aldrich	   F3165	   Rabbit	   1:1000	  	  
Rbx1	   Thermo	  Scientific	   RB-­‐069-­‐P1	   Rabbit	   1:1000	  
VDAC	   Cell	  Signaling	   D73D12	   Rabbit	   1:1000	  
SKP1	   Cell	  Signalling	   2156	   Rabbit	   1:1000	  
Cullin1	   Invitrogen	   	   Mouse	   1:1000	  
HURP	  DLG7	   New	  Balance	   NB	  110-­‐40572	   Mouse	   1:1000	  
Ubiquitin	   	   	   	   	  
Exportin	  1	  /	  CRM1	   Cell	  Signalling	   Sc-­‐74454	   Mouse	   1:1000	  
Neurabin	  2	   Santa	  Cruz	   Sc-­‐14774	   Goat	   1:1000	  
GAPDH	   CST	   2118	   Rabbit	   BSA	  
RanGAP1	   Epitomics	   2771-­‐1	   Rabbit	   1:1000	  
PI31	   Epitomics	   S0243	   Rabbit	   1:1000	  
CIAP1	   	   	   	   	  
Integrin	  beta	  5	   Cell	  Signalling	   csD24A5	   Rabbit	   1:1000	  
Sentrin	  specific	  protease	   Acris	   Ap06461PU-­‐N	   Rabbit	   1:1000	  
VEGRF1	   Abcam	   Ab32152	   Rabbit	   1:1000	  
Table	  2-­‐2:	  Commercial	  antibodies	  
Antibodies	  against	  Sumo1,	  Ubc9,	  were	  kindly	  provided	  by	  Professor	  Ron	  Hay,	  CLS,	  
 Plasmids	  2.1.5
Dr	  M.	  Deak,	  Dr.	  N.	  Wood,	  Mr	  T.	  Macartney,	  and	  Dr.	  S.	  Weidlich	  performed	  the	  cloning,	  
subcloning	  and	  mutagenesis	  of	  the	  constructs	  described	   in	  this	  thesis.	  Constructs	  used	  
are	  shown	  in	  Table	  (Table	  2-­‐3).	  All	  constructs	  encoded	  the	  human	  version	  of	  the	  gene.	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The	   mammalian	   expression	   vector,	   pEBG6P,	   was	   generated	   by	   Dr	  M.	   Deak.	   This	   is	   a	  
modified	  version	  of	  the	  pEBG2T	  vector	  (Sanchez	  et	  al.,	  1994)	  that	  allows	  the	  expression	  
of	   proteins	   with	   an	   N-­‐terminal	   GST	   tag	   followed	   by	   a	   PreScission	   cleavage	   site.	   A	  
mammalian	  expression	  vector	  under	  the	  control	  of	  the	  cytomegalovirus	  promoter	  called	  
pCMV5A	  was	  also	  utilised,	  encoding	  an	  N-­‐terminal	  hemagglutinin	   (HA)-­‐tag	   (Andersson	  
et	   al.,	   1989).	   For	   retroviral	   transduction	   of	   cells	   pBABE	   vector	   encoding	   puromycin	  
selectable	   marker	   was	   used.	   The	   pBABE	   vector	   is	   based	   on	   the	   Moloney	   murine	  
leukemia	  virus	  (MoLV)	  and	  the	  genes	  are	  expressed	  from	  the	  MoLV	  long	  terminal	  repeat	  
(LTR)	  (Morgenstern	  and	  Land,	  1990).	  	  
Protein	  expressed	   Vector	  expressed	   Clone	  
number	  
Flag-­‐Fbxo7	  wildtype	  (human)	   pcDNA5-­‐FRT/TO	   DU35005	  
Flag-­‐Fbxo7	  T22M	  (human)	   pcDNA5-­‐FRT/TO	   DU35006	  
Flag-­‐Fbxo7	  R378G	  (human)	   pcDNA5-­‐FRT/TO	   DU35007	  
Flag-­‐Fbxo7	  R498X	  (human)	   pcDNA5-­‐FRT/TO	   DU35008	  
Flag-­‐Fbxo7	  wildtype	  (mouse)	   pCMV5	   pEBG	  
Flag-­‐Fbxo7	  T22M	  (mouse)	   pCMV5	   pEBG	  
Flag-­‐Fbxo7	  R378G	  (mouse)	   pCMV5	   pEBG	  
Flag-­‐Fbxo7	  R498X	  (mouse)	   pCMV5	   pEBG	  
Flag-Fbxo7-wt	   pCMV5	   DU35005	  
Flag-Fbxo7-T22M	   pCMV5	   DU35006	  
Flag-Fbxo7-R378G	   pCMV5	   DU35007	  
Flag-Fbxo7-R498X	   pCMV5	   DU35008	  
Flag-Fbxo7-Δ329-375 (f-box)	   pCMV5	   DU38462	  
Flag-Fbxo7-P336/A	   pCMV5	   DU38516	  
Flag-Fbxo7-D348/A	   pCMV5	   DU38523	  
Flag-Fbxo7-D361/A	   pCMV5	   DU38527	  
Flag-Fbxo7-E338/A	   pCMV5	   DU38517	  
Flag-Fbxo7-I343/A	   pCMV5	   DU38519	  
Flag-Fbxo7-L335/A	   pCMV5	   DU38515	  
Flag-Fbxo7-L346/A pCMV5	   DU38521	  
Flag-Fbxo7-L347/A pCMV5	   DU38522	  
Flag-Fbxo7-L353/A pCMV5	   DU38525	  
Flag-Fbxo7-L355/A pCMV5	   DU38526 
Flag-Fbxo7-L370/A pCMV5	   DU38528 
Flag-Fbxo7-L371/A pCMV5	   DU38529 
Flag-Fbxo7-R342/A pCMV5	   DU38518 
Flag-Fbxo7-R345/A pCMV5	   DU38520 
Flag-Fbxo7-R350/A pCMV5	   DU38524 
Flag-Fbxo7-R373/A pCMV5	   DU38530 
Flag-Fbxo7-I343/A,L346/A, L347/A, V349A pCMV5	   DU37985 
Flag-Fbxo7-L332/A,L335/A,L337/A,L339A,L341/A pCMV5	   DU37984 
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Flag-Fbxo7-I343/A,L346/A, L347/A, V349A pcDNA5-­‐FRT/TO	   DU41285 
Flag-Fbxo7-L332/A,L335/A,L337/A,L339A,L341/A pcDNA5-­‐FRT/TO	   DU41284 
Flag-Fbxo7-I343/A, L346/A, L347/A, V349A-R378G pcDNA5-­‐FRT/TO	   DU41287 
Flag-Fbxo7-L332/A,L335/A, L337/A, L339A, L341/A-
R378G 
pcDNA5-­‐FRT/TO	   DU41286 
Table	  2-­‐3:	  List	  of	  constructs	  in	  mammalian	  expression	  vectors	  
Constructs	  refer	  to	  the	  human	  protein	  if	  not	  otherwise	  specified.	  
Recombinant	  Protein	  Expressed	   Vector	  	   Clone	  
number	  
DAC-­‐TEV	  human	  FBXO7-­‐wild-­‐type,	  human	  Skp1	  (untagged)	   pFBDM	   /	  
Baculovirus	  
DU23910	  
DAC-­‐TEV	  human	  FBXO7-­‐R378G,	  human	  Skp1	  (untagged)	   pFBDM	   /	  
Baculovirus	  
DU23909	  
DAC-­‐TEV	  human	  FBXO7-­‐R498X,	  human	  Skp1	  (untagged)	   pFBDM	   /	  
Baculovirus	  
DU24109	  
DAC-­‐(blunt)TEV-­‐human	  Cullin1,	  human	  Rbx1,	  human	  Skp1	  
	  
pFBDM	   /	  
Baculovirus	  
DU23403	  
DAC-­‐(blunt)TEV-­‐human	  Cullin1,	  human	  Rbx1,	   pFBDM	   /	  
Baculovirus	  
DU23290	  
Table	  2-­‐4:	  List	  of	  constructs	  for	  insect	  cell	  expression	  	  




pET28a	   DU23357	  
Human	  UBE1	  (N-­‐terminal	  6HIS)	   pFBHTb	   DU3026	  
Human	  UBE2R1	  (N-­‐terminal	  6HIS)	   pET28a	   DU4317	  
Table	  2-­‐5:	  List	  of	  constructs	  for	  bacterial	  expression	  	  
 Inhibitors	  /	  Treatments	  	  2.1.6
Inhibitors	   used	   in	   this	   thesis	   are	   shown	   in	   Table	   2.4.	   Compounds	   were	   dissolved	   in	  
DMSO	   and	   stored	   at	   -­‐80°C.	   MLN4924	   is	   a	   deneddylating	   agent	   of	   Cullins.	   Cullin	  
neddylation	   is	   required	   for	   SCF	   E3	   ubiquitin	   ligase	   activity	   and	   hence	   MLN4924	  
specifically	  inhibits	  E3ligases	  of	  the	  SCF	  type.	  Cullin	  1	  immunoblotting	  can	  be	  used	  as	  a	  
positive	  control	  as	  the	  neddylated	  form	  disappears	  upon	  MLN4924	  treatment.	  CCCP	   is	  
used	  to	  uncouple	  mitochondria.	  	  
Inhibitor	   Target	   Brutto	   Source	   Reference	  
MLN4924	   NEDD8-­‐E1	  activating	  enzyme	   C21H26ClN5O4S	   DSTT	   (Soucy	  et	  al.,	  2009)	  
CCCP	   	   	   	   	  
Table	  2-­‐6	  Inhibitors	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 Buffers	  2.1.7
Tris-­‐based	  CHAPS	  lysis	  buffer:	  CHAPS	  (0.3%	  [w/v]),	  50	  mM	  Tris-­‐HCl	  pH	  7.5,	  1	  mM	  EGTA,	  
1	  mM	  EDTA,	  1	  mM	  sodium	  orthovanadate,	  10	  mM	  sodium-­‐ß-­‐glycerophosphate,	  50	  mM	  
sodium	  fluoride,	  10	  mM	  sodium	  pyrophosphate,	  0.27	  M	  sucrose,	  0.15	  M	  NaCl,	  0.1%	  2-­‐
mercaptoethanol	   and	   either	   1	   mM	   benzamidine	   and	   0.1	   mM	  
phenylmethylsulphonylfluoride	   (PMSF)	   or	   complete	   protease	   inhibitor	   cocktail.	   For	  
some	   experiments	   when	   specifically	   indicated	   CHAPS	   was	   replaced	   by	   the	   harsher	  
detergent	  1%	  (v/v)	  Triton-­‐X100.	  
HEPES	  lysis	  buffer:	  (for	  ubiquitinylation	  assays)	  40	  mM	  Hepes	  pH	  7.5,	  1	  mM	  EDTA,	  0.3%	  
(w/v)	   CHAPS,	   0.5	  mM	   sodium	   orthovanadate,	   10	  mM	   sodium-­‐ß-­‐glycerophosphate,	   50	  
mM	  sodium	  fluoride,	  10	  mM	  sodium	  pyrophosphate,	  0.27	  M	  sucrose,	  0.12	  M	  NaCl	  and	  1	  
mM	  benzamidine	  and	  0.1	  mM	  PMSF.	  
Lysis	   buffer	   inhibits	   proteases,	   kinases,	   phosphatases	   and	   other	   divalent	   cation-­‐
dependent	  enzymes	  ensuring	  that	  the	  phosphorylation	  and	  expression	  levels	  of	  proteins	  
are	   fixed	   at	   the	   levels	   in	   which	   they	   are	   found	   in	   vivo.	   Benzamidine	   and	   PMSF	   or	  
complete	  protease	  inhibitor	  tablets	  prevent	  the	  action	  of	  metallo,	  aspartic,	  cysteine	  and	  
serine	  proteases.	  EDTA	  chelates	  Mg2+	  and	  EGTA	  chelates	  Ca2+.	  Sodium	  fluoride,	  sodium-­‐
ß-­‐glycerophosphate	   and	   sodium	   pyrophosphate	   are	   Ser/Thr	   phosphatase	   inhibitors.	  
Sodium	   orthovanadate	   is	   Tyr	   phosphatase	   inhibitor.	   Sodium	   orhovanadate	   was	  
prepared,	  as	  recommended	  by	  manufacturer,	  by	  repeated	  rounds	  of	  boiling	  and	  cooling	  
until	  the	  solution	  was	  colourless	  at	  pH10	  at	  room	  temperature	  to	  ensure	  that	  it	  is	  in	  the	  
monomeric	  state	  that	  favours	  Tyr	  phosphatase	  inhibition.	  
Buffer	  A:	  50	  mM	  Tris-­‐HCl	  pH	  7.5,	  0.1	  mM	  EGTA,	  and	  0.1%	  2-­‐mercaptoethanol	  
Hepes	  kinase	  buffer:	  (for	  mTOR	  kinase	  assays)	  25	  mM	  Hepes	  pH	  7.5,	  50	  mM	  KCl	  
Tris	  buffered	  saline	  (TBS):	  50	  mM	  Tris-­‐HCl	  pH	  7.5,	  0.15	  M	  NaCl	  
5x	   sodium	   dodecyl	   sulfate	   (SDS)	   sample	   buffer:	   5%	   (w/v)	   SDS,	   5%	   (v/v)	   2-­‐
mercaptoethanol,	  250	  mM	  Tris-­‐HCl	  pH	  6.8,	  32.5%	  (v/v)	  Glycerol,	  bromophenol	  blue	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Tris-­‐glycine	  SDS	  running	  buffer:	  25mM	  Tris-­‐HCl	  pH	  8.3,	  192mM	  Glycine,	  0.1%	  (w/v)	  SDS	  
Tris-­‐glycine	  transfer	  buffer:	  48mM	  Tris-­‐HCl,	  39mM	  Glycine,	  20%	  (v/v)	  Methanol	  
 Cell	  lines	  2.1.8
Human	  heterozygeous	  and	  homozygeous,	  patient	  derived	  FBXO7	  R378G	  fibroblasts	  and	  
FBXO7	   R498X	   lymphoblasts	   were	   kindly	   provided	   by	   Professor	   Henry	   Houlden,	   UCL	  
London.	   All	   other	   cell	   lines	   were	   supplied	   by	   the	   MRC	   Protein	   Phosphorylation	   and	  
Ubiquitylation	  Unit	  (University	  of	  Dundee).	  	  
 Animals	  2.1.9
Mice	   obtained	   from	   Taconic-­‐Artemis	   (Cologne,	   Germany)	   were	   maintained	   under	  
specific	  pathogen-­‐free	  conditions	  and	  routine	  animal	  tail	  and	  ear	  notching	  was	  carried	  
out	  by	  staff	  in	  the	  College	  of	  Life	  Science	  Transgenic	  Unit	  (University	  of	  Dundee).	  Mrs	  G.	  
Fraser	  and	  Mrs	  E.	  Forsyth	  carried	  out	  genotyping	  from	  tail	  biopsies.	  All	  procedures	  were	  
carried	  out	  in	  accordance	  with	  the	  regulations	  set	  by	  the	  University	  of	  Dundee	  and	  the	  
United	  Kingdom	  Home	  Office.	  
 	  Instruments	  2.1.10
Centrifuge	   tubes,	   rotors	  and	  centrifuges	  were	   from	  Beckmann	   (Palo	  Alto,	  USA).	  Trans-­‐
Blot	  Cells,	  iQ5	  real	  time	  PCR	  detection	  system	  and	  gel	  dryer	  apparatus	  were	  from	  BioRad	  
(Herts,	  UK).	  SpeedVac	  was	  from	  CHRIST	  (Osterode,	  Germany).	  Thermomixer	   IP	  shakers	  
were	  from	  Eppendorf	  (Cambridge,	  UK).	  The	  Biofuge	  microcentrifuge	  was	  from	  Haraeus	  
Instruments	   (Osterode,	  Germany).	   pH	  meters	  were	   from	  Horiba	   (Kyoto,	   Japan).	   X-­‐Cell	  
SureLock	   Mini-­‐cell	   electrophoresis	   systems	   and	   X-­‐Cell	   II	   Blot	   modules	   were	   from	  
Invitrogen	   (Paisley,	   UK).	   Polytron	  was	   from	   Kinematica	   (Brinkmann,	   CT,	   USA).	   X-­‐omat	  
autoradiography	  cassettes	  were	  from	  Kodak	  (Liverpool,	  UK).	  The	  Konica	  automatic	  film	  
processor	   was	   from	   Konica	   Corporation	   (Japan).	   Li-­‐Cor	   OdysseyTM	   Infrared	   Imaging	  
System	  was	  from	  Li-­‐Cor	  Biosciences	  (Cambridge,	  UK).	  CO2	  incubators	  were	  from	  Mackay	  
and	   Lynn	   (Dundee,	   UK).	   Tissue	   culture	   class	   II	   safety	   cabinets	   were	   from	  Medical	   Air	  
Technology	  (Oldham,	  UK).	  The	  PCR	  thermocycler	  (PTC-­‐200)	  was	  from	  MJ	  Research.	  The	  
96-­‐well	  Versamax	  plate	  reader	  was	  from	  Molecular	  Devices	  (Wokingham,	  UK).	  Proxeon	  
EasynLC	   chromatography	   system,	   LTQ-­‐Orbitrap	   Classic	   mass	   spectrometer	   and	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Nanodrop	  were	  from	  Thermo	  Scientific	  (Essex,	  UK).	  Scintillation	  counter	  (Tri-­‐Carb	  2800	  
TR)	  was	  from	  Perkin-­‐Elmer.	  	  
2.2 	  Methods	  
 Transformation	  of	  chemically	  competent	  Escherichia	  coli	  (E.coli)	  2.2.1
Calcium	   competent	  E.coli	   DH5α	   (Inoue	   et	   al.,	   1990)	   cells	  were	   provided	   by	   the	  DSTT.	  
Approximately	  10-­‐50	  ng	  DNA	  was	  added	  to	  50	  µl	  of	  competent	  cells	  and	  incubated	  on	  
ice	  for	  5	  min.	  Cells	  were	  then	  subjected	  to	  heat	  shock	  at	  42°C	  water	  bath	  for	  90	  seconds	  
to	  induce	  the	  uptake	  of	  DNA	  and	  briefly	  placed	  back	  on	  ice.	  Cells	  were	  streaked	  onto	  LB	  
agar	  plates	  containing	  200	  µg/mL	  ampicillin	  and	  plates	  incubated	  at	  37°C	  overnight.	  
 Purification	  of	  plasmids	  from	  E.coli	  2.2.2
Transformed	  DH5α	  E.coli	  were	  cultured	  in	  200	  mL	  LB	  containing	  200	  µg/mL	  ampicillin	  at	  
37°C	  while	  shaking	  at	  200	  rpm	  overnight.	  Cells	  were	  pelleted	  by	  centrifugation	  at	  6000	  g	  
for	   15	   min	   at	   4°C.	   Plasmid	   DNA	   was	   purified	   using	   the	   Qiagen	   plasmid	  Maxiprep	   kit	  
according	  to	  the	  manufacturer’s	  instructions.	  	  
 Measurement	  of	  DNA	  and	  RNA	  concentration	  2.2.3
DNA	   and	   RNA	   concentrations	   were	  measured	   using	   NanoDrop	   as	   per	  manufacturer’s	  
instructions.	  RNA	  and	  DNA	  absorb	  at	  260	  nM.	  Absorbance	  was	  also	  measured	  at	  280	  nM	  
because	  calculation	  of	  260/280	  ratio	  allows	  estimation	  of	  purity.	  Ratios	  of	  greater	  than	  
1.8	  are	  accepted	  as	  pure.	  Lower	  ratios	  may	  indicate	  the	  presence	  of	  phenol,	  protein	  or	  
other	  contaminants.	  
 DNA	  mutagenesis	  2.2.4
Site-­‐directed	  mutagenesis	  was	   performed	   using	  QuikChange	   kit	   (Stratagene)	   and	   KOD	  
polymerase	  (Novagen).	  Mutations	  were	  verified	  by	  sequencing.	  
 DNA	  sequencing	  2.2.5
Sequencing	  was	  performed	  by	  DNA	  Sequencing	  and	  Services	  (www.dnaseq.co.uk)	  using	  
Applied	   Biosystems	   Big-­‐Dye	   v.	   3.1	   chemistry	   on	   an	   Applied	   Biosystems	   model	   3730	  
automated	  capillary	  DNA	  sequencer.	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 Cell	  culture	  2.2.6
All	  procedures	  were	  carried	  out	  in	  aseptic	  conditions	  meeting	  biological	  safety	  category	  
2	  regulations.	  Cells	  were	  maintained	  at	  37°C	  in	  a	  5%	  CO2	  water	  saturated	  incubator.	  For	  
the	   passaging	   of	   cells,	   cells	   were	   washed	   with	   PBS	   and	   then	   incubated	   with	  
Trypsin/EDTA	   to	   detach	   the	   cells.	   Detached	   cells	   were	   resuspended	   in	   cell	   culture	  
medium	  and	  split	  at	  a	  1:2	  –	  1:20	  ratios	  for	  continued	  culture.	  	  All	  breast	  cancer	  cell	  lines	  
were	  cultured	  in	  RPMI-­‐1640	  and	  human	  embryonic	  kidney	  293	  (HEK293),	  HeLa	  and	  MEF	  
cells	   in	   Dulbecco’s	   modified	   eagle	   medium	   (DMEM).	   All	   cell	   lines	   were	   grown	   in	   the	  
presence	  of	  10%	  (v/v)	  foetal	  bovine	  serum	  (FBS),	  2	  mM	  L-­‐glutamine,	  100	  U/mL	  penicillin	  
and	   0.1	  mg/mL	   streptomycin.	   For	   primary	  MEF	   culture	  medium	  was	   additionally	   also	  
supplemented	  with	  1x	  non-­‐essential	  amino	  acids	  and	  1	  mM	  sodium	  pyruvate.	  
 Freezing	  /	  thawing	  cells	  2.2.7
Detached	   cells	   were	   centrifuges	   at	   1000	   rpm	   for	   5	   min	   and	   resuspended	   in	   growth	  
medium	  supplemented	  with	  10%	  DMSO.	  1	  mL	  aliquots	  were	  stored	  in	  cryovials	  at	  -­‐80°C	  
prior	   to	   long-­‐term	  storage	   in	   liquid	  nitrogen.	  Cells	  were	   thawed	   in	  a	  37°C	  water	  bath,	  
resuspended	   in	   growth	   medium	   and	   allowed	   to	   adhere	   overnight	   prior	   to	   medium	  
change.	  
 Transfection	  of	  cells	  using	  polyethylenimine	  (PEI)	  2.2.8
Cells	  were	  transiently	  transfected	  using	  the	  polyethylenimine	  (PEI)	  method	  (Durocher	  et	  
al.,	  2002).	  1	  mg/mL	  PEI	  stock	  was	  prepared	  in	  20	  mM	  Hepes	  (pH	  7).	  For	  transfection	  of	  
cells	  grown	  on	  10	  cm	  dishes,	  5	  µg	  of	  DNA	  was	  mixed	  with	  20	  µL	  1mg/mL	  PEI	  and	  1	  mL	  
serum-­‐free	  DMEM	  and	  left	  for	  15	  min	  at	  room	  temperature	  before	  being	  added	  to	  cells.	  
Cells	  were	  harvested	  36	  hrs	  post	  transfection.	  
 Generation	  of	  stable	  cell	  lines	  2.2.9
To ensure low-level uniform expression of recombinant proteins, manufacturer's 
instructions (Invitrogen) were followed to generate stable cell lines that express 
FLAG-tagged forms of proteins (cDNA subcloned into pcDNA5-FRT-TO plasmid) 
in a tetracycline inducible manner. Flp-In T-REx-293 host cells containing 
integrated FRT recombination site sequences and Tet repressor, were co-
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transfected with 9 µg of pOG44 plasmid (which constitutively expresses the Flp 
recombinase), and 1 µg of pcDNA5/FRT/TO vector containing a hygromycin 
resistance gene for selection of the gene of interest with FLAG tag under the 
control of a tetracycline-regulated promoter. Cells were selected for hygromycin 
and blasticidin resistance three days after transfection by adding new medium 
containing hygromycin (100 µg/ml) and blasticidin (7.5 µg/ml). After 3 weeks of 
selection, colonies were trypsinized and expanded. Expression of the 
recombinant protein was induced with 0.1 µg/ml of tetracycline for 24 hours. 
 	  Treatment	  of	  cells	  with	  inhibitors	  and	  other	  agents	  2.2.10
Cells	  were	  treated	  with	  10 µM CCCP or DMSO control for 4 hr (or other time point 
if otherwise indicated) before whole cell lysis. Alternatively, cells were treated 
with the Cullin-deneddylation agent MLN4926 at a concentration of 3uM for 4 
hours and DMSO as a control. 	  
 	  SILAC	  (Stable	  isotope	  labelling	  of	  amino	  acids	  in	  cell	  culture)	  2.2.11
SILAC DMEM (high glucose without NaHCO3, L-glutamine, arginine, lysine and 
methionine; Biosera #A0347) was supplemented with methionine, glutamine, 
NaHCO3, 10 % dialysed FBS (Hyclone) and the following combinations of 
unlabeled and isotopically-labeled arginine (84 µg/ml) and lysine (146 µg/ml): L-
arginine and L-lysine (Sigma–Aldrich) for R0K0 (light); L-arginine-HCl (U-13C6) 
and L-lysine-2HCl (4,4,5,5,D4) for R6K4 (medium); and L-arginine-HCl (U-13C6, 
15N4) and 13C-Llysine-2HCl (U-13C6, 15N2) for R10K8 (heavy). The SILAC 
medium was filtered through a 0.22-µm filter and cells cultured for five passages 
in these media for maximum incorporation of labeled amino acids. Labelling 
efficacy was tested by mass-spectrometry. 
 	  Cell	  /	  tissue	  lysis	  and	  mitochondrial	  fractionation	  of	  cell	  lysates	  2.2.12
Cells were lysed using mammalian cell lysis buffer as listed in 2.1.7. Lysates 
were clarified by centrifugation at 13,000 rpm for 10 min at 4 °C and the 
supernatant was collected. For mitochondrial fractionation, cells were lysed in 
mitochondrial fractionation buffer (refer to Table 2.5) at 4 °C. Cells were 
disrupted using a glass hand held homogeniser (20 passes) and lysates clarified 
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by centrifugation for 10 min at 800g at 4°C. The supernatant was removed and 
further centrifuged at 16,600g for 10min. The resultant supernatant was retained 
as the cytosolic fraction. The pellet containing the mitochondrial fraction was 
resuspended in buffer containing 1% Triton X-100 and centrifuged at 13,000 rpm 
for 10 min. This final supernatant contained solubilized mitochondrial proteins. All 
lysates were snap-frozen at -80°C until use. Lysates intended for mass 
spectrometry analysis were processed immediately without snap freezing to 
avoid possible protein complex disruption. 
 	  Quantification	  of	  protein	  concentration	  with	  Bradford	  assay	  2.2.13
The	  protein	  concentration	  of	  lysates	  was	  estimated	  using	  the	  Bradford	  assay	  {Bradford,	  
1976	   #90).	   Binding	   of	   coomassie	   dye	   to	   protein	   in	   an	   acidic	   medium	   shifts	   the	  
absorption	  maximum	  from	  465	  to	  595	  nm.	  A	  standard	  curve	  was	  generated	  by	  plotting	  
absorbance	   against	   BSA	   standards.	   Lysate	   samples	   diluted	   in	   water	   were	   assayed	   in	  
triplicates	  using	  200	  µL	  of	  Bradford	  reagent	  per	  sample	  and	  absorbance	  at	  595	  nM	  was	  
measured.	  Sample	  concentrations	  were	  calculated	  using	  the	  standard	  curve.	  
 	  Purification	  of	  recombinant	  proteins	  2.2.14
Baculovirus / insect cell expression was used to generate sufficient SCFFBXO7 
components for biochemical assays. Another advantage is thatthis system 
allowed simultaneous expression of up to 3 proteins. Baculoviruses containing 
the open reading frames of the respective constructs with or without tags (Table	  
2-­‐4) were transformed into DH10Bac cells and grown under antibiotic selection 
on plates containing X-gal. White clones, which indicated that bacmids had 
formed, were picked and after a second round of selection were used to prepare 
bacmid DNA. Bacmid DNA was transfected into Sf21 cells using Cellfection II 
(Invitrogen), and the transfection was left for a week to prepare a P0 virus. The 
cells and the medium were harvested and separated by centrifugation. The 
medium was used to infect fresh Sf21 cells at a dilution of 1:50. After several 
dayS (4-5), the cells were collected and used for protein purification. The medium 
was kept and used as a P1 virus stock. For purification of DAC tagged proteins, 
ampicillin sepharose had to be prepared: Ampicillin Sepharose was prepared by 
coupling ampicillin (o.2 M fc) to NHS-activated sepharose. Briefly, NHS-activated 
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Sepharose was washed in 1 mM HCl. The Sepharose was equilibrated in 0.1 M 
NaHCO3, mixed with an equal volume of 0.4 M ampicillin in 0.1 M 
NaHCO3 (pH 7.5), and incubated for 4 h at 22 °C. The unbound ampicillin was 
washed away with 20 volumes of 0.1 M Tris–HCl (pH 7.5). The Sepharose was 
washed with 20 volumes of 20% EtOH and stored at 4 °C in 20% EtOH. 
Ampicillin Sepharose stored at 4 °C in 20% EtOH is stable for at least 6 months. 
Prior to use, ampicillin Sepharose was washed three times with 10 volumes of 
H2O. Cell extracts were diluted to 2 to 4 mg/ml. The cell extract was brought to 
ambient temperature (20–23 °C) and added to the ampicillin Sepharose. The 
extract was mixed for 50 min with ampicillin Sepharose at ambient temperature in 
a tube roller. The Sepharose was sedimented by centrifugation and washed three 
to five times with wash buffer (40 mM Tris–HCl [pH 7.5], 150 mM NaCl, and 
0.03% Brij-35) at ambient temperature. Small sediments (<50 μl) in 1.5-ml 
reaction tubes were washed four times with 1 ml of buffer. Larger sediments were 
washed in 15-ml centrifuge tubes. The total washing time did not exceed 15 min 
in order to minimize losses. Proteins were released by allowing the β-lactamase 
activity of PBP5 to cleave the bond with ampicillin under conditions where PBP5 
cannot easily bind to another immobilized ampicillin. This was achieved by either 
competing with mobile ampicillin or cooling the sample on ice. Any release or 
elution buffer contained 100 mM NaCl, a mild detergent, and 5% glycerol (e.g., 
40 mM Tris–HCl [pH 7.5], 0.1 M NaCl, 0.03% Brij-35, and 5% glycerol). After 
elution or release, the proteins were analyzed by SDS–PAGE. Proteins were 
stained for 1 h with Instant Blue (Expedeon), followed by washing in water{Lee, 
2012 #389}. Proteins were dialysed overnight at 4 °C into storage buffer, snap-
frozen and stored at -80°C until use. His-PI31, His-UBE1 and His-UBE2R1 were 
purified as follows: transformed BL21 cells were grown in LB (Luria Broth), 50 
µg/ml carbenicillin until OD600 of 0.6, then induced with 300 mM IPTG (isopropyl 
β-D-1-thiogalactopyranoside) and expressed overnight at 15 °C. Cells were 
collected, lysed and protein purified using Ni2+ -nitriloacetic acid- Sepharose 
chromatography, followed by dialysis into 50 mM HEPES pH 7.5, 10% glycerol, 
150 mM NaCl, 1 mM DTT).  
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 Covalent	  coupling	  of	  antibodies	  2.2.15
For	  the	  coupling	  of	  antibodies,	  protein	  G-­‐sepharose	  and	  protein	  A-­‐agarose	  beads	  were	  
used.	  Protein	  G,	  isolated	  from	  Group	  G	  Streptococci,	  binds	  to	  the	  Fc	  region	  of	  IgG-­‐class	  
antibodies	   and	  has	   a	  high	   affinity	   for	   antibodies	   generated	   in	  many	   species,	   including	  
sheep.	  Protein	  A,	  which	  originates	   from	  Staphylococcus	  aureus,	  also	  binds	  Fc	   region	  of	  
IgG-­‐class	   antibodies,	   particularly	   those	   generated	   in	   rabbit.	   Covalent	   coupling	   of	  
antibodies	   was	   carried	   out	   using	   dimethyl	   pimelimidate	   (DMP),	   a	   homo-­‐bifunctional	  
imidoester	   that	   reacts	   with	   primary	   amine	   groups,	   as	   the	   cross-­‐linker	   {Harlow,	   2006	  
#718}.	  Protein	  A-­‐	  or	  G-­‐beads	  were	  washed	  in	  PBS	  followed	  by	  incubation	  of	  1	  µL	  or	  resin	  
per	  1	  µg	  of	  antibody	  for	  1-­‐2	  hrs	  at	  4°C.	  Beads	  were	  then	  washed	  twice	  with	  PBS	  followed	  
by	  three	  washes	  with	  0.1	  M	  sodium	  tetraborate	  pH	  9.3.	  Beads	  were	  then	  mixed	  twice	  
for	  30	  min	  in	  sodium	  tetraborate	  containing	  20	  mM	  DMP	  at	  room	  temperature	  followed	  
by	   four	   washes	   with	   50	   mM	   glycine	   pH	   2.5	   to	   remove	   any	   non-­‐covalently	   coupled	  
antibody	  and	  two	  washes	  with	  0.2	  M	  Tris-­‐HCl	  pH	  8.	  Beads	  were	  mixed	  with	  0.2	  M	  Tris-­‐
HCl	  pH	  8	  at	  4°C	  overnight	  to	  quench	  any	  residual	  DMP,	  before	  storage	  in	  PBS	  at	  4°C.	  	  
 	  Anti-­‐diglycine	  remnant	  antibody	  (K-­‐ε-­‐GG)	  Enrichment	  	  2.2.16
Cells	   were	   washed	   with	   PBS	   prior	   to	   harvesting	   and	   lysed	   at	   4	   degrees	   Celcius	   in	  
denaturing	  conditions	  (8M	  Urea).	  Following	  lysis,	  cells	  were	  cen-­‐	  trifuged	  at	  20,000	  x	  g	  
for	  15	  min	  at	  4°C	  to	  remove	  insoluble	  material.	  A	  total	  of	  14	  mg	  of	  protein	  lysates	  (7	  mg	  
of	   the	   SILAC	   light	   labled	   Fbxo7	   wt	   MEFs	   and	   7	   mg	   of	   the	   SILAC	   heavy	   labled	   Fbxo7	  
R378G	   MEFs)	   were	   reduced	   with	   5	   mM	   dithiothreitol	   (DTT)	   for	   45	   min	   at	   room	  
temperature.	  And	  subsequently	  carbamidomethylated	  using	  10	  mM	  iodoacetamide	  for	  
30	  min	  at	  room	  temperature	   in	  the	  dark.	  Lysates	  were	  then	  diluted	  4-­‐fold	  to	  2M	  Urea	  
with	   50	   mM	   Tris-­‐HCL,	   pH	   7.5,	   and	   digested	   overnight	   at	   37	   degrees Celcius with 
sequencing grade trypsin (Promega) at an enzyme to substrate ratio of 1:50. 
Following digestion, samples were acidified with formic acid and desalted using 
500mg tC18 Sep-Pak SPE catridge (Waters). C18 catriges were conditions with 
5ml of 100% MeCN, followed by ollowed by 5 ml of 50% MeCN, 0.1% FA, and 
finally 20 ml of 0.1% trifluoroacetic acid (TFA). Sample was loaded onto the 
conditioned C18 cartridge, washed with 15 ml of 0.1% TFA, and eluted with 6 
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ml of 50% MeCN, 0.1% FA. Desalted samples were dried to completeness 
overnight in a Savant SC210A SpeedVac concentrator (Thermo Scientific). Basic 
Reversed Phase (RP) Chromatography—Off-line basic RP fractionation was 
completed using a custom-manufactured Zorbax 300 Extend-C18 column (9.4   
250 mm, 300 Å, 5  m, Agilent) on an Agilent 1100 series HPLC system. Each 
sample was resuspended in 1.8 ml of basic RP solvent A (2% MeCN, 5 mM 
ammonium formate, pH 10), separated equally into two HPLC vials and injected 
succes- sively with solvent A at a flow rate of 3 ml/min. A 64-min basic RP LC 
method was utilized for off-line fractionation. The gradient consisted of an initial 
increase to 8% solvent B (1.1% B/min) (90% MeCN, 5 mM ammonium formate, 
pH 10) followed by a 38-min linear gradient (0.5% B/min) from 8% solvent B to 
27% B and successive ramps to 31% B (1% B/min), 39% B (0.5% B/min), and 
60% B (3% B/min). A flow rate of 3 ml/min was used for the entirety of the LC 
separation. Upon sample injection, 80 basic RP fractions were collected in a 96-
well polypropylene round bottom plate (GE Healthcare). For K- -GG peptide 
analysis, basic RP fractions were pooled in a non- contiguous manner into eight 
total fractions Fractions were dried to completeness. Dried peptide fractions 
were resuspended in 1.5 ml of IAP buffer and incubated with cross-linked anti-
K-e-GG antibody beads for 1 h on a rotating unit at 4°C. Each basic RP fraction 
was incubated with 31 ug of antibody. Antibody beads were washed four times 
with 1 ml of ice-cold PBS. K-e-GG peptides were eluted by adding 2x 50 ul of 
0.15% trifluoroacetic acetic (TFA) and cleaned by C18. Eluted peptides were 
dried to completeness prior to mass-spectrometry analysis. Also pre-IP fractions 
were collected and prepared for mass-spectrometry. 
 	  Immunoprecipitation	  of	  proteins	  2.2.17
3	   µL	   of	   covalently	   coupled	   antibody	   or	   for	   larger	   sample	   quantities	   1	   µL	   of	   antibody	  
beads	  /	  1	  mg	  of	  lysate	  was	  mixed	  with	  the	  lysate	  for	  1-­‐4	  hrs	  at	  4°C	  on	  a	  rotating	  wheel.	  
Beads	  were	   then	  washes	   twice	  with	   lysis	  buffer	  containing	  0.5	  M	  NaCl	  and	   twice	  with	  
lysis	  buffer	  containing	  0.15	  M	  NaCl	  followed	  by	  2	  washes	  with	  buffer	  A.	  Reducing	  agent	  
was	  omitted	  from	  the	  washes.	  To	  elute	  immunoprecipitates,	  beads	  were	  resuspended	  in	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2x	  SDS	  sample	  buffer	  (or	  2x	  NuPAGE	  LDS	  sample	  buffer	  for	  mass	  spectrometry)	  lacking	  
reducing	   agent	   for	   10	   min	   prior	   to	   filtering	   through	   Spin-­‐X	   columns	   to	   remove	   the	  
antibody-­‐bound	   beads.	   Reducing	   agent	   was	   added	   to	   the	   eluted	   samples	   and	   the	  
samples	  were	  heated.	  	  
Endogenous	  FBXO7	  immunoprecipitations	  from	  tissue	  lysates	  were	  precleared	  at	  least	  3	  
times	  for	  15	  minutes	  with	  preimmune	  sheep	  Immunoglobulins	  (IgG)	  covalently	  coupled	  
to	  G-­‐sepharose	  beads.	  
 	  Resolution	  of	  protein	  samples	  via	  SDS-­‐PAGE	  2.2.18
Sodium	   dodecyl	   sulphate	   polyacrylamide	   gel	   electrophoresis	   (SDS-­‐PAGE)	   resolves	  
proteins	   based	   on	   their	   apparent	   molecular	   weight.	   The	   anionic	   detergents	   SDS	   and	  
lithium	  dodecyl	  sulphate	  (LDS)	  bind	  to	  proteins	  giving	  them	  a	  net	  negative	  charge	  that	  is	  
proportional	  to	  the	  molecular	  mass	  of	  the	  protein.	  Consequently,	  the	  speed	  of	  migration	  
of	  proteins	  through	  a	  PAGE	  matrix	  is	  a	  linear	  function	  of	  the	  logarithm	  of	  their	  molecular	  
weight.	  	  
Resolving	   gels	   contained	   375	  mM	   Tris-­‐HCl	   (pH	   8.6),	   0.1%	   SDS	   and	   8-­‐10%	   acrylamide.	  
TEMED	  and	  ammonium	  persulphate	  (APS)	  were	  used	  to	  initiate	  polymerisation.	  Stacking	  
gels	  contained	  125	  mM	  Tris	  HCl	  pH	  6.8,	  0.1%	  SDS,	  4%	  acrylamide,	  TEMED	  and	  APS.	  
Samples	  were	  prepared	  either	   in	   1x	   LDS	   sample	  buffer	   and	  1x	   sample	   reducing	   agent	  
(for	  use	  with	  pre-­‐cast	  NuPAGE	  4-­‐12%	  Bis-­‐Tris	  gels)	  or	   in	  1x	  SDS	  sample	  buffer	   (for	  use	  
with	  homemade	  gels)	  and	  heated	  at	  heated	  at	  90°C	  for	  5	  min.	  5-­‐20	  µg	  of	  lysate	  or	  10-­‐30	  
µL	   of	   immunoprecipitates	   were	   loaded	   per	   lane	   along	   with	   protein	   standards.	  
Electrophoresis	  was	  carried	  out	  at	  80	  V	  until	  the	  protein	  markers	  started	  to	  resolve	  and	  
then	  the	  voltage	  was	  increased	  to	  160	  –	  180	  V	  until	  the	  dye	  front	  reached	  the	  end	  of	  the	  
resolving	  gel.	  
 	  Coomassie	  staining	  of	  polyacrylamide	  gels	  2.2.19
Polyacrylamide	   gels	   were	   stained	   in	   Instant	   Blue	   staining	   solution	   for	   1-­‐2	   hrs	   and	  
destained	  with	  MilliQ	  water.	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  Transfer	  of	  proteins	  onto	  nitrocellulose	  membranes	  2.2.20
Gels	   were	   sandwiched	   between	   nylon	   sponges,	   Whatman	   3	   mm	   filter	   papers	   and	  
nitrocellulose	  membrane	  all	  soaked	  in	  transfer	  buffer.	  The	  transfer	  cell	  was	  submerged	  
in	  transfer	  buffer	  and	  transfer	  was	  carried	  out	  at	  at	  750	  mA	  for	  1	  hour.	  
 Immunoblotting	  2.2.21
After	  transfer,	  membranes	  were	  stained	  with	  Ponceau	  S	  and	  destained	  in	  distilled	  water	  
in	   order	   to	   visualise	   the	   transferred	   proteins.	   Non-­‐specific	   binding	   of	   antibodies	   was	  
prevented	  by	  incubating	  the	  membranes	  with	  5%	  (w/v)	  skimmed	  milk	  in	  TBST	  for	  1	  hour	  
at	  room	  temperature.	  Membranes	  were	  then	  incubated	  with	  primary	  antibodies	  diluted	  
in	  either	  5%	  (w/v)	  skimmed	  milk	  or	  BSA	  in	  TBST	  at	  4°C	  for	  16	  hrs.	  Membranes	  were	  next	  
washed	  three	  times	  for	  10	  minutes	  with	  TBST.	  Horseradish	  peroxidase	  (HRP)-­‐conjugated	  
secondary	   antibodies	   diluted	   at	   1:2500	   in	   5%	   (w/v)	   skimmed	   milk	   in	   TBST	   were	  
incubated	  with	  the	  membranes	  for	  1	  hr	  at	  room	  temperature	  and	  the	  membranes	  were	  
washed	   three	  more	   times	  with	   TBST.	  Membranes	  were	   incubated	  with	   the	   enhanced	  
chemiluminescence	   (ECL)	   substrate	   and	   exposed	   to	   X-­‐ray	   films	   for	   various	   lengths	   of	  
time.	   Films	   were	   developed	   using	   a	   Konica	   automatic	   developer. Where	   indicated,	  
signals	  were	  visualised	  using	  the	  OdysseyTM	  Infrared	  Imaging	  System	  instead	  of	  ECL.	  The	  
procedure	  was	  the	  same	  but	  the	  secondary	  antibodies	  were	  labelled	  with	  either	  IRD800	  
or	   Alexa680	   dyes	   and	   the	   signal	   captured	   and	   quantified	   with	   an	   Odyssey	   Infrared	  
Imaging	  System.	  
 	  Processing	  protein	  bands	  by	  in-­‐gel	  digestion	  for	  mass	  spectrometry	  analysis	  2.2.22
To	  minimise	   contamination	  with	   proteins	   such	   as	   keratin,	   samples	  were	   handled	   in	   a	  
laminar	  flow	  hood.	  Gels	  were	  cut	  into	  small	  pieces.	  The	  pieces	  were	  sequentially	  washed	  
for	   10	   min	   in	   0.5	   mL	   water,	   50%	   (v/v)	   acetonitrile,	   0.1	   M	   NH4HCO3	   and	   50%	   (v/v)	  
acetonitrile/50	   mM	   NH4HCO3.	   The	   last	   step	   was	   repeated	   until	   the	   pieces	   were	  
colourless.	  Colourless	  gel	  pieces	  were	   incubated	  with	  0.3	  mL	  acetonitrile	  for	  15	  min	  at	  
room	   temperature	   followed	   by	   drying	   in	   a	   Speed-­‐Vac	   at	   45°C.	   Dried	   gel	   pieces	   were	  
incubated	  with	  30	  µL	  25	  mM	  Triethylammonium	  bicarbonate	  buffer	  containing	  5	  µg/mL	  
trypsin	  at	  30°C	   for	  16	  hrs	  on	  a	  shaking	  platform.	  Next	  an	  equal	  volume	  of	  acetonitrile	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was	  added	  and	  the	  peptides	  obtained	  from	  the	  digestion	  were	  extracted	  for	  15	  min	  on	  a	  
shaking	  platform.	  The	  supernatant	  was	  dried	  in	  a	  clean	  tube	  at	  45°C	  using	  Speed-­‐Vac.	  To	  
extract	  further	  peptides,	  100	  µL	  of	  50%	  (v/v)	  acetonitrile	  supplemented	  with	  2.5%	  (v/v)	  
formic	  acid	  was	  added	  to	  the	  gel	  pieces	  and	  incubated	  for	  15	  min	  at	  room	  temperature	  
on	   a	   shaking	   platform.	   The	   supernatant	   was	   combined	   with	   the	   first	   dried	   peptide	  
extract	  and	  dried	  using	  Speed-­‐Vac.	  Dried	  peptides	  were	  stored	  at	  -­‐20°C.	  
 	  Processing	  samples	  by	  solution	  digestion	  for	  mass	  spectrometry	  analysis	  2.2.23
Samples	  were	  prepared	  in	  mass-­‐spectrometry	  compatible	  buffers	  (such	  as	  Rapigest)	  and	  
Tris-­‐HCL	   was	   added	   to	   10	   mM	   to	   ensure	   buffering	   at	   pH	   7.5	   followed	   by	   cysteine	  
alkylation	   in	   10	   mM	   chloroacetamide	   at	   20	   degree	   Celcius	   in	   the	   dark	   for	   30	   min.	  
Samples	  were	  diluted	  to	  0.1%	  RapigestTM	  and	  digested	  with	  1:50	  w/w	  trypsin	  overnight	  
at	   37	   degrees	   Celcius.	   Peptides	   were	   acidified	   with	   1%	   TFA	   (trifluoroacetic	   acid)	   and	  
incubated	  at	  37	  degrees	  Celcius	  for	  1	  hour	  before	  precipitating	  acid-­‐cleaved	  RapigestTM	  
by	   centrifugation	   at	   17000	   x	   g	   for	   10	  min.	   Peptides	   were	   purified	   on	   C18	  MicroSpin	  
Columns	  (the	  Nest	  Group)	  before	  mass-­‐spectrometry	  analysis.	  	  
 	  Mass	  spectrometry	  2.2.24
Liquid	   chromatography–mass	   spectrometry	   (LC-­‐MS)	   was	   performed	   by	   Dr.	   David	  
Campbell,	   Mr.	   Robert	   Gourlay	   and	   Joby	   Varghese	   (MRC,	   College	   of	   Life	   Sciences,	  
University	   of	  Dundee).	   Tryptic	   peptides	  were	   subjected	   to	   LC-­‐MS/MS	  using	   a	   Proxeon	  
EasynLC	   chromatography	   system	   coupled	   with	   a	   Thermo	   LTQ-­‐Orbitrap	   Classic	   mass	  
spectrometer.	  Results	  were	  searched	  against	  the	  SwissProt	  or	  IPI	  mouse	  databases	  using	  
Mascot	  (www.matrixscience.com).	  Data	  analysis	  was	  performed	  using	  Online	  MassSpec	  
Data	  Analysis	  Tool	  (http://www.proteinguru.com/MassSpec/OLMAT).	  	  
The	  mass-­‐spectrometry	  analysis	  of	  the	  di-­‐gly	  experiments	  was	  performed	  by	  Dr.	  Patrick	  
Pedrioli	  and	  Dr.	  Kamila	  Chughtai	  (MRC,	  College	  of	  Life	  Sciences,	  University	  of	  Dundee).	  
Mass	   spectra	   were	   acquired	   on	   a	   LTQ	   Oribitrap	   Velos	   mass	   spectrometer	   (Thermo	  
Scientific)	   operating	   in	   a	   data-­‐dependent	   mode.	   After	   conversion	   to	   mzXML	   the	   raw	  
data	  were	  searched	  using	  Comet	  against	  the	  human,	  or	  mouse,	  protein	  databases.	  For	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SILAC	  samples	  variable	  modification	  of	  lysine	  and	  arginine	  residues	  was	  also	  specified	  as	  
well	  as	  Gly-­‐Gly	  additions	  to	  lysines	  was	  searched	  for.	  
 	  In	  vitro	  SCF	  complex	  formation	  and	  ubiquitinylation	  assays	  2.2.25
Recombinant	   DAC-­‐tagged	   FBXO7	   co-­‐purified	   with	   untagged	   SKP1	   were	   incubated	  
together	   with	   a	   2	   Molar	   excess	   of	   the	   various	   combinations	   of	   other	   SCF	   complex	  
partners	  as	  well	  as	  PI31	  at	  room	  temperature	  for	  1	  hour.	  The	  complex	  was	  then	  purified	  
via	  DAC	  with	  ampicillin	  sepharose	  as	  described	   in	  2.2.14	  and	  otherwise	  treated	   like	  an	  
immunoprecipitation	  as	  decribed	   in	  2.2.17.	  For	   in	  vitro	  ubiquitinylation	  reactions	  wild-­‐
type	   or	  mutant	   FBXO7	   –	   either	   R378G	   or	   R498X	   –	  were	   incubated	   together	  with	   the	  
other	   SCF	   complex	   partners	   and	   His-­‐PI31	   in	   the	   presence	   of	   Flag-­‐Ubiquitin	   (Boston	  
Biochem),	  His-­‐UBE1	  and	  His_UBE2R1	  in	  a	  reaction	  volume	  of	  50ul	  (HEPES	  based,	  2	  mM	  
ATP,	   10	   mM	   Magnesium	   acetate).	   Ubiquitinylation	   reactions	   were	   incubated	   at	   30	  
degrees	  Celcius	  for	  60	  minutes	  and	  terminated	  by	  addition	  of	  SDS	  sample	  buffer.	  For	  all	  
assays,	  reaction	  mixtures	  were	  resolved	  by	  SDS-­‐PAGE	  and	  subjected	  to	  immunoblotting.	  
In	  the	  case	  of	  the	  mitochondrial	  substrate	  assays,	  the	  ubiquitinylation	  reaction	  was	  heat	  
terminated	  and	  intact	  mitochondria	  were	  pelleted	  by	  centrifugation.	  The	  mitochondrial	  
pellet	  was	  washed	  3	  times	  before	  it	  was	  resuspended	  in	  1%	  SDS	  buffer	  and	  subjected	  to	  
sonication	   and	   benzonase	   treatment.	   Mitochondrial	   debris	   was	   removed	   by	  
centrifugation	  and	  the	  supernatatnt	  was	  diluted	  to	  0.1%	  SDS.	  This	  was	  then	  subjected	  to	  
Flag	   immunoprecipitation	  and	   subsequent	  preparation	   for	   in	   solution	   tryptic	  digestion	  
for	  mass-­‐spectrometry	  analysis.	  If	  the	  reaction	  was	  not	  intended	  for	  mass-­‐spectrometry	  
analysis,	   the	   mitochondrial	   pellet	   was	   resolved	   in	   a	   small	   volume	   of	   HEPES	   buffer,	  
benzonase	  was	  added,	  followed	  by	  sonication	  and	  addition	  of	  LDS	  buffer	  for	  resolution	  
by	  SDS-­‐PAGE	  and	  immunoblotting.	  
 	  Generation	   of	   FBXO7	   knock-­‐in	   mouse	   model	   of	   the	   corresponding	   R378G	  2.2.26
mutation	  
A	   FBXO7	   mouse	   model	   with	   constitutive	   knock-­‐in	   of	   the	   R379G	   point	   mutation	  
(corresponding	   to	   the	   human	   pathogenic	   R378G	   mutation)	   with	   optional	   conditional	  
FBXO7	   knock-­‐out	   was	   generated	   using	   the	   Cre/LocP	   methodology(Nagy,	   2000).	   The	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R379G	   mutation	  was	   introduced	  into	  exon	  7	  and	  an	  additional	  silent	  mutation	  for	   the	  
creation	  of	  a	  diagnostic	  restriction	  site.	  Exons	  7	  and	  8	  were	  flanked	  with	  34-­‐base	  pair	  
DNA	   recognition	   sites	   (LoxP	  sites)	   	  and	   selection	  markers	  were	   inserted	  into	   intron	  6	  
and	   8	   flanked	   by	   FRT	   (NeoR)	   and	   F3	   (PuroR)	   sites,	   respectively.	   Homologous	  
recombinant	   clones	   were	   isolated	   by	   using	   the	   double	   positive	   (Neomycin	   and	  
Puromycin	  resistance)	  selection.	  The	   targeting	  vector	  was	   generated	  using	  BAC	   clones	  
from	   the	   C57BL/6J	   RPCIB-­‐731	   BAC	   library	   and	   transfected	   into	   the	   TaconicArtemis	  
C57BL/6N	  Tac	  ES	   cell	   line.	  The	  constitutive	  Knock-­‐	  in-­‐conditional	  Knock-­‐out	  allele	  after	  
Flp-­‐mediated	   removal	   of	   the	   selection	  markers	  expressed	   the	   mutated	   R379G	   Fbxo7	  
protein.	  Heterozygous	  mice	  were	   shipped	   from	  TaconisArtemis	  to	  our	  animal	  unit	  and	  
animals	  were	  bred	  to	  homozygosity.	  
Homozygeous	   R379G	   KI	   animals	  were	   subsequently	   crossed	  with	  mice	   expressing	   the	  
Cre	   recombinase,	   leading	   to	   the	   recombination	   between	   the	   LoxP	   sequences	   and	  
excision	   of	   the	   intervening	   DNA	   and	   either	   ablation	   of	   gene	   expression	   or	   at	   least	  
expression	  of	  a	  truncated	  allele	  product.	  
 	  Extraction	  of	  DNA	  from	  ear	  /	  tail	  biopsies	  2.2.27
Ear	   notches	   were	   taken	   from	   mice	   at	   approximately	   4	   weeks	   of	   age	   by	   staff	   in	   the	  
College	   of	   Life	   Sciences	   Transgenic	   Unit	   (University	   of	   Dundee)	   and	   DNA	   extractions	  
carried	   out	   by	   the	   DNA	   service	   (University	   of	   Dundee).	   For	   confirmation	   of	   mouse	  
genotypes,	   tail	   biopsies	   were	   taken.	   Biopsies	   were	   incubated	   with	   500ul	   1mg/ml	  
Proteinase	  K	  in	  tail	  buffer	  at	  65°C	  overnight.	  167ul	  6M	  NaCl	  was	  added	  to	  each	  tube	  and	  
incubated	   on	   a	   rotating	   wheel	   for	   5min	   at	   room	   temperature.	   This	   was	   followed	   by	  
centrifugation	  at	  13000rpm	  for	  10	  min	  and	  500ul	  isopropanol	  was	  added	  to	  500ul	  of	  the	  
resulting	  supernatant	  and	  incubated	  on	  a	  rotating	  wheel	  for	  1hr	  at	  room	  temperature.	  
The	  mixture	  was	  centrifuged	  at	  13000rpm	  for	  25min,	   the	  pellet	  was	  washed	  with	  1ml	  
70%	   ethanol	   and	   centrifuged	   for	   a	   further	   10min.	   The	   pellet	   was	   left	   to	   air-­‐dry,	  
resuspended	  in	  80ul	  water	  and	  stored	  at	  -­‐20°C.	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  Genotyping	  of	  mice	  via	  PCR	  	  2.2.28
PCR	   reactions	   were	   carried	   out	   in	   order	   to	   genotype	   mice,	   using	   purified	   DNA	   from	  
biopsies.	   For	   FBXO7	   R379G	   knock-­‐in	   mice,	   a	   20ul	   reaction	   contained:	   5ul	   10X	   Taq	  
polymerase	   buffer,	   1ul	   10mM	   dNTPs	   (0.25mM	   final	   concentration),	   2ul	   25mM	  
magnesium	  chloride	  (2.5mM	  final	  concentration),	  1ul	  50pmol/ul	  primer	  1	  (3874_35),	  1ul	  
50pmol/ul	   primer	   2	   (3874_36),	   0.2ul	   Taq	   polymerase,	   37.8ul	   MilliQ	   water	   and	   2ul	  
template	   DNA.	   This	   reaction	   allowed	   detection	   of	   heterozygeous	   and	   homozygeous	  
R379G	  KI	  as	  well	  as	  wildtype-­‐alleles	  (Table	  2-­‐7).	  The	  size	  for	  the	  expected	  fragments	  was	  
210	  basepairs	  (bp)	  for	  the	  wild-­‐type	  and	  329	  bp	  for	  the	  KI	  alleles.	  
	  
	  For	  genotyping	  FBXO7	  mouse	  line	  after	  Cre	  recombination,	  a	  second	  PCR	  reaction	  was	  
carried	  out	  and	  a	  20ul	  reaction	  contained:	  2ul	  10X	  Taq	  polymerase	  buffer,	  0.5ul	  10mM	  
dNTPs	   (0.25mM	   final	   concentration),	   2ul	   25mM	  96	  magnesium	   chloride	   (2.5mM	   final	  
concentration),	   0.5ul	   50pmol/ul	   primer	   1,	   0.5ul	   50pmol/ul	   primer	   2,	   0.25ul	   Taq	  
polymerase,	  11.75ul	  MilliQ	  water	  and	  2ul	  template	  DNA.	  The	  PCR	  programme	  consisted	  
of	  5min	  at	  95°C,	  35	  cycles	  of	  30sec	  at	  95°C,	  30sec	  at	  60°C	  and	  1min	  at	  72°C,	  followed	  by	  
10min	   at	   72°C	   on	   a	   PTC-­‐	   200	   Peltier	   Therma	   Cycler	   DNA	   engine.	   5ul	   of	   DNA	   loading	  
buffer	   was	   added	   to	   the	   PCR	   samples	   and	   these	   were	   run	   on	   a	   1%	   agarose	   gel	   and	  
visualized	  under	  a	  UV	  lamp.	   In	  both	  cases	  P1	  corresponded	  to	  sequences	  found	  in	  both	  
alleles,	  P2	  bound	  within	  the	  region	  excised	  following	  Cre	  recombination	  while	  P6	  (Protor-­‐
1)	  and	  P4	  (Protor-­‐2)	  bound	  downstream	  of	  the	  excised	  region.	  Therefore	  the	  first	  set	  of	  
primer	  combinations	  allowed	  the	   identification	  of	  wild-­‐type,	   floxed	  and	  knock-­‐in	  mice.	  
The	  second	  set	  of	  primer	  combination	  allowed	  the	   identification	  of	  the	  successful	  Cre-­‐
deletion	  recombination	  event.	  	  Mrs	  G.	  Fraser	  and	  Mrs	  E.	  Forsyth	  carried	  out	  the	  majority	  
of	  the	  mouse	  genotyping	  for	  this	  project.	  
Primers	   Sequence	   Detection	  
3874_35	   GTGGTGCAGGGAAACAAGC	   Primer	  pair	  35	  +	  36	  detects	  heterozygous	  /	  
homozygeous	  KI	  and	  wild-­‐type	  alleles	  	  3874_36	   GCTGAATAACAATCTCACCATCC	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  Mouse	  motor	  and	  behavioural	  phenotyping	  2.2.29
2.2.29.1.1 	  General	  phenotypic	  screen	  with	  the	  SHIRPA	  test	  battery	  
Before	   commencing	   the	   phenotypic	   analysis,	   animals	   were	   allowed	   to	   adapt	   to	   their	  
new	  environment	  for	  at	  least	  2	  weeks	  –	  this	  applied	  to	  animals	  that	  had	  to	  be	  moved	  in	  
between	  facilities	  before	  testing.	  All	  mice	  were	  then	  evaluated	  with	  a	  slightly	  modified	  
SHIRPA	   test	   (SmithKline/Harwell/Imperial	   College/Royal	   Hospital/Phenotype	  
Assessment).	   The	   SHIRPA	  primary	   screen	   contains	   40	   scores,	   and	   the	   testing	   protocol	  
followed	  guidelines	  given	  on	  videotape	  as	  well	  as	  at	  the	  ENU	  Mutagenesis	  Programme	  
web	  site	  (http://www.mgu.har.mrc.ac.uk/).	  The	  mice	  were	  first	  placed	  inside	  a	  perspex	  
jar	  for	  5	  min	  and	  evaluated	  for	  body	  position	  (from	  flat	  to	  repeated	  leaping),	  movement	  
(from	   immobile	   to	   extreme),	   respiration	   rate	   (from	   irregular	   to	   normal),	   body	   tremor	  
(from	  absent	  to	  marked),	  and	  number	  of	  fecal	  boli.	  The	  jar	  was	  then	  lifted	  over	  an	  open-­‐
field	  made	  of	  perspex	  with	   four	   transparent	  walls	   (height:	  18	  cm)	  and	  a	  white	  opaque	  
floor	  measuring	  55	  cm	  ×	  33	  cm,	  separated	  by	  black	  line	  drawings	  into	  121	  cm2	  squares	  
(five	  rows	  and	  three	  columns)	  and	  the	  mice	  dropped	  in	  it.	  The	  following	  behaviors	  were	  
recorded:	   transfer	   arousal	   (from	   prolonged	   freezing	   to	   manic-­‐type	   behavior),	   eye	  
opening	  (from	  open	  to	  completely	  closed),	  piloerection	  (none	  or	  coat	  on	  end),	  gait	  (from	  
normal	  to	  incapacitated),	  pelvic	  elevation	  (from	  flattened	  to	  normal),	  tail	  position	  (from	  
dragging	   to	  Straub	   type),	  and	   touch	  escape	   (from	  no	   response	   to	  vigorous	  attemps	  at	  
escaping	  from	  being	  touched).	  
The	  mice	  were	  then	   lifted	  by	  the	  tail	  and	  assessed	  for	  the	  position	  at	  which	  struggling	  
movements	   occurred	   (from	   tail	   to	   no	   struggle	   at	   all)	   as	   well	   as	   trunk	   curl	   (absent	   or	  
present)	  and	  placing	  (absent,	  vibrissae,	  or	  visual)	  responses.	  After	  being	  restrained	  in	  a	  
supine	   position,	   skin	   color	   (from	   blanched	   to	   red),	   lacrimation	   (absent	   or	   present),	  
salivation	  (absent	  or	  present),	  and	  biting	  as	  well	  as	  Pinna	  (from	  absent	  to	  multiple	  flicks)	  
and	   corneal	   (from	   absent	   to	  multiple	   blinks)	   reflexes	   were	   recorded.	   The	   air-­‐righting	  
reflex	  was	   then	  evaluated	  according	   to	   landing	  position	   (on	  all	   four	  paws,	  on	   side,	  on	  
back	  or	  else	  failure	  to	  right	  even	  when	  placed	  on	  its	  back),	  followed	  by	  contact	  righting	  
when	  placed	   inside	   a	   small	   plastic	   tube	   (absent	   or	   present).	   These	   observations	  were	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completed	  by	  noting	  whether	  any	   sign	  of	   fear	   (none,	   freezes	  during	   transfer	   arousal),	  
irritability	  (none,	  struggling	  during	  restraint),	  aggression	  (none	  or	  provoked	  biting),	  and	  
vocalization	   (none	   or	   provoked	   while	   handling)	   arose	   for	   each	   mouse	   and	   its	   body	  
weight.	   The	  main	  difference	   to	   the	  modified	  SHIRPA	   test	  battery	  was	   that	  we	  did	  not	  
record	   acoustic	   startel	   and	   grip	   strength.	   Locomotor	   activity	   was	   also	   measured	  
separately	  in	  a	  more	  elaborate	  fashion	  as	  described	  below.	  	  
2.2.29.1.2 	  Spontaneous	  locomotor	  activity	  
Mice	  were	  handled	  for	  a	  minimum	  of	  3	  days	  before	  the	  start	  of	  locomotor	  monitoring.	  
Mice	  were	  placed	  in	  an	  open-­‐topped	  transparent	  Perspex	  cube,	  30	  x	  30	  x	  30	  cm,	  for	  3	  
daily	  sessions	  of	  30	  min	  each.	  The	  position	  of	  the	  mouse	  was	  monitored	  by	  an	  overhead	  
camera	  connected	  to	  an	  HD	  recorder	  and	  a	  PC	  running	  Any-­‐maze	  (details).	  A	  separate	  
side-­‐mounted	  camera	  recorded	  rearing	  behaviour.	  Total	  distance	  travelled	  (sub-­‐divided	  
into	   three	   10-­‐min	   sessions),	   distance	   travelled	   within	   cm	   of	   the	   box	   walls,	   distance	  
travelled	  in	  the	  centre	  of	  the	  box	  (i.e.	  >	  5	  cm	  from	  the	  walls),	  and	  number	  of	  rears	  were	  
analysed.	  
2.2.29.1.3 	  Gait	  analysis	  
Gait	  analysis	  was	  carried	  out	  in	  a	  narrow	  corridor,	  45	  cm	  long,	  approximately	  5	  cm	  wide,	  
with	  14-­‐cm	  high	  walls.	  At	   the	  end	  of	   the	  corridor	  was	  a	   ‘goal	  box’	   containing	  bedding	  
and	  small	  pieces	  of	  breakfast	  cereal.	  Before	  the	  start	  of	  gait	  analysis,	  mice	  were	  placed	  
into	  the	  goal	  box	  and	  allowed	  to	  explore	  the	  box	  and	  corridor	  for	  two	  15-­‐min	  sessions	  
on	   successive	   days,	   in	   order	   to	   habituate	   them	   to	   the	   apparatus.	   Mice	   were	   also	  
scruffed	   several	   times	   during	   this	   phase	   in	   order	   to	   habituate	   them	   to	   the	   restraint	  
necessary	   for	   subsequent	  paint	  application.	  On	   the	   testing	  day,	  a	   strip	  of	  white	  paper	  
was	  placed	  on	  the	  floor	  of	  the	  corridor.	  Poster	  paint	  was	  applied	  to	  the	  mouse’s	  feet—
red	   for	   the	   forepaws,	   and	   blue	   for	   the	   hind—and	   the	   mouse	   was	   released	   into	   the	  
corridor	  and	  allowed	  to	   run	   towards	   the	  goal	  box.	  A	   run	  was	  considered	  acceptable	   if	  
the	   mouse	   ran	   towards	   the	   goal	   box	   without	   stopping	   or	   changing	   direction.	   Three	  
runs—i.e.	  three	  sets	  of	  paw	  prints—were	  collected	  for	  each	  mouse.	  For	  analysis,	  a	  single	  
gait	  cycle	  from	  each	  run	  was	  selected	  based	  on	  the	  clarity	  of	  the	  paw	  prints.	  Three	  gait	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parameters	   were	   calculated	   from	   the	   paw-­‐print	   records—stride	   length,	   base	   width	  
(front	  and	  hind),	  and	  overlap	  between	  front	  and	  hind	  feet.	  Stride	  length	  was	  defined	  as	  
the	  distance	  between	   the	  centre	  of	  a	  given	  plantar	   from	  one	   footfall	   to	   the	  next;	   this	  
was	  calculated	  separately	  for	  each	  foot,	  and	  the	  results	  were	  averaged.	  Base	  width	  was	  
defined	  as	  the	  distance	  between	  the	  two	  front	  feet	  (front	  base	  width)	  and	  the	  two	  hind	  
feet	  (hind	  base	  width)	  perpendicular	  to	  the	  direction	  of	  travel.	  Two	  front	  and	  hind	  base-­‐
width	  measurements	  were	  made	   for	   each	   run,	   corresponding	   to	   the	   first	   and	   second	  
footfalls	   of	   the	   gait	   cycle,	   and	   these	   data	   were	   averaged.	   Overlap	   was	   calculated	   by	  
measuring	   the	  distance	  between	  the	  centre	  of	   the	   front	  and	  hind	  plantars	   for	  each	  of	  
the	   four	   pairs	   comprising	   the	   selected	   gait	   cycle;	   these	   measurements	   were	   then	  
averaged.	  
2.2.29.1.4 	  Accelerating	  rotarod	  
On	  each	  testing	  day,	  a	  mouse	  was	  placed	  on	  each	  of	  5	  lanes	  of	  a	  rotarod	  (Model	  47600,	  
Ugo	  Basile,	   Italy),	  with	   the	  beam	   (diameter	   =	   3	   cm)	   rotating	   at	   a	   constant	   speed	  of	   6	  
r.p.m.	  Each	  mouse	  occupied	  the	  same	  lane	  during	  each	  testing	  day,	  but	  lane	  occupancy	  
was	  counterbalanced	  between	  subjects	  such	  that	  each	  lane	  was	  used	  by	  approximately	  
the	  same	  number	  of	  wild	   type	  and	  homozygous	  mice	  across	   the	  series	  of	   runs	  carried	  
out	  within	  each	  day.	  Once	  all	  lanes	  were	  occupied,	  the	  beam	  accelerated	  at	  a	  constant	  
rate	  from	  6	  to	  50	  r.p.m.	  over	  a	  300-­‐s	  period.	  Latency	  to	  first	  lose	  grip	  on	  the	  beam	  was	  
recorded.	  ‘Loss	  of	  grip’	  included	  both	  falling	  from	  the	  beam	  and	  clinging	  to	  the	  rotating	  
beam	  to	  avoid	  falling.	  Mice	  that	  fell	  from	  the	  beam	  within	  the	  first	  20	  s	  of	  the	  start	  of	  
acceleration	   were	   placed	   back	   on.	   However,	   in	   these	   cases,	   the	   loss-­‐of-­‐grip	   latency	  
recorded	   still	   corresponded	   to	   the	   first	   fall.	   If	   a	   mouse	   lost	   grip	   because	   of	   turning	  
around	  on	  the	  beam,	  it	  was	  immediately	  placed	  back	  on	  the	  rotarod	  facing	  in	  the	  correct	  
direction;	   these	   incidents	   were	   not	   counted	   in	   the	   analysis	   of	   latency	   to	   lose	   grip.	  
Testing	   continued	   for	   a	   total	   of	   4	   days.	   All	   trials	   were	   recorded	   and	   latencies	   were	  
analysed	  during	  video	  playback.	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2.2.29.1.5 	  Fixed-­‐speed	  rotarod	  
Fixed-­‐speed	   rotarod	   testing	  was	   carried	   out	   in	   a	   single	   day.	  Mice	  were	   placed	  on	   the	  
rotating	  beam,	   and	   latency	   to	   lose	   grip	   (defined	   as	   for	   the	   accelerating	  protocol)	  was	  
recorded	  from	  the	  moment	  the	  mouse	  was	  released.	  Mice	  were	  tested	  at	  approximately	  
1-­‐h	  intervals	  using	  progressively	  increasing	  rotational	  speeds—10,	  20,	  30	  and	  40	  r.p.m.	  
Mice	  that	  fell	  within	  the	  first	  20	  s	  were	  placed	  back	  on	  the	  beam,	  although	  the	  recorded	  
latency	   still	   reflected	   the	   first	   loss	   of	   grip.	   Mice	   occupied	   the	   same	   lanes	   as	   during	  
accelerating	   rotarod	   training.	   All	   trials	   were	   recorded	   and	   latencies	   were	   analysed	  
during	  video	  playback.	  
2.2.29.1.6 	  Balance	  beam	  (or	  elevated	  bridge	  test)	  
The	   balance	   beam	   apparatus	   comprised	   a	   tapering	   aluminium	   beam,	   1	   m	   in	   length,	  
inclined	  upwards	  at	  a	  15-­‐degree	  angle,	  and	   leading	  to	  an	  enclosed	  goal	  box,	  40cm	  cm	  
above	   the	  ground.	  Soft	   towels	  were	  placed	  underneath	   the	  beam	  to	  prevent	   injury	   in	  
the	  event	  of	  a	  fall	  (although	  no	  falls	  occurred	  during	  the	  study).	  The	  beam	  tapered	  from	  
a	  width	  of	  1.2	  cm	  at	  a	  ‘start	  point’,	  15	  cm	  from	  its	  lower	  end,	  to	  0.5	  cm	  at	  a	  ‘finish	  point’,	  
10-­‐cm	  from	  the	  goal	  box.	  On	  the	  underside	  of	  the	  beam,	  2	  cm	  from	  its	  top	  surface,	  were	  
ledges	  extending	  1.5	  cm	  from	  the	  edge	  of	  the	  beam	  on	  both	  sides.	  These	  ledges	  prevent	  
falling	   in	   the	   event	   of	   a	   slip,	   and	   facilitate	   the	   identification	   of	   slips.	   The	   beam	   was	  
brightly	  lit	  in	  order	  to	  encourage	  movement	  towards	  the	  dark	  goal	  box.	  Mice	  were	  first	  
habituated	  to	  the	  goal	  box,	  filled	  with	  bedding	  and	  pieces	  of	  breakfast	  cereal,	  over	  two	  
15-­‐min	  sessions	  on	  successive	  days.	  On	  the	  third	  day,	  mice	  were	  trained	  to	  run	  along	  the	  
beam	  by	  placing	  them	  onto	  the	  beam	  at	  progressively	  greater	  distances	  from	  the	  goal	  
box,	  until	  each	  mouse	  ran	  along	  the	  entire	  length	  of	  the	  beam	  without	  hesitation.	  On	  a	  
subsequent	  testing	  day,	  mice	  were	  placed	  at	  the	  wide	  end	  of	  the	  beam	  and	  allowed	  to	  
run	  towards	  the	  goal	  box	  while	  side-­‐mounted	  cameras	  recorded	  their	  progress.	  This	  was	  
repeated	  8	  times	  for	  each	  mouse,	  with	  runs	  separated	  by	  approximately	  30	  min.	  Video	  
data	  were	  analysed	  off-­‐line;	   the	  number	  of	   foot	   slips	   that	  occurred	  between	   the	  start	  
and	  finish	  points	  was	  recorded	  for	  both	  left	  and	  right	  fore	  and	  hind	  limbs.	  A	  foot	  slip	  was	  
recorded	  each	  time	  a	  paw	  lost	  grip	  on	  the	  upper	  surface	  of	  the	  beam,	  and	  made	  contact	  
with	   the	   ledge	  below.	  Data	   from	   individual	   runs	  were	   only	   included	   if	   the	  mouse	   ran	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along	  the	  top	  surface	  of	  the	  beam	  for	  its	  entire	  length;	  runs	  were	  discarded	  if	  the	  animal	  
‘shuffled’	  along	  the	  beam	  for	  part	  of	  its	  length	  by	  using	  the	  ledge	  for	  support.	  Data	  from	  
each	   two	   successive	   runs	   were	   averaged.	   Data	   from	   a	  mouse	   was	   discarded	   entirely	  
unless	  at	  least	  one	  run	  in	  each	  of	  the	  4	  pairs	  was	  satisfactory.	  	  
 	  Lysis	  of	  mouse	  tissues	  2.2.30
Mouse	   tissues	  were	  rapidly	  excised,	   frozen	   in	   liquid	  nitrogen	  and	  stored	  at	   -­‐80°C	  until	  
use.	  Tissues	  were	  weighed	  and	  homogenised	  in	  a	  10-­‐fold	  excess	  of	  ice-­‐cold	  lysis	  buffer	  
(usually	   TRIS-­‐CHAPS	   buffer	   unless	   otherwise	   stated).	   Lysates	   were	   clarified	   by	  
centrifugation	  at	  3,000	  rpm	  for	  15	  min	  at	  4°C	  and	  supernatants	  then	  further	  centrifuged	  
at	   18,000	   g	   for	   20	  min	   at	   4°C.	   Lysates	   that	   were	   intended	   for	   experiments	   involving	  
mass-­‐spectrometry	   analysis,	   lysates	   were	   also	   filtered	   (0.22um)	   and	   immediately	  
prcessed	  without	  prior	  storage	  at	  -­‐80°C.	  Otherwise,	  lysates	  were	  aliquoted,	  snap	  frozen	  
and	  stored	  at	  -­‐80°C.	  
 	  Mouse	  embryonic	  fibroblast	  (MEF)	  generation	  2.2.31
Female	  mice	  at	  13	  days	  gestation	  were	  culled,	  the	  uterine	  horn	  removed	  and	  embryos	  
placed	  in	  PBS.	  Embryo	  heads	  were	  used	  to	  confirm	  the	  genotype	  by	  PCR	  (performed	  by	  
Mrs	  G.	   Fraser).	   After	   removing	   internal	   organs	   embryos	  were	   chopped	   and	   incubated	  
with	  trypsin	  at	  37°C,	  5%	  CO2	  for	  5-­‐10	  min.	  Cells	  were	  centrifuged	  at	  800	  rpm	  for	  5	  min	  
and	   resuspended	   in	   primary	   MEF	   media	   (Section	   2.2.6).	   After	   24	   hrs,	   cells	   were	  
trypsinised,	   resuspended	   in	   primary	   MEF	   media	   and	   filtered.	   These	   cells	   were	  
designated	  as	  passage	  1	  (P1).	  MEFs	  were	  immortalised	  by	  continues	  passaging	  and	  were	  
considered	   to	   be	   immortalised	   once	   the	   cells	   were	   proliferating	   at	   a	   rate	   similar	   to	  
primary	  MEFs.	  	  
 	  Statistical	  analysis	  2.2.32
Statistical	  significance	  was	  assessed	  by	  one-­‐way	  analysis	  of	  variance	  (ANOVA)	  followed	  
by	   Tukey’s	   multiple	   comparison	   tests	   using	   GraphPad	   Prism	   5.0.	   All	   the	   experiments	  
presented	  in	  this	  thesis	  were	  performed	  at	  least	  two	  or	  three	  times	  with	  similar	  results	  
obtained	  on	  each	  occasion.	  Error	  bars	  indicate	  the	  standard	  deviation	  (SD)	  or	  standard	  
error	  of	  the	  mean	  (SEM),	  as	  indicated	  in	  figure	  legends.	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  Bioinformatics	  2.2.33
Sequence	   alignments	  were	   undertaken	   using	   Clustal	  Omega	   (Sievers	   et	   al.,	   2011)	   and	  
the	  alignments	  were	  annotated	  using	  Jalview	  2	  (Waterhouse	  et	  al.,	  2009b).	  
3 SCFFBXO7	  E3	  ligase	  complex	  formation	  and	  screening	  for	  FBXO7	  
interactors	  in	  the	  stable	  overexpression	  system	  
3.1 Introduction	  
PD	   is	   the	  second	  most	  common	  neurodegenerative	  disorder	  after	  Alzheimer’s	  disease,	  
and	   progression	   of	   symptoms	   correlates	   with	   neurodegeneration	   in	   the	   nigrostriatal	  
dopaminergic	  system.	  In	  fact,	  dopaminergic	  neuronal	  cell	  death	  and	  Lewy	  bodies	  are	  the	  
neuropathological	  hallmark	  of	  PD	  although	  it	  is	  well	  known	  that	  neuronal	  degeneration	  
is	  more	  widespread	  across	  the	  central	  and	  peripheral	  nervous	  system	  as	  reflected	  by	  the	  
multitude	   and	   variety	   of	   clinical	   symptoms.	   Mitochondrial	   dysfunction	   and	   oxidative	  
stress	   are	   believed	   to	   take	   a	   central	   role	   in	   the	   pathogenesis	   of	   PD.	   However,	   the	  
identification	   of	   PD	   associated	   genes	   and	   the	   study	   of	   their	   cellular	   functions	   have	  
sparked	   an	   interest	   in	   the	   ubiquitin	   proteasome	   system(Cook	   et	   al.,	   2012;	   Ebrahimi-­‐
Fakhari	  et	  al.,	  2012;	  Olanow	  and	  McNaught,	  2006):	  Protein	  misfolding	  and	  dysfunctional	  
protein	  clearance	  /	  aggregation	  –	  as	  seen	   in	  many	  neurodegenerative	  diseases	   -­‐	  could	  
be	  the	  result	  of	  disturbed	  quality	  control	  mechanisms	  and	  as	  such	  be	  critically	  involved	  
in	  the	  cascade	  of	  events	  leading	  to	  neurodegeneration	  in	  PD.	  As	  a	  member	  of	  the	  F-­‐box	  
family,	   FBXO7	  possesses	   the	  potential	   to	  act	  as	   the	   substrate	   recognizing	   subunit	  of	  a	  
specific	   type	  of	  E3	  ubiquitin	   ligases,	  and	   is	  as	   such	  well	   suited	   to	  play	  a	  crucial	   role	   in	  
regulating	   protein	   quality	   control	   via	   the	   ubiquitin	   proteasomal	   system.	  Dysfunctional	  
E3	   ligase	   activity	   of	   the	   FBXO7	   pathogenic	  mutants	  may	   therefore	   be	   the	   underlying	  
cause	   of	   FBXO7	   associated	   neurodegeneration.	   However,	   not	   all	   F-­‐box	   proteins	  
assemble	   into	  a	  Skp1-­‐Cullin1-­‐RBX1-­‐F-­‐box	  protein	   (SCF)	   complex	  or	  even	   if	   they	  do,	  do	  
not	  necessarily	  function	  as	  E3	  ubiquitin	  ligases(Skaar	  et	  al.,	  2009c).	  Therefore,	  the	  initial	  
aim	   of	   my	   PhD	   thesis	   was	   to	   develop	   tools	   to	   study	   FBXO7	   and	   then	   to	   establish	  
whether	   the	   FBXO7	   wild	   type	   protein	   and	   the	   pathogenic	   FBXO7	   mutants	   	   -­‐	   T22M,	  
R378G	  and	  R498X	  –	  assemble	  into	  a	  SCF	  E3	  ligase	  complex	  in	  vivo:	  First,	  I	  show	  that	  in	  a	  
	  
	  
	   77	  
stable	  overexpression	  system	  the	  wild-­‐type	  FBXO7	  protein	  does	  exists	  in	  a	  complex	  with	  
SKP1,	  Cullin	  1,	  RBX1.	   	   Second,	   I	   show	   that	  neither	  of	   the	  pathogenic	  mutants	  disrupts	  
complex	   formation	   in	  a	   stable	  overexpression	  system.	  Furthermore,	   I	  demonstrate	   for	  
the	  first	  time	  that	  the	  SCFFBXO7	  complex	  is	  also	  formed	  at	  endogenous	  level	  in	  wild	  type	  
brain	   in	   vivo;	   and	   that	  neither	   the	  R378G	  nor	   the	  R498X	  mutants	  disrupt	  endogenous	  
complex	  formation	  in	  vivo.	  For	  the	  latter,	  I	  make	  use	  of	  a	  FBXO7	  knock-­‐in	  mouse	  model	  
of	   the	  pathogenic	  R378G	  mutation	   (discussed	   in	  chapter	  4)	  as	  well	  as	  patient	  derived,	  
mutation	   specific	   immortalized	   cell	   lines	   (generously	   provided	   by	   Professor	   Henry	  
Houlden,	  UCL).	  	  
3.2 Overexpression	   of	   FBXO7	   wt	   /	   disease	   mutants	   and	  
antibody	  validation	  
 Stable	  overexpression	  of	  human	  FBXO7	  wt	  and	  disease	  mutants	  	  3.2.1
First,	   I	   stabily	   expressed	   the	   human	   FBXO7	   wild-­‐type	   as	   well	   as	   pathogenic	   disease	  
mutants	  as	  N-­‐terminal	  Flag-­‐tagged	  constructs	  in	  Flp-­‐In	  TRex	  HEK293	  (Human	  Embryonic	  
Kidney)	   cell	   lines.	   The	   Flp-­‐In	  HEK293	   cell	   line	   allows	   for	   integration	   and	   expression	   of	  
constructs	   at	   a	   specific	   genomic	   location	   with	   subsequent	   doxycycline	   induced	  
expression.	  The	  advantage	  of	  the	  Flp-­‐In	  system	  is	  that	  equal	  gene	  expression	  is	  obtained	  
in	   an	   isogenic	   cell	   pool.	   Stable	   cell	   lines	  expressing	  either	   Flag-­‐tag	  alone	  or	  human	  N-­‐
terminal	   Flag-­‐tagged	  wild-­‐type	   FBXO7	   or	   disease	  mutants	   (T22M,	   R378G,	   and	   R498X)	  
were	   generated	   and	   induced	   for	   expression	   with	   0.1µg/ml	   doxycycline	   for	   18	   hours	  
(Figure	  11).	  	  
 Validation	  of	  DSTT	  -­‐	  produced	  α 	  human	  FBXO7	  antibody	  3.2.2
Two	  antibodies	  against	  the	  human	  FBXO7	  	  -­‐	  whole	  protein	  -­‐	  antigen	  were	  raised	  by	  the	  
DSTT	  (S916C	  and	  S038D),	  and	  all	  bleeds	  (1-­‐3	  for	  S916C	  and	  1-­‐4	  for	  S038D)	  were	  tested	  
for	   their	   recognition	  of	  over-­‐expressed	  and	  endogenous	  FBXO7	   in	   Flp-­‐In	  TRex	  HEK293	  
whole	   cell	   lysates.	   Data	   is	   shown	   for	   the	   third	   bleeds	   (and	   fourth	   for	   S038D)	   only	   as	  
these	   bleeds	   were	   chosen	   for	   carrying	   out	   future	   experiments.	   Both	   human	   FBXO7	  
antibodies	   successfully	   detect	   stable	   overexpressed	   FBXO7.	   However,	   the	   S038D	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antibody	  also	  detects	  endogenous	  FBXO7	  (uninduced	  panel),	  while	  the	  S916C	  antibody	  
yields	   an	   additional	   unspecific	   signal	   at	   around	   100	   kDa.	   Usually,	   a	   DSTT	   antibody	  
programme	   encompasses	   three	   bleeds;	   it	   is	   worth	   noting	   that	   carrying	   on	   for	   an	  
additional	   fourth	   bleed	   in	   the	   case	   of	   the	   D038D	   antibody	   resulted	   in	   a	   significant	  
improvement	  of	  its	  sensitivity	  (Figure	  11).	  	  
	  
Figure	  11:	  FBXO7	  antibody	   testing	   in	  stable	  overexpression	  system	  of	  FBXO7	  wt	  and	  
pathogenic	  mutants	  
Flp-­‐In	  TRex	  HEK	  293	  cells	  stably	  expressing	  either	  FLAG	  alone,	  human	  FBXO7	  wild	  type	  N-­‐terminal	  FLAG	  or	  
any	  of	  the	  pathogenic	  mutants	  -­‐	  T22M,	  R378G	  and	  R498X	  –	  each	  with	  a	  C-­‐terminal	  FLAG	  were	  stimulated	  
for	  protein	  expression	  with	  0.1	  ug/ml	  of	  doxycycline	  for	  18	  hours.	  Whole	  cell	  lysates	  were	  blotted	  for	  
FLAG	  (Sigma),	  FBXO7	  using	  2	  different	  DSTT	  produced	  anti	  -­‐	  human	  FBXO7	  antibodies	  (S916C	  3.	  bleed,	  
S038D	  3.	  and	  4.bleeds)	  and	  GAPDH	  as	  loading	  control.	  Antibody	  concentration	  for	  immunoblotting	  was	  
1ug/ml	  and	  exposure	  time	  was	  the	  same	  for	  all	  blots.	  
37 kDa - _ GAPDH
75 kDa -
_ Flag
75 kDa - _human Fbxo7
(S916C - 3. bleed)
75 kDa - _human Fbxo7
(S038D - 3. bleed)
75 kDa - _ human Fbxo7
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3.3 SCFFBXO7	   complex	   formation	   in	   the	   stable	   overexpression	  
system	  
Many	   E3	   ubiquitin	   ligases	   are	   modular	   with	   a	   core	   scaffold	   and	   interchangeable	  
substrate-­‐targeting	   subunits,	   of	  which	   the	   SKP1-­‐Cullin1-­‐F-­‐box	   protein	   (SCF)	   complexes	  
are	   the	   best	   characterized.	   Cullin1	   –	   as	   the	   scaffold	   of	   SCF	   complexes	   –	   brings	   the	   2	  
functional	  entities	  of	  the	  complex	  in	  close	  proximity:	  its	  C-­‐terminus	  binds	  the	  small	  RING	  
protein	   RBX1,	   which	   directs	   the	   E2	   enzyme	   to	   the	   E3	   ligase	   complex,	   while	   its	   N-­‐
terminus	  binds	  the	  variable	  F-­‐box	  protein	  via	  the	  small	  adaptor	  SKP1(Skaar	  et	  al.,	  2013).	  
The	  specificity	  of	   the	  E3	   ligase	  complex	  depends	  on	  the	  variable	  substrate	   recognizing	  
subunit	  -­‐	  the	  F-­‐box	  protein	  -­‐;	  and	  thus	  the	  core	  machinery	  can	  be	  used	  to	  ubiquitylate	  a	  
myriad	  of	  different	  substrates.	   If	  the	  hypothesis	   is	  that	  the	  pathomechanism	  of	  FBXO7	  
mediated	  disease	  has	  anything	  to	  do	  with	  its	  potential	  role	  as	  a	  component	  of	  a	  SCF	  E3	  
ubiquitin	  ligase,	  it	  first	  needs	  to	  be	  established	  whether	  FBXO7	  is	  able	  to	  form	  a	  complex	  




Figure	   12:	   F-­‐box	   proteins	   are	   the	   substrate	   recognizing	   subunit	   of	   SCF	   E3	   ubiquitin	  
ligase	  complexes	  
Cullin	  1	  (Cul1)	  serves	  as	  a	  scaffold	  bringing	  RBX1	  at	  its	  carboxy-­‐terminal	  end	  the	  substrate	  recognizing	  F-­‐
box	  protein	  via	  SKP1	  to	  its	  amino-­‐terminal	  end.	  Substrate	  specificity	  is	  hence	  dictated	  by	  the	  F-­‐box	  
protein;	  and	  the	  modular	  assembly	  of	  SCF	  complexes	  allows	  ubiquitinylation	  of	  many	  different	  substrates	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 FBXO7	  assembles	  into	  the	  SCFFBXO7	  complex	  and	  the	  pathogenic	  mutants	  do	  not	  3.3.1
disrupt	  complex	  formation	  	  
Three	   independent	   large	   scale	   Flag-­‐pull-­‐downs	   (about	   30mg	   per	   condition)	   of	   stable	  
expressing	  Flag-­‐tagged	  Fbxo7-­‐wildtype	  and	  disease	  mutants	  (T22M,	  R378G	  and	  R498X)	  
with	  Flag-­‐empty	  vector	  as	   a	   control	   have	   been	   performed.	   In	   order	   to	   analyse	   each	  
immunoprecipitate	   (IP)	   for	   tryptic-­‐peptide	   fingerprinting	   mass-­‐spectrometry,	  50%	  of	  
each	   IP	   product	   was	   resolved	   by	   4-­‐12%	   Bis-­‐Tris	   SDS-­‐PAGE,	   gels	   were	   stained	   with	  
colloidal	   Coomassie	   Blue	   and	   each	   lane	   was	   excise	   into	   same	   size	   fragments	   and	  
prepared	  for	  mass-­‐spectrometry.	  The	  remaining	  50%	  of	  the	  IP	  product	  was	  retained	  for	  
subsequent	  validation	  by	  immunoblotting.	  
	  
Figure	   13:	   Illustration	   of	   FLAG-­‐IP	   of	   FLAG-­‐FBXO7	   constructs	   for	   SCF	   complex	  
identification	  
	  
 MS/MS	  identification	  of	  endogenous	  SCF	  complex	  partners	  in	  Flag-­‐IPs	  of	  stable	  3.3.2
expressing	  Flag-­‐Fbxo7	  constructs	  
Peptide	   mass	   fingerprinting	   analysis	   was	   performed	   using	   OLMAT	  
(http://www.proteinguru.com/MassSpec/OLMAT).	   The	   analysis	   workflow	   entailed	  
subtracting	  all	  the	  proteins	  that	  were	  identified	  in	  the	  Flag-­‐IP	  and	  therefore	  considered	  
as	   unspecific	   interactors	   from	   the	   hit	   lists	   of	   the	   IPs	   from	   the	   Flag-­‐FBXO7-­‐	   wt	   and	   –	  
mutants.	  Additionally,	  a	  generic	  list	  of	  well-­‐known	  contaminants	  was	  removed	  from	  the	  
result	   data;	   amongst	   them	   cytoskeletal	   and	   ribosomal	   protein(Trinkle-­‐Mulcahy	   et	   al.,	  
2008).	  In	  the	  first	  instance	  I	  was	  interested	  to	  see	  whether	  the	  individual	  subunits	  of	  the	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Flag-IP:
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SCF	   E3	   ubiquitin	   ligase	   complex	   were	   amongst	   the	   proteomic	   hits:	   In	   case	   of	   the	  
overexpressed	  Flag-­‐tagged	  FBXO7	  wild-­‐type	  protein,	  FBXO7	  as	  the	  bait	  as	  well	  as	  all	  the	  
other	  complex	  partners	  –	  SKP1,	  Cullin1,	  Rbx1	  -­‐	  could	  be	  identified.	  This	  was	  also	  the	  case	  
for	  the	  disease	  mutants	  FBXO7	  R378G	  and	  R498X,	  but	  not	  for	  the	  T22M	  mutant.	  In	  the	  
FBXO7	  T22M,	  which	   constitutes	   to	   the	   compound	  heterozygeous	  mutations	   that	  have	  
been	  identified	  in	  the	  Dutch	  family,	  RBX1	  was	  not	  seen	  in	  any	  of	  the	  3	  replicates	  for	  the	  
T22M	  mutant(Di Fonzo	  et	  al.,	  2009).	  RBX1	  is	  not	  a	  direct	  binding	  partner	  of	  FBXO7,	  but	  
binds	   indirectly	   via	   SKP1	   and	   Cullin1.	   Hence,	   the	   probability	   of	   detecting	   RBX1	   in	   the	  
immunoprecipitate	   of	   FBXO7	   is	   lower	   than	   that	   of	   SKP1,	   which	   is	   a	   direct	   binding	  
partner	  and	  also	  Cullin1,	  which	  is	  a	  first	  degree	  indirect	  binding	  partner	  as	  reflected	  in	  
the	   mascot	   score.	   Additionally,	   the	   proteasomal	   inhibitor	   PI31	   was	   identified	   in	   all	  
replicates	   of	   all	   conditions	   (wt	   and	   mutants).	   PI31	   and	   FBXO7	   have	   been	   shown	   to	  
physically	   interact	   via	   their	   FP	   domains	   and	   this	   interaction	   is	   at	   least	   of	   functional	  
significance	   in	   the	   drosophila	   melanogaster	   homologue	   of	   FBXO7(Bader	   et	   al.,	   2011;	  
Kirk	  et	  al.,	  2008).	  PI31	  was	  identified	  to	  interect	  with	  overexpressed	  FBXO7	  wild-­‐type	  as	  
well	  as	  with	  all	  the	  disease	  mutants.	  	  
	  
Replicate)1
Protein MW*(kDa) WT T22M R378G R498X
FBXO7 58.9 1632*(95,*43%) 1091*(71,*37%) 1403*(101,*37%) 1639*(110,*52%)
Cullin1 90.3 5900*(330,*65%) 3265*(178,*46%) 4146*(216,*55%) 3021*(178,*47%)
SKP1 18.8 1813*(81,*88%) 288*(29,*34%) 1412*(97,*66%) 925*(47,*52%)
RBX1 12.7 62*(5,*17%) I 53*(6,*35%) 57*(5,*12%)
PI31 30 695*(84,*60%) 400*(52,*45%) 712*(72,*42%) 594*(68,*59%)
Replicate)2
Protein MW*(kDa) WT T22M R378G R498X
FBXO7 58.9 718*(44,*19%) 438*(26,*17%) 2793*(153,*47%) 512*(25,*20%)
Cullin1 90.3 2387*(117,*42%) 42*(2,*1%) 1634*(82,*33%) 2163*(121,*46%)
SKP1 18.8 1271*(73,*66%) 128*(7,*15%) 543*(41,*69%) 983*(71,*66%)
RBX1 12.7 I I 20*(2,*12%) I
PI31 30 718*(44,*19%) 313*(23,*30%) 648*(68,*45%) 199*(19,*13%)
Replicate)3
Protein MW*(kDa) WT T22M R378G R498X
FBXO7 58.9 3395*(211,*52%) 2030*(122,*40%) 2762*(164,*51%) 2368*(154,*47%(
Cullin1 90.3 8597*(409,*82%) 6042*(292,*70%) 6159*(273,*61%) 7930*(394,*80%)
SKP1 18.8 1920*(89,*80%) 2002*(88,*75%) 2179*(95,*80%) 2976*(140,*80%)
RBX1 12.7 *60*(7,*17%) I 23*(4,*12%) 48*(8,*12%)
PI31 30 1372*(157,*60%) 610*(54,*47%) 1352*(96,*61%) 1017*(79,*39%)
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Table	  3-­‐1:	   	   Stable	  overexpressed	  FBXO7	  wt	  as	  well	   as	  pathogenic	  mutants	  assemble	  
into	  the	  SCF	  E3	  ligase	  complex	  as	  identified	  by	  proteomics	  
The	  mascot	  score	  for	  each	  endogenous	  complex	  partner	  that	  immunoprecipitated	  with	  stable	  
overexpressed	  Flag-­‐Fbxo7	  is	  shown	  for	  all	  3	  biological	  replicates.	  In	  brackets	  is	  the	  number	  of	  peptides	  
and	  the	  sequence	  coverage	  in	  percent).	  	  
	  
3.3.2.1 Validation	  of	  SCF	  complex	  formation	  by	  immunoblotting	  
Some	  of	  the	  remaining	  50%	  of	  the	  IP	  products	  was	  used	  for	  4-­‐12%	  Bis-­‐Tris	  SDS-­‐PAGE	  and	  
immunoblotting	   for	   the	   stable	   overexpressed	   FBXO7	   constructs	   using	   α-­‐Flag	   and	   α-­‐
human	  FBXO7	  antibodies	  as	  well	  as	  for	  the	  endogenous	  complex	  partners	  and	  PI31.	  This	  
shows	  that	   the	  wt	  as	  well	  as	  all	  of	   the	  3	  disease	  mutants	   in	   the	  stable	  overexpression	  
system	  are	  able	  to	  physically	  bind	  to	  their	  endogenous	  SCF	  complex	  partners	  as	  well	  as	  
PI31.	   While	   the	   interaction	   with	   RBX1,	   which	   does	   not	   directly	   interact	   with	   FBXO7,	  
could	   not	   be	   detected	   in	   the	   immunoprecipitate	   of	   the	   T22M	  mutant	   by	   proteomics,	  
immunoblotting	   is	   sensitive	  enough	   to	   show	   that	  RBX1	   forms	  a	   complex	  with	  all	   Flag-­‐
FBXO7	  constructs	  including	  the	  T22M	  mutant	  (Figure	  14).	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Figure	   14:	   Stable	   overexpressed	   FBXO7	  wt	   as	  well	   as	   pathogenic	  mutants	   assemble	  
into	  the	  SCF	  E3	  ligase	  complex	  as	  identified	  by	  immunoblotting	  
A:	  Representative	  Colloidal	  blue	  stained	  4-­‐12%	  Bis-­‐Tris	  gel	  of	  50%	  of	  the	  IP	  product	  of	  replicate	  3	  for	  in	  gel	  
tryptic	  digestion	  for	  proteomic	  analysis.	  
B:	  Qualitative	  representation	  of	  results	  from	  all	  3	  replicates	  demonstrating	  that	  all	  endogenous	  SCF	  
complex	  components	  as	  well	  as	  PI31	  are	  present	  in	  the	  Flag-­‐FBXO7	  pull-­‐downs	  of	  the	  wt	  as	  well	  as	  the	  
disease	  mutants.	  The	  exception	  is	  RBX1,	  which	  could	  not	  be	  identified	  in	  any	  of	  the	  3	  IPs	  of	  the	  T22M	  
mutant.	  	  
C:	  Flag	  immunoblotting	  of	  input	  lysates	  (10ug	  each)	  and	  1%	  of	  the	  Flag-­‐IP	  product	  for	  detection	  of	  the	  
stable	  overexpressed	  Flag-­‐Fbxo7	  constructs.	  Immunoblotting	  for	  Cullin1,	  SKP1,	  RBX1,	  and	  PI31	  shows	  that	  
not	  only	  the	  wt,	  but	  also	  all	  of	  the	  pathogenic	  mutants	  assemble	  with	  all	  the	  other	  endogenously	  
expressed	  SCF	  complex	  partners.	  Immunoblotting	  is	  able	  to	  detect	  RBX1	  also	  in	  the	  Flag-­‐IP	  of	  the	  T22M	  
mutant.	  
D:	  Immunoblotting	  of	  input	  lysates	  (10ug)	  and	  1%	  of	  the	  IP	  product	  for	  the	  human	  FBXO7	  antigen.	  
	  
Protein( WT( T22M( R378G( R498X(
Cullin1( ( ( ( (
FBXO7( ( ( ( (
PI31( ( ( ( (
SKP11( (  ( (
RBX1( ( -( ( (
MassAspectrometry(results((
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3.4 Screening	   strategies	   for	   identifying	   FBXO7	   interacting	  
partners	   /	   SCFFBXO7	   substrates	   by	   proteomics	   in	   the	   stable	  
overexpression	  system	  
 LC-­‐MS/MS	  of	  Flag	  IPs	  of	  FBXO7	  wt	  and	  disease	  mutants	  3.4.1
The	   formation	   of	   the	   SCFFBXO7	   complex	   is	   a	   prerequisite	   for	   any	   putative	   function	   of	  
FBXO7	   as	   part	   of	   an	   E3	   ubiquitin	   ligase.	   The	   previous	   experiments	   (3.3)	   show	   that	   at	  
least	   in	   the	   single,	   stable	   overexpression	   system	   FBXO7	   wt	   as	   well	   as	   the	   disease	  
mutants	   are	   able	   to	   form	   a	   complex	  with	   endogenous	   Cullin1,	   SKP1,	   RBX1	   as	  well	   as	  
PI31.	   The	   next	   question	   is	  whether	   it	   is	   possible	   to	   identify	   substrates	   of	   FBXO7	   that	  
interact	  with	   the	   SCFFBXO7	   complex	  with	   sufficient	   affinity	   to	  be	  detectable	  by	   affinity-­‐
purification-­‐mass-­‐spectrometry.	  Furthermore,	  if	  this	  approach	  is	  able	  to	  identify	  possibly	  
FBXO7	  substrates,	  it	  would	  be	  interesting	  to	  investigate	  whether	  there	  are	  differences	  in	  
binding	  partners	  between	  the	  wt	  and	  the	  disease	  mutants	  of	  FBXO7.	  To	  undertake	  this	  
analysis,	   the	   mass-­‐spectrometry	   data	   of	   the	   respective	   immunoprecipitations	   were	  
analysed	  using	  proteinguru	  (www.proteinguru.com).	  Proteinguru	  facilitated	  the	  creation	  
of	   a	   single	   excel	   spread	   sheet	   for	   each	   IP	   of	   all	   conditions	   -­‐	   Flag-­‐FBXO7	  wt	   and	   the	  3	  
disease	  mutants	  –	  and	  replicates	  (see	  3.3.2).	  The	  data	  was	  then	  further	  analysed	  using	  
BioVenn,	  a	   free	  web	  application	  for	  the	  comparison	  and	  visualization	  of	  biological	   lists	  
using	  area-­‐proportional	  Venn	  diagrams(Hulsen	  et	  al.,	  2008).	  This	  showed	  that	  there	  is	  a	  
great	  degree	  of	  variation	  amongst	  the	  replicates	  for	  each	  condition	  in	  terms	  of	  number	  
of	  proteins	   identified.	  Also,	   the	  number	  of	  proteins	   that	  were	   identified	   in	  all	  3	   set	  of	  
experiments	   per	   condition	  was	   rather	   small:	   Only	   28	   proteins	  were	   identified	   in	   all	   3	  
replicate	   experiments	   for	   the	   FBXO7	   wt,	   11	   for	   the	   FBXO7	   T22M,	   35	   for	   the	   FBXO7	  
R378G,	   and	   21	   for	   the	   FBXO7	   498X	   mutants	   (Figure	   15:	   Overlap	   of	   the	   proteomic	  
datasets	   of	   the	   3	   replicate	   experiments	   per	   condition:	   FBXO7	   wt,	   T22M,	   R378G,	   and	  
R498X).	   Interestingly,	   the	   protein	   IDs	   that	   were	   shared	   amongst	   replicates	   mainly	  
belonged	  to	  members	  of	  the	  proteasomal	  machinery,	  to	  the	  SCFFBXO7	  complex	  as	  well	  as	  
PI31.	  This	  was	  true	  for	  the	  FBXO7	  wt	  as	  well	  as	  all	  3	  disease	  mutants.	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Figure	   15:	   Overlap	   of	   the	   proteomic	   datasets	   of	   the	   3	   replicate	   experiments	   per	  
condition:	  FBXO7	  wt,	  T22M,	  R378G,	  and	  R498X	  
A:	  The	  Venn	  diagrams	  show	  the	  degree	  of	  variation	  amongst	  the	  3	  replicates	  per	  condition	  in	  terms	  of	  
absolute	  number	  of	  identified	  proteins	  and	  the	  pool	  of	  protein	  IDs	  that	  were	  identified	  in	  all	  3	  
experiments	  per	  condition.	  Each	  condition	  –	  wt	  and	  mutants	  –	  for	  each	  replicate	  were	  performed	  in	  
parallel;	  replicate	  one	  is	  colour	  coded	  in	  red,	  replicate	  2	  in	  yeallow,	  and	  replicate	  3	  in	  blue.	  
B:	  The	  table	  indicates	  the	  number	  of	  proteins	  that	  were	  identified	  in	  each	  replicate	  experiment	  and	  the	  
number	  of	  proteins	  that	  were	  identified	  in	  all	  3	  sets	  per	  condition.	  
	  
Replicate FBXO7.wt FBXO7.T22M FBXO7.R378G FBXO7.R498X
1 225 237 494 441
2 151 76 181 97
3 408 391 455 260





	   86	  
	  
Table	   3-­‐2:	   Hits	   of	   the	   affinity-­‐purification	   mass-­‐spectrometry	   analysis	   of	   the	   Flag-­‐
FBXO7	  wild-­‐type	  and	  disease	  mutants,	  that	  were	  found	  in	  all	  3	  replicate	  experiments	  
The	  table	  shows	  the	  list	  of	  proteins	  that	  were	  identified	  in	  each	  of	  the	  3	  replicates	  for	  each	  condition	  –	  
Flag-­‐Fbxo7	  wild-­‐type,	  T22M,	  R378G	  and	  R498X	  (“Overlap	  (1,2,3)”	  in	  Venn	  diagram	  in	  Figure	  15).	  
Highlighted	  in	  red	  are	  FBXO7	  as	  the	  bait,	  the	  other	  SCF	  complex	  partners	  (SKP1,	  Cul1,	  and	  RBX1)	  as	  well	  as	  










CUL1% CUL1% CUL1% CUL1%
SKP1% FBXO7% TUBA8% FBXO7%
FBXO7% GNB2L1% SKP1% SKP1%
GNB2L1% IRS4% FBXO7% PSMF1%
PSMF1% PSMF1% GNB2L1% PSMA7%
PSMA7% SKP1% PSMF1% PSMA1%
PSMC5% PRKDC% PSMA1% PSMB5%
PSMA4% PSMB1% PSMD2% PSMC2%
COPS4% PSMA3% PSMB5% PSMA2%
PSMB5% PSMA2% PSMC5% PSMB3%
PSMC1% ZBED4% PSMC2% PSMB1%
PSMA3% %% PSMA7% PSMA5%
PSMA1% %% PSMA6% PSMB2%
PSMA6% %% COPS4% PSMC4%
PSMC2% %% PSMB2% PSMB4%
COPS5% %% PSMA2% PSMA3%
IRS4% %% CTPS% ABCA5%
PSMB2% %% PSMA3% SLX4%
PSMA2% %% PSMB1% SNTN%
PSMB4% %% PSMC6% ASPM%
PSMA5% %% PSMB3% FBF1%
PSMB1% %% PSMC1% %%
PSMG1% %% PSMC4% %%
PSMC4% %% ATAD3B% %%
SLX4% %% PSMB4% %%
ANXA5% %% COPS6% %%
MAGEB18% %% EEF1G% %%
H1FNT% %% PSMA5% %%
%% %% PSMD8% %%
%% %% SLX4% %%
%% %% PSMD14% %%
%% %% MAGEE1% %%
%% %% KCNH5% %%
%% %% ACE% %%
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 LC-­‐MS/MS	  of	  Flag	  IPs	  of	  FBXO7	  mutants	  deficient	  of	  forming	  SCFFBXO7	  complex	  3.4.2
Identifying	  substrates	  of	  E3	   ligases	   is	  notoriously	  difficult	  because	  of	   the	  transient	  and	  
weak	   nature	   of	   this	   interaction.	   Several	   groups	   have	   designed	   general	   screening	  
strategies	   for	   substrate	   identification,	  amongst	   them	  Yumimoto	  et	  al(Yumimoto	  et	  al.,	  
2012).	  Here,	  they	  combine	  differential	  SILAC	  (Stable	  Incorporation	  of	  Aminoacids	  in	  Cell	  
culture)	  labelling	  with	  mutations	  within	  the	  F-­‐Box	  domain	  that	  abolish	  SKP1	  binding.	  The	  
rational	  is	  that	  a	  substrate	  is	  specifically	  recognized	  and	  bound	  by	  the	  F-­‐box	  protein	  as	  
the	   substrate	   recognizing	   subunit	   of	   the	   SCF	   E3	   ubiquitin	   ligase	   complex	   with	  
subsequent	  ubiquitinylation	  and	  degradation	  by	  the	  proteasome	  resulting	  in	  decreased	  
cellular	  expression	  levels	  of	  the	  particular	  substrate.	  In	  contrast,	  a	  F-­‐box	  protein	  mutant	  
deficient	   of	   SKP1	   binding	   and	   hence	   SCF	   complex	   formation,	   is	   expected	   to	   retain	   its	  
ability	  to	  recognize	  and	  bind	   its	  substrate,	  but	   in	  contrast	  to	   its	  wild	  type	  counterpart,	  
not	   result	   in	   ubiquitylation,	   degradation	   and	   reduction	   in	   expression	   levels	   thereof	  
(Figure	  16).	  The	  relative	  difference	  in	  expression	  levels	  of	  proteins	  can	  then	  be	  exploited	  
by	  SILAC	  based	  quantitative	  proteomics	  to	  identify	  putative	  substrates	  of	  a	  particular	  F-­‐
box	   protein	   of	   interest.	   Additionally,	   this	   approach	   is	   expected	   to	   stabilize	   the	  
interaction	  between	  the	  mutant	  F-­‐box	  protein	  and	  its	  substrates	  –	  which	  otherwise	  has	  
been	  described	  as	  a	  “kiss	  and	  run”	  situation	  –	  and	  possibly	  make	  it	  more	  amenable	  for	  
detection	   by	   mass-­‐spectrometry	   of	   the	   immunoprecipitate	   even	   without	   employing	  
SILAC.	  	  
The	  idea	  was	  then	  to	  apply	  this	  approach	  to	  FBXO7.	  However,	  rather	  than	  deleting	  the	  
F-­‐box	  domain	  of	   FBXO7	  as	  a	  whole	  –	  with	   the	   caveat	   that	  deleting	  46	  AA	  might	  have	  
structural	   implications	   for	   its	   interaction	  with	   either	   the	   complex	   or	   its	   substrates	   –	   I	  
first	   intended	   to	   identify	   residues	   within	   the	   F-­‐box	   domain	   of	   FBXO7	   that	   were	  
important	  for	  SKP1	  binding	  and	  hence	  complex	  formation	  (see	  3.4.2.1).	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Figure	   16:	   Strategy	   for	   F-­‐box	   protein	   substrate	   screening	   by	   differential	   proteomics	  
and	  use	  of	  non-­‐SKP1	  binding	  mutants	  
	  A	  substrate	  is	  specifically	  ubiquitylated	  and	  degraded	  upon	  recognition	  by	  the	  substrate	  recognizing	  F-­‐box	  
protein	  subunit	  of	  a	  particular	  ubiquitin	  ligase	  complex	  resulting	  in	  a	  decrease	  in	  its	  cellular	  protein	  
expression	  levels	  (right	  side	  of	  illustration).	  In	  contrast,	  if	  the	  same	  F-­‐box	  protein	  has	  a	  mutation	  in	  its	  F-­‐
box	  domain	  that	  abolishes	  SKP1	  binding	  and	  hence	  complex	  formation,	  the	  expectation	  is	  that	  the	  same	  
substrate	  is	  still	  being	  recognized	  and	  bound	  without	  being	  degraded.	  This	  would	  result	  in	  a	  relative	  
increase	  in	  its	  cellular	  expression	  level	  (left	  side	  of	  the	  panel)	  as	  it	  is	  not	  degraded	  via	  the	  ubiquitin	  
proteasomal	  system.	  This	  difference	  in	  expression	  level	  can	  be	  exploited	  in	  SILAC	  quantitative	  proteomics	  
to	  identify	  putative	  SCF	  substrates.	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3.4.2.1 Screening	  for	  FBXO7	  residues	  important	  for	  SKP1	  binding	  
The	  F-­‐box	  domain	  in	  general	  is	  a	  degenerative	  motif	  consisting	  of	  about	  40	  AA	  residues,	  
and	  for	  most	  F-­‐box	  proteins	  it	  is	  not	  known	  which	  of	  these	  residues	  are	  mandatory	  for	  
the	  interaction	  with	  SKP1(Skaar	  et	  al.,	  2009b).	  An	  exception	  is	  the	  F-­‐box	  protein	  SKP2,	  as	  
a	  crystal	  structure	  of	  the	  human	  SKP2	  bound	  to	  SKP1	  has	  been	  described(Schulman	  et	  
al.,	   2000).	   Figure	   17	   shows	   an	   alignment	   of	   the	   F-­‐box	  motif	   consensus	   sequence	   and	  
SKP2,	  as	  well	  as	  all	   the	  amino	  acids	  that	  constitute	  the	  direct	   interface	  between	  the	  2	  
proteins.	  	  
	  
Figure	  17:	  F-­‐box	  domain	  residues	  of	  potential	  importance	  for	  SKP1	  binding	  
Sequence	  alignment	  of	  the	  F-­‐box	  motif	  consensus	  motif	  and	  the	  region	  around	  the	  F-­‐box	  motif	  of	  the	  
human	  F-­‐box	  protein	  SKP2	  (Q13309,	  AA	  92-­‐156).	  A	  red	  star	  denotes	  the	  AA	  residues	  of	  SKP2	  that	  are	  in	  
contact	  with	  SKP1	  based	  on	  the	  crystal	  structure	  of	  the	  human	  SKP2	  bound	  to	  SKP1	  complex(Schulman	  et	  
al.,	  2000).	  
	  
This	   information	   was	   used	   as	   a	   template	   to	   design	   single	   Alanine	   point	   mutants	   of	  
individual	   residues	  of	   the	  F-­‐box	  domain	  of	  FBXO7	   in	  order	  to	  determine	  the	   individual	  
contribution	  of	  these	  residues	  for	  the	  interaction	  between	  FBXO7	  and	  SKP1:	  In	  the	  first	  
instance,	  the	  relevant	  part	  of	  the	  FBXO7	  sequence	  was	  added	  to	  the	  SKP2	  alignment	  and	  
individual	  FBXO7	  residues	  were	  picked	  for	  site	  directed	  mutagenesis	  of	  the	  Flag-­‐FBXO7-­‐
wt	  template	  (Figure	  18).	  	  
	  
Figure	  18:	   Stretegy	  of	   the	  Alanine	   screen	   to	   identify	   FBXO7	   residues	   responsible	   for	  
interacting	  with	  SKP1	  
Sequence	  alignment	  of	  the	  region	  around	  the	  F-­‐box	  motif	  of	  FBXO7	  (F-­‐box	  motif:	  AA	  329-­‐375)	  and	  SKP2	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the	  AA	  residues	  of	  SKP2	  that	  are	  in	  direct	  contact	  with	  SKP1	  (as	  above	  in	  Figure	  17);	  green	  stars	  directly	  
under	  the	  FBXO7	  sequence	  denote	  the	  residues	  for	  which	  single	  Alanine	  mutants	  of	  FBXO7	  were	  tested	  
and	  the	  blue	  stars	  in	  the	  second	  line	  underneath	  the	  FBXO7	  sequence	  illustrate	  the	  residues	  that	  either	  as	  
quadruple	  (dark	  blue)	  or	  quintuple	  (light	  blue)	  FBXO7	  mutants	  have	  been	  shown	  to	  abolish	  SKP1	  binding	  
in	  the	  literature(Nelson	  and	  Laman,	  2011).	  Additionally,	  a	  Δ	  f-­‐box	  domain	  FBXO7	  mutant,	  where	  all	  46	  AA	  
of	  the	  presumed	  F-­‐box	  domain	  of	  FBXO7	  were	  deleted,	  was	  included	  in	  the	  screen.	  Also,	  a	  SKP2	  double	  
mutant	  unable	  to	  bind	  SKP1	  has	  also	  been	  reported	  in	  the	  literature	  and	  is	  indicated	  with	  black	  
stars(Yumimoto	  et	  al.,	  2012).	  
	  
To	   test	   whether	   these	   single	   Alanine	   mutants	   were	   capable	   of	   SKP1	   binding,	   each	  
construct	  was	  transiently	  transfected	  into	  HEK293	  cells,	  cells	  were	  lysed	  after	  24	  hours	  
and	  subjected	  to	  a	  Flag-­‐IP.	  The	  FLAG-­‐IP	  products	  for	  each	  mutant	  were	  then	  subjected	  
to	   immunoblotting	   for	   FLAG	   as	   well	   as	   SKP1	   to	   demonstrate	   either	   unaffected	   or	  
impaired	  /	  abolished	  SKP1	  binding	  of	  the	  respective	  mutant.	  As	  shown	  in	  Figure	  19,	  the	  
FBXO7	   wt	   construct	   served	   as	   a	   negative	   control	   as	   SKP1	   binding	   was	   unaffected,	  
whereas	  the	  Δ	  f-­‐box	  domain	  FBXO7	  mutant	  served	  as	  a	  positive	  control	  as	  SKP1	  binding	  
was	   completely	   abolished.	   None	   of	   the	   15	   single	   Alanine	   mutants	   within	   the	   F-­‐box	  
domain	  of	  FBXO7	  were	  able	  to	  completely	  abolish	  SKP1	  binding.	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Transient	  transfections	  of	  either	  Flag-­‐empty	  vector	  or	  Flag-­‐tagged	  FBXO7	  wt	  (negative	  control:	  unaffected	  
SKP1	  binding),	  Δ	  f-­‐box	  domain	  FBXO7	  (positive	  control:	  abolished	  SKP1	  binding)	  and	  15	  single	  Alanine	  
mutants	  of	  F-­‐box	  motif	  residues	  of	  FBXO7	  (as	  indicated	  in	  Figure	  18)	  into	  HEK293	  cells	  were	  lysed	  after	  24	  
hours	  and	  1	  mg	  of	  each	  lysate	  was	  subjected	  to	  FLAG	  immunoprecipitation	  for	  2	  hours.	  The	  reactions	  
were	  then	  immunoblotted	  for	  FLAG	  (bait)	  and	  assayed	  for	  their	  ability	  to	  bind	  SKP1.	  
	  
At	   the	   same	   time	   as	   these	   experiments	   were	   performed,	   a	   paper	   was	   published	  
identifying	   2	   FBXO7	  mutants	   in	  whom	  either	   simultaneous	  mutation	   of	   4	   or	   5	   FBXO7	  
residues	   resulted	   in	   abolished	   SKP1	   binding(Nelson	   and	   Laman,	   2011).	   	  We	   therefore	  
included	   these	  mutants	   in	   our	   screen	   together	  with	   some	   of	   the	   single	  mutants	   that	  
appeared	  to	  have	  had	  some	  effect	  on	  SKP1	  binding	  as	  well	  as	  all	  the	  pathogenic	  disease	  
mutants.	   Figure	   20	   shows	   that	   the	   quadruple	   (FLAG-­‐FBXO7	   -­‐	  
I343A+L346A+L347A+V349A)	   and	   quintuple	   FBXO7	   mutants	   (FLAG-­‐FBXO7	   -­‐	  
L332A+L335A+L337A+L339A+L341A)	  were	  indeed	  incapable	  of	  SKP1	  binding,	  whereas	  in	  
comparison	  none	  of	  the	  single	  mutants	  or	  any	  of	  the	  disease	  mutants	  had	  a	  major	  effect	  
on	  SKP1	  binding.	  	  
	  
Figure	   20:	   Confirmation	   of	   abolished	   SKP1	   binding	   of	   previously	   reported	   FBXO7	  
mutants	  	  
FLAG	  immunoprecipitation	  of	  the	  wt,	  Δ	  f-­‐box	  domain,	  pathogenic	  disease	  mutants,	  some	  of	  the	  previously	  
shown	  (Figure	  19)	  single	  mutants	  and	  the	  reported	  quadruple	  and	  quintuple	  FBXO7	  mutants.	  FLAG-­‐IPs	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As	  mentioned	   above	   (3.4.2),	   the	   intention	  was	   to	   utilize	   the	   non-­‐SKP1	  binding	   FBXO7	  
mutants	   in	   a	   proteomic	   screen	   to	   identify	   FBXO7	   substrates.	   I	   was	   interested	   in	  
identifying	   substrates	   of	   the	   FBXO7	   wt	   protein,	   but	   in	   particular	   also	   in	   one	   of	   the	  
pathogenic	   disease	   mutants:	   R378G	   FBXO7.	   This	   particular	   disease	   mutant	   is	   in	  
immediate	   proximity	   of	   the	   F-­‐box	   domain	   (AA	   329-­‐375),	   but	   experiments	   so	   far	   have	  
demonstrated	   that	   it	   neither	   disrupts	   SKP1	   binding	   (Figure	   20)	   nor	   SCFFBXO7	   complex	  
formation	   (Figure	   14).	   I	   therefore	   designed	   an	   additional	   non-­‐SKP1	   binding	  mutant	   –	  
using	   the	   quadruple	   non-­‐SKP1	   binding	   mutant	   as	   a	   template	   (FLAG-­‐FBXO7	   -­‐	  
I343A+L346A+L347A+V349A	   (DU41285)	   –	   for	   the	   R378G	   disease	  mutant:	   FLAG-­‐FBXO7	  
R378G	  plus	   I343A+L346A+L347A+V349A	   (DU41287).	   Figure	  21	   shows	   the	   result	   of	   the	  
stable	  expression	  of	  these	  mutants	  –	  wt	  and	  R378G	  with	  intact	  SKP1	  binding	  as	  well	  as	  
wt	  (DU41285)	  and	  R378G	  (DU51287)	  with	  abolished	  SKP1	  binding.	  As	  expected	  the	  non-­‐
SKP1	  binding	  mutants	  –	  either	  wt	  or	  R378G	  background	  –	  are	  unable	  to	  bind	  SKP1	  or	  any	  
of	  the	  other	  SCF	  complex	  members	  (Cullin	  1	  and	  RBX1)	  while	  binding	  to	  PI31,	  which	  is	  
facilitated	  via	  a	  different	  FBXO7	  domain,	  is	  retained.	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Figure	  21:	  Stable	  expressing	  non-­‐SCF	  complex	  binding	  cell	   lines	  of	  the	  FBXO7	  wt	  and	  
pathogenic	  R378G	  mutant	  
Stable	  expressing	  Flp-­‐In	  TRex	  HEK293	  cell	  lines	  of	  Flag-­‐tagged	  FBXO7	  wt	  and	  the	  disease	  mutants	  R378G	  
and	  R498X	  as	  well	  as	  FLAG-­‐FBXO7	  wt	  and	  R378G	  in	  the	  non-­‐SKP1	  binding	  background	  (FLAG-­‐FBXO7-­‐
I343A+L346A+L347A+V349A)	  were	  subjected	  to	  FLAG-­‐immunoprecipitation	  and	  assayed	  for	  their	  ability	  to	  
bind	  the	  other	  members	  of	  the	  SCF	  complex	  as	  well	  as	  PI31.	  The	  top	  panel	  shows	  input	  lysates	  and	  
complete	  depletion	  of	  the	  FLAG-­‐FBXO7	  constructs	  after	  the	  IP.	  
	  
3.4.2.2 SILAC	  based	  quantitative	  proteomics	  of	  non-­‐SKP1	  binding	  FBXO7	  mutants	  
As	  demonstrated	  in	  3.4.2.1,	  stably	  expressing	  constructs	  of	  all	  FBXO7	  mutants	  employed	  
in	   this	   experiment	   were	  made	   and	   passaged	   at	   least	   5	   times	   in	   the	   respective	   SILAC	  
medium	  to	  achieve	  >97%	  labelling	  efficacy	  for	  each	  condition	  (Table	  3-­‐3).	  After	  inducing	  
construct	   expression	  with	   doxycycline	   for	   18	   hours,	   cells	  were	   harvested	   and	   Flag	   IPs	  
were	  performed.	  Equal	  amounts	  of	  IP	  products	  were	  mixed	  and	  prepared	  for	  in	  solution	  

































































41285:	  Flag-­‐FBXO7-­‐wt	  (I343A,	  L346A,	  L347A,	  V349A) 




	   94	  
	  
Table	  3-­‐3:	  Experimental	  setup	  and	  SILAC	  labelling	  conditions	  
Each	  experiment	  consisted	  of	  3	  conditions.	  Flag-­‐empty	  vector	  was	  labelled	  with	  “light”	  SILAC	  medium	  
(expected	  to	  bind	  “unspecific	  contaminants”),	  either	  the	  SKP1	  -­‐	  binding	  Flag-­‐tagged	  FBXO7	  wt	  or	  SKP1	  –	  
binding	  Flag-­‐tagged	  FBXO7	  R378G	  mutant	  were	  grown	  in	  “medium”	  SILAC	  media	  (in	  experiment	  6,	  the	  
non-­‐SKP1	  binding	  mutant	  of	  Flag-­‐tagged	  FBXO7	  R378G	  was	  also	  used	  in	  “medium”	  SILAC	  label)	  and	  the	  
non-­‐SKP1	  binding	  mutants	  (either	  FLAG-­‐FBXO7	  wt	  -­‐	  L332A+L335A+L337A+L339A+L341A	  (DU41284),	  FLAG-­‐
FBXO7	  wt-­‐	  I343A+L346A+L347A+V349A	  (DU41285),	  FLAG-­‐FBXO7-­‐R378G	  -­‐	  
L332A+L335A+L337A+L339A+L341A	  (DU41286),	  FLAG-­‐FBXO7	  R378G-­‐	  I343A+L346A+L347A+V349A	  
(DU41287),	  or	  FLAG-­‐	  FBXO7	  wt	  –	  Δ-­‐F-­‐box)	  were	  grown	  in	  “heavy”	  SILAC	  medium.	  
	  
The	   proteomics	   raw	   data	   was	   then	   analysed	   using	   maxquant	   and	   the	   following	  
questions	  were	  asked(Cox	  et	  al.,	  2009):	  Which	  proteins	  are	  more	  abundantly	  present	  (at	  
least	  >	  2.5	  fold)	  in	  the	  non-­‐SKP1	  binding	  FBXO7	  wt	  mutant	  (DU41284,	  DU41285	  and	  Δ-­‐F-­‐
box	  FBXO7	  wt)	  than	  in	  the	  FBXO7	  wt	  (Experiment	  1,	  2,	  and	  5)?	  Which	  proteins	  are	  more	  
abundantly	  present	  in	  the	  non-­‐SKP1	  binding	  R378G	  FBXO7	  disease	  mutant	  compared	  to	  
the	  SKP1-­‐binding	  R378G	  FBXO7	  mutants	   (DU41286	  and	  DU41287)	  or	  FBXO7	  wt	  –	  Δ-­‐F-­‐
box	  (Experiment	  3,	  4,	  and	  7)?	  And	  does	  a	  different	  subset	  of	  proteins	  bind	  more	  readily	  
to	  the	  non-­‐SKP1	  binding	  R378G	  FBXO7	  mutant	   in	  comparison	  to	  the	  non-­‐SKP1	  binding	  
FBXO7	  wt	  construct	  (Experiment	  6)?	  Additionally,	  none	  of	  the	  SCF	  complex	  partners	  or	  
any	  of	   the	  potential	  hits	  should	  be	  present	   in	   the	  FLAG-­‐empty	  vector	   IP	   list.	  Table	  3-­‐4	  
illustrates	  the	  analysis	  paradigm.	  	  
LIGHT (K0,R0) MEDIUM (K4, R6) HEAVY (K8, R10)
1 Flag wt 41285
2 Flag wt 41284
3 Flag R378G 41286
4 Flag R378G 41287
5 Flag wt Δ F-box
6 Flag 41287 41285
7 Flag R378G Δ F-box
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Table	  3-­‐4:	  Analysis	  paradigm	  of	  differential	  protein	  complexes	  associated	  with	  SKP1-­‐
binding	  and	  non-­‐binding	  FBXO7	  mutants	  	  
The	  expectation	  is	  that	  the	  non-­‐SKP1	  binding	  mutant	  is	  still	  able	  to	  recognize	  and	  bind	  its	  substrate,	  but	  
without	  immediately	  releasing	  it	  for	  ubiquitylation	  and	  subsequent	  proteasomal	  degradation.	  The	  
substrate	  should	  therefore	  be	  more	  abundantly	  present	  and	  detectable	  in	  the	  IP	  of	  non-­‐SKP1	  binding	  
mutant	  than	  in	  the	  SKP1-­‐binding	  and	  hence	  SCF	  E3	  ligase	  complex	  forming	  counterpart.	  SILAC	  labelling	  of	  
the	  different	  conditions	  allows	  mixing	  the	  samples	  at	  IP	  level	  before	  digestion	  and	  quantitatively	  assessing	  
differences	  in	  protein	  complexes	  associating	  with	  the	  SKP1-­‐binding	  and	  non-­‐SKP1	  binding	  conditions.	  
	  
Coming	  now	  to	  the	  actual	  results:	  As	  expected,	  none	  of	  the	  SCF	  complex	  partners	  was	  
present	  in	  any	  of	  the	  FLAG-­‐empty	  vector	  IPs.	  FBXO7	  should	  have	  been	  equally	  abundant	  
in	  each	  set	  of	  experiments,	  but	  this	  was	  not	  the	  case	  as	  shown	  in	  	  
Table	   3-­‐5:	   The	   ratio	   for	   FBXO7	   varied	   between	   0.76	   and	   0.42	   between	   the	   individual	  
experiments.	   SKP1	   was	   significantly	   less	   abundant	   in	   the	   non-­‐SKP1	   binding	   mutants	  
(about	   factor	   10)	   while	   PI31	   was	   present	   in	   all	   experiments	   with	   a	   ratio	   of	   about	   1.	  
There	  were	  no	  other	  hits	  in	  any	  of	  the	  7	  experiments	  that	  fulfilled	  the	  criteria	  of	  being	  at	  
least	   2.5	   fold	  more	   abundant	   in	   the	   non-­‐SKP1	   binding	   compared	   to	   the	   SCF	   complex	  
binding	  FBXO7	  mutants.	  Data	  is	  shown	  for	  one	  set	  of	  experiments.	  The	  same	  experiment	  
was	   repeated	   twice	   without	   any	   difference	   in	   outcome:	   One	   time,	   lysates	   from	   the	  
different	  SILAC	  conditions	  were	  mixed	  at	  lysate	  level	  rather	  than	  after	  performing	  the	  IP	  
followed	  by	   in	   solution	   tryptic	  digestion	   for	  mass-­‐spectrometry	  analysis	  and	   the	  other	  







FBXO7   
SKP1   
CULLIN1   
RBX1   
PI31   
putative)substrates)   or   or 
Experiment 1 2 3 4 5 6 7
RATIO&(H/L) 41285&(H)&/wt&(M) 41284&(H)&/wt&(M) 41287&(H)&/R378G&(M) 41287&(H)&/R378G&(M) Δ&F3box&(H)&/wt&(M) 41287&(H)&/41285(M) Δ&F3box&(H)&/R378G&(M)
FBXO7 0.76 0.48 0.63 0.63 0.42 0.67 0.45
SKP1 0.08 0.09 0.06 0.06 0.06 0.55 0.05
CULLIN1 3 3 3 3 3 3 3
RBX1 3 3 0.64 0.64 - - 0.74
PI31 1.05 0.82 1.03 1.03 1.07 1.07 1.04
putative&substrates no&hit&>&2.5 no&hit&>&2.5 no&hit&>&2.5 no&hit&>&2.5 no&hit&>&2.5 no&hit&>&2.5 no&hit&>&2.5
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time,	  the	  experiment	  was	  repeated	  exactly	  the	  same	  way	  as	  the	  experiment	   in	  3.4.2.2	  
except	   that	   the	   samples	  were	   not	   prepared	   by	   in	   solution	   tryptic	   digestion	   for	  mass-­‐
spectrometry,	   but	   that	   a	   SDS	   PAGE	   electrophoresis	   was	   performed	   and	   bands	   were	  
prepared	   for	   in-­‐gel	   tryptic	   digestion	   for	   mass-­‐spectrometry	   (data	   of	   the	   latter	   2	  
experiments	  not	  shown).	  
Table	  3-­‐5:	  Results	   for	  SILAC	  based	  proteomics	  of	  SKP1-­‐binding	  and	  non-­‐SKP1	  binding	  
FBXO7	  mutants	  
	  
3.4.2.3 Non-­‐SILAC	  based	  proteomics	  of	  non-­‐SKP1	  binding	  FBXO7	  mutants	  
The	  non-­‐SKP1	  binding	  FBXO7	  mutants	  may	  nonetheless	  represent	  a	  potentially	  powerful	  
tool	  for	  identifying	  FBXO7	  substrates.	  As	  mentioned	  before,	  the	  interaction	  between	  F-­‐
box	   proteins	   and	   their	   substrates	   is	   usually	   transient	   and	   possibly	   weak	   or	   at	   least	  
weaker	  than	  the	  association	  between	  FBXO7	  and	  the	  other	  SCF	  complex	  partners.	  As	  the	  
non-­‐	  SKP1	  binding	  mutants	  are	  expected	  to	  be	  unimpaired	   in	  their	  ability	  to	  recognize	  
and	  bind	   their	   targets	  without	   immediately	  passing	   them	  on	   to	   the	  proteasome,	   they	  
may	   yield	   information	   about	   substrates	   in	   more	   straightforward	   conventional	   mass-­‐
spectrometry	  analysis	  of	  Flag-­‐immunoprecipitation	  complexes	  without	  SILAC	  labelling.	  	  
In	   this	   experiment,	   I	   performed	   FLAG	   immunoprecipitations	   on	   1.5mg	  of	   lysates	   from	  
stable	  expressing	  FBXO7	  constructs	  that	  had	  been	  induced	  overnight:	  Flag-­‐empty	  vector,	  
Flag-­‐tagged	  FBXO7	  wt	  and	  the	  disease	  mutant	  R378G	  and	  the	  non-­‐SKP1	  binding	  mutants	  
FLAG-­‐FBXO7	   wt-­‐	   I343A+L346A+L347A+V349A	   (DU41285),	   and	   FLAG-­‐FBXO7	   R378G-­‐	  
I343A+L346A+L347A+V349A	  (DU41287).	  Before	  harvesting	   the	  cells,	  cells	  were	   treated	  
with	   chemical	   inhibitor	   of	   the	   NEDD8-­‐E1,	  MLN4924	   at	   a	   concentration	   of	   3uM	   for	   4	  
hours	  or	  DMSO	  as	  a	  control.	  By	  inhibiting	  the	  E1	  activating	  enzyme	  of	  NEDD8,	  MLN4924	  
prevents	  the	  neddylation	  of	  cullins,	   thereby	   inactivating	  Cullin	  Ring	  E3	   ligases	  /	  SCF	  E3	  
ligases	  resulting	   in	  accumulation	  of	   their	  substrates(Brownell	  et	  al.,	  2010;	  Soucy	  et	  al.,	  
2009).	   The	   idea	   was	   that	   using	  MLN4924	  might	   facilitate	   the	   identification	   of	   FBXO7	  
substrates	  as	  it	  prevents	  their	  degradation.	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Figure	  22:	  Control	  blots	  of	  FLAG-­‐IPs	  of	  FBXO7	  SKP1	  binding	  and	  non-­‐binding	  mutants	  
for	  LC-­‐MS/MS	  analysis	  
Silver	  stain	  of	  5%	  of	  FLAG-­‐IP	  products	  from	  1.5mg	  lysates	  (top	  left)	  and	  immunoblot	  of	  input	  lysates	  (top	  
right)	  of	  10ug	  of	  input	  lysates	  for	  FLAG	  –	  demonstrating	  equal	  levels	  of	  doxycycline	  induced	  construct	  
expression;	  Cullin	  1	  –	  showing	  the	  disappearance	  of	  the	  neddylated	  Cullin1	  species	  upon	  treatment	  with	  
MLN4924	  as	  a	  control;	  and	  GAPDH	  as	  a	  loading	  control.	  The	  lower	  panel	  shows	  immunoblots	  of	  10%	  of	  
the	  FLAG-­‐IP	  products	  for	  FLAG	  (bait)	  as	  well	  as	  SKP1	  and	  Cullin1	  to	  demonstrate	  that	  deneddylation	  of	  
Cullin	  1	  does	  not	  disrupt	  SCF	  complex	  formation	  of	  the	  SKP1	  binding	  constructs	  (Flag-­‐FBXO7-­‐wt	  and	  FLAG-­‐
Fl
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FBXO7-­‐R378G)	  and	  to	  verify	  that	  the	  non-­‐SKP1	  binding	  mutants	  do	  not	  bind	  SKP1	  nor	  Cullin1.	  The	  
remaining	  85%	  of	  the	  IP	  products	  were	  prepared	  for	  in-­‐solution	  tryptic	  digestion	  for	  LC-­‐MS/MS.	  
	  
The	   data	   was	   analysed	   with	   proteinguru	   to	   compile	   the	   proteomic	   data	   from	   each	  
condition	  into	  a	  single	  excel	  file.	  This	  data	  was	  then	  further	  processed	  using	  BioVenn	  to	  
create	  the	  Venn	  diagrams	  in	  Figure	  23:	  I	  wanted	  to	  know	  which	  proteins	  are	  exclusively	  
amongst	  the	  proteins	  that	  associate	  with	  the	  non-­‐SKP1	  binding	  FBXO7	  constructs	  –	  bind	  
to	  the	  substrate	  recognizing	  F-­‐box	  protein	  without	  being	  ubiquitylated	  for	  proteasomal	  
degradation	  (yellow)	  -­‐	  and	  at	   the	  same	  time	  did	  not	  overlap	  with	  any	  of	   the	  hits	   from	  
the	   analysis	   of	   the	   FLAG-­‐empty	   vector	   alone	   (blue).	   The	   latter	   were	   considered	   as	  
unspecific	   contaminants.	   For	   the	   FBXO7	  wt,	   this	   was	   the	   case	   for	   62	   proteins	   of	   212	  
(29%)	  and	  for	  the	  FBXO7	  R378G	  disease	  mutant,	  44	  proteins	  of	  190	  (23%).	  The	  MLN4924	  
treated	  datasets	  were	  used	   for	   cross-­‐referencing	  protein	   IDs	   and	   can	  be	   found	   in	   the	  
appendix.	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	   23:	   Overlap	   of	   proteomic	   datasets	   of	   SKP1-­‐binding	   and	   non-­‐binding	   FBXO7	  
mutants	  for	  FBXO7	  wt	  and	  the	  R378G	  disease	  mutants	  
The	  Venn	  diagrams	  show	  the	  overlap	  between	  the	  SKP1-­‐binding	  (red)	  and	  non-­‐SKP1	  binding	  (yellow)	  
FBXO7	  constructs	  for	  the	  FBXO7	  wt	  (FBXO7	  wt	  –	  41285)	  and	  the	  R378G	  disease	  mutant	  (FBXO7	  R378G-­‐
41287).	  The	  corresponding	  tables	  underneath	  show	  the	  absolute	  number	  of	  identified	  proteins	  
(duplicates	  removed)	  per	  condition	  and	  experiment.	  Additionally,	  the	  number	  of	  protein	  IDs	  that	  were	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To	  further	  narrow	  down	  the	  list	  of	  potential	  FBXO7	  substrates,	  I	  cross-­‐referenced	  the	  list	  
of	  the	  proteins	  exclusively	  bound	  to	  the	  non-­‐SKP1	  binding	  proteins	  (“41285	  only”	  for	  the	  
FBXO7	  wt	  construct	  and	  “41287	  only”	  for	  the	  FBXO7	  R378G	  mutant)	  against	  the	  list	  of	  
proteins	  that	  were	  present	  in	  corresponding	  MLN4924	  treated	  dataset	  and	  at	  the	  same	  
time	  eliminating	  unspecific	   contaminants	  by	  excluding	   the	  hits	   from	   the	  FLAG-­‐IPs.	   For	  
the	  FBXO7	  wt,	  this	  was	  the	  case	  for	  9	  proteins,	  and	  for	  the	  FBXO7	  R378G	  mutant,	  11	  of	  
44	   proteins.	   Amongst	   them	   were	   Keratins	   and	   cytoskeletal	   proteins	   that	   were	  
considered	   unspecific.	   The	   protein	   IDs	   of	   the	   remaining	   hits	   (as	   long	   as	   >	   2	   unique	  
peptides	  were	  identified)	  is	  shown	  as	  well.	  
	  
	  
Figure	   24:	   Summary	   of	   identified	   proteins	   that	   are	   associated	   with	   the	   non-­‐SKP1	  
binding	  mutants	  of	  the	  FBXO7	  wt	  and	  R3678G	  disease	  mutant.	  
The	  Venn	  diagrams	  show	  overlap	  between	  proteins	  that	  exclusively	  bound	  to	  the	  non-­‐SKP1	  binding	  
mutant	  of	  the	  FBXO7	  wt	  (41285)	  on	  the	  left	  and	  the	  same	  for	  the	  FBXO7	  R378G	  disease	  mutant	  (41287)	  
on	  the	  right	  that	  were	  also	  present	  in	  the	  corresponding	  MLN4924	  treated	  dataset.	  The	  absolute	  number	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“overlap	  group”	  is	  shown	  on	  the	  bottom	  left	  for	  the	  FBXO7	  wt	  and	  on	  the	  bottom	  right	  for	  the	  FBXO7	  
R378G	  mutant	  with	  mascot	  scores	  and	  number	  of	  identified	  peptides	  and	  sequence	  coverage	  in	  brackets.	  
Keratins,	  tubulins	  and	  any	  proteins	  with	  <	  2	  unique	  peptides	  amongst	  the	  overlap	  groups	  are	  not	  shown.	  	  
	  
3.5 Yeast	  two	  -­‐	  hybrid	  screen	  
In	  order	   to	  employ	  an	  alternative	   strategy	   to	   identify	   FBXO7	   interactors,	   a	   yeast	   two-­‐
hybrid	   screen	  was	   performed	   using	   the	   full-­‐length	   FBXO7	   protein	   (Uniprot	   reference:	  
Q9Y3I1)	   as	   bait.	   The	   screen	   done	   by	   Hybrigenics	   (http://www.hybrigenics.com).	   145	  
million	  clones	  of	  an	  adult	  human	  brain	   library	  were	  screened	  and	  a	   total	  of	  90	  clones	  
were	  obtained.	  Sequencing	  of	  the	  corresponding	  plasmids	  only	  yielded	  2	  proteins:	  SKP1	  
and	  PSFM1	  (or	  PI31).	  For	  both	  proteins,	  the	  predicted	  biological	  score	  as	  an	  indicator	  for	  
the	  reliability	  of	   the	   interaction	  was	  very	  high.	  Both	  proteins,	  SKP1	  as	  well	  as	  PI31	  are	  
recognized	   interactors	   of	   FBXO7(Kirk	   et	   al.,	   2008; Skaar	   et	   al.,	   2009a).	   A	   table	  
containing	  all	   the	   raw	  data	  and	  bioinformatics	  analysis	  of	   the	  yeast	   two-­‐hybrid	  screen	  
can	  be	  found	  in	  the	  appendix.	  
	  
Figure	  25:	  Results	  of	  the	  Yeast	  two-­‐hybrid	  screen	  with	  full-­‐length	  FBXO7	  as	  bait	  and	  a	  
human	  brain	  library	  as	  prey	  
90	  positive	  clones	  out	  of	  145	  million	  clones	  of	  an	  adult	  human	  brain	  library	  were	  obtained	  and	  sequenced.	  
These	  corresponding	  sequences	  could	  be	  mapped	  to	  2	  proteins:	  PI31	  (Uniprot	  reference:	  Q92530)	  and	  
SKP1	  (Uniprot	  reference:	  P63208).	  The	  translucent	  boxes	  (pink	  for	  the	  bait	  and	  yellow	  for	  the	  identified	  
interactors)	  indicate	  the	  full-­‐length	  proteins;	  the	  opaque	  boxes	  indicate	  the	  size	  of	  the	  bait	  fragment	  
(pink)	  and	  the	  amino	  acid	  sequence	  shared	  by	  all	  prey	  fragments	  matching	  the	  same	  reference	  protein	  (18	  
fragments	  for	  PI31	  and	  71	  for	  SKP1).	  The	  grey	  boxes	  indicate	  previously	  identified	  interacting	  domains	  of	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3.6 Discussion	  
Little	  was	  known	  about	  FBXO7	  at	  the	  time	  of	  embarking	  on	  my	  PhD	  project	  in	  December	  
2009:	  Mutations	   in	   the	   FBXO7	   gene	  had	  been	   reported	   to	   co-­‐segregate	  with	   an	   early	  
onset	  Parkinsonian	  syndrome	  with	  pyramidal	  features	  in	  a	  single	  consanguineous	  family	  
from	   Iran	   in	   2008(Shojaee	   et	   al.,	   2008).	   FBXO7	   as	   the	   disease	   causing	   gene	   was	  
confirmed	   when	   two	   further	   2	   families	   –	   one	   from	   Italy	   and	   the	   other	   from	   the	  
Netherlands	   –	   with	   a	   similar	   clinical	   syndrome	   associated	   with	   recessive	   FBXO7	  
mutations	  were	  reported	  in	  2009(Di Fonzo	  et	  al.,	  2009).	  Since	  then,	  only	  a	  few	  more	  
patients	  with	   FBXO7	  mutations	  have	  been	   identified	   (as	  discussed	   in	  1.3.2)	   and	   it	   can	  
probably	  be	  assumed	  that	  mutations	  in	  the	  FBXO7	  gene	  are	  not	  a	  major	  contributor	  to	  
PD	  on	  a	  population-­‐based	  level.	  Nonetheless,	  studying	  the	  molecular	  function	  of	  FBXO7	  
in	  health	  and	  disease	  and	  cross-­‐referencing	  it	  with	  our	  existing	  knowledge	  about	  other	  
monogenetic	   PD	   genes	   is	   expected	   to	   shed	   light	   onto	   pathways	   involved	   in	   PD	   and	  
neurodegeneration.	  
FBXO7	  belongs	   to	   the	   family	   of	   F-­‐box	   proteins	   –	   a	   family	   that	   is	   characterized	   by	   the	  
presence	  of	  an	  F-­‐box	  domain,	  which	  mediates	  binding	  to	  the	  small	  protein	  SKP1(Skaar	  et	  
al.,	  2009a).	  The	   interaction	  with	  SKP1	   is	  necessary	   for	   linking	   the	  F-­‐box	  protein	  as	   the	  
variable	  module	  to	  the	  rest	  of	  the	  SCF	  E3	  ubiquitin	  ligase	  complexFigure	  7.	  However,	  not	  
all	   F-­‐box	   proteins	   assemble	   into	   E3	   ligase	   complexes	   with	   Cullin1	   and	   RBX1,	  
demonstrating	   that	   the	   interaction	   with	   SKP1	   is	   necessary,	   but	   not	   sufficient	   for	  
complex	   formation(Skaar	   et	   al.,	   2009a).	   Additionally,	   SCF	   independent	   functions	   have	  
been	  reported	  for	  some	  F-­‐box	  proteins(Jonkers	  and	  Rep,	  2009).	  FBXW8	  is	  an	  example	  of	  
an	  F-­‐box	  protein	   that	  despite	  binding	  to	  SKP1,	  does	  not	   form	  a	  complex	  with	  Cullin	  1,	  
but	  rather	  unconventionally	  with	  Cullin	  7	  and	  RBX1(Litterman	  et	  al.,	  2011).	  The	  function	  
of	   FBXL11	   as	   either	   a	   histone	   demethylase	   or	   in	   complex	   with	   the	   H3K63	  methylase	  
NSD1	  as	  a	  negative	   regulator	  of	  NF-­‐κB	   is	   independent	  of	  SKP1	  binding	  and	  hence	  SCF	  
complex	  formation	  altogether(Du	  et	  al.,	  2013;	  Lu	  et	  al.,	  2010).	  There	  are	  also	  regulatory	  
mechanisms	  of	  F-­‐box	  protein	  function	  within	  the	  context	  of	  SCF	  E3	  ligase	  activity	  that	  is	  
brought	   about	   by	   SCF	   complex	   disruption:	   The	   F-­‐box	   protein	   SKP2	   forms	   a	   SCFSKP2	   E3	  
ubiquitin	   ligase	   complex	   and	   has	   been	   found	   to	   be	   overexpressed	   in	   many	   human	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cancers.	   On	   a	   transcriptional	   level,	   SKP2	   gene	   expression	   is	   negatively	   regulated	   by	  
Foxo3a.	  More	  recently,	  Foxo3a	  has	  been	  shown	  to	  also	  directly	  interact	  with	  SKP2	  and	  
thereby	  promoting	  SCFSKP2	  complex	  disruption.	  This	  in	  turn	  leads	  to	  impaired	  SCFSKP2	  E3	  
ubiquitin	   ligase	   activity	   and	   hence	   stabilization	   of	   p27,	   one	   of	   the	   physiological	  
substrates	   of	   SKP2	   dependent	   ubiquitinylation(Wu	   et	   al.,	   2013a).	   In	   analogy	   to	   F-­‐box	  
proteins,	  BTB	  proteins	  form	  Cullin-­‐RING	  E3	  ubiquitin	  ligase	  complexes	  with	  Cullin	  3.	  The	  
Gordon’s	  hypertension	  syndrome	  is	  an	  example	  where	  human	  pathogenic	  mutations	  in	  
components	   of	   the	   E3	   ligase	   complex	   –	   either	   in	   the	   BTP	   protein	   KLHL3	   or	   Cullin	   3	   –	  
result	  in	  complex	  disruption	  or	  impaired	  binding	  to	  one	  of	  its	  substrates,	  WKN1(Ohta	  et	  
al.,	  2013).	  	  
 FBXO7	   assembles	   into	   a	   SCFFBXO7	   complex	   formation	   and	   the	   pathogenic	  3.6.1
disease	   mutants	   doe	   not	   disrupt	   SCF	   complex	   formation	   in	   the	   stable	  
overexpression	  system	  
It	   was	   therefore	   one	   of	   my	   first	   incentives	   to	   find	   out	   whether	   FBXO7	   does	   indeed	  
assemble	   into	  a	  SCFFBXO7	  E3	   ligase	  complex	   together	  with	  SKP1,	  Cullin1	  and	  RBX1;	  and	  
whether	  the	  pathogenicity	  of	  the	  human	  disease	  mutants	  could	  possibly	  be	  associated	  
with	  SCF	  complex	  disruption.	  In	  section	  3.3,	  I	  show	  that	  the	  FBXO7	  wt	  as	  well	  as	  all	  so	  far	  
reported	  FBXO7	  disease	  mutants	  –	  T22M,	  R378G,	  and	  R498X	  –	  readily	  form	  a	  complex	  
with	  SKP1,	  Cullin1,	  and	  RBX1.	  This	   is	  demonstrated	  by	   tag-­‐immunoprecipitation	  of	   the	  
stable	  expressed	  Flag-­‐tagged	  FBXO7	  constructs	  and	  subsequent	  immunoblotting	  of	  the	  
IP	  products	  for	  endogenous	  SKP1,	  Cullin1,	  and	  RBX1.	  One	  caveat	  for	  the	  conclusion	  that	  
the	  disease	  mutants	  are	  equally	  apt	  to	  assemble	  into	  the	  SCFFBXO7	  complex	  formation	  is	  
that	   the	   Flp-­‐InT-­‐REx-­‐HEK	   293	   host	   cell	   line	   itself	   expresses	   endogenous	   FBXO7	   in	  
addition	  to	  the	  stable	  overexpressed	  FBXO7	  mutants	  (Figure	  14).	  Dimerization	  of	  F-­‐box	  
proteins	   is	  a	  recognized	  phenomenon,	  although	  its	  effect	  on	  substrate	  recognition	  and	  
ubiquitinylation	  in	  vivo	  is	  in	  the	  majority	  of	  cases	  unclear(Skaar	  et	  al.,	  2013).	  For	  FBX04	  it	  
has	   been	   shown	   that	   homodimerization	   is	   essential	   for	   SCFFBX04	   ubiquitin	   E3	   ligases	  
activity	   towards	   its	   substrate	   TRF1(Li	   and	   Hao,	   2010).	   FBXO7	   has	   been	   shown	   to	  
heterodimerize	   with	   PI31(Kirk	   et	   al.,	   2008).	   The	   authors	   also	   suggested	   that	   the	   FP	  
domain,	  which	  facilitates	  heterodimerization	  with	  PI31	  potentially	  allows	  the	  formation	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of	   FBXO7	   homodimers.	   If	   this	   is	   the	   case	   one	  might	   argue	   that	   the	   endogenous	   SCF	  
complex	   partners	   of	   the	   stable	   overexpressed	   FBXO7	  disease	  mutants	   do	   not	   directly	  
interact	  with	  the	  mutant	  FBXO7	  proteins,	  but	  that	  the	   interaction	   is	  rather	   indirect	  via	  
dimerization	  between	  the	  mutant	  FBXO7	  protein	  and	  the	  endogenous	  SCFFBXO7	  complex	  
from	  the	  Flp-­‐InT-­‐REx-­‐293	  host	  cell	  line.	  On	  the	  other	  hand,	  the	  same	  strategy	  –	  utilizing	  
stable	  overexpression	   in	   Flp-­‐InT-­‐REx-­‐HEK	  293	   cells	   –	   has	   allowed	   identifying	  non-­‐SKP1	  
binding	  FBXO7	  mutants.	  Figure	  21	  shows	  that	  despite	  the	  intact	  interaction	  between	  the	  
mutant	   FBXO7	   proteins	   and	   endogenous	   PI31,	   the	   interaction	   between	   the	  
overexpressed	  non-­‐SKP1	  binding	  FBXO7	  mutants	  and	  endogenous	  SKP1,	  Cullin1	  as	  well	  
as	  RBX1	  is	  lost.	  This	  argues	  against	  dimerization	  between	  overexpressed	  FBXO7	  disease	  
mutants	  and	  endogenous	  FBXO7	  from	  the	  Flp-­‐InT-­‐Rex	  HEK	  293	  cell	  line.	  	  
 Interaction	  proteomics	   fails	   to	   identify	   robust	  SCFFBXO7	   targets	   in	   the	   stable	  3.6.2
overexpression	  system	  
The	  preliminary	  evidence	  that	  the	  FBXO7	  wt	  as	  well	  as	  disease	  mutants	  form	  a	  SCFFBXO7	  
complex	   supports	   the	   working	   hypothesis	   that	   FBXO7	   functions	   as	   the	   substrate	  
recognizing	  subunit	  of	  an	  E3	  ubiquitin	  ligase	  enzyme	  and	  that	  the	  pathogenic	  mutations	  
have	  different	  downstream	  effects	  on	  physiological	  FBXO7	  ubiquitinylation	  targets.	  My	  
next	   step	   was	   therefore	   to	   use	   affinity	   purification	   of	   the	   FLAG-­‐FBXO7	   constructs	  
followed	  by	  mass-­‐spectrometry	  and	  thereby	  identifying	  interacting	  proteins.	  Flag-­‐empty	  
vector	   Immunoprecipitations	   were	   used	   as	   a	   control	   to	   identify	   and	   subtract	  
unspecifically	   binding	   background	   proteins	   from	   the	   pool	   of	   hits	   from	   the	   bait	   pull-­‐
downs.	  This	  approach	  has	  worked	  in	  principle	  to	  identify	  and	  confirm	  the	  core	  members	  
of	   the	   SCFFBXO7	   complex.	   Beyond	   that	   the	   success	   of	   identifying	   robust	   interacting	  
partners	  that	  merit	  being	  considered	  as	  potential	  SCFFBXO7	  has	  been	  disappointing.	  The	  
variation	   between	   sample	   replicates	   was	   rather	   high,	   while	   the	   pool	   of	   proteins	   that	  
were	  identified	  in	  all	  3	  biological	  replicates	  for	  each	  condition	  was	  rather	  small	  (Figure	  
15).	  In	  fact,	  amongst	  them	  were	  the	  bait	  -­‐	  Flag-­‐FBXO7	  –	  and	  Cullin	  1	  and	  SKP1.	  RBX1	  as	  
the	   remainder	   of	   the	   SCF	   complex	   on	   the	   other	   hand	  was	   not	   present	   in	   any	   of	   the	  
replicates	   of	   the	   FBXO7	   T22M	   mutant,	   although	   it	   could	   readily	   be	   identified	   by	  
immunoblotting	   of	   the	   same	   samples.	   Other	   proteins	   amongst	   the	   pool	   of	   replicated	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interacting	   proteins	   were	  mainly	   proteasome	   associated	   proteins	   and	   components	   of	  
the	   COP9	   signalosome,	   which	   is	   a	   negative	   regulator	   of	   SCF	   E3	   ligase	   activity	   by	  
mediating	  the	  deneddylation	  of	  the	  Cullin	  subunit(Lyapina	  et	  al.,	  2001).	  The	  only	  other	  
protein	  that	  was	  identified	  in	  each	  replicate	  and	  not	  in	  any	  of	  the	  control	  IPs	  was	  PI31.	  
PI31	   is	   a	   known	   interacting	   protein	   of	   FBXO7	   and	   the	   interaction	   between	   the	  
homologues	  of	  PI31	  and	  FBXO7	  has	  been	  suggested	  to	  be	  a	  regulatory	  mechanism	  for	  
proteasomal	  activity	   in	  Drosophila(Bader	  et	  al.,	  2011;	  Kirk	  et	  al.,	  2008).	  PI31	  was	  also	  
the	   only	   other	   protein	   apart	   from	   SKP1	   that	   was	   identified	   in	   the	   yeast	   two-­‐hybrid	  
screen	  (3.5).	  	  
In	   my	   opinion,	   there	   are	   several	   problems	   with	   the	   approach	   to	   identify	   FBXO7	  
interacting	   proteins	   by	   affinity	   purification	   of	   overexpressed	   tagged	   FBXO7	   and	  
subsequent	   mass-­‐spectrometry:	   There	   is	   a	   rapid	   turnover	   of	   most	   degradative	  
ubiquitinylation	  substrates,	  while	  the	  interaction	  between	  SCF	  E3	  ubiquitin	  ligases	  	  -­‐	  or	  
more	  specifically	  the	  interaction	  between	  the	  F-­‐box	  protein	  subunit	  of	  the	  SCF	  complex	  
–	  and	  their	  respective	  substrate	  is	  typically	  rather	  weak	  and	  only	  transient.	  As	  a	  result,	  
the	  protein	  levels	  of	  a	  particular	  substrate	  that	  is	  being	  ubiquitinylated	  for	  proteasomal	  
degradation	   may	   be	   very	   low	   and	   stringent	   washing	   of	   the	   IP	   complexes	   during	   the	  
procedure	  may	  additionally	  contribute	  to	  allowing	  the	  substrate	  to	  escape	  the	  threshold	  
of	  detection	  by	  mass-­‐spectrometry.	  
In	   fact,	   the	   identification	   of	   F-­‐box	   protein	   substrates	   is	   a	   recognized	   challenge	   in	   the	  
field,	  but	  over	   the	   last	   years	  novel	  proteomic	  approaches	   for	   the	   identification	  of	   SCF	  
substrates	   and	   global	   pool	   of	   ubiquitinylated	   proteins	   and	   ubiquitinylation	   sites	   have	  
been	   developed(Harper	   and	   Tan,	   2012;	   Kim	   et	   al.,	   2011;	   Yen	   and	   Elledge,	   2008;	  
Yumimoto	   et	   al.,	   2012).	   The	   use	   of	   proteasomal	   inhibitors	   –	   either	   MG132	   or	  
Bortezomib	  –	   in	  a	  comparative	   IP-­‐proteomics	  experiment	   that	   is	  performed	   in	  parallel	  
with	  an	  untreated	  experiment	  aims	   to	   identify	   SCF	   substrates	   that	  are	  normally	  being	  
degraded,	  but	  that	  are	  being	  stabilized	  with	  proteasomal	   inhibition.	  This	  approach	  has	  
led	  to	  the	  discovery	  of	  new	  substrates	  of	  the	  F-­‐box	  protein	  βTRCP2	  and	  to	  identify	  the	  
first	   substrate	  of	   the	  orphan	  F-­‐box	  protein	   FBXO22(Harper	  and	  Tan,	  2012).	   Employing	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non-­‐SKP1	   binding	   overexpressed	   F-­‐box	   protein	   mutants	   is	   another	   approach	   of	  
proteomics	   based	   substrate	   trapping(Yumimoto	   et	   al.,	   2012).	   The	   non-­‐SKP1	   binding	  
mutants	  do	  not	  assemble	  into	  a	  SCF	  E3	  ubiquitin	  ligase	  complex,	  but	  retain	  their	  ability	  
to	  recognize	  and	  bind	  substrates.	  As	  these	  substrates	  are	  subsequently	  not	  degraded	  by	  
the	  proteasome,	  their	  relative	  abundance	  and	  therefore	  chance	  for	  detection	  by	  mass-­‐
spectrometry	   increases	   (Figure	   16).	   This	   approach	   is	   referred	   to	   as	   “differential	  
proteomics-­‐based	   identification	   of	   ubiquitinylation	   substrates”	   in	   the	   SILAC	   mode	   or	  
without	  SILAC	  labelling	  in	  the	  peptide	  counting	  mode.	  When	  SILAC	  labelling	  is	  employed,	  
overexpressed	   wild-­‐type	   F-­‐box	   proteins	   are	   grown	   in	   different	   SILAC	   labelled	   media	  
conditions.	  In	  the	  original	  experiments,	  little	  overlap	  was	  seen	  when	  the	  SILAC	  approach	  
was	   compared	   with	   the	   peptide	   counting	   approach	   in	   HeLa	   cells	   for	   the	   well-­‐
characterized	  F-­‐box	  proteins	  FBXW7,	  SKP2,	  and	  FBXL5(Yumimoto	  et	  al.,	  2012).	  A	   rapid	  
exchange	   between	   differently	   labelled	   substrates	   present	   in	   the	  mixed	   lysates	   during	  
the	   immunoprecipitation,	   and	   subsequent	   distortion	   of	   protein	   ratios	   has	   been	  
suggested	  as	  an	  explanation(Harper	  and	  Tan,	  2012).	  Nonetheless,	  as	  a	  proof	  of	  concept	  
study	   this	   particular	   approach	   was	   able	   to	   confirm	   that	   the	   non-­‐SKP1	   binding	   F-­‐box	  
protein	  mutants	  did	  not	  bind	  the	  SCF	  E3	  ligase	  component	  Cullin1	  and	  that	  the	  some	  of	  
the	  known	  substrates	  of	  the	  respective	  F-­‐box	  proteins	  could	  be	  identified(Yumimoto	  et	  
al.,	  2012).	  	  
In	   section	  3.4.2,	   I	   am	  describing	   the	  experiments	   that	   I	  have	  undertaken	   to	  adopt	   the	  
above	  described	  strategies	  for	  the	  identification	  of	  FBXO7	  substrates.	   I	  have	  employed	  
the	  substrate	  trapping	  IP-­‐proteomic	  experiments	  for	  the	  FBXO7	  wt	  as	  well	  as	  the	  disease	  
mutant	  R378G	  –	  in	  both	  cases	  mutating	  4	  amino	  acid	  residues	  within	  the	  F-­‐box	  domain	  
to	   Alanine	   resulted	   in	   abolished	   SKP1	   binding.	   Rather	   than	   deleting	   the	   entire	   F-­‐box	  
domain,	  these	  quadruple	  mutants	  were	  considered	  less	  likely	  to	  disturb	  the	  structure	  of	  
FBXO7	  as	  a	  whole	  as	  well	  as	  any	  potential	  substrate-­‐binding	  domain.	  Stable	  expressing	  
FBXO7	   cell	   lines	   were	   preferred	   over	   transient	   expression	   given	   that	   recombinant	  
protein	   expression	   levels	   can	   be	   adjusted	   more	   towards	   the	   endogenous	   level	   and	  
because	   of	   better	   reproducibility	   in	   replicate	   experiments.	   Figure	   21	   demonstrates	  
equal	  expression	  of	  all	  FBXO7	  constructs	  as	  well	  as	  equal	  levels	  of	  the	  various	  constructs	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after	  Flag-­‐pull-­‐down.	   Immunoblotting	  as	  well	  as	   the	  proteomics	  data	  validate	   that	   the	  
non-­‐SKP1	  binding	  mutants	  do	  indeed	  not	  bind	  to	  the	  complex	  partners	  (Figure	  21,	  Table	  
3-­‐5).	  However,	  as	  shown	  in	  Table	  3-­‐5,	  the	  ratio	  for	  FBXO7	  in	  each	  set	  of	  experiments	  -­‐	  
the	  SKP1	  binding	  versus	  corresponding	  non-­‐SKP1	  binding	  FBXO7	  construct	  –	  was	  not	  1,	  
which	   means	   that	   not	   equal	   amounts	   of	   each	   corresponding	   IP	   product	   was	   mixed	  
resulting	  in	  a	  shift	  in	  the	  baseline	  of	  the	  differential	  ratio	  for	  all	  other	  identified	  proteins.	  
Ultimately,	  no	  proteins	  with	  a	   ratio	  of	  >	  2.5	  were	   identified	   in	   the	   tag-­‐purified	  FBXO7	  
immunocomplexes.	  	  
In	   general,	   one	  of	   the	   advantage	   of	   differential	   SILAC	  proteomics	   is	   that	   differentially	  
labelled	   samples	   are	   being	   combined	   early	   on	   during	   sample	   preparation	   –	   usually	  
directly	  after	  cell	  lysis	  and	  determination	  of	  protein	  concentration	  –	  thereby	  minimizing	  
the	  quantitative	  errors	  caused	  by	  handling	  different	  samples	  in	  parallel.	  In	  the	  context	  of	  
trying	   to	   identify	   FBXO7	   substrates,	   combining	   the	   different	   conditions	   at	   lysate	   level	  
harbours	  the	  danger	  of	  introducing	  distorted	  outcome	  of	  protein	  ratios	  because	  of	  rapid	  
exchange	  between	  differently	   labelled	   substrates	  present	   in	   the	   lysate	  mix	  during	   the	  
immunoprecipitation	  process.	  Likewise,	  combining	  the	  different	  conditions	  after	  the	   IP	  
introduces	   quantitative	   errors	   because	   of	   sample	   handling.	   I	   have	   therefore	   also	  
performed	   individual	   non-­‐SILAC	   based	   IP	   immunocomplex	   proteomics	   of	   the	   various	  
FBXO7	   constructs	   including	   the	   non-­‐SKP1	   binding	   mutants.	   These	   experiments	   were	  
performed	  with	   and	  without	   treatment	   of	   cells	  with	   the	  Nedd8-­‐E1	   activating	   enzyme	  
inhibitor	  MLN4924.	  While	  MG132	  and	  Bortezomib	  are	  unspecific	  proteasomal	  inhibitors,	  
MLN4924	   specifically	   targets	   SCF	   complexes	   as	   Cullin	   neddylation	   is	   considered	  
necessary	   for	   SCF	   complex	   activation	   blocking	   also	   the	   activity	   of	   the	   endogenous	  
SCFFBXO7	   complex(Wu	   et	   al.,	   2013b).	   As	   these	   last	   experiments	   were	   only	   performed	  
recently,	  I	  have	  not	  taken	  any	  validation	  of	  the	  potential	  hits	  listed	  in	  Figure	  24	  forward.	  
This	   decision	   was	   based	   on	   the	   fact	   that	   meanwhile	   I	   have	   shifted	   my	   focus	   on	   the	  
endogenous	  system	  utilizing	  a	  FBXO7	  knock-­‐in	   (KI)	  mouse	  model	  of	  one	  of	   the	  human	  
pathogenic	  FBXO7	  mutations	  (R378G)	  for	  substrate	  identification	  rather	  than	  relying	  on	  
the	  overexpression	  system.	  	  Also	  cross-­‐referencing	  the	  list	  of	  potential	  hits	  from	  the	  Flp-­‐
In	  HEK293	  overexpression	  system	  has	  not	  yielded	  any	  overlapping	  hits	  with	  those	  from	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the	  endogenous	  system	  apart	   from	  the	  other	  SCFFBXO7	  complex	  partners	  and	  PI31.	  The	  
FBXO7	  mouse	  model	  will	  be	  subject	  of	  the	  next	  chapter.	  
However,	  in	  view	  of	  designing	  a	  FBXO7	  mouse	  model	  with	  knock-­‐in	  of	  one	  of	  the	  human	  
pathogenic	  mutations,	   it	  was	  important	  to	  establish	  whether	  the	  individual	  amino	  acid	  
residues	   that	   are	   known	   to	   be	   associated	  with	   autosomal	   recessive	   FBXO7	   disease	   in	  
humans	  –	   T22M,	  R378G,	   and	  R498X	  –	   are	   conserved	  between	   the	  human	  and	  mouse	  
species.	   Figure	  26	   shows	   that	  all	   3	   amino	  acid	   residues	  are	   identical	  between	   those	  2	  
species.	  Next,	  I	  wanted	  to	  know	  whether	  it	  was	  possible	  to	  express	  each	  of	  the	  disease	  
mutants	   either	   in	   the	   human	   or	   mouse	   FBXO7	   background	   and	   that	   each	   mutant	   is	  
indeed	   translated	   into	   a	   protein	   product.	   For	   the	   investigation	   of	   FBXO7	   in	   the	  
endogenous	  system,	  it	  was	  of	  great	  importance	  to	  have	  high	  quality	  antibodies	  against	  
the	   FBXO7	   antigen.	   Figure	   11	   and	   show	   that	   these	   antibodies	   are	   available	   and	   their	  
ability	  to	  also	  pull-­‐down	  FBXO7	  immunocomplexes	  will	  be	  shown	  in	  the	  next	  chapter.	  	  
 Summary	  of	  result	  chapter	  3	  3.6.3
In	  summary,	  my	  first	  result	  chapter	  shows	  that	  FBXO7	  does	  assemble	  into	  the	  SCFFBXO7	  
E3	  ubiquitin	  ligase	  complex	  and	  that	  this	  is	  true	  for	  the	  FBXO7	  widtype	  protein	  as	  well	  as	  
for	  all	  of	  the	  3	  known	  disease	  mutants	  -­‐	  T22M,	  R378G	  and	  R498X.	  These	  findings	  suggest	  
that	   SCF	   complex	   disruption	   is	   an	   unlikely	   mechanism	   by	   which	   the	   FBXO7	   disease	  
mutants	  exert	  their	  pathogenicity.	  The	  Alanine	  mutant	  screen	  of	  single	  residues	  within	  
the	  F-­‐box	  domain	  of	  FBXO7	  gives	  some	  insight	  into	  the	  interaction	  between	  FBXO7	  and	  
SKP1:	  the	  employed	  single	  mutants	  in	  this	  study	  are	  on	  its	  own	  unable	  to	  abolish	  SKP1	  
binding,	   and	  based	  on	  what	  we	   know	   so	   far	   complete	   SCF	   complex	  disruption	   is	   only	  
achieved	  by	  the	  simultaneous	  deletion	  of	  several	  residues	  (>	  4	  amino	  acid	  residues).	  The	  
non-­‐SKP1	  binding	  mutants	  also	  demonstrate	  that	  there	  is	  no	  dimerization	  between	  the	  
endogenous	  SCFFBXO7	   wt	   E3	  ubiquitin	   ligase	   complex	  and	   the	  overexpressed	  mutants.	   If	  
this	  was	  the	  case	  one	  would	  have	  expected	  to	  see	  a	  signal	  for	  SKP1	  in	  the	  immunoblot	  of	  
the	   affinity	   purified	   Flag-­‐immunocomplexes	   as	   Western	   blotting	   does	   not	   allow	  
discrimination	   based	   on	   the	   source	   of	   SKP1	   –either	   bound	   to	   endogenous	   or	  mutant	  
FBXO7.	   Retained	  binding	   of	   the	   tag-­‐immunocomplexes	   to	   PI31,	  which	   is	  mediated	   via	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the	   FP-­‐domain	   upstream	   of	   the	   F-­‐box	   domain	   of	   FBXO7,	   shows	   that	   the	   mutations	  
introduced	   in	   the	   non-­‐SKP1	   binding	   mutants	   does	   not	   cause	   disarray	   of	   the	   protein	  
structure	   to	   such	  an	  extend	   that	  binding	  via	  other	  domains	  would	  be	  affected	   (Figure	  
21).	   Whether	   this	   allows	   any	   conclusion	   on	   towards	   whether	   FBXO7	   (or	   SCFFBXO7	   wt)	  
forms	  homodimers	  is	  an	  open	  question.	  
4 Characterization	  of	  the	  Fbxo7	  mouse	  model	  with	  knock-­‐in	  of	  
the	  corresponding	  human	  disease	  mutant	  R378G	  mutation	  	  
4.1 Introduction	  
The	  identification	  of	  PARK	  genes	  provides	  a	  rational	  basis	  to	  model	  PD	  in	  cells	  or	  animals	  
by	  genetic	  manipulation.	  Mice	  are	  amenable	  to	  genetic	  manipulation	  and	  share	  similar	  
neuronal	   networks	   and	   disease-­‐associated	   gene	   homologous	   with	   their	   human	  
counterpart(Waterston	  et	  al.,	  2002).	  In	  comparison	  to	  other	  animal	  models,	  mice	  have	  a	  
relatively	   long	   life	   span	  of	  about	  2	  years,	  which	   is	  an	   important	  aspect	  when	  studying	  
neurodegenerative	   processes.	   Ideally,	   a	   genetic	   model	   of	   PD	   should	   recapitulate	   the	  
characteristic	  neurodegeneration	  and	  pathological	  hallmarks	  of	  PD	  in	  an	  age	  dependent	  
manner	   and	   also	   demonstrate	   correlates	   of	   the	   clinical	   motor	   and	   behavioural	  
features(Dawson	   et	   al.,	   2010).	   Many	   different	   genetic	   mouse	   models	   of	   PD	   exist	  
including	   conventional	   “transgenic	   models”	   where	   the	   animal	   constitutively	  
overexpresses	   a	   foreign	   protein	   as	   well	   as	   the	   more	   refined	   approach	   where	   the	  
overexpression	  of	  the	  aberrant	  gene	  product	  is	  under	  the	  control	  of	  an	  inducible	  on	  /	  off	  
tetracycline	  promoter	  allowing	  temporal	  and	  spatial	  regulation	  (reviewed	  in	  (Lee	  et	  al.,	  
2012)).	  Gene	  targeting	  strategies	  are	  based	  on	  homologous	  recombination	  events	  and	  
either	   create	   knock-­‐out	   models	   by	   deleting	   crucially	   important	   exons	   or	   introduce	   a	  
premature	   stop	   codon	   to	  prevent	   expression	  of	   a	   functional	   protein	  product,	   or	   gene	  
knock-­‐in	  models	  that	  allow	  the	  discrete	  introduction	  of	  mutations(Capecchi,	  1989).	  Viral	  
models	   to	   introduce	  transgenes	  or	   facilitate	  gene	  knock-­‐down	  are	  also	  being	  used(Lee	  
et	  al.,	  2012).	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4.2 Generation	  of	  the	  Fbxo7	  R379G	  KI	  mouse	  model	  
 Rational	  for	  modelling	  the	  Fbxo7	  R378G	  mutation	  in	  a	  knock-­‐in	  mouse	  model	  4.2.1
The	  plan	  for	  my	  PhD	  project	  was	  to	  generate	  a	  knock-­‐in	  mouse	  line	  modelling	  one	  of	  the	  
human	   disease	   mutations	   in	   the	   FBXO7	   gene.	   The	   knock-­‐in	   gene	   approach	   allows	  
studying	   the	   effect	   of	   one	   particular	  mutation	   in	   the	   endogenous	   system	   rather	   than	  
using	   heterologous	   overexpression	   systems.	  On	   the	   one	   hand,	   I	  wanted	   to	   utilize	   the	  
mouse	   for	  performing	  molecular	  and	  biochemical	   assays	   comparing	   the	  wild-­‐type	  and	  
knock-­‐in	   genotype	   in	   the	   neuronal	   system	   and	   on	   the	   other	   hand	   for	   a	   phenotypic	  
analysis	  to	  establish	  whether	  our	  mouse	  line	  could	  serve	  as	  a	  valid	  model	  of	  PD.	  Figure	  
26	  shows	  a	  sequence	  alignment	  of	  the	  human	  and	  mouse	  FBXO7	  homologous	  and	  that	  
all	  3	  residues	  that	  are	  so	  far	  implicated	  in	  FBXO7	  mediated	  neurodegeneration	  -­‐	  	  T22M,	  
R378G,	  and	  R498X	  –	  are	  conserved	  between	  human	  and	  mouse	  species.	  I	  then	  wanted	  
to	   assess	   expression	   levels	   and	   protein	   stability	   of	   the	   different	   Fbxo7	   mutants	   in	  
comparison	   to	   the	   wild-­‐type	   protein	   as	   any	   impairment	   would	   render	   the	   respective	  
mutant	   unsuitable	   for	   modelling	   in	   a	   KI	   mouse	   model.	   	   Figure	   27	   shows	   the	   stable	  
expression	   in	   case	   of	   the	   human	   disease	   mutants	   and	   transient	   expression	   of	   the	  
equivalent	   mouse	   constructs	   in	   HEK293	   cells	   (each	   with	   C-­‐terminal	   FLAG-­‐tag)	   and	  
suggests	   that	   the	   T22M	  mutant	   is	   expressed	   at	   relatively	   lower	   levels.	   This	   finding	   in	  
combination	  with	  the	  fact	  that	  the	  T22M	  residue	  resides	  only	  in	  the	  N-­‐terminal	  region	  of	  
the	   longer	   isoform	  1	  while	   leaving	   the	  shorter	   isoforms	  of	  FBXO7	  unaffected,	  was	   the	  
rational	  for	  precluding	  the	  T22M	  mutation	  for	  modelling	  in	  a	  Fbxo7	  KI	  mouse	  model.	  The	  
choice	  was	  then	  between	  the	  nonsense	  R498X	  mutation,	  which	  introduces	  a	  premature	  
stop	  codon	  resulting	  with	  truncation	  of	  the	  last	  22	  amino	  acid	  residues	  and	  the	  missense	  
mutation	   R378G,	   which	   is	   located	   in	   juxtaposition	   downstream	   of	   the	   functionally	  
important	  F-­‐box	  domain	  of	  FBXO7.	  In	  general,	  introducing	  a	  missense	  mutation	  into	  a	  KI	  
mouse	   model	   is	   generally	   considered	   more	   subtle	   than	   introducing	   a	   nonsense	  
mutation.	  Nonsense	  mutations	  result	   in	  a	   truncated	  protein	  product,	  but	  also	  harbour	  
the	  the	  risk	  of	  of	  medating	  nonsense-­‐mediated	  mRNA	  decay,	  which	  would	  then	  have	  the	  
same	  effect	  on	  protein	   level	  as	  a	  complete	  gene	  knock-­‐out(Maquat,	  2005).	  Therefore,	  
our	   decision	   fell	   for	  modelling	   the	  missense	  R378G	  FBXO7	   human	  disease	  mutant.	  As	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the	  mouse	  protein	  has	  an	  additional	  amino	  acid	  residue	  within	  in	  the	  FP	  domain	  of	  the	  
FBXO7	   protein,	   its	   amino	   acid	   sequence	   is	   one	   residue	   longer	   (523	   instead	   of	   522	  
residues).	   This	   also	   explains	   why	   the	   arginine	   at	   position	   378	   of	   the	   human	   FBXO7	  
protein	  corresponds	   to	  position	  379	  of	   the	  mouse	  protein.	  There	   is	  an	  overall	   identity	  
between	  the	  mouse	  and	  human	  FBXO7	  protein	  sequences	  of	  73%.	  Figure	  28	  illustrates	  
the	  percentage	  identities	  for	  different	  segments	  and	  domains	  of	  the	  2	  proteins,	  which	  is	  
with	  89%	  highest	  within	  the	  region	  of	  the	  F-­‐box	  domain	  (residues	  325	  –	  380).	  A	  multiple	  
sequence	  alignment	  within	  the	  region	  of	  the	  F-­‐box	  domain	  and	  around	  location	  of	  the	  
disease	  mutant	  R378G	  of	  different	  species	  also	  shows	  there	  is	  a	  high	  degree	  of	  regional	  
conservation	  and	  complete	  conservation	  of	   the	  arginine	  at	  position	  378	  of	   the	  human	  
protein	   (Figure	   29).	   Altogether	   the	   R378G	   FBXO7	   disease	   mutant	   was	   considered	   a	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Figure	  26:	  Sequence	  alignment	  of	  human	  and	  mouse	  FBXO7	  proteins	  
Sequence	  alignment	  of	  the	  longer	  isoform	  1	  of	  human	  and	  mouse	  FBXO7	  (Uniprot	  accession	  numbers:	  
Q9Y3I1	  for	  the	  human	  and	  Q3U7U3	  for	  the	  mouse	  protein)	  were	  performed	  using	  the	  MUSCLE	  alignment	  
program	  and	  annotated	  with	  the	  help	  of	  Jalview(Edgar,	  2004;	  Waterhouse	  et	  al.,	  2009a).	  The	  red	  boxes	  
indicate	  the	  location	  of	  the	  3	  pathogenic	  mutations	  and	  demonstrate	  that	  each	  of	  these	  residues	  is	  
conserved	  between	  the	  human	  and	  mouse	  sequence.	  The	  Percentage	  ID	  using	  MUSCLE	  is	  72.90%	  for	  the	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Figure	  27:	  Expression	  of	  human	  and	  mouse	  Flag-­‐tagged	  FBXO7	  constructs	   in	  HEK293	  
cells	  	  
Either	  stable	  expressing	  FLAG	  alone,	  human	  wild	  type	  or	  human	  pathogenic	  mutants	  (T22M,	  R378G,	  and	  
R498X)	  Flp-­‐In	  TRex	  HEK293	  (10ug	  each)	  or	  transient	  expressing	  mouse	  wild	  type	  and	  corresponding	  
mutants	  (T22M,	  R379G,	  R498X)	  HEK293	  (2ug)	  whole	  cell	  lysates	  were	  used	  for	  immunoblotting	  with	  Flag	  
and	  GAPDH	  as	  a	  loading	  control.	  Expression	  of	  the	  stable	  constructs	  in	  Flp-­‐In	  TRex	  HEK293	  was	  induced	  
with	  0.1	  ug/ml	  of	  doxycycline	  for	  18	  hours.	  The	  expression	  of	  the	  T22M	  FBXO7	  mutant	  is	  impaired	  in	  
comparison	  to	  the	  wt	  and	  the	  other	  mutants;	  a	  finding	  that	  is	  consistent	  between	  the	  human	  and	  the	  
corresponding	  mouse	  construct	  despite	  2	  different	  expression	  systems.	  	  
	  
	  
Figure	   28:	   Percentage	   identity	   between	   human	   and	   mouse	   FBXO7	   amino	   acid	  
sequence	  	  
A	  pairwise	  alignment	  of	  the	  human	  (Q9Y3I1)	  and	  mouse	  (Q3U7U3)	  FBXO7	  protein	  sequence	  (using	  
MUSCLE(Edgar,	  2004))	  and	  calculation	  of	  pairwise	  percentage	  identity	  of	  functional	  domains	  and	  other	  
segments	  as	  well	  as	  of	  the	  last	  24	  residues	  that	  are	  truncated	  in	  the	  R498X	  mutant	  results	  in	  the	  following:	  
73%	  overall	  identity,	  79%	  identity	  between	  the	  UBL	  domain,	  73%	  identify	  within	  the	  FP	  domain,	  89%	  
identity	  within	  the	  F-­‐box	  domain	  and	  69%	  identity	  within	  the	  unstructured	  C-­‐terminal	  region	  of	  the	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Figure	  29:	  Multiple	  sequence	  alignments	  of	  FBXO7	  homologues	  around	  the	  region	  of	  
the	  human	  pathogenic	  mutation	  R378G	  
Sequence	  alignments	  using	  MUSCLE(Edgar,	  2004)	  of	  FBXO7	  homologues	  of	  different	  species	  (Uniprot	  ID	  in	  
brackets)	  in	  the	  region	  of	  the	  F-­‐box	  domain	  –	  shown	  are	  AA	  318-­‐380	  of	  the	  human	  FBXO7	  protein.	  The	  
Arginine	  at	  position	  378,	  which	  is	  one	  of	  the	  affected	  residues	  in	  FBXO7	  associated	  disease	  where	  it	  is	  
mutated	  to	  a	  glycine,	  is	  conserved	  across	  the	  different	  species.	  The	  R378G	  mutant	  is	  the	  particular	  
mutation	  that	  was	  chosen	  for	  our	  FBXO7	  knock-­‐in	  mouse	  model	  (corresponding	  to	  R379G	  Fbxo7	  in	  the	  
mouse	  genome).	  
	  
 The	  Fbxo7	  R379G	  knock-­‐in	  targeting	  strategy	  4.2.2
The	  targeting	  strategy	  to	  insert	  the	  transition	  c>g	  in	  the	  first	  and	  g>c	  in	  the	  third	  position	  
of	  the	  respective	  codon	  in	  exon	  7	  leading	  to	  the	  pathogenic	  missense	  mutation	  R379G	  
as	  well	  as	  additional	  silent	  mutation	  to	  generate	  a	  diagnostic	  restriction	  site	  (BsaJI)	  was	  
designed	  in	  collaboration	  with	  Taconis	  Artemis®,	  who	  also	  generated	  the	  mouse.	  Exons	  
7	  and	  8	  were	  flanked	  by	  loxP	  (locus	  x-­‐over	  P1)	  sites,	  while	  the	  selection	  markers	  flanked	  
by	  FRT	  (NeoR)	  and	  F3	  (PuroR)	  sites	  were	  inserted	  into	  intron	  6	  and	  intron	  8,	  respectively.	  
Homologous	   recombinant	   clones	   will	   be	   isolated	   by	   using	   double	   positive	   selection	  
against	  Neomycine	  and	  Puromycine	  resistance	  to	  increase	  the	  efficacy	  of	  co-­‐integration	  
of	  both	  loxP	  sites	  and	  of	  the	  point	  mutations.	  The	  targeting	  vector	  was	  generated	  using	  
Bacterial	  Artificial	  Chromosome	  (BAC)	  clones	  from	  the	  C57BL/6J	  RPCIB-­‐731	  BAC	   library	  
and	  transfected	  into	  the	  Taconic	  Artemis	  C57BL/6N	  Tac	  ES	  cell	  line.	  Constitutive	  knock-­‐in	  
of	  the	  allele	  after	  Flp-­‐mediated	  removal	  of	  the	  selection	  markers	  leads	  to	  the	  expression	  
of	  the	  R379G	  mutated	  protein	  while	  the	  remaining	  loxP	  sites	  allow	  conditional	  deletion	  
of	   exons	   7	   and	   8	   after	   site-­‐	   and	   time-­‐specific	   Cre-­‐lox	   recombination(Metzger	   and	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exon	   9	   introducing	   a	   premature	   stop	   codon.	   The	   outcome	   of	   whole	   body	   cre-­‐
recombinase	  mediated	  deletion	  of	  exon	  7	  and	  8	  will	  be	  discussed	  in	  4.2.5.	  	  
Figure	   30:	   Targeting	   strategy	   of	   the	   Fbxo7	   constitutive	   Knock-­‐in	   of	   R379G	   point	  
mutation	  with	  optional	  conditional	  Knock-­‐Out	  
Schematic	  illustration	  of	  the	  targeting	  strategy	  as	  explained	  in	  4.2.2.	  The	  2	  genes	  in	  the	  neighbourhood	  of	  
FBXO7	  according	  to	  NCBI	  and	  Ensemble	  databases	  are	  Bpil2	  (Entrez	  ID:	  69754;	  ENSMUSG00000050108)	  is	  
located	  approx.	  33	  kb	  upstream	  of	  the	  Fbxo7	  exon	  7	  in	  a	  head-­‐to-­‐head	  orientation	  and	  Syn3	  (Entrez	  ID:	  
27204;	  ENSMUSG00000059602)	  is	  located	  approx.	  9	  kb	  downstream	  of	  the	  Fbxo7	  exon	  8	  in	  a	  tail-­‐to-­‐tail	  
orientation.	  	  
	  
 DSTT	  α 	  mouse	  FBXO7	  antibody	  programme	  validation	  4.2.3
In	   order	   to	   investigate	   the	   effect	   of	   the	   Fbxo7	   R379G	  mutation	   in	   comparison	   to	   the	  
wild-­‐type	  protein	  in	  the	  endogenous	  neuronal	  system,	  a	  sensitive	  and	  specific	  antibody	  
directed	  against	  FBXO7	  is	  mandatory.	  Therefore,	  a	  DSTT	  antibody	  programme	  to	  raise	  a	  
sheep	   polyclonal	   antibody	   against	   the	   full-­‐length	   mouse	   FBXO7	   protein	   was	   started.	  
Figure	   31	   shows	   that	   this	   antibody	   detects	   the	   mouse	   as	   well	   as	   the	   human	  



























































	   115	  
antibody	  directed	  against	  the	  FLAG	  antigen	  (A).	  In	  (B)	  the	  ability	  of	  the	  DSTT	  antibody	  to	  
not	  only	  detect,	  but	  also	  to	  immunoprecipitate	  endogenous	  FBXO7	  protein	  from	  mouse	  
tissue	  is	  demonstrated.	  	  
	  
Figure	  31:	  Validation	  of	  the α 	  mouse	  FBXO7	  antibody	  programme	  
A:	  HEK293	  whole	  cell	  lysates	  overexpressing	  either	  human	  (stable,	  10ug	  each)	  and	  mouse	  (transient,	  2	  ug	  
each)	  Flag-­‐tagged	  FBXO7	  wt	  and	  disease	  mutants	  were	  immunoblotted	  for	  FLAG	  or	  the	  DSTT	  produced	  
anti	  -­‐	  mouse	  FBXO7	  antibodies	  (S917C	  3.	  bleed)	  and	  GAPDH	  as	  loading	  control.	  Antibody	  concentration	  for	  
immunoblotting	  was	  1ug/ml	  and	  exposure	  time	  was	  the	  same	  for	  all	  blots.	  
B:	  Endogenous	  FBXO7	  immunoprecipitation	  (covalently	  coupled	  anti-­‐mouse	  Fbxo7	  antibody	  (S917D,	  3.	  
bleed)	  from	  3	  mg	  lysate	  of	  different	  wt	  mouse	  tissues.	  Covalently	  coupled	  preimmune	  sheep	  IgG	  served	  as	  
a	  control	  IP.	  Immunoblotting	  for	  FBXO7	  (S917D,	  3.	  bleed)	  of	  10ug	  of	  Flag-­‐FBXO7	  wt	  whole	  cell	  lysate	  and	  
10	  ug	  of	  mouse	  brain,	  testes	  and	  spleen	  tissue	  lysates	  as	  well	  as	  10%	  of	  the	  IP	  products	  of	  FBXO7	  and	  
control.	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 R379G	  Fbxo7	  mouse	  line	  is	  viable	  and	  fertile	  	  4.2.4
The	  R379G	   Fbxo7	   are	   viable	   and	   fertile	   in	   the	   heterozygeous	   and	   homozygous	   state.	  
Both	  heterozygeous	  and	  homozygous	   carriers	  of	   the	  R379G	  point	  mutation	  cannot	  be	  
discriminated	  from	  their	  wild-­‐type	  littermates	  in	  respect	  to	  size,	  viability,	  breeding	  and	  
home	   cage	   behaviour	   (4.3.1).	   Breeding	   heterozygeous	   males	   and	   females,	   the	  
genotypes	   of	   the	   animals	   display	   a	   pattern	   of	   inheritance	   that	   best	   fits	   an	   autosomal	  
recessive	  trait,	  normal	  gender	  distribution	  and	  litter	  size.	  Table	  4-­‐1	  gives	  an	  overview	  of	  
the	   genotype	   frequencies	   of	   offsprings	   from	   heterozygeous	   intercrosses.	  Male	   R379G	  
Fbxo7	  KI	  mice	   in	  the	  homozygous	  state	  are	  also	  able	  to	  propagate	  together	  with	  wild-­‐
type	  females	  (data	  not	  shown).	  Thus,	  R379G	  Fbxo7	  KI	  mice	  are	  viable	  and	  fertile.	  	  
	  
Figure	  32:	  Verification	  of	  correct	  Fbxo7	  genotype	  by	  sequencing	  
A:	  PCR	  for	  mouse	  genotyping:	  A	  210bp	  PCR	  product	  is	  present	  in	  the	  wild-­‐type	  genotype	  (-­‐/-­‐),	  mice	  
homozygous	  for	  the	  R379G	  mutation	  (+/+)	  give	  a	  329	  bp	  product	  and	  heterozygeous	  mice	  (+/-­‐)	  result	  in	  a	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B:	  Sequencing	  traces	  for	  wt,	  het	  and	  hom	  Fbxo7	  R379G	  show	  the	  introduced	  silent	  and	  R379G	  knock-­‐in	  
mutations	  (blue	  boxes).	  
C:	  Sequence	  alignment	  of	  the	  Fbxo7	  reference	  gene	  and	  the	  PCR	  amplified	  and	  sequenced	  homozygous	  
Fbxo7	  genotype	  of	  the	  Fbxo7	  R379G	  KI	  mouse	  line	  confirming	  correct	  targeting	  of	  the	  endogenous	  locus.	  
	  
	  
Table	  4-­‐1:	  Genotype	  frequencies	  of	  offsprings	  of	  Fbxo7	  R379G	  mouse	  line	  
Genotype	  frequencies	  for	  offspring	  at	  weaning	  derived	  from	  heterozygeous	  intercrosses	  are	  indicated.	  If	  a	  
Chi	  square	  test	  is	  applied	  to	  compare	  the	  observed	  and	  expected	  genotype	  distribution	  of	  wild-­‐type	  (+/+),	  
heterozygeous	  (+/-­‐)	  and	  homozygeous	  (-­‐/-­‐)	  R379G	  KI	  Fbxo7	  alleles,	  the	  outcome	  is	  in	  keeping	  with	  an	  
autosomal	  recessive	  pattern	  of	  inheritance	  rather	  than	  chance	  alone	  (p-­‐value:	  >	  0.1	  and	  <	  0.2).	  
	  
 C-­‐terminal	  truncation	  of	  Fbxo7	  results	  in	  lethality	  4.2.5
In	  a	  2	  step	  breeding	  strategy,	  homozygous	  Fbxo7	  R379G	  and	  heterozygeous	  whole	  body	  
expressing	  Cre	  recombinase	  mice	  were	  crossed	  to	  derive	  conditional	  homozygous	  Cre-­‐
loxP	  mediated	   knock-­‐out	   of	   exons	   7	   and	   8	   (Figure	   33).	  While	   heterozygeous	   Cre-­‐loxP	  
mediated	   deletion	   of	   exons	   7	   and	   8	   was	   tolerated	   –	   animals	   are	   vital	   and	   fertile	   –	  
homogenous	  animals	  are	  not:	  Of	  81	  animals,	  16	  pups	  died	  within	  2	  days	  of	  being	  born	  
and	  no	  material	  for	  genotyping	  could	  be	  collected	  -­‐	  the	  animals	  were	  presumably	  eaten	  
by	  their	  mother.	  It	  is	  therefore	  not	  clear	  whether	  homozygous	  genotypes	  were	  amongst	  
the	   dead	   /	   stillborn	   pups.	   Homogenous	   genotypes	   were,	   however,	   detected	   at	  
embryonic	   stage	  E12.5	  days:	  out	  of	  a	   total	  of	  17	  embryos,	  6	  embryos	  had	  a	  genotype	  
corresponding	   to	  successful	  homozygous	  Cre-­‐loxP	  mediated	  deletion	  of	  exons	  7	  and	  8	  
(while	  5	  had	  a	  wt	  and	  6	  a	  wt/Fbxo7	   C-­‐terminal	   trunc	  background)	  best	   fitting	  an	  autosomal	  
recessive	  pattern	  of	  inheritance.	  	  
Genotype ()/)( ()/)+ +)/)+ Total χ 2 p(value
Liveborn)pups
Fbxo7)R379G 30%)(116) 50%)(197) 20%)(77) 390 4.3 >)0.1)and)<)0.2
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Table	   4-­‐2:	   Genotype	   frequencies	   of	   offsprings	   at	  weaning	   age	   and	   embryos	   derived	  
from	  cre-­‐loxP	  mediated	  deletion	  of	  exons	  7	  and	  8	  of	  the	  Fbxo7	  gene	  
No	  pubs	  with	  a	  homogenous	  Fbxo7	  del	  exons	  7	  and	  8	  background	  were	  found	  to	  be	  alive	  at	  weaning	  age.	  16	  
pubs	  were	  found	  dead	  aged	  between	  1	  and	  2	  days,	  but	  no	  material	  for	  genotyping	  could	  be	  collected	  as	  
pubs	  were	  found	  eaten.	  This	  is	  not	  in	  keeping	  with	  the	  expected	  numbers	  of	  	  
	  
 FBXO7	  expression	  in	  Fbxo7	  R379G	  and	  Fbxo7	  	  C-­‐terminal	  truncation	  MEFs	  4.2.6
Murine	  embryonic	  fibroblast	  (MEF)	  cells	  were	  prepared	  from	  wild-­‐type,	  heterozygeous	  
and	  homozygous	  E12.5	   littermates	  of	   the	  Fbxo7	  R379G	  KI	  mouse	   lines	  as	  well	  as	  after	  
Cre-­‐loxP	  mediated	  deletion	  of	   exons	  7	  and	  8	  of	  Fbxo7.	   Each	  of	   the	  different	   cell	   lines	  
was	  immortalized	  by	  serial	  passaging(Xu,	  2005).	  Figure	  33	  shows	  the	  expression	  pattern	  
of	  FBXO7	  in	  the	  2	  different	  cell	  lines;	  in	  particular	  that	  deletion	  of	  exons	  7	  and	  8	  leads	  to	  
a	  C-­‐terminal	   truncated	  version	  of	   the	  FBXO7	  protein,	  which	   is	  expected	  to	  end	  shortly	  
before	   the	  start	  of	   the	  F-­‐box	  domain.	  The	  expectation	   is	   that	   this	  mutant	   is	  unable	   to	  
bind	  to	  SKP1	  and	  hence	   is	  unable	  to	  form	  a	  SCFFBXO7-­‐C-­‐terminal	   truncation	   in	  the	  homozygous	  
state.	  This	  us	  demonstrated	  in	  Figure	  47.	  	  
	  
Genotype ()/)( ()/)+ +)/)+ Total χ2 p(value
Liveborn)pups
Fbxo7&del&exons&7&and&8&) 30%)(25) 49%)(40) 0%)(0) 81 21.7 <0.001
)
Embryos)E12.5
Fbxo7&del&exons&7&and&8&) 5 6 6 17 1.59 <0.5)and)>)0.3
AA1-78 AA180-325 AA330-376 AA424-523
Ubl FP F-box PRR mouse FBXO7 - isoform 11 523
AA1-78 AA180-324
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Figure	  33:	  FBXO7	  expression	  in	  Fbxo7	  R379G	  and	  C-­‐terminal	  truncation	  MEFs	  
A:	  Deletion	  of	  exons	  7	  and	  8	  is	  expected	  to	  yield	  a	  protein	  of	  a	  length	  of	  about	  323	  amino	  acid	  ending	  
before	  the	  start	  of	  the	  F-­‐box	  domain	  (35	  kDa,	  computed	  molecular	  weight	  using	  the	  ProtParam	  tool	  by	  
ExPASy	  (Wilkins	  et	  al.,	  1999)).	  
B:	  FBXO7	  immunostaining	  of	  the	  various	  genotypes	  for	  the	  2	  different	  MEF	  cell	  lines	  are	  indicated	  above	  
and	  run	  in	  duplicates.	  The	  red	  stars	  indicate	  the	  signal	  of	  the	  full-­‐length	  FBXO7	  wt	  and	  R379G	  proteins	  
(upper	  star)	  and	  the	  signal	  for	  the	  shorter	  C-­‐terminal	  truncated	  FBXO7	  mutant	  (lower	  star).	  	  
	  
 Tissue	  expression	  analysis	  of	  FBXO7	  in	  the	  Fbxo7	  R379G	  KI	  mouse	  model	  4.2.7
Little	   is	   known	   about	   the	   tissue	   expression	   pattern	   of	   FBXO7	   in	   general.	   I	   therefore	  
analysed	   the	   distribution	   of	   FBXO7	   protein	   expression	   by	   means	   of	   FBXO7	  
immunoreactivity	   in	   the	   wild-­‐type	   animal	   and	   compared	   it	   to	   expression	   levels	   and	  
distribution	  of	  the	  mutated	  FBXO7	  protein	  product	  of	  the	  Fbxo7	  R379G	  KI	  animal.	  Figure	  
34	  shows	  that	  FBXO7	   is	  widely	  expressed	  across	  a	  panel	  of	  different	   tissues	   (including	  
brain,	   lung,	   liver,	   heart,	   kidney,	   and	   spleen).	   The	   expected	   molecular	   weight	   of	   the	  
longer	  isoform	  1	  (Q3U7U3	  –	  mouse	  FBXO7)	  of	  FBXO7	  is	  58kDa	  while	  the	  shorter	  isoform	  
2	  (Q3UD93	  -­‐	  mouse	  FBXO7)	  is	  49	  kDa,	  but	  several	  more	  transcripts	  could	  potentially	  be	  
expressed	   by	   alternative	   splicing(Di Fonzo	   et	   al.,	  2009).	   The	   FBXO7	   immunoblotting	  
signal	  yields	  several	  bands	  between	  the	  range	  of	  50	  –	  75	  kDa,	  and	  these	  may	  or	  may	  not	  
represent	  different	  isoforms,	  degradation	  products	  or	  posttranslational	  modified	  forms	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With	  regards	  to	  the	  analysis	  of	  the	  Fbxo7	  R379G	  mouse	  model,	  an	  important	  first	  step	  was	  
to	   show	  that	   the	  mutant	  FBXO7	  R379G	  protein	   is	  actually	  expressed	   in	   the	  homozygous	  
state.	   Figure	   34	   and	   Figure	   35	   demonstrate	   that	   this	   is	   the	   case	   for	   animals	   aged	   6	  
weeks	   and	   6	   months,	   albeit	   not	   at	   the	   same	   level	   as	   in	   the	   wild-­‐type	   state.	   To	  
investigate	   this	   further,	   I	   determined	   the	   expression	   levels	   of	   FBXO7	   by	   quantitative	  
immunoblotting	   in	   brain	   lysates	   of	   3	   age	   matched,	   littermate	   wt	   and	   homozygous	  
Fbxo7R379G	   KI	   animals	   at	   10	   months	   of	   age	   (using	   the	   Li-­‐Cor	   Odyseey	   system).	   This	  
analysis	  confirmed	  the	   initial	  observation	  that	  FBXO7	  expression	   levels	   in	  brain	   lysates	  
are	  reduced	  in	  the	  homozygous	  R379G	  KI	  state	  and	  showed	  that	  the	  reduction	  amounts	  
to	   about	   50%(Figure	   36).	   This	   difference	   in	   expression	   levels	   was	   consistent	   across	  
replicate	   experiments	   (data	   not	   shown)	   as	   well	   as	   different	   modes	   of	   detection;	   for	  
example	   by	   differential	   quantitative	   proteomic	   using	  wt	   and	   homozygous	   Fbxo7	   R379G	  
MEFs	  or	  brain	  lysates	  (discussed	  in	  chapter	  5.	  
	  











































	   121	  
Triplicate	  loading	  (10ug	  each,	  prepared	  in	  CHAPS	  lysis	  buffer)	  and	  immunostaining	  for	  FBXO7	  of	  littermate	  
wild-­‐type	  (wt),	  heterozygeous	  (het)	  and	  homozygous	  (hom)	  Fbxo7	  R379G	  KI	  mouse	  cell	  lysates	  across	  a	  panel	  
of	  different	  tissues	  (Fbxo7	  antibody:	  DSTT,	  S917D,	  3rd	  bleed).	  Tubulin	  immunoblots	  are	  shown	  as	  a	  loading	  




Figure	  35:	  Expression	  analysis	  of	  FBXO7	  in	  the	  Fbxo7	  R379G	  KI	  mouse	  model	  at	  6	  weeks	  
Triplicate	  loading	  (10ug	  each,	  prepared	  in	  CHAPS	  lysis	  buffer)	  and	  immunostaining	  for	  FBXO7	  of	  littermate	  
wild-­‐type	  (wt),	  heterozygeous	  (het)	  and	  homozygous	  (hom)	  Fbxo7	  R379G	  KI	  mouse	  cell	  lysates	  across	  a	  panel	  
of	  different	  tissues.	  Tubulin	  as	  a	  loading	  control	  is	  shown	  for	  brain.	  (mouse	  IDs:	  wt	  -­‐	  123206,	  het	  -­‐	  	  

































	   122	  
	  
Figure	  36:	  FBXO7	  expression	  levels	  in	  the	  brain	  are	  reduced	  by	  half	  in	  the	  homozygous	  
Fbxo7	  R379G	  KI	  compared	  to	  the	  wild-­‐type	  state	  at	  10	  months	  of	  age	  
Brain	  lysates	  were	  prepared	  from	  3	  wt	  (WT)	  and	  3	  homozygous	  FBXO7	  R379G	  (KI)	  animals	  (littermate	  pairs)	  
in	  Rapigest	  lysis	  buffer	  at	  the	  same	  time	  and	  each	  sample	  was	  loaded	  in	  duplicates	  for	  quantitative	  
immunostaining	  with	  FBXO7	  and	  Gapdh	  and	  simultaneous	  detection	  by	  the	  Li-­‐Cor	  Odyseey	  system.	  Data	  is	  
presented	  as	  relative	  FBXO7	  levels	  over	  Gapdh	  levels	  +	  SEM.	  FBXO7	  wt	  levels	  were	  set	  to	  1.	  Average	  age	  
of	  each	  group	  (wt	  and	  KI)	  was	  10.3	  months.	  The	  difference	  in	  expression	  level	  by	  genotype	  was	  significant	  
as	  analysed	  by	  a	  paired	  t-­‐test.	  	  
	  
 In	  vivo	  SCFFbxo7	  wt	  complex	  formation	  of	  the	  endogenous	  Fbxo7	  wt	  protein	  4.2.8
In	   Chapter	   2,	   I	   have	   demonstrated	   that	   stable	   overexpressed	   FBXO7	   -­‐	   the	   wild-­‐type	  
protein	   as	   well	   as	   the	   pathogenic	   mutants	   (FBXO7	   T22M,	   R378G,	   and	   R498G)	   -­‐	  
assembles	  together	  with	  endogenous	  SKP1,	  Cullin1	  and	  RBX1	  into	  a	  SCFFBXO7	  E3	  ubiquitin	  
ligase	  complex.	  The	  next	  important	  question	  was	  whether	  I	  could	  reproduce	  this	  finding	  






















1 2 3 4 5 6





3 Fbxo7 wt mice
* t-test (p<0.02)
 3 hom Fbxo7         KI miceR379G
	  
	  
	   123	  
indeed	   exist	   in	   vivo:	   Immunoblotting	   of	   the	   endogenous	   Fbxo7	   immunoprecipitation	  
products	   from	   different	   wild-­‐type	   mouse	   tissues	   including	   brain	   lysates	   allows	   the	  
detection	  of	  the	  other	  SCF	  complex	  partners.	  	  
	  
	  
Figure	  37:	  Endogenous	  SCFFbxo7	  wt	  E3	  ubiquitin	  ligase	  complex	  formation	  in	  vivo	  
Endogenous	  FBXO7	  immunoprecipitation	  (covalently	  coupled	  anti-­‐mouse	  Fbxo7	  antibody	  (S917D,	  3.	  
bleed)	  from	  3	  mg	  lysate	  of	  different	  wt	  mouse	  tissues.	  Covalently	  coupled	  preimmune	  sheep	  IgG	  served	  as	  
a	  control	  IP.	  Immunoblotting	  of	  10%	  of	  the	  IP	  products	  for	  FBXO7	  and	  the	  remainder	  for	  CULLIN1,	  SKP1	  
and	  RBX1	  as	  well	  as	  10ug	  of	  the	  respective	  input	  lysates	  demonstrates	  formation	  of	  the	  SCFFBXO7wt	  complex	  
in	  vivo.	  
 In	   vivo	   SCFFbxo7	   R379G	   complex	   formation	   of	   the	   endogenous	   Fbxo7	   R379G	  4.2.9
mutant	  
I	  was	  then	  interested	  to	  see	  whether	  the	  SCFFbxo7	  E3	  ligase	  complex	  formation	  was	  also	  
possible	  in	  the	  homozygous	  R379G	  KI	  Fbxo7	  mutant	  background.	  	  I	  therefore	  performed	  
immunoprecipitations	  from	  wild-­‐type	  and	  homozygous	  R379G	  KI	  Fbxo7	  brain	  lysates	  in	  
parallel	  and	  subjected	  the	  pull-­‐down	  products	  to	  immunoblotting	  for	  Cullin1,	  Skp1	  and	  
Rbx1.	  Figure	  38	  demonstrates	  that	  the	  other	  endogenous	  SCF	  complex	  partners	  cannot	  
only	  be	  detected	   in	   the	  endogenous	   immunoprecipitate	   from	  wild-­‐type,	  but	  also	   from	  
homozygous	   Fbxo7	   R379G	   KI	   mouse	   brain	   lysates.	   I	   have	   also	   performed	   large-­‐scale	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parallel	   Fbxo7	   immunoprecipitations	   from	  wild-­‐type	   and	   homozygous	   R379G	   KI	   brain	  
lysates	   that	   were	   subjected	   to	   in	   gel	   tryptic	   digestion	   and	   subsequent	   proteomic	  
fingerprint	  analysis.	  The	  proteomic	  analysis	  also	  confirms	  the	  identity	  of	  Cullin	  1,	  Skp1,	  
and	   RBX1	   in	   the	   immunoprecipitate	   of	   both	   genotypes	   (Figure	   39).	   Altogether,	   these	  
findings	   suggest	   that	   the	   pathogenic	   R379G	   KI	   Fbxo7	   mutant	   does	   not	   exert	   its	  
pathogenicity	  by	  completely	  preventing	  association	  of	  Fbxo7	   into	   the	  SCF	  E3	  ubiquitin	  
ligase	  complex.	  	  
	  
Figure	  38:	  Endogenous	  SCFFbxo7	  complex	  formation	  of	  wild-­‐type	  as	  well	  as	  homozygous	  
R379G	  Fbxo7	  derived	  brain	  lysates	  in	  vivo	  
Endogenous	  FBXO7	  immunoprecipitation	  (covalently	  coupled	  anti-­‐mouse	  Fbxo7	  antibody	  (S917D,	  3.	  
bleed)	  from	  3	  mg	  lysate	  of	  wt	  and	  homozygous	  Fbxo7	  R379G	  brain	  lysates.	  Covalently	  coupled	  preimmune	  
sheep	  IgG	  served	  as	  a	  control	  IP.	  Immunoblotting	  of	  10%	  of	  the	  IP	  products	  for	  FBXO7	  and	  the	  remainder	  
for	  CULLIN1,	  SKP1	  and	  RBX1	  demonstrates	  formation	  of	  the	  SCFFBXO7	  complex	  in	  vivo	  for	  both	  genotypes	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Figure	  39:	   Identification	  of	   SCFFBXO7	   complex	  by	  MS	   fingerprint	  analysis	   from	  wt	  and	  
hom	  Fbxo7	  R379G	  brain	  lysates	  
A:	  Representative	  Colloidal	  blue	  stained	  4-­‐12%	  Bis-­‐Tris	  gel	  of	  50%	  of	  the	  IP	  product	  for	  in	  gel	  tryptic	  
digestion	  for	  proteomic	  analysis.	  
B:	  Qualitative	  representation	  of	  results	  from	  3	  replicates	  demonstrating	  that	  all	  endogenous	  SCF	  complex	  
components	  as	  well	  as	  PI31	  are	  present	  in	  the	  endogenous	  FBXO7	  pull-­‐downs	  from	  wt	  as	  well	  as	  
homozygous	  R379G	  mouse	  brain	  lysates.	  	  
	  
 In	  vivo	   SCFFbxo7	   R378G	   complex	   formation	  of	  patient	  derived	  heterozygeous	  and	  4.2.10
homozygous	  R378G	  FBXO7	  cell	  lines	  
Although	  this	  chapter	   is	  dedicated	  to	  the	  study	  of	  the	  R379G	  KI	  Fbxo7	  mouse	  model,	   I	  
am	   including	   data	   derived	   from	   patient	   derived,	   mutation	   specific	   R378G	   FBXO7	   cell	  
lines	   in	   this	   section.	   The	   finding	   that	   there	   is	   intact	   SCFFbxo7	   complex	   formation	   in	   the	  
homozygous	   R379G	   KI	   Fbxo7	   background	   of	   the	   mouse	   model	   is	   of	   significant	  
importance	  and	  warrants	   follow	  up	  whether	   this	   is	  also	   the	  case	   in	   the	  corresponding	  
human	  setting.	  I	  have	  therefore	  subjected	  whole	  cell	  lysates	  derived	  from	  immortalized,	  
patient	   /	   carrier	   derived	   homozygous	   and	   heterozygeous	   R378G	   FBXO7	   fibroblasts	   to	  
endogenous	   FBXO7	   immunoprecipitation	   and	   immunoblotting	   of	   the	   SCF	   complex	  
partners.	   These	   cell	   lines	  were	   kindly	   provided	   by	   Professor	   Henry	   Houlden	   from	   the	  
Institute	   of	   Neurology,	   University	   College	   London.	   Figure	   40	   demonstrates	   that	   the	  
human	  R378G	  FBXO7	  mutant	  is	  equally	  able	  to	  assemble	  into	  the	  SCFFBXO7	  R378G	  complex	  
and	   that	   the	   R379G	   Fbxo7	   KI	   mouse	   model	   faithfully	   recapitulates	   important	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lines	  cannot	  be	  used	  to	  address	  the	  second	  finding	  in	  the	  corresponding	  R379G	  Fbxo7	  KI	  
mouse	  model,	  which	  is	  the	  effect	  of	  the	  R379G	  mutant	  homozygosity	  on	  the	  reduction	  
of	  Fbxo7	  protein	  expression	  levels.	  I	  have	  demonstrated	  a	  consistent	  reduction	  of	  Fbxo7	  
protein	   levels	   in	   the	   homozygeous	   R379G	   genotype	   in	   comparison	   to	   wild-­‐type	  
littermate	   control	   animals.	   Although	   the	   expression	   level	   of	   the	   homozygeous	   R378G	  
FBXO7	  patient	  appears	  to	  be	  higher	  than	  that	  of	  the	  heterozygeous	  carrier,	  it	  needs	  to	  
be	  noted	   that	   this	   is	   only	  data	   from	  2	   individuals.	   It	  would	  however	  be	   interesting	   to	  




Figure	   40:	   Endogenous	   SCFFBXO7	   complex	   formation	   in	   patient	   derived,	   mutation	  
specific	  R378G	  cell	  lines	  
Homozygous	  and	  heterozygeous	  immortalized	  fibroblasts	  derived	  from	  a	  patient	  with	  FBXO7	  associated	  
disease	  due	  to	  homozygosisty	  for	  the	  R378G	  FBXO7	  gene	  mutation	  and	  an	  unaffected	  family	  member	  with	  
carrier	  status	  were	  subjected	  to	  endogenous	  FBXO7	  immunoprecipitation	  (covalently	  coupled	  α human	  
FBXO7	  (S038D,	  4th	  bleed)	  and	  preimmune	  sheep	  IgG	  as	  a	  control.	  10	  %	  of	  the	  IP	  product	  was	  used	  for	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FBXO7	  immunoblotting,	  the	  remaining	  90%	  for	  immunoblotting	  of	  the	  other	  SCF	  complex	  members	  as	  
well	  as	  PI31.	  
	  
 Proteomic	   fingerprint	   analysis	   of	   endogenous	   FBXO7	   IPs	   (wild-­‐type	   mouse	  4.2.11
brain)	  
Having	  demonstrated	  that	  the	  SCFFBXO7	  E3	  ubiquitin	  ligase	  complex	  exists	  in	  vivo	  the	  next	  
step	  was	  to	  use	  proteomic	  fingerprint	  analysis	  to	  identify	  FBXO7	  interacting	  partners	  in	  
the	   immunoprecipitate	   of	   endogenous	   FBXO7	   from	   mouse	   brain	   tissue	   lysates.	   The	  
ultimate	  goal	  is	  to	  identify	  FBXO7	  interacting	  partners	  that	  possibly	  function	  as	  SCFFBXO7	  
ubiquitylation	   substrates.	   As	   pointed	   out	   in	   previous	   sections,	   the	   limitation	   of	   this	  
approach	   is	   that	   the	   interaction	  between	  FBXO7	  and	  any	  putative	  substrates	  needs	  to	  
be	  sufficiently	  strong	  to	  withstand	  the	  handling	  –	  in	  particular	  the	  washing	  procedures	  –	  
of	  the	  immunoprecipitate.	  I	  have	  performed	  a	  total	  of	  3	  large	  scale	  biological	  replicates	  
of	   endogenous	   FBXO7	   pull-­‐downs	   from	  wt	   and	   2	   replicates	   from	   homozygous	   FBXO7	  
R379G	   mouse	   brain	   tissue	   lysates	   using	   preimmune	   sheep	   Immunoglobulines	   as	   a	  
control	  IP	  to	  identify	  unspecifically	  binding	  proteins.	  Figure	  41	  gives	  an	  overview	  of	  the	  
overlap	  between	   the	  3	   replicates	   from	  wild-­‐type	  brain.	  Presented	  are	   the	  numbers	  of	  
proteins	  that	  were	  identified	  in	  each	  replicate	  after	  subtracting	  any	  proteins	  that	  were	  
also	  found	  in	  any	  of	  the	  3	  preimmune	  IgG	  controls.	  Altogether,	  42	  proteins	  of	  these	  hits	  
were	   found	   in	   all	   3	   endogenous	   FBXO7	  pull-­‐downs	   from	  wild-­‐type	   brain	   reducing	   the	  
chance	  of	  unspecificity.	  Amongst	  these	  42	  proteins	  were	  FBXO7	  as	  the	  bait	  and	  CULLIN1	  
and	  SKP1	  as	  SCF	  complex	  partners.	  RBX1	  was	  not	  amongst	  the	  overlapping	  group	  as	   it	  
was	   only	   detected	   in	   2	   of	   the	   3	   replicates.	   The	   overlapping	   list	   also	   contains	   2	   other	  
proteins	   that	   have	   previously	   been	   reported	   to	   interact	   with	   FBXO7:	   Exportin	   1	   and	  
PI31(Kirk	   et	   al.,	  2008; Nelson	   and	   Laman,	   2011).	  With	   regards	   to	   the	  other	   proteins,	  
there	   are	   4	   components	   of	   adaptor	   protein	   complexes	   involved	   in	   protein	   transport	  
vesicles	   in	   different	  membrane	   traffic	   pathways	   (AP-­‐1	   and	   AP2	   subunits).	   Huntingtin-­‐
interacting	  protein	  1-­‐related	  protein	  also	  relates	  to	  the	  function	  of	  (Rao	  et	  al.,	  2001)	  and	  
is	   known	   to	   interact	   with	   AP-­‐2.	   Then	   there	   are	   several	   members	   of	   the	   COP9	  
signalosome	   complex,	   which	   regulates	   the	   activity	   of	   SCF	   E3	   ligase	   complexes;	   for	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example	  by	  deneddylation	  of	  Cullins(Kato	  and	  Yoneda-­‐Kato,	  2009)	  and	  also	  proteasomal	  
subunits.	  Arf-­‐GAP	  is	  a	  GTPase-­‐activating	  protein	  and	  isoform	  1	  is	  brain	  specific	  where	  it	  
participates	  in	  the	  prevention	  of	  neuronal	  apoptosis	  by	  enhancing	  PI3	  kinase	  activity(Xia	  
et	  al.,	  2003).	  Liprin-­‐α	  proteins	  may	  act	  as	  scaffolding	  molecules	  important	  for	  neuronal	  
synapse	   maturation(Spangler	   and	   Hoogenraad,	   2007).	   Additionally,	   2	   subunits	   of	   the	  
Serine	  /	   threonine-­‐protein	  phosphatase	  PP1	  and	  the	  protein	  phosphatase	  1	  regulatory	  
subunit	   9B	   (Neurabine	   2)	   as	   well	   as	   the	   calcium-­‐binding	   protein	   nucleobindin,	   the	  
sodium-­‐	   and	   chloride	   dependent	   GAPA	   transporter	   3	   and	   the	   tubulin	   polymerization-­‐
promoting	  protein	  were	  found	  in	  all	  3	  wild-­‐type	  replicates.	  Furthermore,	  2	  members	  of	  
the	   reticulon	   family	   and	   3	  members	   of	   the	   RanBP2/RanGAP1*SUMO1/UBC9	   E3	   sumo	  
ligase	  complex	  were	  found	  in	  all	  3	  FBXO7	  pull-­‐downs	  from	  wild-­‐type	  brain.	  
	  
	  
Figure	  41:	  Venn	  diagram:	  Overlap	  between	  3	  endogenous	  FBXO7	  IP	  from	  wt	  brain	  
Number	  of	  proteins	  found	  in	  each	  of	  the	  3	  endogenous	  FBXO7	  IPs	  from	  wt	  brain	  after	  excluding	  any	  hits	  
that	  were	  identified	  in	  any	  of	  the	  3	  preimmune	  IgG	  controls	  and	  the	  number	  of	  hits	  that	  were	  common	  to	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Table	  4-­‐3:	   Identity	  of	   the	  proteins	   found	   in	   all	   3	   replicate	   FBXO7	   IPs	   from	  wild-­‐type	  
brain	  
Overlap((1,2,3) MW((kDA) 1 2 3
F5box(only(protein(7 58 1517%(59,%31%) 1877%(66,%30%) 1024%(40,%28%)
Cullin51* 90 6370%(337,%75%) 5185%(290,%72%) 390%(28,%25%
S5phase(kinase5associated(protein(1* 19 359%(12,%47%) 1063%(56,%82%) 1477%(56,%76%)
Proteasome(inhibitor(PI31(subunit* 30 22%(7,%18%) 108%(9,%25%) 110%(10,%18%)
COP9%signalosome%complex%subunit%4 46 113%(4,%7%) 207%(8,%13%) 242,%(12,%19%)
COP9%signalosome%complex%subunit%3 48 58%(1,%3%) 81%(4,%4%) 109%(5,%11%)
COP9%signalosome%complex%subunit%6 36 44%(8,%23%) 31%(4,%4%) 71%(3,%9%)
COP9%signalosome%complex%subunit%4 46 113%(4,%7%) 207%(8,%13%) 242,%(12,%19%)
COP9%signalosome%complex%subunit%5 38 143%(6,%12%) 48%(4,%12%) 43,%(5,%11%)
Proteasome%subunit%alpha%typeE1 30 250%(19,%19%) 616%(44,%64%) 286%(21,%34%)
Proteasome%subunit%alpha%typeE5 27 110%(6,%22%) 556%(31,%56%) 370%(16,%37%)
Proteasome%subunit%alpha%typeE7 28 24%(2,%3%) 541%(25,%58%) 202%(13,%27%)
Proteasome%subunit%alpha%typeE6 28 177%(9,%21%) 494%(17,%42%) 275%(12,%24%)
Proteasome%subunit%alpha%typeE2 26 131%(5,%13%) 285%(21,%50%) 404%(21,%42%)
Proteasome%subunit%alpha%typeE3 28 148%(9,%21%) 368%(20,%33%) 178%(17,%30%)
Proteasome%subunit%alpha%typeE4 30 56%(3,%12%) 298%(12,%38%) 201%(13,%43%)
Proteasome%subunit%beta%typeE2 23 75%(2,%4%) 249%(17,%35%) 292%(18,%37%)
Proteasome%subunit%beta%typeE6 26 72%(6,%16%) 120%(3,%8%) 216%(5.%13%)
Proteasome%subunit%beta%typeE4 29 34%(3,%14%) 188%(14,%35%) 174%(14,%25%)
Proteasome%subunit%beta%typeE7 30 24%(2,%3%) 194%(23,%37%) 339%(20,%22%)
E3%SUMOEprotein%ligase%RanBP2 345 3298%(228,%38%) 993%(60,%13%) 4922%(249,%55%)
Ran%GTPaseEactivating%protein%1 64 704%(34,%34%) 488%(20,%21%) 1274%(44,%40%)
GTPEbinding%nuclear%protein%Ran 25 183%(16,%31%) 160%(15,%31%) 87%(5,%11%)
Exportin51* 123 1736%(108,%47%) 151%(19,%13%) 1119%(64,%38%)
ReticulonE1 84 45%(1,%1%) 402%(17,%21%) 193%(11,%5%)
ReticulonE4 127 590%(48,%14%) 90%(11,%10%) 1407%(79,%56%)
NeurabinE2 90 2300%(153,%58%) 1584%(83,%51%) 302%(21,%24%)
LiprinEalphaE3 117 2432%(147,%53%) 3821%(195,%58%) 4315%(181,%60%)
LiprinEalphaE2 144 67%(7,%1%) 62%(9,%4%) 133%(17,%7%)
APE2%complex%subunit%alphaE1 109 485%(24,%9%) 1904%(97,%51%) 1199%(67,%40%)
APE2%complex%subunit%alphaE2 105 357%916,%125) 1233%(76,%43%) 569%(31,%22%)
APE1%complex%subunit%betaE1 105 88%(12,%9%) 568%(44,%30%) 964%(43,%36%)
APE2%complex%subunit%mu 50 20%(5,%9%) 837%(39,%47%) 276%(21,%31%)
ForminElike%protein%1 123 624%(53,%25%) 361%(36,%20%) 1694%(106,%43%)
Tubulin%polymerizationEpromoting%protein 24 1469%(102,%73%) 1415%(53,%52%) 298%(20,%33%)
Serine/threonineEprotein%phosphatase%PP1Ealpha%catalytic%subunit 38 838%(42,%43%) 610%(29,%44%) 29%(1,%3%)
Serine/threonineEprotein%phosphatase%PP1Egamma%catalytic%subunit 38 642%(33,%41%) 523%(21,%36%) 73%(4,%11%)
ArfEGAP%with%GTPase,%ANK%repeat%and%PH%domainEcontaining%protein%3 99 458%(18,%10%) 31%(4,%2%) 66,%(2,%1%)
NucleobindinE2 50 363%(38,%23%) 229%(21,%28%) 355%(37,%45%)
BTB/POZ%domainEcontaining%protein%KCTD3 89 230%(36,%31%) 157%(30,%23%) 299%(27,%37%)
HuntingtinEinteracting%protein%1Erelated%protein 120 109%(13,%13%) 87%(10,%6%) 242%(21,%18%)
Protein%enabled%homolog 86 79%(11,%11%) 153%(15,%16%) 73%(5,%5%)
SodiumE%and%chlorideEdependent%GABA%transporter%3 71 28%(2,%3%) 127%(2,%2%) 48%(1,%2%)
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Identities	  and	  molecular	  weight	  (in	  kDa)	  of	  the	  proteins	  that	  overlapped	  in	  all	  3	  endogenous	  FBXO7	  pull-­‐
downs	  from	  wild-­‐type	  brain	  after	  excluding	  any	  hits	  that	  were	  also	  present	  in	  the	  preimmune	  IgG	  controls.	  
Shown	  are	  mascot	  scores	  of	  each	  protein	  as	  identified	  in	  the	  individual	  replicate	  with	  number	  of	  unique	  
peptides	  and	  percentage	  of	  sequence	  coverage	  in	  brackets.	  SCF	  E3	  ubiquitin	  ligase	  complex	  partners	  as	  
well	  as	  previously	  reported	  Fbxo7	  interacting	  partners	  are	  printed	  in	  bold	  and	  with	  a	  star.	  Proteins	  are	  
grouped	  according	  to	  function	  /	  interacting	  complex	  partners.	  
	  
 Proteomic	   fingerprint	   analysis	   of	   endogenous	   FBXO7	   IPs	   (hom	   FBXO7R379G	  4.2.12
brain)	  
I	   was	   then	   interested	   in	   comparing	   the	   findings	   of	   the	   endogenous	   FBXO7	  
immunoprecipitations	   from	  wild-­‐type	   to	   those	   from	  homozygous	  Fbxo7	  R379G	  mouse	  
brain	   lysates.	   Proteins	   that	   only	   associate	  with	   one	   genotype	   and	   not	  with	   the	   other	  
may	  be	  interesting	  candidates	  for	  further	  analysis.	  I	  have	  therefore	  compiled	  the	  results	  
of	   the	   2	   replicate	   pull-­‐downs	   from	   homozygous	   Fbxo7	   R379G	   KI	   brain	   lysates	   (which	  
were	  done	  in	  parallel	  with	  wild-­‐type	  experiments)	  and	  comparing	  them	  to	  the	  results	  of	  
the	  wild-­‐type	  experiments	  results	  in	  the	  following:	  a	  total	  of	  50	  proteins	  were	  identified	  
in	   the	  wild-­‐type	   background,	  whereas	   42	   proteins	  were	   identified	   in	   the	   homozygous	  
R379G	  KI	  genotype.	  Amongst	  these	  hits	  were	  29	  proteins	  that	  were	  shared	  between	  the	  
2	   genotypes	   and	   21	   proteins	   that	   could	   only	   be	   identified	   in	   the	   wild-­‐type	   while	   13	  
proteins	  could	  only	  be	  identified	  in	  the	  homozygous	  KI	  background.	  	  
	  
Figure	   42:	  Overlap	   between	   endogenous	   FBXO7	   IP	   from	  wild-­‐type	   and	  homogenous	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The	  Venn	  diagram	  shows	  the	  overlap	  between	  proteomic	  hits	  for	  the	  endogenous	  FBXO7	  IPs	  from	  wild-­‐
type	  and	  homozygous	  R379G	  KI	  brain	  lysates	  of	  2	  biological	  replicates.	  For	  each	  replicate	  littermate	  wt	  
and	  hom	  KI	  mice	  were	  sacrificed	  and	  the	  whole	  experiment	  was	  done	  in	  parallel	  (date	  of	  experiments:	  
2011/12/15	  and	  2012/05/31).	  Mass-­‐spectrometry	  raw	  data	  was	  processed	  using	  proteinguru	  
(http://www.proteinguru.com/MassSpec/OLMAT)	  to	  exclude	  any	  hits	  that	  were	  identified	  in	  any	  of	  the	  
preimmune	  IgG	  controls	  and	  to	  compile	  the	  data	  in	  single	  excel	  sheets.	  Venn	  diagram	  and	  overlapping	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Table	  4-­‐4:	  List	  of	  proteins	  identified	  in	  endogenous	  FBXO7	  IP	  experiments	  present	  either	  in	  both	  genotypes	  or	  wild-­‐type	  and	  
homozygous	  R379G	  alone	  
Amongst	  the	  proteins	  identified	  in	  both	  groups	  are	  FBXO7	  as	  the	  bait	  and	  2	  other	  SCFFBXO7	  E3	  ubiquitin	  ligase	  complex	  members	  and	  the	  previously	  identified	  FBXO7	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 Validation	  of	  proteomic	  hits	  from	  endogenous	  brain	  FBXO7	  IPs	  4.2.13
I	  employed	  different	  strategies	  in	  trying	  to	  validate	  the	  interaction	  between	  FBXO7	  and	  
its	   putative	   interactors:	   First,	   I	  wanted	   to	   see	  whether	   a	   putative	   interactor	   could	   be	  
detected	   by	   direct	   immunoblotting	   of	   the	   endogenous	   FBXO7	   immunoprecipitations	  
from	  brain.	  I	  then	  tried	  to	  employ	  co-­‐immunoprecipitating	  FBXO7	  from	  brain	  using	  the	  
putative	   interactor	   as	   bait.	   However,	   there	   are	   many	   factors	   that	   may	   preclude	   the	  
detection	  of	  FBXO7	  in	  the	  co-­‐immunoprecipitate	  of	  any	  putative	  interactor	  /	  substrate:	  
For	   example,	   it	   is	   well	   recognized	   that	   the	   interaction	   between	   a	   substrate	   and	   its	  
respective	   F-­‐box	   protein	   as	   the	   substrate-­‐recognizing	   subunit	   of	   the	   SCF	   E3	   ligase	  
complex	   is	   stimulus-­‐dependent	   –	   for	   instance	   many	   substrates	   need	   to	   be	  
phosphorylated	  in	  order	  to	  be	  recognized	  by	  their	  respective	  F-­‐box	  protein(Skaar	  et	  al.,	  
2013).	   Immunoprecipitating	   the	  whole	   pool	   of	   a	   given	   substrate	  might	   dilute	   out	   the	  
interaction	   with	   FBXO7.	   It	   may	   therefore	   be	   prudent	   not	   to	   automatically	   exclude	  
proteins	   that	   do	   not	   co-­‐immunoprecipitate	   FBXO7	   from	   the	   list	   of	   potential	   FBXO7	  
substrates.	  Apart	  from	  immunoprecipitations,	  I	  also	  looked	  at	  expression	  levels	  of	  some	  
of	  the	  proteins:	  If	  a	  protein	  is	  ubiquitylated	  for	  proteasomal	  degradation	  in	  an	  SCFFBXO7	  
manner,	   expression	   levels	   might	   increase	   upon	   proteasomal	   inhibition	   (MG132	  
inhibition)	   and	   also	   by	   inactivating	   SCF	   E3	   ligase	   complexes	   by	   Cullin-­‐deneddylation	  
(MLN4924:	  Cullin	  deneddylator).	  For	  these	  experiments	  I	  have	  used	  MEF	  lysates,	  as	  they	  
are	  amenable	  for	  manipulation	  with	  inhibitor	  treatments	  as	  well	  as	  brain	  lysates	  of	  wild-­‐
type	   and	   homozygous	   R379G	   KI	   animals	   to	   investigate	   whether	   there	   was	   genotype-­‐
dependent	  difference	  in	  expression	  levels.	  
4.2.13.1 Validation	  by	  immunoblotting	  -­‐	  PI31	  and	  Exportin	  1	  
Amongst	  the	  list	  of	  proteomic	  hits	  are	  2	  proteins	  that	  have	  previously	  been	  identified	  as	  
FBXO7	  interactors:	  PI31	  and	  Exportin	  1.	  PI31	  has	  been	  shown	  to	  physically	  interact	  with	  
FBXO7	   via	   an	   N-­‐terminal	   FP	   domain	   that	   is	   present	   in	   both	   proteins	   by	   means	   of	  
mutational	  analysis	  in	  cell	  culture	  and	  biophysical	  studies(Kirk	  et	  al.,	  2008).	  A	  functional	  
implication	  for	   the	  2	  proteins	  as	  proteasomal	  regulators	  stems	  from	  genetic	  studies	   in	  
Drosophila(Bader	  et	  al.,	  2011).	  FBXO7	  has	  been	  shown	  to	  contain	  a	   functional	  nuclear	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export	   sequence,	   which	  mediates	   binding	   to	   the	   nuclear	   export	   protein,	   EXPORTIN	   1	  
(CRM1).	  As	   this	  nuclear	  export	   sequence	   is	   embedded	   in	   the	  F-­‐box	  domain	  of	   FBXO7,	  
SKP1	   and	   Exportin	   1	   have	   been	   suggested	   to	   bind	   competitively.	   These	   studies	   were	  
performed	  using	  N-­‐terminal	  tagged	  FBXO7	  constructs	  in	  U2OS	  cells(Nelson	  and	  Laman,	  
2011).	   Figure	   43	   and	   Figure	   44	  demonstrate	   that	   the	   interaction	  between	   FBXO7	  and	  
Exportin	  1	  as	  well	   as	  PI31	   is	   also	  preserved	   in	   the	  endogenous	   system	  using	  neuronal	  
material	  for	  the	  wild-­‐type	  as	  well	  as	  the	  homozygous	  R379G	  genotype.	  Table	  4-­‐5	  gives	  
an	  overview	  of	  the	  proteomic	  data	  for	  each	  replicate	  IP	  per	  genotype.	  
	  
Figure	  43:	  Detection	  of	  Exportin	  1,	  Reticulon	  4	  and	  Neurabin	  2	  in	  endogenous	  FBXO7	  
IPs	  from	  brain	  by	  immunoblotting	  
Endogenous	  FBXO7	  immunoprecipitation	  products	  from	  wild-­‐type	  as	  well	  as	  homozygous	  R379G	  mouse	  
brain	  lysates	  were	  blotted	  for	  FBXO7	  along	  with	  Exportin	  1,	  Nogo	  (brain	  specific	  isoform)	  and	  Neurabin	  2.	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Figure	  44:	  Detection	  of	  PI31	  in	  endogenous	  FBXO7	  IPs	  from	  brain	  by	  immunoblotting	  
Endogenous	  FBXO7	  immunoprecipitation	  products	  from	  wild-­‐type	  as	  well	  as	  homozygous	  R379G	  mouse	  
brain	  lysates	  were	  blotted	  for	  PI31.	  The	  control	  IP	  with	  preimmune	  sheep	  Immunoglobulin	  shows	  that	  the	  
interactions	  are	  specific.	  	  
	  
	  
Table	  4-­‐5:	  Proteomic	  data	  for	  PI31	  and	  Exportin	  1	  of	  each	  replicate	  IP	  
Molecular	  weight	  for	  each	  protein	  and	  mascot	  score	  with	  number	  of	  identified	  peptides	  and	  sequence	  
coverage	  in	  brackets	  for	  each	  of	  the	  3	  replicate	  endogenous	  FBXO7	  IPs	  from	  wild-­‐type	  and	  the	  2	  replicates	  
from	  homozygous	  R379G	  KI	  brain	  lysates.	  The	  candidate	  proteins	  were	  not	  present	  in	  any	  of	  the	  control	  
IgG	  immunoprecipitations.	  
	  
4.2.13.2 Validation	  by	  immunoblotting	  –	  E3	  SUMO	  ligase	  RANBP2	  /	  RanGap1*Sumo1	  /	  
Ubc9	  complex	  
SUMOylation	  is	  yet	  another	  essential	  posttranslational	  modification	  essential	  for	  proper	  
cellular	  physiological	   function,	  which	   in	  analogy	  to	  ubiquitylation	   involves	  a	  cascade	  of	  
E1	   activating	   enzyme	   (Aos1/Uba2),	   E2	   conjugating	   enzyme	   Ubc9	   and	   one	   of	   several	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nuclear	  transport	  and	  mitosis,	  but	  is	  also	  one	  of	  the	  few	  known	  proteins	  with	  SUMO	  E3	  
ligase	  activity(Pichler	  et	  al.,	  2002).	  It	  has	  recently	  been	  shown	  that	  the	  E3	  SUMO	  ligase	  
activity	   of	   RanBP2	   depends	   on	   its	   assembly	   as	   a	   multisubunit	   complex	   consisting	   of	  
SUMO1-­‐modfied	   RanGAP1,	   RanBP2	   and	   Ubc9(Werner	   et	   al.,	   2012)(Figure	   45).	   An	  
interesting	   observation	   is	   that	   all	   subunits	   of	   the	   RanBP2/	   RanGAP1*Sumo1/Ubc9	  
complex	   are	   amongst	   the	   proteomic	   hits	   of	   the	   endogenous	   FBXO7	   pull-­‐downs	   from	  
wild-­‐type	  as	  well	  as	  homozygous	  R379G	  KI	  brain	  lysates.	  Table	  4-­‐6	  gives	  an	  overview	  of	  
the	  proteomic	  data	   for	  each	   replicate	   IP	  per	  genotype.	  RanBP2	   is	  a	   very	   large	  protein	  
(MW	   345	   kDa)	   and	   several	   commercial	   antibodies	   that	   I	   tested	   were	   unsuitable	   for	  
detecting	  and	  immunoprecipitating	  endogenous	  RanBP2.	  A	  DSTT	  antibody	  program	  was	  
therefore	   started	   (against	   AA2553-­‐1838	   of	   the	   human	   RANBP2	   protein,	   NP_006258	   -­‐	  
Figure	  45),	  which	  successfully	  detects	  and	  immunoprecipitates	  endogenous	  human	  and	  
mouse	  RanBP2	  proteins	  (data	  not	  shown).	  Figure	  46	  and	  Figure	  47	  show	  that	  there	  were	  
specific	  signals	  for	  RanGap1	  and	  RanBP2	  when	  the	  FBXO7	  IP	  products	  from	  wild-­‐type	  as	  
well	   as	   homozygous	   R379G	   KI	   brain	   lysates	  were	   subjected	   to	   immunoblotting.	   Using	  
the	  in	  the	  previous	  section	  (4.2.5)	  described	  homozygous	  Fbxo7C-­‐terminal	   truncation	  MEFs	  as	  
an	  endogenous	  means	  to	  show	  that	  the	  interaction	  between	  RanBP2	  and	  the	  C-­‐terminal	  
truncated	  FBXO7	  protein	  is	  either	  preserved	  or	  lost,	  I	  also	  subjected	  endogenous	  FBXO7	  
pull-­‐downs	   from	   wild-­‐type	   and	   homozygous	   Fbxo7C-­‐terminal	   truncation	   MEFs	   to	   RanBP2	  
immunoblotting.	   As	   the	   Fbxo7C-­‐terminal	   truncation	   protein	   lacks	   the	   F-­‐box	   domain,	   SKP1	  
binding	  and	  SCF	  complex	  formation	  is	   lost	  as	  documented	  by	  the	  Cullin	  1	  immunoblot.	  
Nevertheless,	  RanBP2	  and	  appears	  to	  interact	  with	  the	  N-­‐terminal	  half	  of	  FBXO7.	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Figure	  45:	  RanBP2	  and	  sumoylated	  RanGAP1	   forms	   the	  catalytically	  active	  E3	  SUMO	  
ligase	  
RanBP2	  associated	  with	  sumoylated	  RanGAP1	  and	  UBC9	  to	  function	  as	  an	  E3	  SUMO	  ligase	  localized	  at	  
nuclear	  pore	  complexes.	  RanBP2	  comprises	  a	  Leucin-­‐rich	  domain	  (LR),	  several	  Zinc	  finger	  motifs	  (ZN),	  four	  
Ran	  binding	  domains,	  several	  FG	  repeats	  (not	  shown),	  and	  a	  cyclophilin-­‐like	  domain	  (Cy).	  The	  E3	  ligase	  
domain	  is	  situated	  between	  2	  Ran	  binding	  domains.	  IR1	  and	  IR2	  have	  been	  described	  as	  UBC9	  binding	  
sites.	  Our	  DSTT	  antibody	  programme	  was	  raised	  against	  the	  E3	  ligase	  domain	  of	  RanBP2	  indicated	  by	  red	  
line	  (figure	  modified	  according	  to	  Figure	  1	  in	  (Werner	  et	  al.,	  2012)).	  
	  
	  
Table	   4-­‐6:	   Proteomic	   data	   for	   RANBP2	   /	   RanGap1*Sumo1	   /	   Ubc9	   complex	   of	   each	  
replicate	  IP	  
Molecular	  weight	  for	  each	  protein	  and	  mascot	  score	  with	  number	  of	  identified	  peptides	  and	  sequence	  
coverage	  in	  brackets	  for	  each	  of	  the	  3	  replicate	  endogenous	  FBXO7	  IPs	  from	  wild-­‐type	  and	  the	  2	  replicates	  





RanBP2 345 2 993&(60,&13%) 1 68&(8,&1%)
3 4922&(249,&55%) 2 3663&(198,&47%)
1 704&(34,&34%)
64 2 448&(20,&21%) 1 308&(20,&19%)
3 1274&(44,&40%) 2 1507&(48,&45%)
1 39&(1,&8%)
18 2 / 1 32&(4,&27%)
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Figure	   46:	   Detection	   of	   RanGAP1	   in	   endogenous	   FBXO7	   IPs	   from	   brain	   by	  
immunoblotting	  
The	  immunoblots	  on	  the	  left	  hand	  side	  show	  lysates	  of	  transient	  overexpressed	  Flag-­‐tagged	  RanGAP1,	  
Flag-­‐empty	  vector	  as	  well	  as	  wt	  and	  homozygous	  R379G	  KI	  brain	  lysates.	  RanGap1	  has	  a	  molecular	  size	  of	  
about	  64	  kDa,	  and	  is	  usually	  modified	  with	  SUMO1	  reflected	  in	  the	  second	  slightly	  larger	  lane.	  The	  
immunoblot	  on	  the	  right	  hand	  side	  shows	  that	  the	  SUMO-­‐modified	  form	  of	  RanGAP1	  can	  be	  detected	  in	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Figure	   47:	   Detection	   of	   RanBP2	   in	   endogenous	   FBXO7	   IPs	   from	   brain	   by	  
immunoblotting	  
A:	  R379G	  KI	  brain	  lysates:	  The	  top	  panel	  shows	  the	  FBXO7	  immunoblot	  of	  input	  and	  post-­‐IP	  lysates,	  FBXO7	  
immunoprecipitation	  products	  (5%)	  as	  well	  as	  appropriate	  controls	  for	  wt	  and	  homozygous	  R379G	  KI	  brain	  
lysates.	  The	  lower	  panel	  shows	  input	  lysates	  and	  FBXO7	  immunoprecipitation	  products	  and	  IgG	  controls	  
immunoblotted	  for	  RanBP2:	  there	  is	  a	  specific	  signal	  for	  RanBP2	  in	  the	  endogenous	  FBXO7	  IP	  product	  
from	  brain	  for	  both	  genotypes.	  
B:	  C-­‐terminal	  truncation	  MEFs:	  Endogenous	  FBXO7	  immunoprecipitations	  and	  controls	  were	  performed	  
using	  wild-­‐type	  and	  homozygous	  Fbxo7C-­‐terminal	  truncation	  (C-­‐terminal	  deletion	  starting	  immediately	  upstream	  
of	  the	  start	  of	  the	  F-­‐box	  domain-­‐	  see	  4.2.5)	  mouse	  embryonic	  fibroblast	  lysates.	  The	  Cullin	  1	  immunoblot	  
serves	  as	  a	  control	  for	  SCF	  complex	  disruption;	  if	  the	  SKP1	  binding	  domain	  is	  missing	  -­‐	  as	  it	  is	  the	  case	  in	  
the	  C-­‐termninal	  truncation	  MEFs	  –	  SKP1	  cannot	  interact	  with	  Fbxo7	  for	  complex	  assembly.	  The	  
immunoblot	  for	  RanBP2	  shows	  that	  the	  interaction	  between	  FBXO7	  and	  RanBP2	  is	  still	  persevered	  if	  the	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4.2.13.3 Fbxo7	  is	  not	  a	  target	  of	  SUMOylation	  with	  Sumo1	  
Given	  that	  both	  the	  wild-­‐type	  as	  well	  as	  the	  R379G	  KI	  Fbxo7	  proteins	  associate	  with	  the	  
RANBP2	   /	   RanGap1*Sumo1	   /	   Ubc9	   E3	   SUMO	   ligase	   complex,	   I	   wanted	   to	   explore	  
whether	   Fbxo7	   was	   possibly	   a	   SUMOylation	   target.	   I	   therefore	   used	   a	   6His_SUMO	  
overexpression	  protocol	  to	  test	  whether	  Fbxo7	  was	  modified	  by	  SUMO1(Tatham	  et	  al.,	  
2009).	   6His-­‐SUMO1	   stabily	   expressed	   in	   HeLa	   cells	   was	   purified	   from	   extracts	   using	  
Nickel-­‐affinity	   purification	   under	   denaturing	   conditions.	   This	   should	   allow	   the	   co-­‐
purification	   of	   any	   proteins	   that	   undergo	   posttranslational	   modification	   with	   SUMO.	  
Figure	  48	  shows	  that	  neither	  Flag-­‐FBXO7-­‐wt	  nor	  the	  Flag-­‐FBXO7-­‐R378G	  mutant	  undergo	  
SUMOylation	   in	   vivo	   under	   these	   conditions.	  As	  positive	   control	   serves	   Flag-­‐RanGAP1,	  
for	  which	  a	  band	  shift	  to	  the	  higher	  molecular	  SUMOylated	  form	  is	  marked	  with	  2	  red	  
asterisks	  upon	  co-­‐purification	  with	  6	  HIS-­‐SUMO1.	  
	  
Figure	  48:	  FLAG-­‐FBXO7-­‐wt	  and	  FLAG-­‐FBXO7-­‐R378G	  are	  not	  modified	  by	  SUMO1	  
Immunoblots	  from	  nickel-­‐affinity	  purification	  from	  stable	  expressing	  6His-­‐SUMO1	  HeLA	  cells	  transiently	  
transfected	  either	  with	  Flag-­‐empty	  vector,	  Flag-­‐RanGAP1,	  Flag-­‐FBXO7-­‐wt	  or	  FLAG-­‐FBXO7-­‐R378G	  under	  
denaturing	  condition.	  The	  top	  panel	  shows	  the	  Flag-­‐immunoblot	  of	  the	  crude	  input	  lysates	  -­‐	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right	  hand	  side.	  The	  latter	  demonstrates	  the	  band	  shift	  of	  the	  higher	  molecular	  weight	  species	  of	  
RanGAP1	  in	  its	  SUMOylated	  state	  (**).	  This	  serves	  as	  a	  positive	  control.	  There	  is	  no	  band	  shift	  observed	  
with	  FBO7.	  The	  lower	  panel	  shows	  the	  SUMO1	  immunoblot	  of	  the	  crude	  input	  lysates.	  The	  high	  molecular	  
weight	  smear	  corresponds	  to	  proteins	  modified	  by	  SUMO1.	  
	  
 Validation	  by	  immunoblotting	  –	  Reticulon	  4	  4.2.14
The	   Reticulon	   4	   gene	   gives	   rise	   to	   at	   least	   3	   isoforms	   of	   Nogo	   proteins,	   A,	   B,	   and	   C,	  
which	  share	  a	  C-­‐terminal	  homology	  domain	  of	  about	  188	  AA.	  Little	  is	  known	  about	  their	  
physiological	  function,	  but	  they’ve	  been	  discovered	  and	  studied	  in	  the	  context	  of	  injury	  
and	  repair	  of	  fibre	  tracts	  in	  the	  CNS(Schwab,	  2010).	  DSTT	  antibodies	  against	  Nogo	  B	  are	  
available	   allowing	   detection	   and	   immunoprecipitation	   of	   endogenous	   Nogo	   proteins	  
from	   brain,	   and	   these	   were	   used	   for	   my	   validation	   of	   Reticulon	   4.	   The	   longer	   Nogo	  
isoform	   A	   and	   the	   shorter	   isoform	   B	   co-­‐elute	   with	   endogenous	   Fbxo7	   when	  
immunoprecipitated	  from	  wild-­‐type	  and	  KI	  mouse	  brain	  as	  shown	  by	  immunoblotting	  in	  
Figure	  49.	  I	  also	  immunoblotted	  the	  endogenous	  FBXO7	  pull-­‐downs	  from	  wild-­‐type	  and	  
homozygous	  Fbxo7C-­‐terminal	   truncation	  MEFs	  for	  Nogo.	  Figure	  50	  shows	  that	  the	  N-­‐terminal	  
half	  of	  FBXO7	   is	  sufficient	  to	  maintain	  the	   interaction	  with	  both	  Nogo	   isoforms	  (A	  and	  
B).	  Table	  4-­‐7	  gives	  an	  overview	  of	  the	  proteomic	  data	  for	  Reticulon	  4	  for	  each	  individual	  
endogenous	   FBXO7	   pull-­‐down	   from	   brain.	   Reticulon	   4	   was	   not	   present	   in	   any	   of	   the	  
controls.	  
	  
Figure	   49:	   Detection	   of	   Nogo	  A	   and	  Nogo	   B	   (Reticulon	   4)	   in	   endogenous	   FBXO7	   IPs	  
from	  brain	  by	  immunoblotting	  
The	  top	  panel	  shows	  that	  the	  brain	  specific	  Reticulon	  4	  isoform	  (Nogo	  A)	  can	  be	  detected	  in	  the	  FBXO7	  IP	  
products	  from	  both	  wt	  as	  well	  as	  homozygous	  R379G	  KI	  brain	  lysates,	  but	  not	  in	  the	  IgG	  control.	  The	  lower	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Figure	   50:	   Detection	   of	   Nogo	  A	   and	  Nogo	   B	   (Reticulon	   4)	   in	   endogenous	   FBXO7	   IPs	  
from	  MEFs	  by	  immunoblotting	  
Endogenous	  FBXO7	  immunoprecipitations	  and	  controls	  were	  performed	  using	  wild-­‐type	  and	  homozygous	  
Fbxo7C-­‐terminal	  truncation	  (C-­‐terminal	  deletion	  starting	  immediately	  upstream	  of	  the	  start	  of	  the	  F-­‐box	  domain-­‐	  
see	  4.2.5)	  mouse	  embryonic	  fibroblast	  lysates.	  The	  Cullin	  1	  immunoblot	  confirms	  that	  in	  case	  of	  the	  C-­‐
terminal	  truncation	  MEFs	  complex	  formation	  is	  disrupted	  due	  to	  lack	  of	  the	  binding	  domain	  for	  SKP1.	  The	  
immunoblot	  for	  Nogo	  shows	  that	  the	  interaction	  between	  FBXO7	  and	  Nogo	  A	  /	  B	  is	  still	  persevered	  if	  the	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Table	  4-­‐7:	  Proteomic	  data	  for	  Reticulon	  4	  (Nogo)	  of	  each	  replicate	  IP	  
Molecular	  weight	  for	  each	  protein	  and	  mascot	  score	  with	  number	  of	  identified	  peptides	  and	  sequence	  
coverage	  in	  brackets	  for	  each	  of	  the	  3	  replicate	  endogenous	  FBXO7	  IPs	  from	  wild-­‐type	  and	  the	  2	  replicates	  
from	  homozygous	  R379G	  KI	  brain	  lysates.	  The	  candidate	  protein	  was	  not	  present	  in	  any	  of	  the	  control	  IgG	  
immunoprecipitations.	  
	  
 Validation	  by	  co-­‐immunoprecipitation	  4.2.15
My	   efforts	   to	   validate	   the	   proteomic	   hits	   from	   the	   endogenous	   FBXO7	  
immunoprecipitations	  by	  co-­‐immunoprecipitating	  FBXO7	  vice	  versa	  have	  been	  laborious	  
and	   inconsistent.	   I	   have	   been	   able	   to	   co-­‐immunoprecipitate	   FBXO7	   with	   large-­‐scale	  
(lysates	   from	   1	   mouse	   brain	   per	   immunoprecipitation	   (about	   25mg))	   pull-­‐downs	   of	  
RanBP2	  as	  well	   as	  Nogo	   from	  brain	   lysates	   from	  both	  genotypes,	  but	   I	  have	  not	  been	  
able	  to	  consistently	  reproduce	  these	  findings	  in	  repeat	  experiments.	  Additionally,	  I	  have	  
performed	  endogenous	  Reticulon	  4	  /	  nogo	  as	  well	  as	  RanBP2	  affinity	  purifications	  from	  
brain	  lysates	  followed	  by	  protoeamic	  analysisPerforming	  mass-­‐spectrometry	  fingerprint	  
analysis:	  In	  these	  experiments	  Fbxo7	  was	  not	  detected	  amongst	  the	  proteomic	  hits	  (data	  
not	  shown).	  	  
	  
Figure	  51:	  Co-­‐immunoprecipitation	  of	  FBXO7	  with	  RanBP2	   from	  wt	  and	  homozygous	  
R379G	  KI	  brain	  lysates	  
Large	  scale	  RanBP2	  immunoprecipitation	  from	  about	  25	  mg	  (lysate	  from	  1	  animal	  per	  IP)	  of	  wild-­‐type	  and	  
homozygous	  R379G	  KI	  brain	  lysates	  allows	  the	  detection	  of	  FBXO7	  as	  a	  co-­‐eluting	  protein	  by	  
MW#(kDa)
1 1736%(108,%47%)
Reticulon#4 127 2 151%(19,%13%) 1 43%(8,%6%)






























wt KI wtKI wtKI




	   144	  
immunoblotting.	  The	  panels	  on	  the	  left	  hand	  side	  (A)	  show	  the	  immunoblot	  for	  RanBP2	  as	  the	  bait	  with	  
input	  lysates	  and	  the	  FBXO7	  immunoblot	  of	  75%	  of	  the	  RanBP2	  IP	  and	  control	  for	  both	  genotypes.	  An	  
FBXO7	  pull-­‐down	  from	  1	  mg	  of	  tissue	  served	  as	  a	  control	  for	  the	  correct	  size	  of	  FBXO7.	  The	  right	  hand	  side	  




Figure	   52:	   Co-­‐immunoprecipitation	   of	   FBXO7	   with	   Nogo	   from	   wt	   and	   homozygous	  
R379G	  KI	  brain	  lysates	  
Large	  scale	  Nogo	  immunoprecipitation	  from	  about	  25	  mg	  (lysate	  from	  1	  animal	  per	  IP)	  of	  wild-­‐type	  and	  
homozygous	  R379G	  KI	  brain	  lysates	  allows	  the	  detection	  of	  FBXO7	  as	  a	  co-­‐eluting	  protein	  by	  
immunoblotting.	  The	  panels	  on	  the	  left	  hand	  side	  (A)	  show	  the	  immunoblot	  for	  Nogo	  as	  the	  bait	  with	  
input	  lysates	  and	  the	  FBXO7	  immunoblot	  of	  75%	  of	  the	  RanBP2	  IP	  and	  control	  for	  both	  genotypes.	  An	  
FBXO7	  pull-­‐down	  from	  1	  mg	  of	  tissue	  served	  as	  a	  control	  for	  the	  correct	  size	  of	  FBXO7.	  The	  right	  hand	  side	  
(B)	  shows	  the	  entire	  outline	  of	  the	  FBXO7	  immunoblot	  for	  the	  RanBP2	  IP	  with	  a	  shorter	  and	  a	  longer	  
exposure	  time.	  
	  
 Expression	   analysis	   of	   potential	   FBXO7	   interactors	   in	   wt	   and	   homozygous	  4.2.16
R379G	  KI	  lysates	  
In	  this	  section	  I	  have	  used	  brain	  lysates	  from	  wild-­‐type,	  heterozygeous	  and	  homozygous	  
R379G	  KI	  animals	  for	  immunoblotting	  of	  FBXO7,	  SCF	  complex	  members	  and	  some	  of	  the	  
putative	   FBXO7	   interactors	   as	   identified	   by	   the	   endogenous	   FBXO7	  
immunoprecipitations.	  Figure	  53	  shows	  that	  there	  is	  no	  difference	  in	  RanBP2	  expression	  
levels	  between	  the	  wild-­‐type	  and	  the	  homozygous	  R379G	  KI	  genotype	  (brain	  and	  MEF	  
lysates).	   The	   same	   can	   be	   observed	   for	   Nogo	   A	   and	   Nogo	   B	   (Reticulon	   4)	   as	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homozygous	   R379G	   KI	   brain	   lysates.	   I	   have	   then	   subjected	   brain	   lysates	   of	   all	   3	  
genotypes	  to	  immunoblotting	  for	  FBXO7,	  GAPDH	  as	  a	  loading	  control,	  all	  other	  members	  
of	  the	  SCF	  E3	  ligase	  complex	  as	  well	  as	  PI31,	  Neurabin	  2,	  Exportin	  1,	  RanBP2,	  Nogo	  A	  and	  
B.	  Although	  not	  amongst	  the	  list	  of	  putative	  FBXO7	  interactors	  in	  my	  study,	  I	  have	  also	  
included	  CIAP1	  and	  HURP	  in	  the	  expression	  analysis	  as	  they	  are	  amongst	  the	  previously	  
identified	   FBXO7	   interactors	   in	   other	   studies(Chang	   et	   al.,	   2006;	   Hsu	   et	   al.,	   2004).	  
RanGAP	  1	  could	  not	  be	  blotted	  for	  because	  the	  antibody	  was	  not	  suitable	  to	  work	  with	  
these	  particular	   lysates	   (Figure	  55).	  Overall,	  no	  striking	  differences	   in	  expression	   levels	  
were	   seen	   for	   the	   candidates	   blotted	   for	   except	   for	   the	   robust	   hypomorphism	  of	   the	  
homozygous	  R379G	  KI	  genotype.	  	  
I	  was	  then	  interested	  to	  see	  whether	  treatment	  with	  the	  MLN4294	  compound	  –	  a	  Cullin	  
deneddylating	   reagent	   which	   thereby	   also	   negatively	   regulates	   the	   activity	   of	   Cullin	  
dependent	   SCF	   E3	   ligases	   –	   had	   a	   genotype	   dependent	   effect	   on	   any	   the	   expression	  
level	  of	  any	  of	  these	  proteins.	  For	  this	  experiment,	  I	  used	  not	  only	  littermate	  wild-­‐type	  
and	  homozygous	  R379G	  KI	  MEFs,	  but	  also	  littermate	  wild-­‐type	  and	  homozygous	  Fbxo7C-­‐
terminal	  truncation	  MEFs.	  The	  latter	  lack	  the	  C-­‐terminal	  half	  of	  the	  FBXO7	  protein	  including	  the	  
functionally	   important	  F-­‐box	  domain.	  Figure	  56	  shows	  that	   there	  was	  mainly	  an	  effect	  
on	   RanGAP1.	   RanGAP1	   has	   an	   expected	   molecular	   weight	   of	   64	   kDa,	   but	   usually	   a	  
second	   species	   at	   a	   higher	   molecular	   weight	   exists	   due	   to	   stable	   SUMOylation	   with	  
SUMO1.	   The	   pool	   of	   not-­‐SUMOylated	   RanGAP1	   appears	   to	   be	   relatively	   lower	   in	   the	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Figure	   53:	   No	   difference	   in	   RanBP2	   expression	   levels	   between	  wt	   and	   homozygous	  
R379G	  KI	  brain	  and	  MEF	  lysates	  
RanBP2	  expression	  levels	  in	  brain	  (lysed	  in	  CHAPS)	  and	  MEFs	  (lysed	  in	  Urea)	  do	  not	  show	  a	  difference	  
between	  the	  wild-­‐type	  and	  homozygous	  R379G	  KI	  genotype.	  The	  top	  panel	  shows	  a	  shorter	  and	  the	  
middle	  panel	  a	  longer	  exposure	  time	  for	  the	  RanBP2	  immunoblot.	  An	  immunoblot	  against	  tubulin	  serves	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Figure	   54:	   No	   difference	   in	   Nogo	   A	   and	   B	   expression	   levels	   between	   wt	   and	  
homozygous	  R379G	  KI	  brain	  lysates	  
A:	  Li-­‐Cor	  quantification	  of	  Nogo	  A	  and	  Nogo	  B	  in	  whole	  brain	  urea	  lysates	  from	  wild-­‐type,	  heterozygeous	  
and	  homozygous	  R379G	  KI	  animals	  at	  10	  months	  of	  age	  expressed	  as	  mean	  (with	  SEM)	  in	  relation	  to	  wild-­‐
type	  expression	  levels	  and	  standardized	  against	  HSP90.	  The	  difference	  between	  the	  heterozygeous	  and	  
homozygous	  in	  comparison	  to	  the	  wild-­‐type	  expression	  level	  was	  not	  significant	  (P>	  0.05).	  B:	  Respective	  
immunoblots	  that	  were	  used	  for	  LICOR	  quantification.	  	  
	  
	  
Figure	  55:	  Expression	  analysis	  of	  potential	  interactors	  in	  brain	  lysates	  from	  wt,	  het	  and	  
hom	  R379G	  KI	  animals	  	  
Rapigest	  brain	  lysates	  (15	  ug	  each)	  from	  3	  animals	  of	  each	  genotype	  (wt,	  heterozygeous	  and	  homozygous	  
R379G	  KI	  animals	  at	  1	  month	  of	  age)	  were	  subjected	  to	  immunoblotting	  for	  FBXO7,	  Gapdh	  as	  well	  as	  the	  
other	  members	  of	  the	  SCF	  complex	  and	  putative	  interactors.	  There	  is	  no	  apparent	  difference	  in	  levels	  of	  
any	  of	  the	  candidates	  except	  for	  FBXO7	  itself.	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Figure	  56:	  Expression	  levels	  of	  FBXO7	  and	  putative	  interactors	  in	  MLN4926	  
Littermate	  wild-­‐type	  and	  homozygous	  Fbxo7C-­‐terminal	  truncation	  (KO)	  as	  well	  as	  littermate	  wt	  and	  homozygous	  
R379G	  KI	  MEFs	  were	  treated	  for	  18	  hours	  with	  the	  neddylation	  8	  inhibitor	  MLN4924	  at	  5uM	  (MLN4924	  
inhibits	  Cullin	  1	  neddylation,	  thereby	  inhibiting	  Cullin	  dependent	  SCF	  E3	  ligase	  activity)	  or	  DMSO	  control	  
before	  cells	  were	  lyses	  under	  denaturing	  conditions	  in	  SDS.	  Duplicate	  loading	  of	  corresponding	  lysates	  
were	  subjected	  to	  immunoblotting	  for	  FBXO7,	  GAPDH	  as	  a	  loading	  control,	  as	  well	  as	  PI31,	  RanGAP1	  and	  
Exportin1.	  The	  Cullin	  1	  blot	  demonstrates	  the	  disappearing	  band	  shift	  (neddylated	  form	  of	  Cullin	  1)	  with	  
MLN4296	  treatment.	  	  
	  
4.3 Behavioural	  phenotyping	  of	  the	  Fbxo7	  R379G	  Knock-­‐in	  mouse	  
model	  
The	   aim	   was	   to	   perform	   a	   phenotypic	   analysis	   of	   the	   Fbxo7R379G	   KI	   mouse	   model	   in	  
comparison	  to	  wild-­‐type	  littermates.	  A	  total	  of	  35	  animals	  were	  tested	  (13	  wild-­‐type	  and	  
22	  homozygous	  KI	  animals)	  at	  a	  single	  time	  point	  at	  about	  10	  months	  of	  age.	  Amongst	  
these	  animals	  were	  12	  gender-­‐matched,	   littermate	  pairs	  of	  wild-­‐type	  and	  homozygous	  
KI	  animals	  (mean	  age	  of	  the	  littermate	  pairs	  was	  307	  days	  at	  the	  time	  of	  testing)	  derived	  
from	   heterozygeous	   x	   heterozygeous	   breedings.	   An	   overview	   of	   all	   the	   general	  
characteristics	   of	   the	   animals	   is	   given	   in	   4.3.1.	   In	   section	   4.3,	   the	   results	   of	   the	   12	  
littermate	  pairs	  will	  be	  presented	  (unless	  otherwise	  stated)	  as	  they	  ensure	  a	  high	  degree	  
_-Gapdh37 kDa-
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of	  comparability.	  The	  mouse	  behavioural	  phenotyping	  was	  performed	  with	  the	  help	  of	  
Dr.	   Stephen	   Martin,	   manager	   of	   the	   behavioural	   neuroscience	   core	   facility	   at	   the	  
University	  of	  Dundee	  (Ninewells	  Campus,	  NW).	  Dr.	  Martin	  supported	  me	  in	  performing	  
the	  experiments,	  gathering	  the	  raw	  data	  and	  the	  analysis	  thereof.	  All	  mice	  were	  tested	  
at	   around	   the	   same	   time,	   but	   the	   animals	   were	   housed	   in	   different	   facilities	   at	   2	  
different	   sites.	   This	   was	   due	   to	   unforeseen	   problems	   with	   inter-­‐facility	   transfer	   of	  
animals	   due	   to	   differences	   in	   the	   facilities’	   “specific	   pathogen	   freeness”.	   	   Post	   hoc	   it	  
turned	   out	   that	   there	   was	   an	   unexpected	   and	   significant	   difference	   in	   body	   weight	  
between	  animals	  house	   in	  one	  facility	  compared	  to	  the	  other	  –	  animals	  housed	  at	  the	  
College	  of	  Life	  Sciences	   	   (CLS)	  were	  significantly	  heavier	   than	  those	  housed	  at	   the	  NW	  
campus.	  The	  correlation	  between	  body	  weight	  and	  housing	  facility	  was	  greater	  than	  that	  
seen	  for	  gender	  and	  genotype	  did	  not	  significantly	   influence	  the	  weight	  of	  the	  animals	  
(Table	  4-­‐8).	  Figure	  57	  shows	  the	  bodyweight	  of	  each	  animal	  according	  to	  genotype	  and	  
gender,	   and	   t-­‐test	   analysis	   revelas	   that	   there	   is	   no	   significant	   difference	   in	   mean	  
bodyweight	  between	  the	  2	  genotypes	  and	  gender.	  There	  is	  also	  no	  significant	  difference	  
in	  mean	  body	  weight	  between	  the	  wild-­‐type	  and	  homozygous	  R379G	  KI	  Fbxo7	  genotype	  
when	  male	  and	  female	  animals	  are	  combined	  in	  the	  analysis	  (littermate	  pairs	  as	  well	  as	  
all	  35	  animals;	  data	  not	  shown).	  
	  
Table	  4-­‐8:	  Correlation	  matrix	  of	  variables	  influencing	  body	  weight	  for	  all	  35	  animals	  
Pearson’s	  correlation	  values	  (as	  r2)	  between	  different	  variables	  for	  all	  35	  animals	  (21	  male	  and	  14	  females;	  
13	  wt	  and	  22	  homozygous	  R379G	  KI;	  19	  housed	  at	  NW	  and	  16	  housed	  at	  CLS).	  There	  is	  a	  significant	  
correlation	  between	  body	  weight	  (in	  grams	  on	  day	  1	  of	  testing)	  not	  only	  for	  gender,	  but	  also	  for	  where	  the	  
animals	  were	  housed.	  Genotype	  did	  not	  significantly	  affect	  body	  weight.	  	  
Weight' Genotype' Gender' Housing'facility'
Genotype' 0.00'
Gender' 0.03' 0.05'
Housing'facility' ''''0.51**' 0.02' 0.02'





	   150	  
(Variables:	  mean	  latency	  to	  loose	  grip	  (days	  1-­‐4)	  (in	  seconds),	  genotype	  (wt=1,	  hom	  KI=	  -­‐2),	  gender	  
(male=1,	  female=-­‐1),	  body	  weight	  on	  trial	  day	  1	  (in	  grams)	  and	  housing	  facility	  (Ninewells	  campus=1,	  
College	  of	  Life	  Sciences=-­‐1).	  Stars	  indicate	  the	  level	  of	  significance.	  	  
	  
	  
Figure	  57:	  Dotblots	  of	  bodyweight	  in	  relation	  to	  gender	  and	  genotype	  	  
The	  panel	  on	  the	  left	  shows	  bodyweight	  of	  the	  littermate	  pairs	  in	  relation	  to	  gender	  and	  genotype	  while	  
the	  panel	  on	  the	  right	  shows	  it	  for	  all	  35	  animals.	  Individual	  animals	  are	  represented	  either	  as	  triangular	  or	  
round	  shape	  dependent	  on	  which	  facility	  they	  were	  housed	  in	  (triangular:	  College	  of	  Life	  Science;	  round:	  
Ninwells	  site).	  The	  weight	  in	  grams	  corresponds	  to	  day	  1	  of	  testing	  (means	  and	  standard	  error	  of	  the	  
mean	  are	  indicated	  by	  bars).	  T-­‐test	  analysis	  confirms	  that	  the	  difference	  in	  mean	  weight	  between	  the	  2	  
genotypes	  and	  per	  gender	  does	  not	  significantly	  differ.	  The	  graph	  also	  demonstrates	  that	  the	  animals	  
housed	  at	  the	  CLS	  site	  tend	  to	  be	  heavier	  irrespective	  of	  genotype	  or	  gender.	  	  
	  
 General	  neurological	  screen	  of	  wild-­‐type	  and	  Fbxo7R379G	  KI	  mouse	  (SHIRPA)	  4.3.1
All	  35	  mice	  underwent	  the	  SHIRPA	  test	  battery	  as	  an	  initial	  general	  neurological	  screen.	  
The	  protocol	  involves	  a	  three	  stage	  screening	  procedure	  designed	  to	  mimic	  the	  human	  
neurological	  and	  psychiatric	  diagnostic	  procedure(Masuya	  et	  al.,	  2005).	  Table	  4-­‐9	  shows	  
the	   results	   for	   the	   wild-­‐type	   and	   homozygeous	   R379G	   Fbxo7	   littermate	   pairs	   (n=12	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irregular	  coat	  can	  be	  an	   indication	  for	  an	  underlying	   illness	   if	   it	   is	  seen	   in	  combination	  
with	  other	  features	  that	  are	  generally	  accepted	  as	  sick	  rodent	  signs	  (such	  as	  for	  example	  
discharge	  from	  the	  eyes,	  hunched	  posture,	  skin	  lesions,	  reluctance	  to	  move,	  poor	  body	  
condition)(Pettan-­‐Brewer	  and	  Treuting,	  2011).	  Other	  signs	  of	  an	  underlying	  illness	  were	  
not	  seen	  in	  the	  homozygeous	  R379G	  Fbxo7	  KI	  mice	  and	  hence,	  the	  irregularities	  in	  coat	  
appearance	  are	  unlikely	   a	   reflection	  of	   such.	   The	  difference	   in	   transfer	   arousal	   –	  with	  
the	   homozygeous	   R379G	   Fbxo7	   KI	   mice	   demonstrating	   more	   often	   freezing	   –	   could	  
potentially	  be	  a	  reflection	  of	  a	  difference	  in	  anxiety	  behaviour(Hafezparast	  et	  al.,	  2002).	  
There	   was	   however	   no	   difference	   in	   the	   locomotor	   activity	   analysis	   between	   the	   2	  
genotype	   (4.3.2),	   which	   would	   have	   corrobotorated	   a	   behavioural	   phenotype	   of	   the	  
homozygeous	   R379G	   Fbxo7	   KI	   animals.	   Overall,	   the	   modified	   SHIRPA	   analysis	   of	   the	  
littermate	  wild-­‐type	  and	  homozygeous	  R379G	  KI	  Fbxo7	  mice	  did	  not	  show	  a	  consistent	  
difference	  in	  their	  general	  phenotype.	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Table	  4-­‐9:	  Results	  of	  the	  modified	  SHIRPA-­‐analysis	  of	  the	  Fbxo7	  wt	  and	  homozygeous	  
R379G	  KI	  littermate	  pairs	  
wt#(n=12) Hom#KI#(n=12) p#0#value
1 Body#weight#(g) 32.33#+#2.22 33.25#+#2.58 n.s.
2 Body#position# Inactive 0 0
Active 12 12 n.s.
excessive#active# 0 0
3 Tremor Absent 12 12 n.s.
Present 0 0
4 Palpebral#closure Eyes#open 12 12 n.s.
Eyes#closed 0 0
5 Coat#appearance Tidy#and#well#groomed 12 8 p<0.05
Irregularities 0 4
6 Whiskers Absent 2 3 n.s.
Present 10 9
7 Lacrimation Absent 12 12 n.s.
Present 0 0
8 Defecation Absent 2 2 n.s.
Present 10 10
9 Transfer#arousal Extended#freeze 0 2 p<0.05
Brief#freeze 1 3
Immediate#movement 11 7
10 Locomotor#activity see#1.3.1.2.#for#detailed#analysis n.s.
11 Gait Fluid#movement 12 11 n.s.
Lack#fluidity 0 1 n.s.
12 Tail#elevation Dragging 0 0
Horizontal#extension 12 12
Elevated#tail 0 0





15 Skin#colour Blanched 0 0 n.s.
Pink 12 12
Bright,#deep#red 0 0
16 Trunk#curl Absen 0 0 n.s.
Present 12 12
17 Limb#grasping Absent 12 12 n.s.
Present 0 0
18 Pinna#reflex Present 12 12 n.s.
Absent 0 0
19 Corneal#reflex Present 12 12 n.s.
Absent 0 0
20 Righting#reflex Present 12 12 n.s.
Absent 0 0
21 Contact#righting#reflex Present 12 11 n.s.
Absent 0 1
22 Evidence#of#biting Present 0 1 n.s.
Absent 12 11
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Amongst	  the	  parameters	  tested,	  coat	  appearance	  and	  transfer	  arousal	  behaviour	  differed	  between	  the	  2	  
genotypes.	  The	  homozygeous	  KI	  animals	  demonstrated	  more	  often	  localized	  patchy	  hair	  loss	  at	  the	  back.	  
Irregularities	  in	  coat	  appearance	  can	  be	  an	  indication	  for	  an	  underlying	  illness	  if	  seen	  in	  combination	  with	  
other	  features	  of	  generally	  accepted	  sick	  rodent	  signs	  (which	  was	  not	  the	  case	  here)(Pettan-­‐Brewer	  and	  
Treuting,	  2011).	  The	  only	  difference	  in	  the	  arena	  was	  a	  difference	  in	  transfer	  arousal,	  where	  the	  
homozygeous	  KI	  animals	  demonstrated	  more	  often	  freezing,	  which	  is	  a	  behaviour	  that	  can	  be	  influenced	  
by	  expoloratory,	  emotional	  and	  arousal	  behaviour(Hafezparast	  et	  al.,	  2002).	  	  
	  
 Testing	  of	  spontaneous	  locomotor	  activity	  4.3.2
The	  open-­‐field	   test	  allows	   testing	  of	   spontaneous	   locomotor	  activity	  by	  observing	  and	  
recording	  an	  animal’s	  movement	  around	  an	  open	  area.	  Typically,	  a	  mouse	  will	  run	  to	  the	  
walled	  edge	  and	  explore	  its	  surrounding	  while	  staying	  close	  to	  the	  wall	  as	  it	  fears	  novel	  
and	  open	   spaces.	  As	   the	   animal	   habituates	   to	   its	   new	   surrounding,	   its	   anxiety	  usually	  
diminishes	   and	   it	   will	   increasingly	   venture	   out	   to	   explore	   the	   centre	   of	   the	   arena.	   In	  
addition	   to	   general	   locomotion,	   rearing	   is	   another	   variant	   of	   the	   search	   phase	   of	  
exploratory	  behaviour	   in	  mice;	   it	  serves	  to	  provide	  head	  elevation	  to	   investigate	  more	  
distant	  stimuli	  and	  is	  usually	  accompanied	  by	  undirected	  sniffing.	  This	  natural	  behaviour	  
can	   be	   exploited	   in	   the	   open-­‐field	   locomotor	   activity	   test	   to	   measure	   anxiety-­‐like	  
behaviour(Brooks	   and	   Dunnett,	   2009).	   There	   was	   no	   difference	   in	   the	   total	   distance	  
travelled,	  number	  of	  rears,	  or	  distance	  travelled	  in	  the	  periphery	  or	  centre	  of	  the	  arena	  
between	  wild-­‐type	  and	  homozygous	  Fbxo7R379G	  KI	  mice:	  Figure	  58	  shows	  the	  locomotor	  
results	   for	   the	   littermate	  pairs	   (rearing	  not	  shown).	  There	  was	  also	  no	  difference	  seen	  




	   154	  
	  
Figure	  58:	  Open-­‐field	  test	  for	  littermate	  pairs	  
A:	  Total	  distance	  travelled	  by	  each	  group	  (wt	  and	  hom	  KI)	  in	  each	  of	  the	  3	  daily	  sessions	  of	  30	  min	  subdivided	  into	  10	  min	  intervals	  (mean	  +	  SEM).	  B:	  
Percentage	  of	  the	  total	  distance	  that	  was	  travelled	  in	  the	  periphery	  versus	  the	  centre	  of	  the	  arena.	  C:	  Number	  of	  rears	  during	  all	  3	  sessions	  (mean	  +	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 Gait	  analysis	  4.3.3
Foot	  prints	  left	  on	  paper	  by	  a	  mouse	  walking	  down	  a	  narrow	  corridor	  whose	  fore	  and	  
hind	  paws	  are	  dyed	  with	  different	  colours	  was	  used	  to	  analyse	  a	  range	  of	  gait	  
parameters	  such	  as	  stride	  length,	  base	  width,	  and	  overlap	  between	  fore	  and	  hind	  
paws.	  There	  was	  no	  difference	  in	  any	  of	  these	  parameters	  between	  the	  littermate	  
pairs	  to	  suggest	  that	  the	  homozygous	  Fbxo7R379G	  KI	  mice	  had	  any	  problems	  with	  
motor	  coordination	  and	  synchrony	  during	  normal	  walking	  (data	  not	  shown).	  The	  
same	  was	  observed	  when	  all	  35	  animals	  were	  included	  in	  the	  analysis.	  	  	  
 Rotarod	  performance	  to	  assess	  motor	  coordination	  and	  balance	  4.3.4
The	   rotarod	   is	   a	   specifically	   designed	   instrument	   to	   assess	   neurological	   deficits	   in	  
rodents(Dunham	  and	  Miya,	  1957),	  and	   is	  one	  of	   the	  most	  commonly	   tests	  used	   to	  
assess	   motor	   coordination	   and	   balance	   in	   mice.	   The	   mice	   are	   either	   tested	   on	  
separate	  trials	  at	  a	  series	  of	  fixed	  speeds	  (fixed	  speed	  protocol)	  or	  during	  increasing	  
revolutions	   of	   the	   rod	   in	   each	   trial	   (accelerating	   protocol)	   and	   their	   latency	   to	   fall	  
down	  is	  measured.	  There	  are	  several	  recognized	  confounding	  factors	  of	  the	  rotarod	  
test:	  1)	  animals	  that	  don’t	  perform	  and	  fall	  off	  as	  soon	  as	  they	  are	  placed	  on	  the	  rod	  
–	   these	  can	  be	  excluded	  as	  outliers	   from	  the	  analysis.	   	  2)	  animals	  may	  cling	   to	   the	  
beam	  and	  rotate	  with	  it	  without	  falling	  off	  and	  3)	  	  body	  weight	  of	  the	  animals	  -­‐	  heavy	  
mice	   perform	  worse	   than	   light	   mice(Brooks	   and	   Dunnett,	   2009).	   In	   this	   study,	   all	  
animals	   performed	   during	   the	   rotarod	   test	   to	   satisfaction	   and	   in	   addition	   to	   the	  
latency	  to	  fall,	  also	  the	   latency	  to	   loose	  grip	   (the	  point	  when	  the	  animal	  clings	  and	  
starts	   to	   rotate	   with	   the	   beam	   rather	   than	   to	   walk)	   was	   recorded.	   Results	   are	  
presented	  as	  “latency	  to	  loose	  grip”.	  	  
 Rotarod	  performance	  during	  the	  accelerating	  protocol	  4.3.5
There	  is	  a	  significant	  group	  difference	  in	  the	  overall	  rotarod	  performance	  during	  the	  
accelerating	  protocol	  between	  the	  littermate	  wild-­‐type	  and	  Fbxo7R379G	  KI	  pairs	  at	  10	  
months	  of	  age	  (Figure	  59).	  Figure	  60	  demonstrates	  that	  the	  overall	  performance	  of	  
the	  R379G	  KI	  Fbxo7	  animals	  was	  significantly	   impaired	   in	  comparison	  to	  their	  wild-­‐
type	  littermate	  controls.	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Figure	   59:	   Impaired	   motor	   performance	   of	   the	   R379G	   KI	   Fbxo7	   animals:	  
Accelerating	  rotarod	  test	  	  
The	  graphs	  shows	  the	  mean	  latencies	  to	  loose	  grip	  of	  all	  4	  trial	  days	  for	  each	  group	  of	  littermate	  pairs	  
of	  wt	  and	  homozygous	  R379G	  KI	  animals.	  A	  paired	  t-­‐test	  demonstrates	  that	  the	  group	  difference	  
between	  wt	  and	  mutant	  animals	  is	  significant	  on	  day	  2	  (p=0.04)	  and	  day	  4	  (p=0.01).	  
	  
Figure	   60:	   Significant	   group	   difference	   between	   wt	   and	   homozygous	   R379G	   KI	  
animals	  across	  all	  4	  trial	  days	  during	  the	  accelerating	  protocol	  
The	  graph	  shows	  the	  mean	  latencies	  (raw	  data,	  not	  adjusted	  for	  weight	  of	  the	  animals)	  to	  loose	  grip	  
of	  all	  4	  trial	  days	  for	  each	  group	  of	  littermate	  pairs	  of	  wt	  and	  homozygous	  R379G	  KI	  animals.	  A	  paired	  
t-­‐test	  demonstrates	  that	  the	  group	  difference	  between	  wt	  and	  mutant	  animals	  is	  significant	  (p=0.02).	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The	   impact	   of	   body	   weight	   on	   the	   performance	   in	   the	   rotarod	   experiment	   has	  
already	  been	  pointed	  out.	  Figure	  61	  shows	  the	  relationship	  between	  bodyweight	  and	  
rotarod	  performance	  for	  all	  paired	  animals.	  The	  respective	  linear	  regression	  lines	  per	  
genotype	   show	   that	   body	   weight	   affects	   rotarod	   performance	   likewise	   and	  
irrespective	  of	  genotype.	  
	  
Figure	  61:	  Mean	  latency	  during	  accelerating	  protocol	  (days	  1-­‐4)	  versus	  body	  weight	  
Body	  weight	  of	  the	  animals	  significantly	  affects	  their	  performance	  in	  the	  accelerating	  protocol	  of	  the	  
rotarod	  test.	  Mean	  latency	  to	  lose	  grip	  of	  all	  4	  trial	  days	  for	  each	  animal	  is	  blotted	  against	  its	  body	  
weight	  on	  trial	  day	  1.	  The	  genotype	  of	  each	  animal	  is	  indicated	  as	  a	  red	  dot	  for	  homozygous	  R379G	  KI	  
and	  as	  a	  black	  triangle	  for	  wt	  animals.	  The	  respective	  linear	  regression	  lines	  per	  genotype	  show	  that	  
body	  weight	  affects	  rotarod	  performance	  likewise	  and	  irrespective	  of	  genotype.	  (Linear	  regression	  
line	  for	  all	  paired	  animals	  irrespective	  of	  genotype:	  r2	  =	  0.51,	  p	  <	  0.001;	  line	  not	  shown	  in	  graph)	  
	  
 Rotarod	  performance	  during	  the	  fixed	  speed	  protocol	  4.3.6
The	  fixed	  speed	  protocol	  provides	  separate	  data	  on	  each	  range	  of	  rotation	  speeds.	  
There	   is	   a	   trend	   towards	   a	   better	   performance	   in	   the	   fixed	   speed	  protocol	   by	   the	  
group	   of	   wild-­‐type	   animals	   in	   comparison	   to	   their	   Fbxo7R379G	   KI	   littermates	   (Figure	  
62).	   This	   difference	   reaches	   statistical	   significance,	   when	   the	   difference	   in	   body	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weight	  is	  being	  adjusted	  for	  by	  performing	  an	  analysis	  of	  covariance.	  The	  same	  can	  
be	  observed	  when	  all	  35	  animals	  are	  being	  taken	  into	  account	  (data	  not	  shown).	  
	  
Figure	  62:	  Fixed	  speed	  rotarod	  performance	  of	  littermate	  pairs	  
The	  mean	  latency	  to	  loose	  grip	  for	  each	  group	  (raw	  data,	  not	  adjusted	  for	  weight	  of	  the	  animals)	  is	  
blotted	  for	  each	  trial	  of	  different	  rotational	  speeds	  used	  (data	  is	  expressed	  as	  mean	  +	  S.E.M.	  either).	  
The	  group	  difference	  between	  wt	  and	  homozygous	  R379G	  KI	  animals	  is	  not	  significant	  unless	  the	  
difference	  in	  body	  weight	  is	  taken	  into	  account.	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Figure	  63:	  Relationship	  between	  bodyweight	  and	  fixed	  speed	  rotarod	  performance	  
at	  30rpm	  
Body	  weight	  of	  the	  individual	  animals	  is	  blotted	  against	  the	  latency	  to	  loose	  grip	  (Y	  scale	  as	  log10	  of	  
latency	  to	  loose	  grip	  in	  seconds)	  for	  the	  fixed	  speed	  rotarod	  performance	  at	  30	  rpm.	  Also	  shown	  are	  
the	  respective	  regression	  lines	  for	  each	  genotype,	  demonstrating	  that	  the	  effect	  of	  body	  weight	  is	  the	  
same	  on	  the	  performance	  for	  each	  genotype.	  
	  
4.4 Discussion	  
My	  second	  result	  chapter	  is	  about	  the	  generation	  and	  characterization	  of	  the	  FBXO7	  
mouse	  model	  with	  knock-­‐in	  of	  one	  of	   the	  human	  pathogenic	  mutations	  associated	  
with	  early	  onset	  Pyramidal-­‐Parkinsonism	  and	  my	  endeavour	  to	  identify	  endogenous	  
FBXO7	  interacting	  partners	  in	  the	  neuronal	  system.	  To	  focus	  my	  study	  on	  FBXO7	  was	  
particularly	   interesting	   because	   of	   several	   reasons:	   As	   a	   putative	   SCF	   E3	   ubiquitin	  
ligase	  component	  FBXO7	  is	   likely	  to	  play	  a	  role	   in	  the	  ubiquitin	  proteasome	  system	  
(UPS)	   and	   there	   is	   emerging	   evidence	   that	   the	  UPS	  plays	   an	   important	   role	   in	   the	  
pathomechanism	   of	   Parkinson’s	   disease	   and	   neurodegenerative	   processes	   in	  
general(Cook	  et	  al.,	  2012;	  Dennissen	  et	  al.,	  2012;	  Ebrahimi-­‐Fakhari	  et	  al.,	  2012).	   In	  
comparison	   to	   the	  other	  genetic	  Parkinsonian	   syndromes	   for	  which	  animal	  models	  
exist,	   FBXO7	   associated	   disease	   has	   a	   relatively	   complex	   clinical	   phenotype	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(parkinsonism	   and	   pyramidal	   symptoms)	   with	   very	   early	   onset	   justifying	   the	  
reasonable	   expectation	   that	   a	   FBXO7	   animal	   model	   might	   recapitulate	   important	  
aspects	  of	  the	  human	  phenotype.	  I	  have	  already	  explained	  in	  4.2.1	  why	  we	  chose	  to	  
model	   the	   R378G	   mutation	   in	   the	   FBXO7	   KI	   mouse	   model	   for	   my	   thesis:	   the	  
particular	  residue	  is	  highly	  conserved	  as	  demonstrated	  in	  the	  sequence	  alignment	  of	  
different	   FBXO7	  homologues	   (Figure	  29)	  and	   resides	   in	   very	   close	  proximity	  of	   the	  
functionally	  important	  F-­‐box	  domain	  of	  the	  FBXO7	  protein.	  As	  the	  mouse	  homologue	  
is	  one	  amino	  acid	   longer	   than	   the	  human	  one,	   the	  human	  R378G	  FBXO7	  mutation	  
corresponds	   to	   R379G	   Fbxo7	   in	   the	   mouse.	   The	   R379G	   KI	   mouse	   model	   was	  
commercially	   generated	   by	   Taconis	   Artemis®	   and	   in	   general,	   the	   Fbxo7	   R379G	   KI	  
mouse	  line	  is	  viable	  and	  fertile.	  
The	   Fbxo7	   R379G	   KI	   mouse	   model	   was	   designed	   as	   a	   conditional	   model	   of	   cre-­‐
mediated	  deletion	  of	  exons	  7	  and	  8,	  which	   should	   result	   in	   loss	  of	   function	  of	   the	  
Fbxo7	   gene	   by	   deleting	   part	   of	   the	   F-­‐box	   domain	   and	   by	   generating	   a	   frame	   shift	  
from	  exon	   6	   to	   a	   premature	   stop	   codon	   in	   exon	   9.	   Two	  observations	  were	  made:	  
First,	  Cre-­‐deletion	  of	  exons	  7	  and	  8	  of	  the	  Fbxo7	  gene	  (KO)	  did	  not	  yield	  any	  viable	  
offspring	  in	  the	  homozygous	  state,	  while	  it	  was	  tolerated	  in	  the	  heterozygeous	  state.	  
Second,	  the	  truncated	  mRNA	  product	  of	  the	  Cre-­‐deletion	  KO	  allele	  was	  transcribed	  
and	  translated	  resulting	  in	  the	  expression	  of	  a	  323	  AA	  long	  mutant	  protein,	  which	  in	  
fact	  could	  be	  detected	  in	  the	  homozygous	  state	  in	  immortalized	  MEFs	  derived	  from	  
embryo	   dissections	   at	   E	   12.5	   days.	   The	   truncated	   protein	   product	   lacks	   the	   C-­‐
terminal	  part	  of	  the	  Fbxo7	  protein	  including	  the	  F-­‐box	  domain.	  It	  is	  not	  clear	  from	  my	  
study	   at	   which	   exact	   developmental	   stage	   from	   E12.5	   onwards,	   the	   C-­‐terminal	  
truncation	  mutation	  exerts	  its	  lethal	  effect,	  as	  this	  would	  require	  staged	  dissections	  
from	   E12.5	   to	   the	   end	   of	   gestation	   ideally	   in	   combination	   with	   pathological	  
evaluation	  of	  the	  embryos.	  This	  is	  clearly	  very	  interesting	  and	  will	  be	  followed	  up	  in	  
future	   experiments.	   However,	   it	   could	   be	   speculated	   that	   the	   lethality	   of	   this	  
particular	  mutant	  could	  be	  linked	  to	  the	  function	  of	  Fbxo7	  as	  an	  SCFFbxo7	  E3	  ubiquitin	  
ligase	  given	   that	   the	   lack	  of	   the	  F-­‐box	  domain	  prevents	   complex	  assembly.	   In	   fact,	  
the	  C-­‐terminal	  deletion	  MEF	  cell	  lines	  were	  used	  as	  an	  endogenous	  negative	  control	  
for	   SCF	   complex	   formation	   and	   also	   as	   a	   cellular	   model	   for	   looking	   at	   expression	  
levels	  of	  putative	  Fbxo7	  interacting	  proteins.	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 Availability	  of	  a	  sensitive	  and	  specific	  α 	  mouse	  Fbxo7	  antibody	  4.4.1
My	  specific	  aim	  was	  to	  study	  the	  function	  of	  Fbxo7	  in	  the	  endogenous	  system	  rather	  
than	   using	   heterologous	   overexpression.	   This	   necessitates	   the	   availability	   of	   a	  
sensitive	   and	   specific	   antibody	   against	   Fbxo7.	   I	   show	   in	   section	   4.2.3	   that	   the	   in-­‐
house	  DSTT	   generated	   antibody	  which	  was	   raised	   against	   the	  whole	  mouse	   Fbxo7	  
protein,	  is	  able	  to	  detect	  and	  also	  immunoprecipitate	  endogenous	  Fbxo7.	  At	  least	  2	  
FBXO7	  isoforms	  are	  known	  to	  exist,	  but	  theoretically	  there	  could	  be	  more	  isoforms	  
of	  different	  length	  depending	  on	  alternative	  splicing(Di Fonzo	  et	  al.,	  2009; Zhao	  et	  
al.,	  2011).	   In	   the	  Fbxo7	  tissue	  panel	   immunoblotting,	   I	  observe	  2	  main	  bands	  most	  
likely	   corresponding	   to	   the	   longer	   isoform	   1	   (Uniprot	   Q3U7U3:	   523AA,	   computed	  
molecular	  weight	  using	  ProtParam	  tool	  by	  ExPASy(Wilkins	  et	  al.,	  1999):	  58	  kDa)	  and	  
the	   shorter	   isoform	   2	   (Uniprot	   Q3UD93:	   443	   AA,	   computed	  molecular	   weight:	   49	  
kDa)	  of	  the	  mouse	  Fbxo7	  protein.	  There	  is	  a	  tissue-­‐specific	  distribution	  pattern	  with	  
the	   longer	   isoform	  1	  predominantly	  being	  present	   in	  brain,	  while	  for	  example	  both	  
isoforms	   are	   present	   in	   an	   equal	   ratio	   in	   spleen	   and	   heart.	   Figure	   33	   also	  
demonstrates	   the	   specificity	   of	   the	   Fbxo7	   antibody:	   the	   Fbxo7	   immunoblot	   of	   the	  
truncated	  Fbxo7	  protein	  in	  Fbxo7	  C-­‐terminal	   trunk	  MEF	  lysates	  is	  devoid	  of	  any	  signals	  in	  
the	  molecular	  weight	  range	  between	  >	  37	  kDa	  and	  75kDa	  in	  the	  homozygous	  state	  
(computed	   molecular	   weight	   of	   35	   kDa)	   while	   showing	   the	   signals	   for	   the	   larger	  
isoform	   1	   and	   several	   smaller	   bands	   in	   the	   heterozygeous	   state.	   Additionally,	   the	  
specificity	  of	  the	  antibody	  has	  been	  confirmed	  by	  proteomic	  fingerprinting	  as	  Fbxo7	  
of	  in-­‐gel	  trypsin	  digested	  gel	  bands	  within	  the	  range	  of	  50	  –	  75	  kDa	  (as	  demonstrated	  
in	   the	  proteomic	  data	  of	   the	  endogenous	  Fbxo7	   immunoprecipitation	  experiments	  
as	  shown	  in	  4.2.11.).	  
 Reduced	   Fbxo7	   protein	   levels	   in	   the	   homozygous	   Fbxo7	   R379G	   mutant	  4.4.2
protein	  
The	  next	  step	  was	  to	  look	  at	  the	  expression	  profile	  of	  the	  R379G	  knock-­‐in	  insertion	  at	  
the	  endogenous	  Fbxo7	   locus	  by	   immunoblotting.	  Testing	  a	  panel	  of	   tissues	  derived	  
from	  littermate	  wild-­‐type,	  heterozygeous	  and	  homozygous	  R379G	  Fbxo7	  animals	  at	  
6	  weeks	  as	  well	  as	  6	  months	  of	  age	  shows	  that	  Fbxo7	  is	  widely	  expressed	  –	  at	  least	  in	  
the	  tissues	  tested	  including	  brain,	  lung,	  spleen,	  liver,	  kidney,	  and	  heart.	  Additionally,	  
it	  was	  evident	  that	  there	  was	  a	  consistent	  reduction	  in	  expression	  level	  of	  the	  Fbxo7	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R379G	  mutant	  in	  the	  homozygous	  state.	  I	  quantified	  this	  difference	  for	  brain	  lysates	  
derived	  from	  3	  littermate	  pairs	  of	  wild-­‐type	  and	  homozygous	  R379G	  Fbxo7	  animals	  
using	   the	   LI-­‐COR	   system:	   In	   comparison	   to	   the	   wild-­‐type	   Fbxo7	   protein	   the	  
expression	  of	  the	  homozygous	  R379G	  mutant	  is	  reduced	  by	  half	  (0.54).	  So	  far,	  brain	  
tissue	   from	   patients	  with	   FBXO7	   dependent	   disease	   has	   not	   become	   available	   for	  
autopsy	   studies	   as	   yet.	   Recently,	   FBXO7	   immunoreactivity	   was	   reported	   to	   be	  
present	   in	  different	  regions	  of	  normal	  human	  brain	  samples,	  and	  the	  same	  pattern	  
was	  observed	  in	  samples	  derived	  from	  patients	  with	  sporadic	  PD(Zhao	  et	  al.,	  2013).	  
Furthermore,	   FBXO7	   immunoreactivity	   was	   detected	   in	   α−synuclein-­‐positive	  
inclusion	   bodies,	   but	   not	   in	   tau-­‐positive	   inclusions.	  With	   regards	   to	   the	   individual	  
pathogenic	   mutations,	   the	   expression	   of	   the	   T22M	   FBXO7	   has	   been	   looked	   at	   in	  
immortalized	  fibroblast	  cell	  lines	  from	  one	  heterozygeous	  carrier	  and	  2	  homozygous	  
affected	   siblings	   in	   comparison	   to	   3	   unrelated	   controls.	   The	   T22M	  mutation	   only	  
affects	  the	  longer	  isoform	  one,	  which	  was	  absent	  in	  the	  2	  homozygous	  patients	  and	  
present	   in	   the	   healthy	   controls	   and	   decreased	   in	   the	   heterozygeous	   carrier	   in	  
comparison	  to	   the	  controls.	   Immunoblotting	  of	   immortalized	   lymphoblast	  cell	   lines	  
from	  one	  homozygous	  patient	  and	  3	  heterozygeous	  carriers	  of	  the	  R498X	  mutation	  
as	  well	  as	  of	  one	  related	  and	  3	  unrelated	  healthy	  controls	  showed	  marked	  reduction	  
of	  both	  bands	  for	  the	  mutation	  carriers	  and	  absent	  FBXO7	  signals	  in	  the	  case	  of	  the	  
homozygous	   patients(Zhao	   et	   al.,	   2011).	   This	   is	   the	   only	   available	   information	   on	  
comparative	   expression	   levels	   between	   endogenous	  wild-­‐type	   and	   2	   of	   the	   Fbxo7	  
disease	  mutants	  –	  T22M	  and	  R498X.	  No	  data	   is	   available	  on	   the	  expression	  of	   the	  
FBXO7	   R378G	   mutant.	   In	   the	   future,	   it	   would	   be	   critical	   to	   attempt	   to	   establish	  
whether	   the	   R378G	   mutation	   in	   human	   patients	   reduces	   the	   expression	   of	   the	  
FBXO7	  protein	  and	  whether	  this	  is	  linked	  to	  the	  development	  of	  PD.	  	  
Given	   the	   lack	   of	   knowledge	   about	   the	   effect	   of	   the	  R378G	  FBXO7	  mutant	   on	   the	  
protein	  levels	  of	  FBXO7	  in	  humans,	  I	  can	  only	  speculate	  about	  the	  significance	  of	  the	  
reduction	  on	  protein	  expression	  that	  I	  observe	  in	  the	  R379G	  KI	  Fbxo7	  mouse	  model:	  
It	   could	   either	   be	   an	   artefact	   of	   the	   knock-­‐in	   strategy	   or	   in	   fact	   recapitulate	   an	  
intrinsic	  property	  of	  the	  R378/9G	  mutation.	  At	   least	   in	  the	   in	  vitro	  setting	  Skp1	  has	  
been	   suggested	   to	   stabilize	   the	   confirmation	   of	   F-­‐box	   proteins,	   which	   in	   turn	  
increases	  their	  expression	  levels(Yoshida	  et	  al.,	  2011).	  In	  an	  in	  vitro	  binding	  assay	  the	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R378G	  FBXO7	  mutant	  has	  been	  demonstrated	   to	  bind	  with	   lower	   affinity	   to	   Skp	  1	  
than	   the	  wild-­‐type	   FBXO7	   protein(Nelson	   and	   Laman,	   2011).	   If	   these	   observations	  
were	   extrapolated	   into	   the	   in	   vivo	   system,	   the	   substitution	   of	   the	   basic,	   polar	  
arginine	   with	   the	   neutral,	   non-­‐polar	   glycine	   at	   residue	   378	   of	   the	   FBXO7	   protein	  
could	  result	  in	  a	  decrease	  in	  affinity	  to	  Skp1	  and	  ultimately	  in	  a	  decrease	  in	  stability	  
and	  hence	  expression	   level	  of	  the	  FBXO7	  R378G	  mutant.	   If	  FBXO7	   is	   indeed	  critical	  
for	  protein	  quality	  control	   in	   the	  brain,	   reduced	   levels	  of	  FBXO7	   in	   the	  brain	  could	  
account	  for	  a	  threshold	  effect	  and	  thereby	  cause	  PD.	  	  
 In	   vivo	   SCFFbxo7	   complex	   formation	   of	   the	   endogenous	   Fbxo7	   wild-­‐type	  4.4.3
protein	  
My	   thesis	   is	   centred	   around	   the	   hypothesis	   that	   Fbxo7	   functions	   as	   the	   substrate	  
recognizing	   subunit	   of	   a	   SCF	   E3	   ubiquitin	   ligase	   complex	   and	   that	   the	   pathogenic	  
effect	  of	   its	  human	  disease	  mutants	   is	  exerted	  by	  a	  perturbation	  thereof.	  A	  critical	  
milestone	   was	   therefore	   to	   show	   that	   the	   wild-­‐type	   Fbxo7	   protein	   does	   in	   fact	  
assemble	   into	   a	   SCF	   complex	   in	   the	   endogenous	   system.	   This	   is	   unequivocally	  
demonstrated	   in	   sections	   4.2.8	   and	   4.2.11:	   Immunoblotting	   of	   endogenous	   Fbxo7	  
immunoprecipitations	   from	   different	   mouse	   tissues	   –	   including	   brain	   -­‐	   allows	   the	  
detection	   of	   endogenous	   Cullin1,	   Skp1	   and	  Rbx1.	   Furthermore,	   the	   identity	   of	   the	  
SCF	   complex	   partners	   is	   also	   confirmed	   by	   proteomic	   fingerprinting	   of	   the	  
endogenous	   Fbxo7	   immunoprecipitation	   products	   from	   wild-­‐type	   mouse	   brain	  
lysates.	  This	   is	  the	  first	  time	  that	  the	  actual	  existence	  of	  the	  endogenous	  SCFFbxo7-­‐wt	  
E3	  ubiquitin	  ligase	  complex	  has	  been	  demonstrated.	  	  
 In	  vivo	  SCFFbxo7	  complex	  formation	  of	  the	  endogenous	  Fbxo7	  R379G	  mutant	  4.4.4
protein	  
The	   next	   important	   question	   was	   to	   establish	   whether	   the	   Fbxo7	   R379G	   disease	  
mutant	   was	   equally	   capable	   of	   SCF	   E3	   ligase	   complex	   formation.	   I	   have	   already	  
discussed	   in	  the	  previous	  chapter	  that	  SCF	  complex	  disruption	  could	  be	  a	  potential	  
pathomechanistic	   effect	   of	   the	   human	   FBXO7	   disease	   mutants.	   Of	   all	   known	  
pathogenic	   FBXO7	   mutants,	   the	   R378G	   mutant	   would	   have	   been	   the	   most	   likely	  
candidate	  to	  disrupt	  SCF	  complex	  formation	  given	  the	  juxtaposition	  of	  the	  mutated	  
amino	  acid	  residue	  to	  the	  functionally	  important	  F-­‐box	  domain:	  The	  R378G	  mutation	  
resides	  only	  3	  AA	  residues	  downstream	  of	  the	  F-­‐box	  domain,	  which	  mediates	  binding	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to	   the	  SCF	  complex	  via	  Skp1.	  Furthermore,	   in	  vitro	  data	  has	  already	  proposed	   that	  
the	  R378G	  Fbxo7	  mutant	  impairs	  SKP1	  binding(Nelson	  and	  Laman,	  2011).	  However,	  
the	   corresponding	   R379G	   Fbxo7	   mouse	  mutant	   does	   not	   prevent	   Skp1	   binding	   in	  
vivo.	  	  
 In	   vivo	   SCFFbxo7-­‐R378G	   complex	   formation	   of	   patient	   derived	   heterozygeous	  4.4.5
and	  homozygous	  R378G	  FBXO7	  cell	  lines	  
A	  very	  important	  finding	  is	  that	  SCF	  complex	  formation	  could	  also	  be	  reproduced	  in	  
human	   derived,	   mutation	   specific	   fibroblast	   cell	   lines.	   Ultimately,	   the	   goal	   of	   my	  
thesis	   is	   to	   gain	   insight	   into	   the	   physiological	   function	   of	   FBXO7	   and	   the	  
pathomechanism	  of	  the	  human	  disease	  mutants	  –	  in	  particular	  the	  R378G	  mutation.	  
This	   section	  demonstrates	   that	   the	  R379G	  Fbxo7	   KI	  mouse	  model	   recapitulates	   an	  
important	  biochemical	  property	  of	  the	  corresponding	  human	  mutation	  and	  serves	  as	  
an	  additional	  step	  in	  the	  validation	  process	  of	  findings	  made	  in	  the	  R379G	  Fbxo7	  KI	  
mouse	  model.	  	  
 Identifying	  Fbxo7	  interactors	  by	  means	  of	  proteomic	  fingerprint	  analysis	  of	  4.4.6
endogenous	  Fbxo7	  immunoprecipitations	  from	  wild-­‐type	  brain	  
A	   challenge	   in	   the	   field	   of	   SCF	   E3	   ubiquitin	   ligases	   is	   the	   identification	   of	  
substrates(Harper	   and	   Tan,	   2012).	   The	   main	   problem	   is	   the	   transient	   and	   usually	  
weak	  interaction	  between	  a	  substrate	  and	  its	  given	  E3	  ligase,	  which	  is	  also	  the	  likely	  
cause	   why	   the	   majority	   of	   substrates	   are	   potentially	   destined	   to	   escape	   the	  
detection	   by	   the	   affinity-­‐purification-­‐mass-­‐spectrometry	   approach	   (as	   discussed	   in	  
the	  previous	  chapter).	  However,	  there	  are	  examples	  of	  partially	  retained	  substrate-­‐
ligase	   interactions	   after	   immunoprecipitation:	   β-­‐TrCP	   was	   discovered	   to	   be	   the	  
substrate-­‐recognizing	   subunit	   of	   the	   E3	   ligase	   that	   targets	   IκB	   for	   proteasomal	  
degradation.	  Other	  examples	  include	  the	  ribonucleotide	  reductase	  M2	  and	  CP110	  as	  
degradation	   targets	   of	   the	   F-­‐box	   protein	   cyclin	   F(D'Angiolella	   et	   al.,	   2012;	  
D'Angiolella	   et	   al.,	   2010).	  Most	   published	   reports	   investigate	   E3	   ligase	   –	   substrate	  
interactions	   in	   the	   tagged	  overexpression	   system.	   I	   have	   now	  adopted	   the	   affinity	  
purification	  proteomics	  approach	  to	  the	  endogenous	  system;	  3	  large-­‐scale	  replicates	  
from	   wild-­‐type	   brain	   have	   been	   performed	   and	   the	   combined	   list	   of	   proteins	  
identified	  in	  the	  control	  experiments	  were	  subtracted	  from	  each	  set	  of	  hits	  identified	  
in	  the	  endogenous	  Fbxo7	  immunoprecipitation:	  of	  the	  263	  identified	  hits	  in	  replicate	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1,	  188	  hits	  in	  replicate	  2,	  and	  238	  hits	  in	  replicate	  3,	  42	  proteins	  could	  be	  identified	  in	  
every	  single	  set	  of	  experiments	  (Figure	  39).	  Amongst	  these	  42	  proteins	  were	  FBXO7,	  
Cullin	  1	  and	  Skp1	  as	  the	  bait	  and	  members	  of	  the	  SCF	  E3	  ligase	  complex	  (Rbx1	  was	  
not	  amongst	  the	  list	  of	  overlapping	  proteins	  as	  it	  was	  not	  identified	  in	  one	  of	  the	  3	  
replicates).	   With	   regards	   to	   previously	   identified	   FBXO7	   interactors,	   PI31	   and	  
Exportin	   1	   were	   also	   amongst	   this	   list.	   	   Otherwise	   the	   list	   contained	   multiple	  
proteasomal	   subunits	   and	   several	   members	   of	   the	   COP9	   signalosome	   complex,	  
which	   is	   involved	   in	  regulating	  the	  activity	  of	  Cullin-­‐dependent	  SCF	  E3	   ligases	  (Kato	  
and	   Yoneda-­‐Kato,	   2009;	   Lyapina	   et	   al.,	   2001).	   Altogether	   the	   association	   of	   Fbxo7	  
with	  the	  groups	  of	  aforementioned	  proteins	  supports	  the	  notion	  that	  Fbxo7	  actually	  
plays	  a	   role	   in	   the	  ubiquitin	  proteasome	  system	  and	  that	   the	  affinity	  purification	  –	  
mass-­‐spectrometry	   approach	   is	   well	   capable	   of	   reliably	   identifying	   the	   interaction	  
between	  complex	  partners.	  	  
Amongst	  the	  remaining	  proteins	  in	  the	  list	  of	  overlapping	  hits	  that	  are	  present	  in	  all	  3	  
endogenous	   Fbxo7	   immunoprecipitations	   from	   brain,	   are	   3	   proteins	   that	   together	  
function	  as	  an	  E3	  SUMO	  ligase:	  RanBP2,	  RanGAP1*SUMO1	  and	  Ubc9(Werner	  et	  al.,	  
2012).	  RanBP2	  in	  association	  with	  RanGAP1*SUMO1	  /	  Ubc9	  is	  one	  of	  the	  few	  known	  
proteins	   or	   rather	   protein	   complexes	   with	   E3	   SUMO	   ligase	   activity	   and	   the	  
SUMOylation	  of	  RanGAP1	  is	  not	  RanBP2-­‐dependent,	  but	  rather	  a	  prerequisite	  for	  the	  
association	  with	  it(Werner	  et	  al.,	  2012).	  RanBP2	  is	  a	  large	  357	  kDa	  scaffolding	  protein	  
involved	   in	   pleiotropic	   functions	   depending	   on	   context	   and	   respective	   binding	  
partners:	  it	  is	  a	  component	  of	  the	  cytoplasmic	  filaments	  of	  the	  nuclear	  pore	  complex	  
during	  interphase	  and	  after	  nuclear	  envelope	  breakdown	  is	  then	  present	  mainly	  in	  a	  
soluble	   form,	   but	   occurs	   also	   attached	   to	   the	   kinethochor	   of	   the	   mitotic	  
spindle(Joseph	  et	  al.,	  2002;	  Wu	  et	  al.,	  1995;	  Yokoyama	  et	  al.,	  1995).	  The	  fraction	  of	  
RanBP2,	  RanGAP1*SUMO1	  /	  Ubc9	  that	  localizes	  to	  the	  kinetochore	  is	  dependent	  on	  
the	   interaction	   with	   RanGTP	   and	   Exportin	   1(Arnaoutov	   et	   al.,	   2005).	   Although	  
RanGTP	  is	  not	  amongst	  the	  group	  of	  overlapping	  proteins,	  it	  was	  actually	  present	  in	  2	  
of	  the	  3	  endogenous	  Fbxo7	  immunoprecipitations	  from	  wild-­‐type	  brain	  (replicate	  1:	  
mascot	  score	  –	  160	  (15	  identified	  peptides	  and	  31%	  sequence	  coverage;	  replicate	  2:	  
mascot	   score	   –	   87	   (11	   identified	   peptides	   and	   11%	   sequence	   coverage;	  molecular	  
weight	   of	   Ran	   is	   24	   kDa).	   CRM1	   is	   a	   nuclear	   transport	   receptor,	  which	   recognizes	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proteins	  containing	  a	  leucine-­‐rich	  nuclear	  export	  sequence	  in	  order	  to	  facilitate	  their	  
nuclear	  export(Hutten	  and	  Kehlenbach,	  2007).	  CRM1	  has	  been	  described	  to	  interact	  
with	   RanBP2	   via	   its	   8-­‐fold	   zink	   finger	   motif	   (Figure	   45)(Singh	   et	   al.,	   1999).	   The	   2	  
known	  endogenous	   substrates	   of	   the	  RanBP2,	   RanGAP1*SUMO1	   /	  Ubc9	   E3	   SUMO	  
ligase	   comprise	   the	   Topoisomerase	   2	   α	   and	   Borealin;	   which	   both	   reside	   at	   the	  
kinetochore	  /	  centromere(Dawlaty	  et	  al.,	  2008;	  Klein	  et	  al.,	  2009).	  Moreover,	   it	  has	  
been	   shown	   that	   the	   localisation	   of	   Borealin	   to	   the	   centromere	   depends	   on	  
CRM1(Knauer	   et	   al.,	   2006).	   CRM1	   has	   also	   been	   suggested	   to	   be	   involved	   in	   the	  
subcellular	   localization	   of	   FBXO7	   via	   a	   functional	   leucin-­‐rich	   recruitment	   motif	  
localized	  near	  the	  N-­‐terminal	  start	  of	  its	  F-­‐box	  domain(Nelson	  and	  Laman,	  2011).	  It	  is	  
a	   matter	   of	   speculation	   whether	   Fbxo7	   could	   actually	   be	   a	   target	   of	   RanBP2	  
mediated	   SUMOylation	   and	   be	   recruited	   to	   the	   complex	   by	   its	   interaction	   with	  
CRM1.	   The	   detection	   of	   posttranslational	   modification	   with	   SUMO	   species	   in	   vivo	  
can	  be	  difficult	  as	  usually	  only	  a	  small	  pool	  of	  a	  given	  protein	  is	  modified(Tatham	  et	  
al.,	  2009).	  I	  have	  employed	  a	  dual-­‐overexpression	  system	  to	  look	  into	  the	  possibility	  
whether	  Fbxo7	  could	  be	  sumoylated	  by	  SUMO1.	  While	  the	  positive	  control	  RanGAP1	  
demonstrates	   a	   band	   shift	   towards	   the	   higher-­‐molecular	   weight	   species	   of	   its	  
sumoylated	   form,	   no	   band	   shift	   is	   observed	   with	   either	   the	   wild-­‐type	   or	   R378G	  
mutant	   FBXO7.	   There	   are	   limitations	   to	   this	   approach	   and	   it	   is	   not	   possible	   to	  
conclude	  that	  FBXO7	  is	  not	  a	  SUMOylation	  target.	  All	  I	  can	  say	  is	  that	  I	  have	  not	  been	  
able	  to	  gather	  further	  corroborating	  evidence	  for	  the	  SUMOylation	  of	  FBXO7	  other	  
than	  its	  physical	  association	  with	  the	  SUMOylation	  machinery.	  	  
I	   have	  also	  undertaken	  2	   large-­‐scale	  endogenous	  Fbxo7	   immunoprecipiations	   from	  
homozygous	  R379G	  KI	  brain	  lysates	  in	  comparison	  to	  parallel	  immunoprecipitations	  
from	  wild-­‐type	  brain	  lysates.	  There	  was	  a	  remarkable	  overlap	  between	  the	  proteins	  
that	   were	   identified	   in	   both	   wild-­‐type	   as	   well	   as	   homozygous	   R379G	   KI	   Fbxo7	  
experiments.	  Amongst	  the	  proteins	  identified	  for	  both	  genotypes	  were	  the	  bait,	  SCF	  
complex	  partners	  Cullin	  1,	  Skp1	  as	  well	  as	  Exportin	  1	  and	  PI31.	  Amongst	   the	  other	  
overlapping	  proteins	  were	  also	  	  RanBP2	  and	  RanGAP1	  as	  members	  of	  the	  RanBP2	  E3	  
SUMO	  ligase,	  Reticulon	  4,	  proteasomal	  subunits.	  	  
I	   have	   then	   undertaken	   further	   efforts	   to	   validate	   the	   affinity-­‐purified	   proteomic	  
hits.	  In	  the	  first	  instance	  I	  have	  demonstrated	  the	  ability	  to	  detect	  PI31,	  Exportin	  1,	  
	  
	  
	   167	  
RanBP2,	  RanGAP1,	  Neurabin	  2	  as	  well	   as	  Nogo	  A	  and	  B	   (Reticulon	  4)	   in	   the	  Fbxo7	  
immunoprecipitation	  products	  from	  both	  wild-­‐type	  as	  well	  as	  homozygous	  R379G	  KI	  
brain	  lysates.	  The	  gold	  standard	  for	  proving	  the	  validity	  of	  an	  interaction	  between	  2	  
proteins	   is	   to	   show	   that	   they	   co-­‐immunoprecipitate	   with	   each	   other.	   For	   this	  
efficient	  antibodies	  directed	  against	   the	  proteins	  of	   interest	  are	  necessary	   that	  not	  
only	   allow	   detection	   by	   immunoblotting,	   but	   also	   immunoprecipitation.	   For	  
Reticulon	  4	  as	  well	  as	  RanBP2,	   in	  house	  DSTT	  generated	  antibodies	  are	  available.	   I	  
have	  been	  able	  to	  detect	  Fbxo7	  by	  co-­‐immunoprecipitation	  with	  Reticulon	  4	  (Nogo	  
B)	  as	  well	  as	  with	  RanBP2	  as	  demonstrated	   in	   (Figure	  51	  and	  Figure	  52).	  However,	  
this	  was	  not	  a	  consistent	  finding	  in	  replicate	  experiments	  and	  only	  possible	  in	  large-­‐
scale	   experiments.	   I	   have	   been	   unable	   to	   identify	   Fbxo7	   by	  mass-­‐spectrometry	   in	  
single	   immunoprecipitations	  of	  RanBP2	  as	  well	   as	  Nogo	  B	   /	  Reticulon	  4	   from	  wild-­‐
type	  brain	  lysates.	  Unspecific	  cross-­‐reactivity	  is	  a	  concern	  in	  the	  endogenous	  system,	  
but	  the	  validation	  of	  each	  of	  the	  antibodies	  did	  not	  suggest	  that	  the	  α	  mouse	  Fbxo7	  
antibody	   detects	   either	   RanBP2	   or	   Nogo	   A	   /	   B.	   Vice	   versa,	   there	  was	   no	   signal	   in	  
keeping	   with	   the	  molecular	   size	   /	   pattern	   of	   Fbxo7	   in	   the	   antibody	   validation	   for	  
Nogo	  B	  (Reticulon	  4)	  nor	  RanBP2	  (data	  not	  shown).	  Overall,	  I	  have	  high	  confidence	  in	  
the	  specificity	  of	  the	  α	  mouse	  Fbxo7	  antibody	  used	  in	  this	  study	  given	  that	  it	  reliably	  
detects	   Fbxo7	   in	   complex	  with	   its	   SCF	  binding	  partners	  as	  well	   as	  other	  previously	  
reported	  interacting	  proteins	  such	  as	  PI31	  and	  Exportin	  1.	  I	  can	  however	  not	  rule	  out	  
that	   the	   Fbxo7	   antibody	   itself	   impacts	   on	   the	   interaction	   between	   Fbxo7	   and	   its	  
substrates.	  An	  alternative	  explanation	  for	  why	  it	  is	  difficult	  to	  co-­‐immunoprecipitate	  
Fbxo7	   with	   putative	   interacting	   partners	   is	   that	   Fbxo7	   interacts	   with	   only	   a	   small	  
pool	   of	   a	   posttranslationally	   modified	   form	   of	   the	   respective	   protein.	   The	  
posttranslationally	   modification	   is	   then	   either	   reversed	   during	   the	   affinity	  
purification	  or	  the	  interaction	  of	  the	  small	  pool	  of	  the	  modified	  protein	  with	  Fbxo7	  is	  
diluted	  below	  the	  threshold	  of	  detection.	  
In	   the	  end,	   there	   is	  one	  main	  difficulty	   in	   the	  evaluation	  of	   the	   significance	  of	  any	  
detected	   interaction	   between	   Fbxo7	   and	   other	   proteins:	   the	   lack	   of	   a	   functional	  
read-­‐out.	   The	   finding	   that	   FBXO7	   actually	   assembles	   into	   a	   SCFFBXO7	   E3	   ubiquitin	  
ligase	  complex	  in	  vivo	  has	  never	  been	  shown	  before	  and	  no	  in	  vitro	  or	   in	  vivo	  assay	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exists	   that	   would	   allow	  monitoring	   the	   Fbxo7-­‐dependent	   E3	   ligase	   activity	   of	   the	  
SCFFBXO7	  complex	  against	  a	  pool	  of	  validated	  FBXO7	  substrates.	  	  
 Behavioural	   and	  motor	  phenotypic	  analysis	  of	   the	  R379G	  Fbxo7	   KI	  mouse	  4.4.7
model	  
The	   main	   reason	   for	   generating	   the	   R379G	   Fbxo7	   KI	   mouse	   line	   was	   to	   have	  
sufficient	  neuronal	  material	  available	  for	  the	  biochemical	  study	  of	  the	  effect	  of	  one	  
of	  the	  human	  pathogenic	  mutations	  at	  the	  endogenous	  Fbxo7	  locus	  and	  to	  compare	  
it	  with	   its	  wild-­‐type	  counterpart.	  The	  behavioural	  and	  motor	  phenotypic	  analysis	   is	  
only	  a	  small	  part	  of	   this	  study.	  Many	  PD	  mouse	  models	  have	  been	  developed	  over	  
the	  last	  3	  decades,	  either	  based	  on	  neurotoxicity	  or	  genetic	  approaches.	  Prior	  to	  the	  
identification	   of	   genetic	   factors	   for	   PD,	   neurotoxic	   models	   using	   compounds	   that	  
produce	   reversible	   (for	   example	   reserpine)	   or	   irreversible	   (1-­‐mehyl-­‐1,2,3,6-­‐
tetrahydropiridine,	   6-­‐hydroxydopamine,	   paraquat,	   or	   rotenone)	   effects	   mainly	   on	  
the	  basal	  ganglia	  were	  used(Tieu,	  2011).	  In	  genetic	  PD	  mouse	  models	  overexpression	  
is	  usually	  used	   the	  mimic	   the	  effect	  of	  autosomal	  dominant	  mutations	  as	   they	  are	  
regarded	   as	   a	   “gain	  of	   function”,	  while	   for	  modelling	   autosomal	   recessive	   genes	   –	  
regarded	  to	  elicit	  their	  pathogenic	  effects	  via	  “loss	  of	  function’	  -­‐	  either	  gene	  knock-­‐
out	   or	   knock-­‐in	   of	   a	   particular	   pathogenic	  mutation	   is	   used(Lee	   et	   al.,	   2012).	   The	  
expectation	   is	   that	   these	   mouse	   models	   can	   be	   utilized	   for	   gaining	   insight	   into	  
disease	   mechanisms,	   but	   with	   the	   small	   molecules’	   therapeutic	   approach	   at	   the	  
horizon	   that	   they	   could	   potentially	   be	   exploited	   for	   screening	   and	   testing	   new	  
therapeutic	  compounds	  or	  the	  discovery	  of	  biomarkers.	  So	  far,	  therapies	  are	  mainly	  
symptomatic	   rather	   than	   targeted	  at	   the	  actual	  disease	  process	  and	  a	  diagnosis	  of	  
PD	   on	   clinical	   grounds	   is	   only	   possible	   when	   the	   disease	   process	   is	   already	  
significantly	   advanced.	   Ideally,	   a	   PD	   mouse	   model	   should	   recapitulate	   the	  
progressive	  key	  clinical	  and	  neuropathological	  hallmarks	  of	  PD.	  So	   far,	  none	  of	   the	  
existing	   genetic	  models	  meets	   these	   criteria	   in	   full.	  Many	   different	   genetic	  mouse	  
models	  exist	  for	  α-­‐synuclein	  and	  LRRK2,	  the	  2	  autosomal	  dominant	  forms	  of	  genetic	  
PD	  (reviewed	   in(Dawson	  et	  al.,	  2010;	  Lee	  et	  al.,	  2012)).	  With	  regards	  to	  autosomal	  
recessive	   PD,	   several	   groups	   have	   generated	   constitutive	   PARKIN	   knock-­‐out	   mice,	  
which	   have	   failed	   to	   show	   any	   dopaminergic	   cell	   loss	   and	   only	   minimal	   motor	  
phenotypes(Goldberg	  et	  al.,	  2003;	  Itier	  et	  al.,	  2003;	  Von	  Coelln	  et	  al.,	  2004).	  A	  viral	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induced	   conditional	   PARKIN	   knock-­‐out	   mouse	   model	   does	   show	   progressive	  
dopaminergic	  cell	   loss	  10	  months	  after	  PARKIN	  deletion	  as	  well	  as	  accumulation	  of	  
Parkin	   E3	   ligase	   substrates	   and	   mitochondrial	   dysfunction(Shin	   et	   al.,	   2011).	   The	  
PINK1	   knock-­‐out	   mouse	   models	   including	   one	   shRNA-­‐mediated	   knock-­‐down	  
approach	  have	  also	  not	  resulted	  in	  significant	  nigrostriatal	  degenerative	  phenotypes,	  
but	   also	   show	   mild	   mitochondrial	   abnormalities	   and	   subtle	   deficits	   in	   dopamine	  
metabolism(Gispert	  et	  al.,	  2009;	  Kitada	  et	  al.,	  2007;	  Zhou	  et	  al.,	  2007).	  One	  of	  these	  
PINK1	  mouse	  models	  also	   showed	  a	  mild	  group	  difference	   in	  dopamine	  content	   in	  
the	   striatum	   and	   reduces	   spontaneous	   voluntary	   activities	   of	   the	   genetically	  
modified	  mice	   in	   comparison	   to	   the	  wild-­‐type(Gispert	   et	   al.,	   2009).DJ-­‐1	   knock-­‐out	  
mice	   present	   with	   a	   similarly	   mild	   phenotype	   as	   the	   models	   for	   PINK1	   and	  
PARKIN(Chen	   et	   al.,	   2005;	   Goldberg	   et	   al.,	   2005).	   Even	   the	   triple	   knock-­‐out	   of	  
PINK1/PARKIN/DJ-­‐1	   fails	   to	   develop	   a	   nigrostriatal	   phenotype(Kitada	   et	   al.,	   2009).	  
The	   assessment	   of	   the	   respective	   motor	   phenotypes	   of	   these	   mouse	   models	   is	  
incongruent,	  making	  a	  direct	  comparison	  difficult.	  For	   the	  evaluation	  of	   the	  R379G	  
Fbxo7	  KI	  mouse	  model	  I	  have	  restricted	  my	  analysis	  to	  one	  time-­‐point	  at	  a	  mean	  age	  
of	   10	   months.	   I	   first	   wanted	   to	   establish	   whether	   there	   was	   a	   group	   difference	  
between	  the	  wild-­‐type	  and	  R379G	  KI	  Fbxo7	  genotype	  at	  a	  later	  stage	  during	  the	  life	  
span	  of	  the	  animals	  before	  embarking	  on	  a	  longitudinal	  study	  with	  repeated	  testing.	  
The	  behavioural	  phenotyping	   in	   this	   study	  mainly	   focuses	  on	  motor	   function	  using	  
rotarod	   and	   gait	   analysis.	   PD,	   however,	   also	   manifests	   with	   many	   non-­‐motor	  
features	   and	   these	   can	   equally	   be	   explored	   by	   a	   more	   behavioural	   phenotyping	  
approach	  (reviewed	  in	  (Taylor	  et	  al.,	  2010)).	  The	  open	  field	  test	  used	  in	  this	  study	  to	  
assess	   spontaneous	   locomotor	   activity	   can	   also	   reflect	   anxiety-­‐like	  
behaviours(George	   et	   al.,	   2008;	   Taylor	   et	   al.,	   2010).	   Overall,	   there	   was	   no	   group	  
difference	   in	   the	   general	   neurological	   SHERPA	   screen,	   the	   open	   field	   spontaneous	  
locomotor	  assessment	  or	   the	  gait	  analysis	  between	  the	  wild-­‐type	  and	  homozygous	  
R379G	  Fbxo7	  KI	  animals.	  It	  is	  recognized	  that	  body	  weight	  is	  a	  significant	  confounder	  
of	  rotarod	  performance(Brooks	  and	  Dunnett,	  2009).	  Gender	  significantly	   influenced	  
body	  weight	  of	  the	  animals,	  but	  not	  genotype	  (Figure	  57).	  Although	  the	  housing	  site	  
–	  Ninwells	  or	  CLS	  campus	  –	  had	  an	  unexpected	  effect	  on	  body	  weight,	   this	  did	  not	  
result	   in	   a	   bias	   of	  my	   analysis	   as	   paired	   animals	  were	  mainly	   housed	   at	   the	   same	  
location.	  A	  very	  exciting	  fiding	  was	  that	  there	  was	  a	  difference	  in	  motor	  performance	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as	  measured	  by	  the	  rotarod	  analsysis	  between	  the	  wild-­‐type	  and	  the	  homozygeous	  
R379G	  KI	  FBbxo7	  genotype:	  While	  there	  was	  a	  trend	  towards	  poorer	  performance	  of	  
the	  R379G	  Fbxo7	  KI	  littermate	  pairs	  in	  the	  fixed	  speed	  rotarod	  analysis,	  there	  was	  a	  
significant	  impairement	  of	  the	  R379G	  KI	  animals	  in	  the	  accelerating	  rotarod	  analysis.	  
The	  2	  operational	  rotarod	  approaches	  –	  accelerating	  speed	  versus	  fixed	  speed	  –	  have	  
been	  suggested	  to	  be	  differentially	  sensitive	  to	  different	  aspects	  of	  motor	  function:	  
While	   during	   the	   accelerating	   protocol,	  mice	   loose	   their	   grip	   due	   to	   the	   changing	  
requirements	   of	   the	   accelerating	   rod,	   mice	   don’t	   have	   to	   adjust	   their	   stepping	  
pattern	   during	   the	   fixed-­‐speed	   variant(Brooks	   and	   Dunnett,	   2009;	  Monville	   et	   al.,	  
2006).	   For	   the	   analysis	   of	   the	   Fbxo7	   KI	  mosue	  model,	   the	   accelerating	   protocol	   is	  
more	  sensitive	  to	  pick	  up	  a	  difference	  between	  the	  2	  genotypes.	  
Overall,	   the	   finding	   that	   there	   is	   a	   significant	   difference	   in	   rotarod	   performance	  
between	  the	  wild-­‐type	  and	  R379G	  Fbxo7	  KI	  animals	  is	  very	  encouraging.	  It	  warrants	  a	  
longitudinal	   study	   across	   different	   time	   points	   and	   beyond	   the	   age	   of	   10	  months.	  
The	  longitundinal	  study	  will	  help	  to	  clarify	  at	  which	  age	  the	  mutant	  animals	  devlop	  a	  
motor	  eficit	  and	  whether	  this	  deficit	  is	  progressive	  over	  time.	  	  Furthermore,	  it	  will	  be	  
crucial	   to	   correlate	   the	   deficit	   in	   motor	   performance	   with	   a	   neurodegenerative	  
phenotype	   in	   immunopathological	   mouse	   brain	   studies.	   Littermate	   genotype-­‐
matched	   pairs	   have	   been	   sacrificed,	   subjected	   to	   whole	   body	   perfusion	   with	   a	  
fixating	   reagent	   and	   brains	   have	   been	   harvested	   for	   further	   processing	   for	  
immunohistochemistry.	   It	   has	   to	   be	   taken	   into	   account	   that	   no	   neuropathological	  
study	  of	  human	  FBXO7	  dependent	  disease	  has	  been	  reported	  as	  yet.	  
 Summary	  of	  Chapter	  4	  4.4.8
The	  second	  result	  chapter	  is	  dedicated	  to	  the	  characterization	  of	  the	  Fbxo7	  knock-­‐in	  
mouse	  model	  of	  one	  of	  the	  pathogenic	  FBXO7	  mutations	  (R378G	  in	  humans)	  and	  the	  
endogenous	   study	   of	   Fbxo7	   in	   brain	   comparing	   the	   wild-­‐type	   to	   the	   homozygous	  
Fbxo7	   KI	   genotype.	   A	   first	   finding	   is	   that	   Fbxo7	   is	   widely	   expressed	   in	   different	  
tissues	   and	   that	   the	   R379G	   Fbxo7	   KI	   mouse	   displays	   a	   hypomorphic	   expression	  
pattern	   in	   the	   homozygous	   state.	   In	   brain	   lysates,	   the	   difference	   amounts	   to	   a	  
reduction	  by	  half.	  If	  this	  is	  not	  an	  intrinsic	  artefact	  of	  the	  genetic	  mouse	  model,	  the	  
reduction	   in	   protein	   levels	   of	   the	   pathogenic	   mutant	   could	   amount	   to	   a	  
pathomechanistic	   threshold	   effect.	   A	   second	   important	   and	   novel	   finding	   is	   that	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endogenous	   Fbxo7	   assembles	   together	   with	   Cullin	   1,	   Skp1,	   and	   Rbx1	   to	   form	   the	  
SCFFbxo7	  E3	  ubiquitin	  ligase	  complex	  in	  vivo.	  The	  demonstration	  that	  the	  homozygous	  
R379G	  Fbxo7	  mutant	  is	  equally	  capable	  of	  SCF	  E3	  ligase	  formation,	  a	  feature	  that	  is	  
retained	   in	  human	  patient-­‐derived	  homogenous	  R378G	  FBXO7	   fibroblast	   cell	   lines.	  
This	  allows	  the	  conclusion	  that	  the	  pathogenic	  R378G	  FBXO7	  mutant	  does	  not	  exert	  
its	   pathogenicity	   via	   disruption	   of	   the	   SCF	   E3	   ligase	   complex.	   Using	   endogenous	  
Fbxo7	   affinity	   purification	   in	   combination	   with	   mass-­‐spectrometry	   has	   confirmed	  
PI31	  and	  Exportin	  1	  to	  not	  only	  interact	  with	  Fbxo7	  in	  heterologous	  systems,	  but	  also	  
on	   the	   endogenous	   level	   in	   brain	   samples	   of	   wild-­‐type	   and	   homozygous	   R379G	  
Fbxo7	  KI	  mice.	  I	  have	  identified	  potentially	  novel	  Fbxo7	  interacting	  partners	  of	  which	  
the	   RanBP2/ranGAP1*SUMO1/UBC9	   E3	   SUMO	   ligase	   complex	   is	   one	   of	   the	   most	  
exciting	  findings.	  This	  warrants	  further	  exploration	  as	   it	  could	  be	  a	  further	  example	  
of	   the	   crosstalk	   between	   the	   ubiquitylation	   and	   sumoylation	   system.	   Last	   but	   not	  
least,	   the	   preliminary	   phenotype	   analysis	   of	   the	   R379G	   Fbxo7	   KI	   mouse	   line	   has	  
revealed	  a	  significant	  motor	  deficit	  of	  the	  homozygous	  KI	  animals	   in	  comparison	  to	  
the	  wild-­‐type	  genotype.	  A	  neuropathological	  study	  to	  assess	  whether	  this	  deficit	   in	  
motor	   performance	   correlates	   to	   a	   dopaminergic	   neuronal	   cell	   loss	   is	   still	  
outstanding.	  
5 Quantitative	   proteomics	   comparing	   the	   proteome	   /	  
ubiquitinome	  of	  the	  wild-­‐type	  and	  R379G	  Fbxo7	  KI	  mouse	  
and	   set	   up	   of	   an	   in	   vitro	   Fbxo7	  dependent	   ubiquitylation	  
assay	  
	  
In	  this	  chapter,	  I	  am	  focusing	  on	  quantitative	  proteomics	  comparing	  either	  the	  whole	  
proteome	  in	  mouse	  brain	  or	  the	  pool	  of	  ubiquitin	  modified	  proteins	   in	  MEF	  lysates	  
between	   the	   wild-­‐type	   and	   homozygous	   R379G	   Fbxo7	   KI	   genotype.	   The	   working	  
hypothesis	  of	  my	  thesis	  is	  that	  FBXO7	  functions	  as	  the	  substrate	  recognizing	  subunit	  
of	  an	  SCF	  E3	  ubiquitin	   ligase	  complex,	  and	  as	  such	   is	   involved	   in	   targeting	  proteins	  
for	  degradation	  by	  the	  ubiquitin	  proteasome	  system.	  Quality	  control	  and	  regulation	  
of	  abundance	  of	  such	  proteins	  may	  be	  crucial	  for	  neuronal	  health	  and	  perturbation	  
thereof	  a	  first	  step	  towards	  FBXO7	  dependent	  disease.	  Therefore,	  I	  was	  interested	  in	  
looking	  at	  proteins	  whose	  abundance	  is	  either	  decreased	  or	  increased	  in	  whole	  brain	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lysates	   dependent	   on	   the	   presence	   of	   the	   R379G	   Fbxo7	   KI	   mutation	   in	   its	  
homozygous	   state.	   Here,	  ex	   vivo	   stable	   isotope	   dimethyl	   labelling	   at	   peptide	   level	  
was	   used	   to	   prepare	   the	   brain	   samples	   of	   the	   2	   genotypes	   for	   quantitative	  
proteomics(Boersema	  et	  al.,	  2009).	   In	  another	  approach	   I	   set	  out	   to	   systematically	  
identify	   differences	   in	   ubiquitylation	   targets	   in	   a	   site-­‐specific	   manner	   using	  
quantitative	   di-­‐GLY	   capture	   proteomics(Kim	   et	   al.,	   2011;	   Wagner	   et	   al.,	   2011).	  
Quantitative	   di-­‐GLY	   capture	   proteomics	   combines	   in	   vivo	   SILAC	   labelling	   with	  
antibody-­‐based	  affinity	  enrichment	  of	  “di-­‐GLY	  remnant	  motifs”-­‐	  containing	  peptides	  
prior	   to	   proteomic	   profiling	   of	   the	   wild-­‐type	   in	   comparison	   to	   the	   homozygous	  
R379G	  Fbxo7	  KI	  ubiquitinome	  in	  MEF	  lysates	  (Figure	  65).	  This	  chapter	  also	   includes	  
the	  set	  up	  of	  an	   in	  vitro	  FBXO7	  ubiquitylation	  assay	  as	  the	  identification	  of	  putative	  
FBXO7	   substrates	   necessitates	   their	   validation	   with	   a	   functional	   read-­‐out.	   A	  
prerequisite	  was	  the	  recombinant	  expression	  of	  all	   the	  components	  of	  the	  SCFFBXO7	  
E3	   ubiquitin	   ligase	   complex,	   which	   is	   not	   a	   trivial	   undertaking,	   and	   the	   in	   vitro	  
SCFFBXO7	   complex	   formation.	   Subsequently,	   I	   have	   successfully	   set	   up	   an	   assay	   to	  
monitor	  FBXO7	  free	  ubiquitin	  chain	  production	  and	  have	  made	  preliminary	  progress	  
in	   assaying	   substrate	   ubiquitylation.	   I	   received	   significant	   help	   from	   the	   following	  
people	  in	  the	  MRC	  Unit:	  Dr.	  Matthias	  Trost	  helped	  with	  the	  ex	  vivo	  dimethyl	  labelling	  
of	  the	  brain	  samples	  for	  the	  whole	  proteome	  analysis	  in	  wild-­‐type	  and	  homozygous	  
R379G	  Fbxo7	  KI	  brain	  samples.	  Dr.	  Kamila	  Chughtai,	  a	  postdoctoral	  researcher	  in	  Dr.	  
Patrick	   Pedriolis’	   laboratory	   supported	   me	   in	   the	   setting	   up	   and	   adopting	   the	  
quantitative	  di-­‐GLY	  capture	  protocol	  and	  performed	  the	  mass-­‐spectrometry	  analysis.	  
Dr.	  Axel	  Knebel	  and	  his	  team	  –	  Dr.	  Richard	  Ewan,	  Mr.	  Dan	  Fountaine,	  and	  Miss	  Clare	  
Johnson	  –	  were	  critical	  for	  the	  production	  of	  the	  required	  recombinant	  proteins	  and	  
helped	  me	  in	  the	  development	  of	  the	  in	  vitro	  FBXO7	  assay.	  
5.1 Differential	   enrichment	   of	   the	   ubiquitylated	   proteome	  
from	  SILAC	   labelled	  wt	  and	  homozygous	  R379G	  Fbxo7	  KI	  
MEFs	  
My	   hypothesis	   throughout	   this	   thesis	   is	   that	   FBXO7	   functions	   as	   the	   substrate	  
recognizing	  subunit	  of	  an	  SCFFBXO7	  complex	  and	  that	  the	  pathogenicity	  of	  the	  human	  
disease	  mutants	   is	   linked	   to	   the	   FBXO7	   –	   dependent	   function	   of	   the	   E3	   ubiquitin	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ligase	  activity	  of	   the	  SCF	  complex.	   I	  have	   therefore	  embarked	  on	  a	  differential	   “di-­‐
Glycine”	   capture	   experiment	   that	   aims	   to	   systematically	   identify	   Fbxo7-­‐dependent	  
ubiquitylation	   targets	   in	  a	   site-­‐specific	  manner	  while	   comparing	   the	  wild-­‐type	  with	  
the	  homozygous	  R379G	  Fbxo7	  KI	   genotype	   in	   SILAC	   labelled	  MEFs.	   The	  underlying	  
principle	  of	  the	  “di-­‐Glycine”	  capture	  experiment	  is	  that	  an	  antibody	  is	  available	  with	  
specificity	   for	   the	   signature	   peptide	   (di-­‐Glycin),	   which	   is	   left	   on	   an	   ubiquitylated	  
protein	   after	   tryptic	   digestion;	   affinity	   purification	   with	   this	   antibody	   then	   allows	  
enrichment	  of	  ubiquitylated	  species	  at	  peptide	  level(Kim	  et	  al.,	  2011;	  Wagner	  et	  al.,	  
2011;	  Xu	  et	  al.,	  2010)	  (Figure	  64).	  	  
	  
Figure	  64:	  Principle	  of	  the	  Di-­‐glycine	  enrichment	  of	  ubiquitylated	  species	  at	  peptide	  
level	  
After	  tryptic	  digestion	  of	  an	  ubiquitin-­‐modified	  protein,	  a	  di-­‐Glycine	  remnant	  of	  Ubiquitin	  (signature)	  
remains	  covalently	  attached	  to	  the	  lysine	  residue	  (K*)	  of	  the	  ubiquitinylated	  protein	  that	  is	  resistant	  
to	  further	  tryptic	  digestion.	  The	  Di-­‐glycine	  antibody	  is	  used	  for	  enriching	  ubiquitylated	  proteins	  at	  
peptide	  level.	  The	  di-­‐Glycin	  tag	  results	  in	  a	  114.1	  Da	  mass-­‐shift	  of	  the	  ion	  fragment	  and	  forms	  the	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Figure	  65:	  SILAC	  -­‐	  base	  quantitative	  di-­‐Glycine	  capture	  proteomics	  to	  compare	  the	  
ubiquitinome	  of	  wt	  and	  hom	  R379G	  Fbxo7	  MEFs	  
Immortalized	  mouse	  embryonic	  fibroblasts	  derived	  from	  littermate	  wt	  and	  homozygous	  R379G	  Fbxo7	  
KI	  embryos	  (E12.5)	  were	  grown	  in	  differential	  SILAC	  media	  until	  full	  label	  incorporation	  was	  achieved	  
(>98%).	  Cells	  were	  then	  harvested	  under	  denaturing	  conditions,	  mixed	  in	  a	  1:1	  ratio,	  and	  digested	  
with	  trypsin	  prior	  to	  affinity	  purification	  of	  di-­‐Glycin-­‐peptides.	  The	  sample	  was	  then	  analysed	  by	  mass-­‐
spectrometry;	  while	  the	  differential	  SILAC	  labelling	  allowed	  determining	  the	  relative	  abundance	  of	  
each	  peptide	  according	  to	  genotype,	  the	  intact	  di-­‐glycine	  modification	  of	  the	  peptides	  yields	  the	  
specific	  site	  reveals	  the	  specific	  site	  of	  the	  ubiquitin	  modification	  of	  the	  original	  protein.	  (Not	  shown	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The	   labelling	   efficacy	   for	   the	   homozygous	   R379G	   Fbxo7	   KI	   MEF	   cell	   lines	   was	  
determined	  as	  >98%,	  which	   is	  considered	  “complete”	   incorporation	  of	   the	  “heavy”	  
stable	   isotopes	   Lysine	   and	  Arginine	   (K8,	   R10)	   (Figure	   66).	   For	   a	   global	   comparison	  
between	   the	  wild-­‐type	  and	  homozygous	  R379G	  Fbxo7	  KI	  MEFs,	   a	   small	   fraction	  of	  
each	   sample	   was	   separately	   digested	   with	   trypsin	   and	   subjected	   to	   mass-­‐
spectrometry:	   The	   same	   number	   of	   proteins	   (about	   2500)	   with	   an	   80%	   overlap	  
between	  the	  wild-­‐type	  and	  homozygous	  R379G	  Fbxo7	  KI	  MEFs	  was	  found	  (data	  not	  
shown).	  	  
	  
Figure	  66:	  Labeling	  efficacy	  of	  the	  hom	  R379G	  Fbxo7	  KI	  MEF	  cell	  line	  
The	  graph	  shows	  the	  incorporation	  rate	  of	  the	  “heavy”	  SILAC	  label	  for	  the	  hom	  R379G	  Fbxo7	  KI	  MEF	  
cell	  line	  (K8R10).	  Arginine	  and	  Lysine	  incorporation	  are	  blotted	  individually	  as	  well	  as	  together.	  The	  y-­‐
axis	  indicates	  the	  percentage	  of	  peptides	  labelled	  versus	  the	  percentage	  of	  label	  incorporation	  on	  the	  
x-­‐axis.	  Overall,	  there	  is	  an	  incorporation	  efficacy	  of	  >98%,	  which	  is	  considered	  “complete”	  labelling	  
efficacy.	  
	  
Two	  biological	  replicate	  experiments	  have	  been	  performed.	  Using	  the	  described	  
workflow	  in	  Figure	  65,	  2060	  unique	  endogenous	  ubiquitylation	  sites	  that	  were	  
mapped	  to	  a	  single	  lysine	  with	  a	  localisation	  probability	  of	  over	  0.9	  in	  replicate	  1	  and	  
999	  unique	  endogenous	  ubiquitylation	  sites	  were	  identified	  in	  replicate	  2	  (Figure	  67).	  
The	  differential	  SILAC	  –based	  proteomics	  allowed	  determining	  the	  relative	  
abundance	  of	  these	  peptides	  depending	  on	  genotype	  –	  ion	  fragments	  originating	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from	  wild-­‐type	  MEFs	  (“light”/K0R0)	  had	  a	  relative	  lower	  mass	  than	  those	  derived	  
from	  the	  heavy	  labelled	  homozygous	  R379G	  Fbxo7	  KI	  MEFs.	  Therefore,	  the	  following	  
question	  could	  be	  asked:	  are	  there	  any	  ubiquitinylated	  peptides	  that	  are	  more	  
abundant	  in	  either	  the	  wild-­‐type	  or	  the	  homozygous	  R379G	  Fbxo7	  KI	  genotype	  –	  
reflecting	  proteins	  that	  are	  ubiquitinylated	  in	  an	  Fbxo7	  genotype	  -­‐	  dependent	  
manner?	  Peptides	  were	  considered	  to	  be	  differentially	  ubiquitinylated	  if	  there	  was	  
an	  at	  least	  2	  fold	  difference	  in	  their	  abundance	  between	  the	  2	  genotypes	  (expressed	  
as	  an	  XPRESS	  ratio	  of	  either	  >	  2	  or	  <	  0.5):	  Di-­‐Glycine	  peptides	  that	  were	  at	  least	  2-­‐
fold	  more	  abundant	  in	  the	  wild-­‐type	  background	  and	  which	  are	  present	  in	  both	  
replicate	  experiments	  are	  listed	  in	  Table	  5-­‐1	  (XPRESS	  ratio	  >	  2).	  These	  peptides	  
reflect	  proteins	  that	  are	  preferentially	  ubiquitinylated	  in	  the	  wild-­‐type	  Fbxo7	  
genotype.	  Di-­‐glycine	  peptides	  with	  were	  at	  least	  2-­‐fold	  more	  abundant	  in	  the	  
homogenous	  R379G	  Fbxo7	  KI	  genotype	  and	  which	  were	  identified	  in	  both	  replicate	  
experiments	  are	  found	  in	  Table	  5-­‐2	  (XPRESS	  ratio	  <	  0.5).	  These	  peptides	  reflect	  
proteins	  that	  are	  preferentially	  ubiquitinylated	  in	  the	  R379G	  Fbxo7	  KI	  Fbxo7	  
genotype.	  Amongst	  the	  former	  group	  –preferential	  ubiquitinylation	  status	  in	  the	  
Fbxo7	  wild-­‐type	  background	  –	  were	  peptides	  that	  could	  be	  mapped	  to	  3	  closely	  
related	  proteins:	  VDAC	  1,2,	  and	  3.	  Given	  that	  each	  of	  these	  3	  proteins	  was	  identified	  
with	  several	  Di-­‐glycine	  modified	  peptides	  that	  even	  had	  the	  highest	  Xpress	  ratios	  
identified	  in	  this	  study,	  VDAC	  1,	  2	  and	  3	  were	  considered	  to	  be	  potentially	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Figure	  67:	  Enrichment	  efficacy	  of	  the	  DiGlycine	  affinity	  purification	  of	  replicates	  1	  
and	  2	  
In	  replicate	  1,	  6430	  distinct	  peptides	  have	  been	  identified	  without	  the	  signature	  peptide	  (K*GG)	  
indicative	  of	  ubiquitinylation	  at	  protein	  level.	  2060	  peptides	  were	  identified	  with	  a	  distinct	  site	  of	  
K*GG	  modification(P>0.9,	  localization	  probability).	  In	  replicate	  2,	  7056	  unmodified	  sites	  and	  999	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Table	  5-­‐1:	  List	  of	  di-­‐Glycine	  modified	  peptides	  that	  are	  preferentially	  ubiquitinylated	  in	  the	  Fbxo7	  wild-­‐type	  background	  (>	  2-­‐fold)	  
List	  of	  di-­‐Glycine	  modified	  peptides	  that	  are	  more	  likely	  (>2-­‐fold	  difference	  in	  XPRESS	  ratio	  of	  wild-­‐type	  (light)	  versus	  R379G	  KI	  (heavy)	  labled	  MEFs)	  ubiquitinylated	  in	  
the	  Fbxo7	  wild-­‐type	  genotype	  in	  MEFs	  in	  at	  least	  1	  of	  the	  2	  biological	  replicate	  experiments.	  The	  table	  list	  each	  of	  the	  identified	  peptides	  and	  corresponding	  protein	  









Q91X82 Txnip protein K.SFEVVFNDPEKVYGSGEK[242.14]VAGR.V
Q91X82 Txnip protein K.SFEVVFNDPEKVYGSGEK[242.14]VAGR.V
Q91X82 Txnip protein K.SFEVVFNDPEK[136.11]VYGSGEK[250.15]VAGR[166.11].V
Q91X82 Txnip protein K.SFEVVFNDPEK[136.11]VYGSGEK[250.15]VAGR[166.11].V
Q91X82 Txnip protein K.SFEVVFNDPEK[136.11]VYGSGEK[250.15]VAGR[166.11].V







Q60930 VDAC 2 K.SC[160.03]SGVEFSTSGSSNTDTGK[242.14]VSGTLETK.Y
Q60930 VDAC 2 K.SC[160.03]SGVEFSTSGSSNTDTGK[242.14]VSGTLETK.Y
Q60932?1 VDAC 1 K.TKSENGLEFTSSGSANTETTK[242.14]VNGSLETK.Y
Q60930 VDAC 2 K.SC[160.03]SGVEFSTSGSSNTDTGK[242.14]VSGTLETK.Y
Q60930 VDAC 2 K.SC[160.03]SGVEFSTSGSSNTDTGK[242.14]VSGTLETK.Y
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Table	  5-­‐2:	  List	  of	  di-­‐Glycine	  modified	  peptides	  that	  are	  preferentially	  ubiquitinylated	  in	  the	  Fbxo7	  R379G	  KI	  background	  (>	  2-­‐fold)	  
List	  of	  di-­‐Glycine	  modified	  peptides	  that	  are	  more	  likely	  (with	  a	  >	  2-­‐fold	  difference)	  ubiquitinylated	  in	  the	  Fbxo7	  R379G	  KI	  genotype	  in	  MEFs	  (	  <	  0.5	  XPRESS	  ratio	  of	  
wild-­‐type	  (light)	  versus	  R379G	  KI	  (heavy)	  labled	  MEFs)	  in	  at	  least	  1	  of	  the	  2	  biological	  replicate	  experiments.	  The	  table	  list	  each	  of	  the	  identified	  peptides	  and	  
corresponding	  protein	  name,	  Uniprot	  accession	  number,	  protein	  name,	  peptide	  sequence,	  as	  well	  as	  localization	  probability.	  The	  XPRESS	  ratio	  is	  a	  quantitation	  tool	  for	  
MS/MS	  analysis
Probability
P26645 Myristoylated1alanine3rich1C3kinase1 K.TAAK[250.15]GEATAER[166.11]PGEAAVASSPSK[136.11].A 0.94
Q91WG231 Isoform121of1Rab1GTPase3binding1effector1 K.DSISSYETQIAALK[250.15]QER[166.11].Q 1.00
Q91WG231 Isoform121of1Rab1GTPase3binding1effector1 K.DSISSYETQIAALK[250.15]QER[166.11].Q 1.00
Q91WG231 Isoform121of1Rab1GTPase3binding1effector1 K.DSISSYETQIAALK[242.14]QER.Q 1.00
Q91WG231 Isoform121of1Rab1GTPase3binding1effector1 K.DSISSYETQIAALK[242.14]QER.Q 1.00
Q91WG231 Isoform121of1Rab1GTPase3binding1effector1 K.DSISSYETQIAALK[242.14]QER.Q 1.00
Q91WG231 Isoform121of1Rab1GTPase3binding1effector1 K.DSISSYETQIAALK[242.14]QER.Q 1.00
Q91WG231 Isoform121of1Rab1GTPase3binding1effector1 K.DSISSYETQIAALK[250.15]QER[166.11].Q 1.00
Q91WG231 Isoform121of1Rab1GTPase3binding1effector1 K.DSISSYETQIAALK[250.15]QER[166.11].Q 1.00
Q91WG231 Isoform121of1Rab1GTPase3binding1effector1 K.DSISSYETQIAALK[250.15]QER[166.11].Q 1.00
Q91WG231 Isoform121of1Rab1GTPase3binding1effector1 K.DSISSYETQIAALK[250.15]QER[166.11].Q 1.00
Q64282 Interferon-induced protein with tetratricopeptide repeats 1 K.EAEALIQSEQLSK[250.15]R[166.11].S 1.00
P63024 Vesicle-associated membrane protein 3 R.DQK[242.14]LSELDDRADALQAGASQFETSAAK.L 0.99
P63024 Vesicle-associated membrane protein 3 R.DQK[242.14]LSELDDRADALQAGASQFETSAAK.L 0.99
P63024 Vesicle-associated membrane protein 3 R.DQK[242.14]LSELDDRADALQAGASQFETSAAK.L 1.00
P63024 Vesicle-associated membrane protein 3 R.DQK[242.14]LSELDDRADALQAGASQFETSAAK.L 1.00
P63024 Vesicle-associated membrane protein 3 R.DQK[242.14]LSELDDRADALQAGASQFETSAAK.L 1.00
P63024 Vesicle-associated membrane protein 3 R.DQK[242.14]LSELDDRADALQAGASQFETSAAK.L 1.00
P63024 Vesicle-associated membrane protein 3 R.DQK[250.15]LSELDDR[166.11]ADALQAGASQFETSAAK[136.11].L 1.00
P63024 Vesicle-associated membrane protein 3 R.DQK[250.15]LSELDDR[166.11]ADALQAGASQFETSAAK[136.11].L 1.00
P63024 Vesicle-associated membrane protein 3 R.DQK[250.15]LSELDDR[166.11]ADALQAGASQFETSAAK[136.11].L 1.00
P63024 Vesicle-associated membrane protein 3 R.DQK[250.15]LSELDDR[166.11]ADALQAGASQFETSAAK[136.11].L 1.00
Q9JKF1 Ras1GTPase3activating3like1protein K.SLNIK[250.15]TDPVDIYK[136.11].S 0.95
Q9JKF1 Ras1GTPase3activating3like1protein K.SLNIK[250.15]TDPVDIYK[136.11].S 0.95
Q9JKF1 Ras1GTPase3activating3like1protein K.SLNIK[250.15]TDPVDIYK[136.11].S 0.97
Q9JKF1 Ras1GTPase3activating3like1protein K.SLNIK[250.15]TDPVDIYK[136.11].S 0.97
Q9JKF1 Ras1GTPase3activating3like1protein K.SLNIK[250.15]TDPVDIYK[136.11].S 0.98
Q9JKF1 Ras1GTPase3activating3like1protein K.SLNIK[250.15]TDPVDIYK[136.11].S 0.98
Q63918 Serum1deprivation3response1protein R.DNSQVNAVTVHTLLDK[250.15]L.V 1.00
Q63918 Serum1deprivation3response1protein R.DNSQVNAVTVHTLLDK[250.15]L.V 0.95
P5877431 Tropomyosin beta chain R.C[143.00]K[250.15]QLEEEQQALQK[136.11].K 1.00
P5877431 Tropomyosin beta chain R.C[143.00]K[250.15]QLEEEQQALQK[136.11].K 1.00
P5877431 Tropomyosin beta chain R.C[143.00]K[250.15]QLEEEQQALQK[136.11].K 1.00
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Table	  5-­‐3:	  Differential	  site-­‐specific	  K*GG	  modifications	  of	  VDAC	  1,	  2,	  and	  3	  in	  wild-­‐type	  and	  R379G	  Fbxo7	  KI	  MEFs	  	  
List	  of	  all	  di-­‐Glycine	  modified	  lysine	  peptides	  that	  mapped	  to	  either	  VDAC	  1,	  2,	  or	  3	  and	  had	  an	  Xpress	  ratio	  (Ratio	  wild-­‐type	  (light)	  /	  R379G	  KI	  (heavy))	  of	  over	  2	  in	  any	  
of	  the	  2	  biological	  replicate	  experiments	  and	  a	  localization	  probability	  of	  >	  0.9.	  Shown	  are	  Uniprot	  accession	  number,	  protein	  name,	  peptide	  sequence,	  and	  for	  each	  
replicate	  probability,	  ions,	  and	  Xpress	  ratio	  as	  well	  as	  the	  specific	  modification	  site	  (as	  identified	  in	  the	  respective	  mouse	  VDAC	  protein).	  
	  
Probability Ratio&(wt)light&/&R379G&KI&)&heavy) Probability Ratio&(wt)light&/&R379G&KI&)&heavy)
Q60932 VDAC41 44K.TKSENGLEFTSSGSANTETTK[242.14]VNGSLETK.Y 0.97 12.48 0.96 3.73 K66
Q60930 VDAC42 44K.SC[160.03]SGVEFSTSGSSNTDTGK[242.14]VSGTLETK.Y 0.97 11.54 0.95 5.5 K64
Q60930 VDAC42 44K.SC[160.03]SGVEFSTSGSSNTDTGK[242.14]VSGTLETK.Y 1.00 11.54 0.95 5.5 K64
Q60930 VDAC42 44K.SC[160.03]SGVEFSTSGSSNTDTGK[242.14]VSGTLETK.Y 0.99 15.4 0.95 5.5 K64
Q60930 VDAC2 44K.SC[160.03]SGVEFSTSGSSNTDTGK[242.14]VSGTLETK.Y 1.00 15.66 0.95 5.5 K64
Q60931 VDAC43 44K.SC[160.03]SGVEFSTSGHAYTDTGK[242.14]ASGNLETK.Y 1.00 5.71 1.00 1.88 K53
Q60932 VDAC41 44K.LTFDSSFSPNTGK[242.14]K.N 0.96 20.98 K122
Q60932 VDAC41 44K.LTFDSSFSPNTGK[242.14]K.N 0.99 20.98 K122
Q60930 VDAC42 44K.LTFDTTFSPNTGK[242.14]K.S 0.91 20.9 K121
Q60930 VDAC42 44K.LTFDTTFSPNTGK[242.14]K.S 0.99 20.9 K121
Q60930 VDAC42 44K.LTFDTTFSPNTGK[242.14]K.S 0.99 20.9 K121
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 K*GG-­‐specific	  ubiquitylation	  sites	  of	  VDAC	  1,	  2,	  and	  3	  5.1.1
Table	  5-­‐3	  shows	  the	  respective	  lysine	  residues	  of	  VDAC	  1,	  2	  and	  3	  that	  were	  found	  to	  be	  
preferentially	  ubiquitinylated	   in	   the	  Fbxo7	  wild-­‐type	  genotype	   in	  MEFs	  with	  an	  Xpress	  
ratio	  of	  >	  2	   in	  any	  of	   the	  2	  biological	   replicates	  and	  a	   localization	  probability	  of	  >	  0.9.	  
VDAC	  proteins	  are	  abundantly	  found	  in	  the	  outer	  mitochondrial	  membrane	  and	  form	  a	  
pore	   that	   regulates	   the	   transport	   of	   metabolites	   between	   the	   cytoplasm	   and	   the	  
mitochondria	   by	   switching	   between	   open	   and	   closed	   states(Mannella,	   1982;	  
Rostovtseva	  and	  Colombini,	  1997;	  Zalman	  et	  al.,	  1980).	  They	  have	  also	  been	  suggested	  
to	  interact	  with	  mitochondrial	  hexokinase	  isoforms	  and	  thereby	  play	  an	  important	  role	  
in	   bioenergetics	   pathways(Fiek	   et	   al.,	   1982;	   Linden	   et	   al.,	   1982).	   To	   be	   an	   important	  
component	  of	  the	  apoptotic	  machinery	   is	  yet	  another	  function	  that	  has	  been	  assigned	  
to	  VDAC	  proteins(Shimizu	  et	  al.,	  1999).	  VDAC	  proteins	  are	  present	  in	  all	  eukaryotic	  cells	  
and	  share	  conserved	  structural	  and	  functional	  features(Young	  et	  al.,	  2007).	  There	  are	  3	  
VDAC	   proteins	   in	   mammals	   and	   Figure	   68	   shows	   the	   sequence	   alignment	   of	   the	   3	  
proteins	  in	  mouse.	  The	  3	  VDAC	  proteins	  show	  a	  high	  degree	  of	  sequence	  conservation	  
amongst	   each	   other	   (>	   67%),	   and	   are	   highly	   conserved	   between	   mouse	   and	   human	  
homologous	   (for	  VDAC	  1,	   the	  percentage	   identity	   is	  98.59%;	   for	  VDAC	  2,	   it	   is	  94.56%;	  
and	   for	  VDAC	  3,	  98.23%	  as	  calculated	  by	   the	  pairwise	  alignment	  calculation	   feature	   in	  
MUSCLE)(Edgar,	   2004)	   (see	   Appendix	   for	   pairwise	   alignment	   of	   human	   and	   mouse	  
VDAC1,	  2,	  and	  3).	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Figure	  68:	  Sequence	  alignment	  of	  all	  3	  VDAC	  proteins	  in	  mouse	  and	  indication	  of	  the	  
ubiquitinylation	  sites	  that	  are	  differentially	  modified	  in	  an	  Fbxo7	  dependent	  manner	  
The	  Sequence	  alignment	  of	  the	  mouse	  VDAC	  1	  (Uniprot	  accession	  number:	  Q60932),	  VDAC	  2	  (Q60903),	  
and	  VDAC	  3	  (Q60931)	  were	  performed	  using	  MUSCLE	  and	  annotated	  with	  the	  help	  of	  Jalview(Edgar,	  2004;	  
Waterhouse	  et	  al.,	  2009a).	  The	  percentage	  ID	  using	  MUSCLE	  is	  71.53%	  between	  VDAC	  1	  and	  VDAC	  2;	  
67.49%	  between	  VDAC	  1	  and	  VDAC3;	  and	  73.14%	  between	  VDAC	  2	  and	  VDAC	  3.	  Indication	  of	  the	  
differentially	  targeted	  ubiquitinylation	  sites	  of	  the	  wild-­‐type	  versus	  R379G	  KI	  genotype	  in	  MEFs.	  	  
	  
Recently,	   the	   three-­‐dimensional	   structure	   of	   reconstructed	   recombinant	   human	   and	  
mouse	   VDAC	   1	   proteins	   has	   been	   solved	   using	   nuclear	   magnetic	   resonance,	   X-­‐ray	  
crystallography,	  or	  a	   combination	  of	   the	   latter	   two	   techniques(Bayrhuber	  et	  al.,	  2008;	  
Hiller	  et	  al.,	  2008; Ujwal	  et	  al.,	  2008):	  VDAC	  1	  features	  a	  19-­‐sheeted	  β-­‐barrel	  with	  the	  
first	  and	  last	  sheet	  being	  parallel	  and	  a	  helical	  region	  within	  the	  pore.	  The	  structures	  of	  
the	   mouse	   and	   human	   homologous	   are	   almost	   identical	   in	   keeping	   with	   their	   high	  
degree	   of	   conservation	   of	   99%	   -­‐	   they	   only	   differ	   by	   4	   amino	   acid	   residues.	   Based	   on	  
modelling	  studies,	  the	  structures	  of	  VDAC	  2	  and	  3	  are	  considered	  also	  to	  be	  in	  keeping	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A	  very	   interesting	   finding	   is	   that	   the	  various	  Di-­‐Glycine	   sites	   that	  have	  unambiguously	  
been	   identified	   in	   this	   study	   (Table	   5-­‐3)	   converge	   onto	   2	   lysine	   residues	   that	   are	  
completely	   conserved	   between	   VDAC	   1,	   2,	   and	   3:	   The	   first	   identified	   Di-­‐Glycine	   site	  
corresponds	   to	   K66	   in	   VDAC	   1,	   K65	   in	   VDAC	   2,	   and	   K53	   in	   VDAC	   3;	   and	   the	   second	  
identified	  Di-­‐Glycine	  site	  corresponds	  to	  K122	  in	  VDAC	  1,	  K121	  in	  VDAC	  2,	  and	  K109	  in	  
VDAC	   3	   (A	   in	   Figure	   69).	   Furthermore,	   these	   sites	   are	   also	   conserved	   between	   the	  
mouse	  and	  human	  homologous	  of	  VDAC	  1,	  2,	  and	  3	  and	  the	  corresponding	  residues	  for	  
the	  2	  sites	  are	  listed	  in	  the	  table	  (C)	  of	  Figure	  69.	  The	  availability	  of	  a	  three-­‐dimensional	  
structure	   of	   the	   mouse	   VDAC	   1	   protein	   allows	   mapping	   their	   positional	   orientation.	  
Figure	  69:	  C	  highlights	  that	  the	  2	  are	  not	  buried	   into	  any	  of	   the	  19	  transmembrane	  β-­‐
sheets,	  but	   is	  potentially	  accessible	   for	  being	  modified	  by	  ubiquitinylation	   in	  an	  Fbxo7	  
wild-­‐type	   dependent	   manner.	   There	   is	   an	   on-­‐going	   debate	   as	   to	   whether	   the	   three-­‐
dimensional	   structures	   of	   the	   available	   mouse	   and	   human	   VDAC	   1	   proteins	   actually	  
correspond	  to	  their	  native	  confirmation,	  as	  they	  fail	  to	  consolidate	  important	  functional	  
data(Colombini,	   2009).	   Figure	   70	   highlights	   the	   differences	   in	   folding	   pattern	   and	  
residues	   buried	   in	   the	   transmembrane	   domains	   between	   the	   actually	   resolved	   NMR	  
structure	   (A)	   and	   the	   predictions	   based	   on	   the	   wealth	   of	   functional	   data	   (B)	   for	   the	  
human	  VDAC	  1.	  The	  2	  corresponding	  D-­‐glycine	  sites	  are	  in	  both	  scenarios	  not	  buried	  into	  
the	   depths	   of	   the	   transmembrane	   domains.	   The	   discrepancies	   between	   the	   2	  models	  
have	   been	   suggested	   to	   arise	   from	   the	   experimental	   procedure	   involving	   the	  
recombinant	   expression	   and	   refolding	   in	   inclusion	   bodies:	   The	   particular	   refolding	  
pattern	  on	  which	   the	  NMR	  structure	   is	  based	  on	   is	  preferential	  and	  alternative	   to	   the	  
native	   state	   (discussed	   in(Colombini,	   2009)).	   However,	   not	   only	   its	   native	   folding	  
pattern,	  but	  also	  its	  orientation	  within	  the	  outer	  mitochondrial	  membrane	  is	  at	  debate:	  
it	   is	   therefore	  not	  entirely	  clear	  which	  site	  of	   the	  β	  barrel	   faces	  the	  cytosol	  and	  which	  
the	   inner	  mitochondrial	  membrane.	   The	   current	   understanding	   is	   that	   the	   C-­‐terminal	  
region	  of	  VDAC	  1	   faces	  the	  cytosol.	   It	   is	   therefore	  not	  entirely	  clear	  whether	  the	  2	  Di-­‐
Glycine	   modified	   lysine	   residues	   of	   VDAC	   1	   face	   the	   cytosol	   or	   towards	   the	   inner	  
mitochondrial	  membrane.	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In	  conclusion	  my	  differential	  enrichment	  of	   the	  ubiquitylated	  species	   in	  SILAC	   labelled	  
wild-­‐type	   and	  homozygous	  R379G	  Fbxo7	   KI	  MEFs	   clearly	   identifies	   2	   highly	   conserved	  
lysine	   residues,	   which	   are	   conserved	   amongst	   VDAC	   1,	   2,	   and	   3	   in	  mouse	   as	   well	   as	  
human	   homologous,	   to	   be	   preferentially	   ubiquitinylated	   in	   a	   Fbxo7	   wild-­‐type	  
background.	   This	   experiment	   looks	   at	   the	   ubiquitinylation	   landscape	   in	   an	   Fbxo7	  
genotype	  dependent	  manner	   in	  wild-­‐type	  and	  homozygous	  R379G	  Fbxo7	  KI	  MEFs,	  but	  
does	  not	  allow	  the	  conclusion	  that	  Fbxo7	   is	  directly	   involved	   in	   the	  ubiquitinylation	  of	  
the	   3	   VDAC	   proteins	   at	   the	   specified	   sites.	   A	   prerequisite	   would	   also	   be	   that	   the	  
respective	  lysine	  residues	  are	  accessible	  to	  the	  SCFFbxo7	  E3	  ubiquitin	  ligase	  complex.	  
	  
Figure	  69:	  The	  K*GG	  sites	  identified	  in	  this	  study	  are	  conserved	  across	  VDAC1,	  2,	  and	  3	  	  
A:	  Alignment	  of	  mouse	  sequences	  of	  VDAC	  1,2	  and	  3	  in	  the	  region	  of	  the	  identified	  K*RR	  sites	  shows	  that	  
the	  individual	  sites	  identified	  converge	  onto	  2	  lysine	  residues	  that	  are	  completely	  conserved	  between	  the	  
3	  proteins.	  	  
B:	  The	  K*GG	  sites	  identified	  in	  this	  study	  are	  highlighted	  in	  structure	  of	  the	  mouse	  VDAC	  1	  protein	  (image	  
of	  PDB	  ID:	  3EMN(Ujwal	  et	  al.,	  2008)	  created	  with	  Protein	  Workshop(Moreland	  et	  al.,	  2005)).	  They	  are	  
located	  at	  the	  surface	  of	  the	  protein	  rather	  than	  buried	  into	  any	  of	  its	  transmembrane	  domains.	  	  	  
C:	  The	  2	  K*GG	  sites	  identified	  in	  this	  study	  are	  also	  conserved	  across	  the	  human	  and	  mouse	  homologous	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Figure	  70:	  Differences	   in	   folding	  patterns	  of	  human	  VDAC	  1	  between	  NMR	  structure	  
and	  predications	  from	  functional	  studies	  
Original	  figure	  from	  (Colombini,	  2009)	  shows	  the	  differences	  in	  folding	  pattern	  between	  the	  human	  
VDAC1	  structures	  as	  determined	  my	  NMR	  (A)	  and	  the	  predictions	  based	  on	  functional	  studies	  (B).	  The	  
corresponding	  lysine	  residues	  that	  have	  been	  identified	  to	  be	  preferentially	  ubiquitinylated	  by	  the	  Fbxo7	  
wild-­‐type	  genotype	  in	  my	  study	  are	  highlighted	  in	  red.	  In	  either	  case	  the	  2	  sites	  are	  not	  buried	  inside	  the	  
transmembrane	  spanning	  β-­‐sheets	  of	  VDAC	  1.	  	  	  
	  
 Predominantly	  cytosolic	  localization	  of	  endogenous	  FBXO7	  in	  HEK293	  cells	  5.1.2
To	  gain	  inside	  into	  endogenous	  FBXO7	  in	  human	  HEK293	  cells	  localizes	  to	  the	  cytosolic	  
or	  mitochondrial	  compartment,	  FlpIn	  TRex	  HEK293	  cells	  stably	  expressing	  either	  FLAG-­‐
empty	   vector	   or	   human	   PINK1-­‐wild-­‐type-­‐C-­‐terminal	   FLAG	   were	   induced	   for	   protein	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mitochondrial	  decoupling	  agent	  CCCP	  (10uM)	  or	  DMSO	  as	  a	  control	   for	  4	  hours.	   It	  has	  
been	   shown	   for	   PINK1	   that	  mitochondrial	  membrane	  depolarization	  with	  CCCP	  at	   the	  
given	   concentration	   leads	   to	   stabilization	   and	  activation	  of	   PINK1	   in	   the	  mitochondria	  
and	   subsequent	   phosphorylation	   of	   PARKIN	   at	   Serin	   65(Kondapalli	   et	   al.,	   2012).	   I	  
therefore	  decided	  to	  use	  the	  PINK1	  translocation	  /	  stabilization	  as	  a	  positive	  control	  for	  
efficient	   mitochondrial	   perturbation	   in	   my	   Fbxo7	   localization	   experiment.	   Figure	   71	  
shows	   that	   PINK1	   –	   the	   full-­‐length	   (63	   kDa)	   as	  well	   as	   the	   cleaved	   form	   (53	   kDa)	   -­‐	   is	  
present	   under	   basal	   conditions,	   and	   treatment	   with	   CCCP	   leads	   to	   a	   pronounced	  
stabilization	  of	   full-­‐length	  PINK1	   in	   the	  mitochondrial	   fraction	   compared	   to	   treatment	  
with	   DMSO.	   In	   contrast,	   endogenous	   FBXO7	   was	   mainly	   identified	   in	   the	   cytosolic	  
fraction	   irrespective	   of	   CCCP	   treatment	   or	   not.	   The	   stable	   expressing	   cell	   lines	   were	  
kindly	  provided	  by	  Chandana	  Kondapalli,	  author	  of	  the	  above	  mentioned	  study.	  At	  least	  
under	  conditions	  used	  in	  this	  experiments	  –	  especially	  duration	  of	  CCCP	  treatment	  of	  4	  
hours	  –	  does	  not	  allow	  detection	  of	  endogenous	  FBXO7	  in	  the	  mitochondrial	  fraction	  as	  
is	   stable	   overexpressed	   PINK1.	   This	   would	   suggest	   that	   any	   SCFFBXO7	   wt	   E3	   ubiquitin	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Stable	  PINK1	  wild-­‐type-­‐FLAG	  or	  FLAG-­‐empty-­‐vector	  expressing	  HEK293	  cells	  were	  induced	  for	  protein	  
expression	  (0.1	  ug/ml	  for	  24	  hours)	  and	  stimulated	  with	  the	  mitochondrial	  decoupling	  reagent	  CCCP	  at	  
10uM	  for	  4	  hours.	  DMSO	  served	  as	  a	  negative	  control.	  Cytosolic	  and	  mitochondrial	  fractions	  were	  
subjected	  to	  immunoblotting	  for	  PINK1	  (positive	  control	  for	  efficient	  mitochondrial	  membrane	  
depolarization	  with	  subsequent	  mitochondrial	  stabilization	  of	  PINK1)	  and	  FBXO7.	  VDAC	  and	  Hsp90	  served	  







5.2 Quantitative	   global	   proteomics	   to	   identify	   differences	   in	  
expression	   levels	   across	   the	   whole	   proteome	   of	   wild-­‐type	  
and	   hom	   R379G	   Fbxo7	   KI	   brain	   lysates	   using	   ex	   vivo	  
dimethyl	  labeling	  
The	   aim	  was	   to	   identify	   proteins	  whose	   expression	   levels	   significantly	   differ	   in	  whole	  
brain	  tissue	  lysates	  dependent	  on	  the	  genotype	  of	  the	  animals.	  The	  expectation	  is	  then	  
that	  the	  difference	   in	  expression	   level	  of	  any	  such	  protein	  reflects	  the	  altered	  SCFFBXO7	  	  
E3	  ligase	  activity	  of	  the	  mutant	  Fbxo7	  protein	  in	  comparison	  to	  the	  wild-­‐type.	  In	  order	  to	  
study	  and	  quantify	  the	  effect	  of	  the	  mutant	  Fbxo7	  protein	  in	  the	  endogenous	  system	  in	  
brain	   lysates,	  ex	  vivo	   chemical	   labeling	  was	  used(Boersema	  et	  al.,	  2009)	   (Figure	  72):	  3	  
littermate	   pairs	   of	   wild-­‐type	   and	   homozygous	   R379G	   Fbxo7	   KI	   mouse	   brains	   with	   a	  
mean	  age	  of	  10	  months	  were	  used.	  Individual	  brains	  were	  lysed	  in	  RapiGest	  buffer	  and	  
equal	   amounts	   of	   each	   sample	   (200ug	   each)	   were	   digested	   with	   Trypsin.	   This	   was	  
followed	  by	   stable	   isotope	   incorporation	   at	   peptide	   level	   using	   dimethyl	   labelling	   and	  
subsequent	  multiplex	   quantitative	   proteomics(Boersema	   et	   al.,	   2009).	   The	   differential	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dimethyl	   labelling	   permits	   us	   to	   distinguish	   peptides	   arising	   from	  either	   the	  wild-­‐type	  
(“light”)	  or	  the	  homozygous	  R379G	  Fbxo7	  KI	  (“heavy”)	  brain	  samples	  and	  the	  differential	  
peptide	  abundance	   is	  then	  calculated	  as	  the	  ratio	  of	  extracted	   ion	   intensities	  between	  
the	   2	   genotypes.	   Conventionally,	   a	   1.5	   ratio	   is	   applied	   as	   a	   threshold(Blagoev	   et	   al.,	  
2004;	  Margolin	  et	  al.,	  2009).	  Figure	  73	   illustrates	   the	   important	   steps	   in	   this	  protocol:	  
sample	   preparation	   and	   tryptic	   digestion,	   ex	   vivo	   differential	   labelling,	   mixing	   of	   the	  
paired	  wild-­‐type	  and	  homozygous	  R379G	  Fbxo7	  KI	  brain	   samples	  at	  peptide	   level	   at	   a	  
ration	  of	  1:1	  and	  multiplex	  quantitative	  proteomic	  analysis.	  	  
	  
Figure	  72:	  Principle	  of	  chemical	  dimethyl	  labelling	  at	  peptide	  level	  
After	  tryptic	  digestion,	  derived	  peptides	  of	  the	  different	  samples	  are	  labelled	  with	  isotopomeric	  dimethyl	  
label:	  all	  primary	  amines	  in	  a	  peptide	  mixture	  are	  converted	  to	  dimethylamines	  to	  form	  
monomethylamines.	  By	  using	  combinations	  of	  different	  isotopomeres	  of	  formaldehyde	  and	  
cyanoborohydride,	  differential	  labelling	  can	  be	  obtained	  that	  differ	  in	  mass	  by	  a	  minimum	  of	  4	  kDa,	  which	  
is	  the	  basis	  for	  differential	  detection	  by	  multiplex	  mass-­‐spectrometry.	  (R:	  rest	  of	  the	  peptide	  that	  is	  being	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Figure	  73:	  Schematics	  of	  ex	  vivo	  differential	  chemical	  labelling	  of	  wild-­‐type	  and	  R379G	  
Fbxo7	  KI	  brains	  for	  quantitative	  whole	  proteome	  analysis	  	  
The	  experiment	  was	  performed	  in	  parallel	  with	  3	  littermate	  pairs	  of	  wt	  and	  hom	  R379G	  Fbxo7	  KI	  animals	  
with	  a	  mean	  age	  of	  10	  months.	  Brains	  were	  harvested	  and	  immediately	  homogenized	  in	  RapiGest	  lysis	  
buffer.	  Protein	  concentration	  was	  determined	  and	  200ug	  of	  each	  of	  the	  6	  samples	  was	  digested	  with	  
Trypsin	  overnight	  at	  37	  degrees	  Celsius.	  	  Samples	  were	  then	  subjected	  to	  on	  column	  dimethyl	  labelling	  
(light	  label	  for	  wild-­‐type	  and	  intermediate	  label	  for	  hom	  KI	  samples)	  and	  subsequently	  peptides	  from	  
littermate	  wt	  and	  hom	  Fbxo7	  KI	  pairs	  were	  mixed	  at	  a	  1:1	  ratio.	  The	  samples	  were	  then	  analysed	  by	  
multiplex	  quantitative	  proteomics.	  Protein	  X	  illustrates	  an	  example	  of	  a	  protein	  that	  is	  differentially	  
targeted	  by	  the	  SCFFbxo7wt	  E3	  ligase	  complex	  for	  degradation	  by	  the	  ubiquitin	  proteasome	  system.	  Hence,	  
its	  expression	  level	  is	  lower	  in	  the	  wt	  genotype	  its	  relative	  detection	  by	  mass-­‐spectrometry	  lower.	  	  
	  
In	  total,	  6998	  proteins	  were	  identified	  with	  at	  least	  2	  peptides.	  107	  of	  the	  6998	  proteins	  
differed	  more	  than	  1.5	  fold	  in	  their	  expression	  levels,	  but	  only	  15	  changed	  reliably	  (p	  <	  
0.05)	   (Table	   5-­‐4:	   A),	   whereas	   the	   majority	   of	   proteins	   remained	   unchanged.	   The	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times	   higher	   to	   11	   times	   lower	   in	   the	   wild-­‐type	   brain	   samples.	   I	   had	   previously	  
determined	  that	  the	  expression	  level	  of	  Fbxo7	  differ	  about	  2-­‐fold	  between	  the	  wild-­‐type	  
and	   homozygous	   R379G	   Fbxo7	   KI	   genotype	   by	   immunoblotting	   and	   Li-­‐COR	  
quantification	  (Figure	  36).	  The	  same	  difference	  was	  observed	  in	  this	  experiment:	  Fbxo7	  
protein	   levels	  were	  reduced	  by	  half	   in	   the	  homozygous	  R379G	  Fbxo7	  KI	  genotype	  (p	  =	  
0.051)	   (Table	   5-­‐4:B).	   Fbxo7	   therefore	   served	   as	   an	   internal	   quality	   control	   and	   the	  
difference	  in	  expression	  levels	  was	  equivalent	  to	  that	  seen	  by	  immunoblotting.	  	  
	  
Table	   5-­‐4:	  Differentially	   expressed	  hits	   across	   the	  proteome	  of	   dimethyl	   labelled	  wt	  
(light)	   and	   hom	   R379G	   (heavy)	   Fbxo7	   KI	   brain	   samples	   (3	   biological	   replicates,	  
ratio>1.5)	  
A:	  Of	  all	  7000	  proteins	  identified	  All	  differentially	  expressed	  proteins	  in	  wt	  and	  hom	  R379G	  Fbxo7	  KI	  brain	  
samples	  of	  3	  replicates	  with	  a	  ratio	  in	  expression	  levels	  as	  detected	  by	  quantitative	  proteomics	  of	  at	  least	  
1.5	  and	  a	  p-­‐value	  of	  less	  than	  0.05.	  Proteins	  with	  an	  at	  least	  2-­‐fold	  excess	  in	  the	  wild-­‐type	  genotype	  are	  
highlighted	  in	  light	  green,	  whereas	  proteins	  with	  an	  at	  least	  2-­‐fold	  excess	  are	  highlighted	  in	  rose.	  B:	  Fbxo7	  
was	  found	  to	  differ	  between	  the	  2	  genotypes	  with	  a	  ratio	  of	  0.5	  (reduction	  by	  half	  in	  hom	  R379G	  KI	  
compared	  to	  wt),	  but	  the	  p-­‐value	  was	  0.051,	  which	  is	  the	  reason	  why	  F-­‐box	  7	  is	  not	  listed	  amongst	  the	  




Protein(name MW((kDa) fold(change((H/L) Unique(peptides Sequence(coverage([%] p(value
F-box only protein 7 59 0.514 4 13.2 0.051
Protein(names MW((kDa) fold(change((H/L) Unique(peptides Sequence(coverage([%]
Integrin(beta;Integrin(beta,5 90 0.01 4 9.7
Glycosyltransferase,like(domain,containing(protein(1 51 0.13 2 6.5
Latrophilin,2 167 0.27 7 6
60S(ribosomal(protein(L36a 12 0.41 3 28.3
Sentrin,specific(protease(7 116 0.49 5 8.4
Ras,specific(guanine(nucleotide,releasing(factor(RalGPS1 65 0.57 1 8.2
Protein(SMG9 58 1.51 8 24.8
Protein(sprouty(homolog(2 35 1.72 2 9.5
Vascular(endothelial(growth(factor(receptor(1 150 1.96 7 6.8
Intraflagellar(transport(protein(20(homolog 15 1.97 2 17.4
Protein(Pcdhb20 88 2.37 5 11.8
Protein(KTI12(homolog 38 3.37 2 10
Glycosylphosphatidylinositol(anchor(attachment(1(protein 68 6.60 4 8.4
Neuroepithelial(cell,transforming(gene(1(protein 68 9.85 2 2.9
Neurogenic(differentiation(factor(2 41 11.59 3 11.7
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 Immunoblotting	   for	   candidate	   hits	   from	   the	   differential	   whole	   proteome	  5.2.1
experiment	  from	  wt	  and	  hom	  R379G	  Fbxo7	  KI	  brain	  	  
In	  an	  effort	  to	  validate	  the	  hits	  from	  the	  differential	  whole	  proteome	  experiment	  I	  have	  
used	   commercially	   available	   antibodies	   for	   immunoblotting.	   The	   antibodies	   were	  
considered	  specific	  when	  they	  reliably	  detected	  a	  signal	  of	  the	  respective	  size	  and	  when	  
they	  had	  been	  used	   in	  other	  publications.	   Figure	  74	   shows	   the	   immunoblot	   for	  Fbxo7	  
and	  Gapdh	  as	  loading	  control	  for	  duplicate	  whole	  brain	  lysates	  for	  the	  3	  littermate	  wild-­‐
type	  and	  homozygous	  R379G	  Fbxo7	  KI	  pairs	  (corresponding	  to	  the	  3	  biological	  replicates	  
used	   in	  the	  proteomic	  experiments).	  This	  shows	  that	  despite	  some	  variation	  there	   is	  a	  
stronger	  signal	  for	  Fbxo7	  in	  the	  wild-­‐type	  compared	  to	  the	  homozygous	  R379G	  Fbxo7	  KI	  
samples	   corresponding	   with	   the	   2-­‐fold	   higher	   abundance	   levels	   determined	   by	   the	  
proteomic	  analysis.	  No	  clear	  pattern	  of	  differential	  expression	  between	  the	  2	  genotypes	  
is	  seen	  for	  any	  of	  the	  other	  proteins	  that	  were	  subjected	  to	  immunoblotting:	  According	  
to	  the	  proteomic	  analysis,	   the	  abundance	  of	   Integrin	  beta	  5	   is	  100	  times	  higher	   in	  the	  
wild-­‐type	   compared	   to	   the	   homozygous	   R379G	   Fbxo7	   KI,	   while	   the	   difference	   for	  
Sentrin-­‐sepcific	  protease	  7	  is	  2-­‐fold	  higher	  in	  the	  wild-­‐type	  genotype.	  The	  same	  can	  be	  
observed	   for	   proteins	   whose	   abundance	   has	   been	   measured	   to	   be	   higher	   in	   the	  
homozygous	   R379F	   Fbxo7	   KI	   brain	   samples:	   the	   expression	   for	   both	   neurogenic	  
differention	  factor	  2	  and	  neuroepithelial	  cell-­‐transforming	  gene	  protein	  1	  was	  measured	  
to	   be	   about	   10	   times	   higher	   in	   the	   homozygous	   R379G	   KI	   genotype.	   Overall,	   the	  
validation	  of	  the	  differential	  whole	  proteome	  analysis	  in	  the	  quest	  to	  identify	  genotype	  
specific	  differences	  in	  wild-­‐type	  and	  homozygous	  R379G	  KI	  Fbxo7	  brain	  samples	  was	  not	  
taken	   any	   further.	   I	   will	   explain	   in	   the	   discussion	   why	   we	   thought	   that	   lysates	   as	  
complex	   as	   those	   from	   whole	   brain	   are	   not	   the	   most	   suitable	   material	   to	   study	  
differences	  in	  protein	  expression	  between	  the	  Fbxo7	  wildtype	  and	  mutant	  genotypes.	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Figure	  74:	  Immunoblotting	  of	  whole	  brain	  lysates	  from	  the	  3	  littermate	  pairs	  (wt	  and	  
hom	  R379G	  Fbxo7	  KI)	  used	  in	  the	  proteomic	  analysis	  	  
The	  same	  RapiGest	  whole	  brain	  samples	  from	  3	  littermate	  wt	  and	  hom	  R379G	  Fbxo7	  KI	  pairs	  that	  were	  
used	  for	  the	  proteomic	  analysis	  were	  subjected	  to	  immunoblotting	  (loading	  in	  duplicates,	  15	  ug	  each).	  
According	  to	  the	  quantitative	  proteomic	  analysis	  Integrin	  beta	  1	  and	  Sentrin	  specific	  protease	  have	  a	  
genotype-­‐specific	  higher	  expression	  level	  in	  the	  wild-­‐type,	  and	  neurogenic	  differention	  factor	  2	  and	  
neuroepithelial	  cell-­‐transforming	  gene	  protein	  1	  have	  a	  higher	  expression	  pattern	  in	  the	  hom	  R379G	  
Fbxo7	  KI,	  while	  VEGFR1	  is	  equally	  expressed.	  Immunoblotting	  does	  not	  show	  a	  genotype	  specific	  
difference	  in	  expression	  pattern	  for	  any	  of	  the	  proteins	  blotted	  for	  except	  for	  Fbxo7,	  but	  either	  no	  or	  a	  
high	  intra-­‐individual	  difference	  irrespective	  of	  genotype.	  
	  
5.3 In	  vitro	  SCFFBXO7	  complex	  formation	  
An	   important	   aspect	   in	   the	   validation	   of	   potential	   FBXO7	   targets	   for	   SCFFBXO7	   E3	  
ubiquitin	   ligase	   dependent	   degradation	   by	   the	   ubiquitin	   proteasome	   system	   is	   the	  
availability	  of	  a	  functional	  read-­‐out.	  I	  have	  therefore	  set	  out	  to	  establish	  conditions	  for	  
1 2 3 4 5 6
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in	  vitro	  SCFFBXO7	  E3	  ubiquitin	  ligase	  assays	  to	  directly	  assess	  the	  impact	  of	  FBXO7	  on	  any	  
putative	  targets.	  The	  first	  important	  step	  was	  to	  express	  and	  purify	  high	  yields	  of	  all	  the	  
components	  of	   the	  SCFFBXO7	  complex:	  Cullin	  1,	  SKP1,	  RBX1	  and	  of	  course	  the	  wild-­‐type	  
and	  FBXO7	  disease	  mutants.	  Cullin1	  and	  RBX1	  form	  the	  catalytical	  core	  of	  the	  complex	  
in	   terms	   of	   being	   responsible	   for	   the	   recruitment	   of	   the	   E2	   ubiquitin	   conjugating	  
enzyme,	  while	  SKP1	  functions	  an	  adaptor	  to	  link	  interchangeable	  F-­‐box	  proteins	  via	  their	  
SKP1-­‐binding	  F-­‐box	  domain	  to	  the	  Cullin1	  /	  RBX1	  core.	  It	  is	  then	  the	  F-­‐box	  proteins	  that	  
bring	   the	   substrate	   to	   the	   E3	   ligase	   complex	   and	   thereby	   dictating	   substrate-­‐
specificity(Deshaies	  and	  Joazeiro,	  2009).	  Figure	  75	  illustrates	  the	  complex	  and	  extensive	  
interactions	   between	   the	   various	   SCF	   complex	   partners,	   which	   adopt	   an	   overall	   rigid	  
structure(Schulman	  et	  al.,	  2000;	  Wu	  et	  al.,	  2003;	  Zheng	  et	  al.,	  2002).	  	  
 Expression	   and	   purification	   strategy	   of	   the	   recombinant	   SCFFBXO7	   complex	  5.3.1
components	  
Because	   of	   the	   overall	   rigid	   structure	   of	   the	   SCF	   complex,	   it	   has	   therefore	   been	  
suggested	   that	  co-­‐expression	  and	  co-­‐purification	  of	  at	   least	  2	   subunits	  of	   the	  complex	  
together	   yields	   soluble	   and	   functional	   components	   of	   the	   E3	   ligase	   complex(Li	   et	   al.,	  
2005).	   In	   this	   study,	   I	   used	   co-­‐expressed	   insect	   cell	   expressed	   DAC-­‐tagged	   Cullin1	   /	  
untagged	   RBX1	   as	   well	   as	   His-­‐tagged	   Cullin1	   /	   untagged	   RBX1/	   untagged	   SKP1	  
components	  as	  well	  as	  co-­‐expressed	  DAC-­‐tagged	  FBXO7	  –	  either	  as	  wild-­‐type,	  or	  disease	  
mutants	  R378G	  and	  R498X	  -­‐	  and	  untagged	  SKP1.	  The	  initial	  affinity	  purification	  selected	  
for	   the	   DAC-­‐tag	   in	   case	   of	   the	   Cullin	   and	   FBXO7	   components.	   In	   case	   of	   the	   Cullin1	  
component,	   the	   purification	   step	   was	   followed	   by	   cleavage	   by	   the	   protease	   Tev	   to	  
release	  and	  remove	  free	  DAC.	  Additionally,	  single	  expressed	  His-­‐tagged	  PI31	  was	  used.	  
Figure	  76	  shows	  the	  final	  recombinant	  protein	  complex	  components	  and	  demonstrates	  
good	  expression	  and	  purification	  of	  all	   recombinant	  proteins	  except	   for	  SKP1,	  when	   it	  
co-­‐expression	  and	  co-­‐purified	  with	  the	  mutant	  R378G	  FBXO7:	  Subjecting	  serial	  dilutions	  
of	  the	  FBXO7	  wild-­‐type	  /	  SKP1	  complex	  components	  in	  comparison	  to	  the	  FBXO7	  R379G	  
mutant	   /	   SKP1	   to	   immunoblotting	   for	   SKP1,	   clearly	   demonstrates	   that	   SKP1	   is	   not	   as	  
efficiently	   co-­‐purified	   with	   the	   R378G	   mutant	   than	   with	   the	   FBXO7	   wild-­‐type.	   Re-­‐
sequencing	  of	  the	  original	  baculoviral	  constructs	  confirmed	  that	  both	  the	  untagged	  SKP1	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and	  DAC-­‐FBXO7	  cassettes	  contained	  the	  correct	  sequences	  and	  that	  the	  mutant	  FBXO7	  
construct	  only	  differed	  by	  the	  correct	  insertion	  of	  the	  corresponding	  mutation.	  At	  least	  3	  
separate	   expression	   and	   purification	   procedures	   of	   each	   of	   the	   2	   FBXO7	   constructs	  
yielded	  the	  same	  result:	  SKP1	  was	  not	  as	  efficiently	  co-­‐purified	  with	  the	  R378G	  FBXO7	  
mutant	  (Figure	  77).	  	  
	  
	  
Figure	   75:	   SCF	   E3	   ubiquitin	   ligase	   complex	   and	   its	   relation	   to	   E1,	   E2	   and	   potential	  
targets	  
RBX1	  binds	  to	  the	  C-­‐terminus	  of	  Cullin	  1	  via	  its	  N-­‐terminus	  and	  via	  its	  N-­‐terminus	  to	  an	  E2	  conjugating	  
enzyme.	  Cullin	  1	  binds	  SKP1	  via	  its	  N-­‐terminus	  and	  SKP1	  in	  turn	  acts	  as	  an	  adaptor	  for	  a	  multitude	  of	  
different	  F-­‐box	  proteins	  each	  with	  their	  own	  set	  of	  substrates.	  RBX1/Cullin1	  catalyses	  then	  the	  transfer	  of	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Figure	   76:	   Expression	   of	   the	   components	   of	   the	   recombinant	   SCFFBXO7	   complex	  
components:	   co-­‐expressed	   and	   purified	   Cullin	   1	   /	   Skp1	   /	   Rbx1	   and	   Fbxo7	   /	   SKP1	   as	  
well	  as	  single	  expressed	  and	  purified	  His-­‐PI31	  
Recombinant	  FBXO7-­‐wild-­‐type	  and	  Fbxo7-­‐R379G	  mutant	  proteins	  were	  each	  co-­‐expressed	  as	  full-­‐length,	  
DAC-­‐tagged	  proteins	  together	  with	  untagged	  SKP1	  in	  insect	  cells	  from	  a	  dual	  baculovirus	  vector	  and	  
affinity	  purified	  for	  DAC.	  Full	  length	  PI31	  was	  expressed	  with	  a	  6His-­‐tag	  and	  DAC-­‐tagged,	  full-­‐length	  Cullin	  
1	  was	  co-­‐expressed	  with	  untagged	  Rbx1	  and	  untagged	  SKP1	  followed	  by	  cleavage	  of	  the	  DAC-­‐tag	  by	  the	  
protease	  Tev.	  Serial	  dilutions	  (in	  ng)	  for	  each	  construct	  were	  prepared	  for	  immunoblotting	  with	  the	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Figure	   77:	   Re-­‐expression	   and	   purification	   confirmed	   the	   consistently	   lower	   co-­‐
purification	  of	  SKP1	  with	  the	  R378G	  FBXO7	  mutant	  
A	  second	  and	  also	  third	  (data	  not	  shown)	  preparation	  of	  the	  DAC-­‐FBXO7	  wild-­‐type	  and	  DAC-­‐FBXO7	  R378G	  
mutant	  	  each	  co-­‐expressed	  with	  untagged	  SKP1	  shows	  consistently	  the	  lower	  abundance	  of	  SKP1	  when	  it	  
is	  co-­‐purified	  with	  the	  FBXO7	  R378G	  mutant.	  Also	  shown	  is	  a	  second	  preparation	  of	  the	  Cullin1	  /	  SKP1	  /	  
RBX1	  co-­‐expression	  construct	  (duplicate	  loading,	  150ng	  each,	  immunoblotting	  for	  the	  respective	  
antibodies	  as	  shown).	  	  
	  
 Preparation	  of	  recombinant	  SCFFBXO7	  E3	  ubiquitin	  ligase	  complexes	  5.3.2
After	  expressing	  each	  of	  the	  different	  components	  of	  the	  SCF	  complex	  for	  the	  wild-­‐type	  
as	  well	  as	  the	  R378G	  FBXO7	  disease	  mutant,	  I	  moved	  on	  to	  prepare	  recombinant	  SCF	  E3	  
ubiquitin	   ligase	   complexes.	   Successful	   SCF	   complex	   formation	   is	   a	   prerequisite	   for	  
functional	   E3	   ligase	   activity	   for	   further	   assay	   development.	   In	   principle,	   the	   different	  
components	  of	  the	  final	  complex	  should	  readily	  assemble	  upon	  mixing.	  As	  we	  suspected	  
PI31	  to	  be	  possibly	  part	  of	  the	  SCFFBXO7	  complex,	  I	  included	  PI31	  in	  the	  analysis	  and	  aim	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plus	  PI31)	  complex	  formation.	  A	  molar	  ratio	  of	  1:2:2	  was	  used	  for	  DAC-­‐FBXO7	  (wild-­‐type	  
as	  well	  as	  R378G	  mutant)	   /	  SKP1	   :	  Cullin1	  /	  SKP1	  /	  RBX1	   :	  His-­‐PI31.	  During	   initial	  pilot	  
experiments	  I	  had	  used	  a	  Cullin1	  construct	  from	  a	  dual	  expression	  vector	  co-­‐expressing	  
only	  RBX1	  (data	  not	  shown),	  but	  because	  of	  the	  significantly	  lower	  abundance	  of	  SKP1	  in	  
the	  co-­‐purification	  with	  the	  FBXO7	  R378G	  mutant,	  I	  switched	  to	  using	  Cullin	  1	  expressed	  
from	  a	  multi-­‐baculoviral	   construct	  co-­‐expressing	  RBX1	  as	  well	  as	  SKP1.	  The	  SKP1	   from	  
the	  Cullin1	  co-­‐purification	  served	  as	  an	  alternative	  source	  of	  SKP1	  in	  the	  FBXO7	  R378G	  
mutant	   complex	   formation	   experiment.	   After	   direct	  mixing	   of	   the	   individual	   complex	  
components,	   DAC-­‐affinity	   purification	   of	   the	   DAC-­‐tagged	   FBXO7	   component	   allowed	  
successful	   separation	   of	   the	   complex	   from	   the	   excessive	   components	   that	   were	   not	  
assembled	   into	   a	   complex	   with	   FBXO7.	   Figure	   78	   and	   Figure	   79	   show	   2	   replicate	  
experiments	   of	   successful	   SCFFBXO7	   and	   even	   pentameric	   SCFFBXO7	   *	   PI31	   complex	  
formation	  for	  the	  FBXO7	  wild-­‐type	  construct.	  The	  same	  was	  not	  observed	  for	  the	  FBXO7	  
R378G	   disease	   mutant.	   The	   co-­‐expression	   and	   co-­‐purification	   of	   the	   FBXO7	   R378G	   /	  
Skp1	  (5.3.1)	  had	  already	  pointed	  towards	  impaired	  binding	  of	  SKP1	  to	  the	  FBXO7	  R378G	  
mutant.	   Despite	   compensating	   for	   the	   relatively	   lower	   abundance	   of	   SKP1	   in	   the	  
complex	  formation	  experiment	  with	  alternatively	  sourced	  SKP1	  (from	  the	  Cullin1	  /	  SKP1	  
/	  RBX1)	  construct,	  the	  FBXO7	  R378G	  mutant	  was	  unable	  to	  form	  a	  SCFFBXO7	  R378G	  E3	  ligase	  
complex	  (Figure	  80).	  To	  corroborate	  that	  it	  is	  actually	  the	  substitution	  of	  an	  Arginine	  by	  
a	   Glycine	   in	   juxtaproximity	   to	   the	   F-­‐box	   domain	   at	   position	   378	   of	   FBXO7	   that	   is	  
responsible	   for	   impaired	   SKP1	   binding	   in	   vitro,	   I	   have	   also	   included	   another	   FBXO7	  
disease	   mutant:	   FBXO7	   R498X.	   Figure	   80:	   A	   shows	   the	   Coomassie	   gel	   picture	   of	   the	  
purified	  FBXO7	  wild-­‐type	  /	  Skp1,	  FBXO7	  R378G	  /	  Skp1	  as	  well	  as	  FBXO7	  R498X	  /	  Skp1	  
indicating	   that	   SKP1	   fails	   to	   effectively	   co-­‐purify	   with	   the	   DAC-­‐affinity	   purification	   of	  
DAC-­‐tagged	  FBXO7,	  while	   it	   is	   effectively	   co-­‐purified	  with	   the	  wild-­‐type	  as	  well	   as	   the	  
R498X	  FBXO7	  mutant.	  Figure	  80:	  B	  demonstrates	  the	  ability	  of	  the	  wild-­‐type	  as	  well	  as	  
the	  R498X	  FBXO7	  mutant	  to	  form	  a	  SCFFBXO7	  complex	  (with	  an	  without	  PI31),	  while	  the	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Figure	  78:	  Successful	  recombinant	  SCF	  complex	  formation	  of	  the	  FBXO7	  wild-­‐type:	  
Replicate	  1	  
DAC-­‐tagged	  FBXO7	  wild-­‐type	  /	  Skp1,	  untagged	  Cullin	  1	  /	  SKP1	  /	  RBX1	  and	  His-­‐tagged	  PI31	  were	  incubated	  
alone	  or	  in	  all	  possible	  combinations	  with	  each	  other	  prior	  to	  affinity	  purification	  by	  DAC-­‐tag	  binding	  to	  
ampicillin	  sepharose.	  Co-­‐eluting	  proteins	  were	  considered	  to	  be	  in	  a	  stable	  complex	  with	  the	  DAC-­‐purified	  
FBXO7.	  Shown	  are	  immunoblots	  for	  all	  components	  of	  input	  and	  DAC-­‐purification.	  The	  DAC-­‐pull-­‐down	  of	  
the	  individual	  components	  –	  when	  DAC-­‐tagged	  FBXO7	  is	  not	  present	  -­‐	  serve	  as	  a	  control	  and	  shows	  that	  
complex	  formation	  is	  not	  due	  to	  unspecific	  DAC-­‐binding.	  The	  FBXO7	  wild-­‐type	  is	  able	  to	  form	  a	  tetrameric	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Figure	   79:	   Successful	   recombinant	   SCF	   complex	   formation	   of	   the	   FBXO7	   wild-­‐type:	  
Replicate	  2	  
Biological	  replicate	  experiment:	  DAC-­‐tagged	  FBXO7	  wild-­‐type	  /	  Skp1,	  untagged	  Cullin	  1	  /	  SKP1	  /	  RBX1	  and	  
His-­‐tagged	  PI31	  were	  incubated	  alone	  or	  in	  all	  possible	  combinations	  with	  each	  other	  prior	  to	  affinity	  
purification	  by	  DAC-­‐tag	  binding	  to	  ampicillin	  sepharose.	  Co-­‐eluting	  proteins	  were	  considered	  to	  be	  in	  a	  
stable	  complex	  with	  the	  DAC-­‐purified	  FBXO7.	  The	  FBXO7	  wild-­‐type	  is	  able	  to	  form	  a	  tetrameric	  SCFFBXO7	  
complex	  as	  well	  as	  a	  pentameric	  SCFFBXO7	  *	  PI31	  complex.	  
His-PI31
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Figure	  80:	  Inability	  of	  the	  R378G	  FBXO7	  mutant	  to	  form	  a	  recombinant	  SCFFBXO7	  R378G	  
complex	  
A:	  Coomassie	  gel	  of	  the	  purified	  FBXO7	  wild-­‐type	  /	  SKP1,	  FBXO7	  R378G	  /	  SKP1	  and	  FBXO7	  R498X	  /	  SKP1	  
demonstrated	  that	  SKP1	  is	  ineffectively	  co-­‐purified	  with	  the	  R378G	  mutant	  while	  it	  efficiently	  binds	  to	  the	  
wild-­‐type	  as	  well	  as	  the	  R498X	  FBXO7	  mutant	  (loading	  of	  100	  and	  300	  ng	  for	  each	  construct).	  
B:	  Either	  DAC-­‐tagged	  FBXO7	  wild-­‐type	  /	  Skp1	  or	  the	  2	  DAC-­‐tagged	  FBXO7	  disease	  mutants	  (R378G	  and	  
R498X)	  or	  untagged	  Cullin	  1	  /	  SKP1	  /	  RBX1	  and	  His-­‐tagged	  PI31	  were	  incubated	  alone	  or	  in	  all	  possible	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eluting	  proteins	  were	  considered	  to	  be	  in	  a	  stable	  complex	  with	  the	  DAC-­‐purified	  FBXO7.	  The	  
immunoblots	  for	  the	  input	  of	  all	  components	  of	  the	  complex	  is	  shown	  on	  the	  left,	  while	  the	  actual	  DAC-­‐
pull	  downs	  is	  shown	  on	  the	  right.	  The	  wild-­‐type	  as	  well	  as	  the	  R498X	  FBXO7	  disease	  mutant	  are	  both	  
capable	  of	  tetrameric	  SCFFBXO7	  complex	  as	  well	  as	  a	  pentameric	  SCFFBXO7	  *	  PI31	  complex.	  The	  R378G	  FBXO7	  
mutant	  is	  however	  unable	  to	  form	  a	  complex	  due	  to	  its	  inability	  to	  bind	  SKP1.	  	  
	  
 Setting	  up	  a	  SCFFBXO7	  E3	  ligase	  activity	  assay	  in	  vitro	  5.3.3
A	   sensitive	  means	   for	   assaying	   the	   potential	   activity	   of	   any	   SCF	   E3	   ubiquitin	   ligase	   in	  
vitro	  is	  to	  evaluate	  its	  capacity	  for	  free	  ubiquitin	  chain	  formation.	  For	  this	  I	  have	  used	  a	  
modified	  protocol	  from	  (Lorick	  et	  al.,	  1999;	  Yang	  et	  al.,	  2005)	  and	  incubated	  DAC-­‐FBXO7	  
/	   SKP1	   as	   well	   as	   Cullin1	   /	   SKP1	   /	   RBX1	   together	   with	   recombinantely	   expressed	   E1	  
activating	  enzyme	  Ube1	   (DU32888),	   the	  E2	  conjugating	  enzyme	  UBE2R1	  and	  Ubiquitin	  
(either	  Flag-­‐	  or	  untagged)	  in	  the	  presence	  of	  Magnesium	  and	  ATP	  at	  30	  degrees	  for	  45	  
minutes.	  The	  assay	  was	  terminated	  by	  the	  addition	  of	  SDS-­‐loading	  buffer.	   I	  monitored	  
the	  effect	  of	   the	  R378G	  and	  R498X	  mutants	   in	  comparison	  to	   the	  FBXO7	  wild-­‐type	  on	  
the	   capacity	   of	   free	   ubiquitin	   chain	   formation	   as	   well	   as	   the	   presence	   or	   absence	   of	  
PI31.	   Free	   ubiquitin	   chain	   formation	   was	   assessed	   by	   the	   absence	   or	   presence	   and	  
intensity	  of	  high	  molecular	  weight	  species	  of	  ubiquitin	  upon	  immunoblotting.	  Figure	  81	  
illustrates	  the	  ability	  of	  the	  FBXO7	  wild-­‐type	  constructs	  to	  form	  free	  ubiquitin	  chains	  in	  
the	  presence	  of	  Cullin1,	  Skp1,	  Rbx1,	  E1	  and	  E3	  as	  well	  as	  Ubiquitin,	  magnesium	  and	  ATP.	  
Although	   there	   is	   background	   free	   ubiquitin	   chain	   formation	  with	   either	   the	   E1	   or	   E2	  
alone	   or	   a	   combination	   thereof,	   the	   FBXO7	   wild-­‐type	   construct	   is	   able	   to	   mount	   a	  
significantly	  more	  intense	  response	  in	  terms	  of	  free	  chain	  formation	  above	  and	  beyond	  
this	  background.	  To	  show	  that	  this	   increase	   in	  response	   is	  due	  to	  the	  specific	  effect	  of	  
the	  addition	  of	  an	  F-­‐box	  protein,	  I	  have	  also	  used	  recombinant	  β-­‐TRCP	  (Fbxw1)	  as	  well	  
as	  Fbxw7	  (cdc4),	  both	  components	  of	  other	  well	  categorized	  SCFF-­‐box	  protein	  complexes	  –	  
as	  a	  positive	  control:	  the	  wild-­‐type	  FBXO7	  had	  the	  same	  capacity	  to	  form	  free	  ubiquitin	  
chains	   as	   seen	  with	  β-­‐TRCP	  and	   Fbxw7.	   The	   addition	  of	   albumin	   served	   as	   a	   negative	  
control	   as	   it	   did	   not	   change	   the	   background	   level	   and	   equally,	   PI31	   did	   not	   have	   an	  
additional	   effect	  on	   the	   free	  ubiquitin	   chain	   formation	  either.	   Importantly,	   the	  R378G	  
FBXO7	   disease	   mutant	   was	   also	   not	   able	   to	   mount	   a	   free	   chain	   formation	   response	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above	  and	  beyond	  the	  background	  and	  was	  comparable	  to	  that	  of	  E1*E2*Cullin1	  /	  Skp1	  
/	   Rbx1	   alone	   or	   in	   combination	   with	   either	   albumin	   or	   PI31.	   This	   outcome	   was	  
anticipated	  due	  to	  the	  inability	  of	  the	  R378G	  FBXO7	  mutant	  to	  bind	  to	  Skp1	  and	  hence	  
assemble	  into	  the	  SCFFBXO7	  R378G	  E3	  ubiquitin	  ligase	  complex.	  Next,	  I	  wanted	  to	  compare	  
the	  FBXO7	  wild-­‐type	  with	  the	  R378G	  and	  R498X	  disease	  mutants	  in	  terms	  of	  their	  effect	  
on	   free	   ubiquitin	   chain	   formation	   and	   also	   explore	   the	   impact	   of	   adding	   PI31	   to	   the	  
complex.	   Figure	   82	   shows	   that	   the	   wild-­‐type	   and	   FBXO7	   R498X	   mutant	   are	   equally	  
capable	  of	  free	  ubiquitin	  chain	  formation,	  while	  the	  FBXO7	  R378G	  mutant	  is	  not.	  When	  
PI31	  is	  added	  to	  the	  individual	  complexes,	  the	  ability	  to	  form	  free	  ubiquitin	  chains	  of	  the	  
SCFFBXO7	  wt	  and	  SCFFBXO7	  R498X	  is	  impaired	  suggesting	  a	  negative	  regulatory	  role	  for	  PI31	  in	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Figure	  81:	  Free	  ubiquitin	  chain	  formation	  as	  functional	  read-­‐out	  for	  SCFFBXO7	  E3	  ligase	  
assay	  
0.5ug	  of	  either	  the	  wild-­‐type	  or	  R378G	  mutant	  FBXO7	  construct	  were	  added	  to	  the	  other	  ubiquitylation	  
assay	  components	  (E1:	  human	  recombinant	  His-­‐UBE1	  expressed	  in	  insect	  cells	  (0.1ug),	  E2:	  human	  
recombinant	  His-­‐UBE2R1	  expressed	  in	  E.	  coli	  (1ug);	  E3:	  human	  recombinant	  Cullin	  1	  /	  Skp1	  /	  Rbx1	  co-­‐
expressed	  in	  insect	  cells	  (0.5ug)	  and	  0.5mM	  Flag-­‐Ubiquitin).	  The	  reaction	  was	  initiated	  by	  adding	  
ATP/Mg2+at	  30	  degrees	  Celsius	  and	  terminated	  after	  45	  minutes	  by	  the	  addition	  of	  SDS-­‐Page	  loading	  buffer.	  
1/10	  of	  the	  reaction	  was	  then	  resolved	  by	  SDS-­‐Page	  per	  immunoblot.	  Already	  the	  E1,	  E2	  and	  Cullin	  /	  Rbx1	  
/	  Skp1	  reaction	  without	  the	  Fbxo7	  protein	  is	  able	  to	  generate	  free	  Ubiquitin	  chains	  as	  demonstrated	  in	  the	  
Flag-­‐immunoblot	  with	  a	  K48	  specific	  linkage	  (K-­‐48	  immunoblot)	  as	  expected	  for	  the	  E2	  enzyme	  used	  in	  
this	  assay.	  However,	  the	  addition	  of	  the	  wild-­‐type	  FBXO7	  results	  in	  a	  significant	  increase	  in	  the	  generation	  
of	  free	  ubiquitin	  changes	  (‘autoubiquitylation’)	  in	  comparison	  to	  the	  baseline	  chain	  formation	  by	  E1,	  E2	  
and	  Cullin1	  /	  Rbx1	  /	  Skp1	  alone.	  In	  contrast,	  the	  R379G	  FBXO7	  mutant	  is	  unable	  to	  mount	  an	  additional	  
ubiquitinylation	  response	  –	  as	  one	  would	  expect	  given	  that	  the	  mutant	  Fbxo7	  protein	  is	  unable	  to	  interact	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Figure	  82:	  In	  vitro	  free	  ubiquitin	  chain	  formation	  assay	  of	  FBXO7	  wt	  in	  comparison	  to	  
the	  disease	  mutants	  R378G	  and	  R498X	  and	  the	  effect	  of	  PI31	  	  
Reaction	  set	  up	  as	  in	  Figure	  81	  for	  FBXO7	  wild-­‐type	  and	  the	  disease	  mutants	  R378G	  and	  R498X	  in	  the	  
presence	  or	  absence	  of	  PI31	  to	  assess	  free	  ubiquitin	  chain	  formation.	  Immunoblots	  for	  Flag	  and	  K48-­‐
linkage	  specific	  ubiquitin	  as	  the	  functional	  read-­‐out	  and	  the	  individual	  components	  of	  the	  reaction	  except	  
for	  the	  E2	  (for	  which	  no	  antibody	  for	  immunoblotting	  was	  available).	  The	  inability	  of	  the	  R378G	  FBXO7	  
mutant	  to	  form	  free	  ubiquitin	  chains	  in	  vitro	  is	  most	  likely	  due	  to	  its	  impaired	  binding	  to	  Skp1	  and	  the	  
remainder	  of	  the	  SCF	  complex.	  The	  wild-­‐type	  and	  R498X	  FBXO7	  mutant	  are	  capable	  to	  form	  free	  ubiquitin	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 Failed	   reconstitution	   of	   the	   in	   vitro	   E3	   ligase	   activity	   assay	  with	   endogenous	  5.3.4
SCFFBXO7	  complexes	  
My	  findings	  from	  the	  in	  vitro	  SCFFBXO7	  complex	  formation	  and	  activity	  assay	  have	  
unanimously	  demonstrated	  that	  the	  recombinantly	  expressed	  FBXO7	  R378G	  mutant	  is	  
incapable	  of	  efficiently	  binding	  to	  Skp1	  and	  hence	  assembly	  into	  a	  functional	  SCFFBXO7	  
R378G	  E3	  ligase	  complex	  in	  the	  setting	  used	  in	  this	  thesis.	  This	  is	  in	  contrast	  to	  what	  I	  have	  
observed	  in	  the	  in	  vivo	  system	  and	  on	  the	  endogenous	  level:	  I	  have	  previously	  shown	  
that	  patient	  derived	  homozygous	  R378G	  FBXO7	  fibroblasts	  as	  well	  as	  brain	  lysates	  from	  
homozygous	  R379G	  KI	  Fbxo7	  mice	  are	  readily	  able	  to	  form	  a	  SCFFBXO7	  R378/9G	  E3	  ubiquitin	  
ligase	  complex.	  Only	  one	  of	  mainy	  possibilities	  to	  explain	  and	  consolidate	  this	  
discrepancy	  is	  to	  assume	  that	  the	  R378G	  mutation	  does	  indeed	  affect	  binding	  to	  Skp1,	  
but	  that	  there	  are	  additional	  compensatory	  complex	  partners	  or	  conditions	  in	  the	  in	  vivo	  
setting.	  I	  have	  therefore	  tried	  to	  reconstitute	  the	  in	  vitro	  E3	  activity	  assay	  with	  
endogenous	  SCFFBXO7	  complexes	  that	  were	  immunoprecipitated	  from	  wild-­‐type	  and	  
homozygous	  R378G	  brain	  lysates	  using	  either	  preimmune	  IgG	  or	  G-­‐sepharose	  alone	  as	  a	  
negative	  control.	  However,	  as	  the	  expression	  level	  of	  the	  homozygous	  R379G	  Fbxo7	  KI	  
mutant	  is	  reduced	  by	  about	  half	  in	  comparison	  to	  the	  Fbxo7	  wild-­‐type	  protein,	  I	  have	  set	  
up	  conditions	  to	  assure	  that	  about	  the	  same	  amount	  of	  SCFFbxo7	  immunocomplexes	  are	  
being	  immunoprecipitate.	  Figure	  83	  shows	  that	  by	  using	  double	  the	  amount	  of	  
homozygous	  R379G	  Fbxo7	  KI	  lysates	  in	  comparison	  to	  the	  wild-­‐type	  protein	  
approximately	  equal	  amounts	  of	  Fbxo7	  is	  being	  immunoprecipitated	  for	  each	  genotype	  
and	  that	  the	  relative	  levels	  of	  the	  individual	  SCF	  complex	  partners	  do	  also	  not	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Figure	   83:	   The	   relative	   stoichiometry	   of	   SCFFbxo7	   complex	   partners	   does	   not	  
significantly	  differ	  between	  wild-­‐type	  and	  homozygous	  R379G	  Fbxo7	  KI	  brain	  lysates	  
Immunoprecipitation	  of	  endogenous	  Fbxo7	  from	  double	  the	  amount	  of	  homozygous	  R379G	  Fbxo7	  KI	  brain	  
lysates	  in	  comparison	  to	  wild-­‐type	  Fbxo7	  lysates	  (derived	  from	  2	  different	  genotypes	  for	  each	  genotype)	  
shows	  that	  the	  relative	  stoichiometry	  of	  Fbxo7	  from	  either	  wild-­‐type	  or	  homozygous	  R379G	  Fbxo7	  KI	  
lysates	  and	  each	  of	  the	  other	  SCF	  complex	  partners	  –	  Cullin1,	  Skp1,	  and	  Rbx1	  -­‐	  is	  about	  the	  same.	  The	  
immunoblots	  on	  the	  left	  hand	  side	  show	  input	  and	  post-­‐IP	  lysates	  in	  a	  1:2	  ratio	  for	  the	  wild-­‐type	  and	  
homozygous	  R379G	  Fbxo7	  KI	  brain	  lysates	  and	  in	  a	  1:1	  ratio	  for	  the	  other	  SCF	  complex	  partners	  while	  the	  
right	  hand	  side	  shows	  the	  immunoprecipitation	  products	  in	  a	  1:2	  ratio	  (wt	  :	  hom	  R379G	  Fbxo7	  KI).	  	  
	  
I	  have	  then	  applied	  the	  1:2	  ratio	  for	  the	  reconstitution	  of	  the	  in	  vitro	  free	  ubiquitin	  chain	  
assay	  with	   endogenous	   Fbxo7	   immunoprecipitated	   SCFFbxo7	   complexes	   from	  wild-­‐type	  
and	   homozygous	   R379G	   Fbxo7	   KI	   brain	   lysates	   (Figure	   84).	   Preimmune	   IgG	  
immunoprecipitations	  as	  well	  as	  brain	   lysate	   incubations	  with	  G-­‐sepharose	  alone	  were	  
used	   as	   controls	   and	   show	   that	   there	   are	   sufficient	   contaminating	   molecules	   in	   the	  
control	   experiments	   that	   mask	   any	   specific	   effect	   that	   might	   be	   due	   to	   the	   SCFFbxo7	  
complex	  either	  in	  its	  wild-­‐type	  or	  homozygous	  R379G	  form.	  I	  have	  subsequently	  tried	  to	  
adjust	   the	  time	  of	   the	  duration	  of	   the	  assay	   from	  30	  over	  20	  to	  10	  minutes	  as	  well	  as	  
subjecting	  the	  immunoprecipitation	  products	  to	  more	  stringent	  washing	  conditions	  prior	  
to	   in	   vitro	   assay	   reconstitution	  without	   significant	   improvement	  of	   the	   signal	   to	  noise	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optimized	   in	  the	  future,	  as	   it	   is	  one	  mean	  of	  combining	  and	  comparing	   in	  vitro	  with	   in	  
vivo	  derived	  data.	  	  	  
	  
Figure	   84:	   Failed	   reconstitution	   of	   in	   vitro	   assay	   with	   affinity	   purifications	   of	  
endogenous	  SCFFBXO7	  E3	  ubiquitin	  ligase	  complexes	  
Endogenous	  Fbxo7	  affinity	  purifications	  of	  endogenous	  SCFFBXO7	  complexes	  from	  wild-­‐type	  and	  
homozygeous	  R379G	  Fbxo7	  KI	  brain	  lysates	  and	  controls	  -­‐	  preimmune	  IgG	  IPs	  and	  G-­‐sepharose	  only.	  To	  
compensate	  for	  the	  reduced	  expression	  level	  of	  the	  homozygous	  R379G	  Fbxo7	  KI	  mutant,	  I	  used	  1.3	  mg	  of	  
brain	  lysates	  from	  the	  wild-­‐type	  and	  2.6	  mg	  of	  brain	  lysates	  from	  the	  mutant	  with	  the	  same	  amount	  of	  
beads.	  The	  Fbxo7	  immunoblot	  shows	  the	  reduced	  expression	  of	  the	  mutant	  Fbxo7	  in	  the	  input	  lysate,	  
while	  about	  equal	  amounts	  of	  Fbxo7	  were	  found	  in	  the	  IP	  product.	  Post-­‐immunoprecipitation	  lysates	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Skp1	  immunoblot	  confirms	  that	  the	  homozygous	  R379G	  Fbxo7	  KI	  mutant	  is	  indeed	  capable	  of	  Skp1	  
binding	  and	  represents	  one	  of	  the	  SCF	  complex	  members.	  Equal	  amounts	  of	  immunoprecipitation	  
reactions	  were	  washed	  with	  4	  x	  1	  ml	  of	  either	  0.5M	  NaCl	  CHAPS	  lysis	  buffer	  and	  then	  washed	  once	  with	  
reaction	  buffer	  prior	  to	  reconstituting	  the	  immunocomplexes	  attached	  to	  beads	  with	  reaction	  buffer.	  E1	  
and	  E2	  enzymes,	  Flag-­‐ubiquitin	  as	  well	  as	  ATP	  and	  Magnesium	  were	  added.	  The	  whole	  reaction	  was	  
incubated	  at	  30	  degrees	  Celsius	  for	  30	  min	  before	  termination	  with	  LDS	  loading	  buffer.	  The	  Flag	  
immunoblot	  shows	  that	  there	  was	  no	  difference	  between	  the	  FBXO7	  wt,	  KI,	  and	  pre-­‐immune	  complexes	  
as	  well	  as	  even	  G-­‐sephararose	  alone.	  	  
	  
5.4 Preliminary	  data	  towards	  the	  validation	  of	  VDAC	  proteins	  as	  
SCFFBXO7	  ubiquitinylation	  targets	  
 Immunoblotting	  of	  MEF	  and	  brain	   lysates	   for	  VDAC	  proteins	  with	  commercial	  5.4.1
VDAC	  antibodies	  
I	   have	   used	   different	   commercial	   antibodies	   for	   looking	   at	   VDAC	   expression	   levels	   in	  
wild-­‐type	   and	   homozygous	   R379G	   Fbxo7	   KI	   MEF	   whole	   cell	   lysates.	   In	   view	   of	   the	  
complex	  structure	  of	  the	  VDAC	  proteins	  with	  multi-­‐transmembrane	  spanning	  domains,	  I	  
considered	  it	  important	  to	  be	  aware	  against	  which	  antigen	  the	  respective	  antibody	  was	  
raised:	   The	   pan-­‐VDAC	   antibody	   (source:	   polyclonal	   rabbit),	   which	   is	   supposed	   to	  
recognize	  all	  3	  VDAC	  proteins,	  is	  raised	  against	  a	  synthetic	  peptide	  corresponding	  to	  the	  
N-­‐terminus	  of	  human	  VDAC	  1.	  The	  VDAC	  3	  antibody	  (source:	  polyclonal	  rabbit)	  is	  raised	  
against	  the	  N-­‐terminal	  amino	  acid	  residues	  73-­‐122	  of	  human	  VDAC	  3,	  while	  the	  VDAC	  1	  
antibody	  (source:	  polyclonal	  rat)	   is	  raised	  against	  a	  synthetic	  peptide	  corresponding	  to	  
amino	  acid	  residue	  S104	  of	  human	  VDAC	  1.	  Except	  for	  the	  immunoblot	  with	  the	  VDAC	  1	  
antibody,	  there	  was	  no	  difference	  in	  expression	  levels	  between	  the	  2	  genotypes	  (Figure	  
85).	   The	   immunoblot	   for	   the	   VDAC	   1	   antibody	   shows	   2	   bands	   for	   each	   lysate	   and	  
although	  the	  upper	  band	  is	  slightly	  more	  intense	  in	  the	  wild-­‐type	  Fbxo7	  lysates,	  it	  is	  not	  
clear	  whether	  it	  corresponds	  to	  the	  unmodified	  or	  ubiquitin-­‐modified	  form.	  I	  have	  since	  
generated	  inducible	  stable	  expressing	  cell	  lines	  for	  VDAC	  1	  –	  C-­‐terminal	  FLAG	  in	  FLP-­‐in-­‐
TRex	   cells	   and	   also	   tested	   a	   further	  monoclonal	   VDAC	   antibody,	   which	   was	   raised	   in	  
rabbit	  against	  a	  synthetic	  peptide	  corresponding	  to	   the	  N-­‐terminus	  of	  human	  VDAC	  1.	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Figure	   86	   shows	   the	   immunoblot	   of	   induced	   and	   uninduced	   cytosolic	   as	   well	   as	  
mitochondrial	  fractions	  of	  the	  VDAC	  1-­‐	  C-­‐terminal	  FLAG	  HEK293	  cell	  line	  and	  in	  the	  first	  
line	   shows	   that	   the	   Flag-­‐expressing	   VDAC	   1	   construct	   is	   exclusively	   found	   in	   the	  
mitochondrial	   fraction	   suggesting	   that	   the	   C-­‐terminal	   tag	   does	   not	   interfere	   with	   its	  
correct	   subcellular	   localization.	   It	   also	   shows	   that	   the	   commercial	   monoclonal	   VDAC	  
antibody	  is	  specific.	  I	  am	  intending	  to	  use	  the	  stable	  VDAC1-­‐C-­‐terminal	  FLAG	  cell	  line	  for	  
preparing	   intact	  mitochondrial	   pellets	   as	   substrates	   in	   in	   vitro	   FBXO7	   ubiquitinylation	  
studies	  in	  the	  future.	  
	  
Figure	  85:	  VDAC	  immunoblot	  of	  wt	  and	  hom	  R379G	  Fbxo7	  KI	  MEFS	  using	  commercial	  
antibodies	  
Wt	  and	  hom	  R379G	  Fbxo7	  KI	  denaturing	  lysates	  (15	  ug	  each)	  with	  duplicate	  loading	  was	  subjected	  to	  
immunoblotting	  with	  3	  different	  commercial	  VDAC	  antibodies	  as	  well	  as	  Fbxo7.	  The	  immunoblot	  for	  the	  
VDAC	  1	  antibody	  (AP1059,	  EMD)	  shows	  2	  bands	  for	  each	  lysate	  and	  although	  the	  upper	  band	  is	  slightly	  
more	  intense	  in	  the	  wild-­‐type	  Fbxo7	  lysates,	  it	  is	  not	  clear	  whether	  it	  corresponds	  to	  the	  unmodified	  or	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Figure	  86:	  Generation	  of	   an	   inducible,	   stable	   expressing	  VDAC	  1-­‐C-­‐terminal	   Flp-­‐In	   T-­‐
REx	  HEK	  293	  cell	  	  
Stable	  expression	  of	  VDAC1-­‐C-­‐terminal	  FLAG	  was	  induced	  with	  0.1ug/ml	  doxycycline	  for	  18	  hours	  prior	  to	  
either	  treating	  them	  with	  10uM	  CCCP	  or	  DMSO	  for	  4	  hours	  (as	  well	  as	  uninduced	  cells).	  Cells	  were	  then	  
harvested	  and	  mitochondrial	  and	  cytosolic	  fractions	  prepared.	  Cytosolic	  and	  mitochondrial	  fractions	  were	  
then	  subjected	  to	  immunoblotting	  for	  either	  FLAG	  or	  the	  monoclonal	  VDAC1	  antibody.	  The	  Flag	  
immunoblot	  shows	  that	  the	  stable	  construct	  is	  specifically	  expressed	  in	  the	  mitochondrial	  fraction;	  the	  
VDAC1	  antibody	  detects	  equivalent	  bands	  at	  the	  same	  molecular	  weight	  in	  both	  the	  uninduced	  as	  well	  as	  
induced	  state	  suggesting	  that	  the	  antibody	  is	  specific.	  	  
	  
 Failed	   trial	   to	   detect	   endogenous	   VDAC	   proteins	   in	   a	   pool	   of	   ubiquitylated	  5.4.2
proteins	  using	  tandem-­‐ubiquitin	  binding	  entities	  
Immunoblotting	  for	  several	  VDAC	  antibodies	  did	  not	  allow	  unequivocal	  identification	  of	  
the	   ubiquitinylated	   form	   of	   the	   VDAC	   proteins	   in	   wild-­‐type	   and	   homozygous	   R379G	  
Fbxo7	  KI	  MEFs.	  In	  an	  alternative	  strategy	  to	  identify	  and	  compare	  ubiquitinylated	  forms	  
of	  VDAC	  between	  the	  2	  genotypes	  in	  vivo,	  I	  have	  employed	  tandem-­‐repeated	  ubiquitin-­‐
binding	  entities	  (TUBEs)	  that	  are	  based	  on	  ubiquitin-­‐associated	  domains	  to	  purify	  poly-­‐
ubiquitinylated	   proteins	   from	   wild-­‐type	   and	   homozygous	   R379G	   Fbxo7	   KI	   brain	  
lysates(Hjerpe	  et	  al.,	  2009;	  Hjerpe	  and	  Rodriguez,	  2008).	  In	  order	  to	  determine	  whether	  
TUBEs	   could	   be	   used	   to	   capture	   endogenously	   ubiquitinylated	   VDAC	   proteins,	   I	   have	  
subjected	   the	   TUBEs	   pull	   downs	   to	   immunoblotting	   for	   VDAC.	   Figure	   87	   shows	   that	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molecular	   weight	   species	   of	   VDAC’s	   –	   that	   would	   suggest	   their	   posttranslational	  
modification	  with	  polyubiquitin	  –	  is	  being	  captured	  by	  this	  approach.	  	  
	  
Figure	   87:	   No	   VDAC	   proteins	   are	   detected	   in	   the	   TUBEs	   pull-­‐down	   of	   endogenous	  
polyubiquitinylated	  species	  from	  wt	  and	  hom	  R379G	  Fbxo7	  brain	  lysates	  
10	  mg	  1%	  triton	  X	  lysates	  from	  wt	  and	  hom	  R379G	  Fbxo7	  brains	  were	  prepared	  and	  subjected	  to	  
covalently	  coupled	  TUBEs	  to	  G-­‐sepharose.	  The	  immunoblots	  show	  15	  ug	  of	  each	  input	  and	  post-­‐TUBEs	  IP	  
lysates	  as	  well	  as	  5%	  of	  the	  IP	  product	  for	  the	  Ubiquitin	  and	  30%	  for	  the	  VDAC	  blot.	  While	  the	  Ubiquitin	  
blot	  shows	  efficient	  enrichment	  of	  ubiquitinylated	  species	  from	  endogenous	  brain	  lysates,	  no	  higher	  
molecular	  weight	  species	  of	  VDAC	  proteins	  are	  detected.	  	  
	  
 In	  vitro	  Fbxo7	  ubiquitinylation	  assay	  with	  mitochondrial	  pellet	  as	  substrate	  	  5.4.3
Having	   set	   up	   the	   in	   vitro	   SCFFBXO7	   autoubiquitinylation	   assay,	   my	   next	   aim	   was	   to	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process	  of	  expressing	  recombinant	  VDAC	  proteins	  reconstituted	  in	  detergent	  micelles	  in	  
analogy	   to	   the	   protocol	   that	   allowed	   solving	   the	   β-­‐barrel	   structure	   of	   VDAC1.	   In	   the	  
meantime,	   I	   have	   used	   freshly	   prepared	   intact	   mitochondria	   from	   HEK293	   cells	   as	   a	  
substrate.	  In	  the	  first	  instance,	  I	  have	  tried	  to	  determine	  the	  in	  vitro	  ubiquitinylation	  of	  
VDAC	  proteins	  by	  immunoblotting	  of	  the	  direct	  product	  of	  the	   in	  vitro	  assay	  as	  well	  as	  
after	   a	   FLAG-­‐purification	   to	   enrich	   for	   any	   FLAG-­‐ubiquitin	   modified	   mitochondrial	  
proteins.	  The	  final	  FLAG-­‐purification	  step	  was	  also	  introduced	  to	  prepare	  the	  respective	  
samples	  for	  mass-­‐spectrometry	  analysis.	  The	  expectation	  is	  that	  if	  an	  endogenous	  outer	  
mitochondrial	  membrane	  protein	  –	  those	  proteins	  (such	  as	  VDACs)	  that	  are	  accessible	  to	  
ubiquitin	   modification	   when	   intact	   mitochondrial	   pellets	   are	   being	   used	   in	   this	  
experiment	   –	   is	   in	   vitro	   ubiquitinylated	   in	   a	   SCFFBXO7	   dependent	   manner,	   higher	  
molecular	  weight	  FLAG-­‐ubiquitinylated	  species	  of	  that	  particular	  protein	  could	  either	  be	  
detected	  by	  direct	  immunoblotting	  or	  subsequently	  by	  proteomic	  analysis	  of	  the	  FLAG-­‐
purification.	   Figure	   88	   shows	   the	   immunoblot	   of	   the	   FLAG	  and	  VDAC	   immunoblots	   of	  
the	  in	  vitro	  ubiquitinylation	  reaction	  before	  and	  after	  the	  subsequent	  FLAG-­‐purification	  
step:	   The	   VDAC	   immunoblot	   confirms	   that	   endogenous	   VDAC	   proteins	   were	   indeed	  
present	   in	   the	   intact	   mitochondrial	   pellet	   that	   was	   used	   as	   a	   substrate,	   but	   without	  
being	   able	   to	   demonstrate	   a	   discernable	   difference	   dependent	   on	   the	   absence	   or	  
presence	  of	  an	  F-­‐box	  protein	  in	  the	  assay.	  I	  had	  used	  the	  FBXO7	  wild-­‐type	  as	  well	  as	  the	  
R379G	  mutant,	  but	   also	   the	  F-­‐box	  protein	  βTRCP	  as	   a	   control.	   The	  VDAC	   immunoblot	  
also	   demonstrates	   that	   the	   FLAG-­‐pull-­‐down	   failed	   to	   enrich	   for	   any	   potential	   VDAC	  
protein.	   Interestingly,	   the	   FLAG-­‐immunoblot	   shows	   a	   differential	   pattern	   of	   higher	  
molecular	   weight	   species	   –	   possibly	   corresponding	   to	   in	   vitro	   ubiquitinylated	  
mitochondrial	  membrane	  proteins	  –	  for	  the	  SCFFBXO7	  wt	  and	  SCF-­‐βTRCP	  dependent	   in	  vitro	  
ubiquitinylation	   reactions.	   Exactly	   these	   higher	   molecular	   weight	   species	   of	   FLAG-­‐
ubiquitin	   /	   FLAG-­‐ubiquitin	   modified	   proteins	   were	   actually	   purified	   by	   the	   FLAG-­‐pull-­‐
down.	  Some	  of	  the	  FLAG-­‐purified	  in	  vitro	  assay	  was	  also	  prepared	  and	  analysed	  by	  mass-­‐
spectrometry.	  As	  expected,	  VDAC	  proteins	  were	  not	  amongst	  the	  identified	  hits	  –	  given	  
the	  absent	  VDAC	  signal	  in	  the	  corresponding	  immunoblot.	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Figure	  88:	  In	  vitro	  FBXO7	  ubiquitinylation	  assay	  with	  intact	  mitochondria	  as	  substrates	  
Intact	  mitochondria	  prepared	  from	  HEK293	  cells	  were	  used	  as	  a	  substrate	  for	  an	  in	  vitro	  	  SCFF-­‐box	  protein	  E3	  
ubiquitinylation	  with	  either	  FBXO7	  wild-­‐type,	  R378G	  or	  β-­‐TRCP.	  The	  reaction	  was	  heat-­‐inactivated	  and	  
2%SDS	  was	  used	  for	  mitochondrial	  pellet	  lysis	  and	  sonication.	  Some	  material	  was	  retained	  for	  
immunoblotting	  (right	  hand	  side	  on	  immunoblots:	  pre-­‐IP),	  but	  most	  of	  it	  was	  used	  for	  a	  FLAG-­‐IP	  to	  
immunoprecipitate	  any	  Flag-­‐ubiquintylated	  mitochondrial	  proteins.	  The	  FLAG	  immunoblot	  shows	  the	  in	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Cullin1	  /	  RBX1	  /	  SKP1)	  as	  a	  control	  as	  well	  as	  the	  product	  of	  the	  FLAG-­‐immunoprecipitation	  of	  the	  in	  vitro	  
ubiquitinylation	  product.	  The	  FLAG-­‐immunoblot	  shows	  a	  differential	  pattern	  of	  higher	  molecular	  weight	  
species	  –	  possibly	  corresponding	  to	  in	  vitro	  ubiquitinylated	  mitochondrial	  membrane	  proteins	  –	  for	  the	  
SCFFBXO7	  wt	  and	  SCF-­‐βTRCP	  dependent	  in	  vitro	  ubiquitinylation	  reactions,	  but	  no	  difference	  between	  the	  
control	  (E1,2,3	  and	  MP	  alone)	  and	  the	  R378G	  FBXO7	  as	  expected.	  The	  VDAC	  immunoblot	  failed	  to	  pick	  up	  
a	  signal	  in	  the	  IP	  samples	  and	  shows	  the	  same	  signal	  for	  all	  input	  /	  post	  assay	  samples.	  	  
	  
I	  have	  subsequently	  worked	  towards	  optimizing	  the	  assay	  and	  post-­‐assay	  purification	  of	  
potential	   FLAG-­‐ubiquitinylated	   species	   mainly	   by	   using	   different	   mitochondrial	   pellet	  
lysis	   conditions	   post-­‐	   in	   vitro	   assay	   and	   adjusting	   the	   FLAG-­‐pull-­‐down	   procedure.	  
Additionally,	  I	  have	  used	  intact	  mitochondrial	  pellets	  from	  HEK293	  cells	  that	  were	  either	  
treated	   with	   CCCP	   or	   DMSO	   control.	   This	   was	   to	   see	   whether	   mitochondrial	  
depolarization	   was	   a	   requirement	   for	   subsequent	   SCFFBXO7	   dependent	   in	   vitro	  
ubiquitinylation.	  Figure	  89	  shows	  the	  FLAG	   immunoblot	  of	   the	   in	  vitro	  ubiquitinylation	  
assay	  with	  intact	  mitochondria	  from	  HEK293	  cells	  -­‐	  that	  were	  either	  CCCP	  stimulated	  or	  
not	   -­‐	   as	  a	   substrate	  and	   in	   the	  presence	  or	  absence	  of	   recombinant	  wild-­‐type	  FBXO7.	  
The	  majority	  of	  the	  FLAG-­‐purified	  assay	  product	  was	  prepared	  for	  in-­‐gel	  tryptic	  digestion	  
and	   subsequent	   mass-­‐spectrometry	   analysis.	   It	   has	   to	   be	   noted	   that	   the	   proteomic	  
identification	  of	  Di-­‐glycine	  peptides	  is	  unable	  to	  differentiate	  whether	  the	  modification	  
was	  an	   in	  vivo	  residual	  one	  or	  a	  result	  of	  the	  SCFFBXO7	  dependent	   in	  vitro	  reaction.	  The	  
aim	  of	  the	  proteomic	  analysis	  was	  to	  detect	  VDAC	  peptides	  with	  a	  di-­‐Glycine	  signature	  in	  
only	  those	  reactions	  where	  recombinant	  FBXO7	  was	  present.	  Figure	  89	  shows	  the	  Flag-­‐
immunoblot	   the	   pre-­‐immunoprecipitation	   /	   post	   in	   vitro	   ubiquitinylation	   samples	   and	  
the	  FLAG	  immunoprecipitations	  of	  the	  controls	  (without	  FBXO7,	  but	  with	  mitochondrial	  
pellets	  either	   treated	  or	  untreated	  with	  CCCP)	  and	   the	  FBXO7	   in	  vitro	  ubiquitinylation	  
reactions	   with	   mitochondrial	   pellets	   from	   either	   untreated	   or	   CCCP	   treated	   intact	  
mitochondrial	   preparations.	   The	   FLAG-­‐enrichment	   aimed	   to	   purify	   FLAG-­‐ubiquitin	  
modified	  mitochondrial	  proteins.	  Separating	  the	  individual	  samples	  on	  a	  gel	  by	  SDS	  page	  
allowed	   to	   eliminate	   all	   free	   FLAG-­‐tagged	   ubiquitin	   by	   excluding	   the	   corresponding	  
molecular	  weight	  bands	  from	  the	  analysis.	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Figure	   89:	   In	   vitro	   FBXO7	   ubiquitinylation	   assay	   with	   intact	   mitochondria	   from	  
untreated	  and	  CCCP	  treated	  HEK293	  cells	  as	  substrates	  
Intact	  mitochondria	  prepared	  from	  HEK293	  cells	  either	  untreated	  or	  CCCP	  treated	  (3	  hours,	  10uM)	  were	  
used	  as	  substrates	  for	  an	  in	  vitro	  SCFFBXO7	  wt	  E3	  ubiquitinylation	  reaction.	  The	  reaction	  was	  heat-­‐inactivated	  
and	  2%	  SDS	  was	  used	  for	  mitochondrial	  pellet	  lysis	  and	  sonication.	  Upper	  panel:	  Some	  material	  was	  
retained	  for	  post	  in	  vitro	  assay	  /	  pre	  FLAG-­‐IP	  imput	  (left-­‐hand	  side)	  and	  post-­‐FLAG	  IP	  (right-­‐hand	  side)	  
immunoblotting	  with	  FLAG.	  Lower	  panels:	  Most	  of	  the	  FLAG-­‐IP	  product	  (95%)	  was	  used	  for	  Coomassie	  
staining	  of	  a	  SDS	  PAGE	  resolution	  (4-­‐12%)	  for	  subsequent	  in	  gel-­‐tryptic	  digestion	  for	  mass-­‐spectrometry	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Figure	   90	   shows	   a	   qualitative	   schematic	   of	   the	   proteomic	   analysis	   of	   the	   FLAG	  
immunoprecipitation	   of	   the	   in	   vitro	   ubiquitinylation	   assay.	   It	   shows	   that	   I	   am	  
successfully	   immunoprecipitating	   VDAC	   proteins	   with	   a	   FLAG	   tag	   possibly	   suggesting	  
that	  they	  Flag-­‐ubiquitin	  modified	  in	  the	  course	  of	  the	  in	  vitro	  ubiquitinylation	  reaction.	  
Alternatively,	  they	  could	  bind	  unspecifically	  to	  FLAG.	  However,	  VDAC	  proteins	  were	  also	  
found	  in	  gel	  pieces	  corresponding	  to	  a	  higher	  molecular	  weight	  than	  that	  of	  unmodified	  
VDACs.	  These	  could	  potentially	  represent	  posttranslationally	  modified	  VDAC	  species.	  No	  
VDAC	   peptide	   carrying	   the	   Di-­‐glycine	   signature	   of	   a	   peptide	   that	   is	   ubiquitinylated	   at	  
protein	   level.	   Without	   enrichment,	   the	   detection	   of	   Di-­‐Glycine	   peptides	   is	   difficult.	  
These	  experiments	  are	  overall	  encouraging,	  but	  need	  to	  be	  repeated	  and	  scaled	  up	  to	  
allow	  simultaneous	  immunoblotting	  for	  VDAC	  as	  well.	  An	  alternative	  strategy	  to	  the	  post	  
assay	   FLAG	   immunoprecipitation	   would	   be	   to	   perform	   a	   Di-­‐Glycine	   enrichment	   step	  
prior	   to	  the	  proteomic	  analysis.	  Certainly	  a	  plethora	  of	  different	  experiments	  could	  be	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Figure	  90:	  Proteomic	  analysis	  of	  the	  mitochondrial	  pellet	  substrate	  assay	  for	  SCFFBXO7	  
Schematic	  representation	  of	  proteomic	  analysis	  with	  respect	  to	  the	  identification	  of	  VDAC	  proteins,	  Di-­‐
Glycine	  peptides	  and	  ubiquitin	  for	  each	  gel	  piece	  from	  Figure	  89.	  NA:	  Some	  of	  the	  samples	  have	  not	  yet	  
been	  analysis	  or	  were	  unsuitable	  for	  analysis.	  VDAC	  proteins	  have	  a	  molecular	  weight	  of	  about	  30	  kDa.	  	  
	  
5.5 Discussion	  
In	  this	  last	  result	  chapter	  I	  am	  making	  use	  of	  the	  homozygous	  R379G	  Fbxo7	  KI	  mouse	  to	  
explore	   the	   Fbxo7-­‐dependent	   proteome	   as	   well	   as	   ubiquitinome	   by	   quantitative	  
proteomics	   in	   the	  endogenous	  system.	  While	   I	  had	  used	  proteomics	   in	   the	  previous	  2	  
results	  chapters	  for	  mapping	  protein	  interactions,	  the	  aim	  is	  now	  to	  look	  at	  differential	  
post-­‐translational	   modification	   states	   (“ubiquitinome”)	   as	   well	   as	   comparative	  
expression	   proteomics	   (“whole	   proteome”)	   between	   the	   wild-­‐type	   and	   homozygous	  
R379G	  Fbxo7	  KI	  genotypes.	  Last	  but	  not	  least,	  I	  am	  also	  focusing	  on	  setting	  up	  an	  in	  vitro	  
ϭ͕Ϯ͕ϯ͕W/ϯϭ͕&ůĂŐͲhďŝƋƵŝƟŶ͕DŐͬdW++ + +
Fbxo7-wt- + - +
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SCFFBXO7	  ubiquitinylation	  assay	  as	  a	  functional	  read-­‐out	  for	  the	  FBXO7-­‐dependent	  SCF	  E3	  
ligase	  activity.	  	  
 Differential	  enrichment	  of	  the	  ubiquitylated	  proteome	  from	  SILAC	  labelled	  wt	  5.5.1
and	  homozygous	  R379G	  Fbxo7	  KI	  MEFs	  
Quantitative	   ubiquitin	   remnant	   profiling	   combines	   SILAC	   labelling	  with	   an	   enrichment	  
step	   for	   Di-­‐Glycine	   modified	   peptides	   prior	   to	   differential	   proteomic	   analysis.	   I	   was	  
interested	   in	   using	   this	   approach	   to	   identify	   Di-­‐Glycine	   modification	   sites	   that	   are	  
altered	   as	   a	   consequence	   of	   the	   difference	   between	   the	   wild-­‐type	   and	   homozygous	  
R379G	  KI	  genotype	  in	  MEFs.	  MEFs	  were	  used	  in	  this	  study,	  as	  they	  are	  amenable	  to	   in	  
vivo	   differential	   labelling	   by	   SILAC,	   while	   Di-­‐Glycine	   enrichment	   was	   used	   as	   the	  
difference	  in	  mass-­‐shift	  between	  a	  modified	  and	  unmodified	  peptide	  allows	  unequivocal	  
insight	  into	  its	  ubiquitinylation	  status	  at	  a	  specific	  site.	  	  So	  far,	  more	  than	  20000	  unique	  
ubiquitinylation	  sites	  have	  been	  reported	  using	  Di-­‐glycine	  affinity	  proteomics(Emanuele	  
et	  al.,	  2011;	  Kim	  et	  al.,	  2011;	  Wagner	  et	  al.,	  2011;	  Xu	  et	  al.,	  2010).	  Still,	  many	  already	  
known	  ubiquitinylation	   targets	  have	  not	  been	   identified	   in	  any	  of	   these	  studies.	   It	  has	  
been	   suggested	   that	   this	   reflects	   their	   overall	   low	   abundance	   on	   protein	   level(Harper	  
and	  Tan,	  2012).	  Another	  reason	  is	  the	  incomplete	  depletion	  of	  all	  di-­‐Glycine	  peptides	  by	  
the	   Di-­‐Glycine	   antibody.	   Efforts	   have	   been	   undertaken	   to	   increase	   the	   in-­‐depths	  
coverage	   of	   the	   ubiquitinome	   as	  well	   as	   the	   efficiency	   of	   depletion	   by	   the	  Di-­‐Glycine	  
antibody	  and	  mainly	   included	  optimizing	  the	  ratio	  of	  peptide	  input	  and	  antibody	  used,	  
Di-­‐Glycine	   antibody	   cross-­‐linking,	   and	   basic	   reversed	   phase	   chromatography	   prior	   to	  
fractionated	  Di-­‐Glycine	  enrichment	  and	  proteomic	  analysis(Udeshi	  et	  al.,	  2012;	  Udeshi	  
et	   al.,	   2013).	   In	   my	   experiment	   I	   have	   incorporated	   these	   aforementioned	   technical	  
refinements.	   I	   have	   completed	   2	   biological	   replicate	   experiments	   identifying	   2060	  
unique	  ubiquitinylation	   sites	   in	   the	   first	  and	  999	   in	   the	   second	  experiment.	  How	  does	  
this	   compare	   to	   studies	   published	   in	   the	   literature?	   Prior	   to	   using	   the	   Di-­‐Glycine	  
enrichment	  strategy,	  the	  reported	  number	  of	  ubiquitinylation	  sites	  in	  large-­‐scale	  studies	  
was	  around	  110	  sites	  in	  yeast	  and	  up	  to	  100	  sites	  in	  human	  cell	  lines(Denis	  et	  al.,	  2007;	  
Meierhofer	  et	  al.,	  2008;	  Peng	  et	  al.,	  2003;	  Tan	  et	  al.,	  2008;	  Vasilescu	  et	  al.,	  2005).	  In	  the	  
original	  Di-­‐Glycine	  enrichment	  report,	  374	  unique	  di-­‐glycine	  modified	   lysine	  sites	  were	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identified	  in	  236	  ubiquitinylated	  proteins	  from	  HEK293	  cells(Xu	  et	  al.,	  2010).	  Another	  Di-­‐
Glycine	  enrichment	  study	  identified	  753	  unique	  sites	   in	  471	  proteins	  from	  HEK293	  and	  
U2OS	  osteosarcoma	  cell	  lines(Danielsen	  et	  al.,	  2011).	  Although	  the	  number	  of	  identified	  
sites	  has	   in	  very	   recent	   times	   risen	   from	  more	   than	  5000	  and	  even	  up	   to	  20000	  sites,	  
this	   could	   only	   be	   achieved	   by	   using	   either	   large	   amount	   of	   input	   material,	   the	  
completion	   of	   many	   experimental	   replicates	   (>4)	   and	   also	   the	   use	   of	   proteasomal	  
inhibition(Emanuele	   et	   al.,	   2011;	   Kim	   et	   al.,	   2011;	   Udeshi	   et	   al.,	   2012;	  Wagner	   et	   al.,	  
2011).	   20000	  non-­‐redundant	   sites	   have	   been	  detected	   in	   the	   combined	   analysis	   from	  
replicates	  of	  5	  different	  mouse	  tissues,	  but	  only	  a	  few	  thousand	  sites	  were	  identified	  in	  
each	   individual	   tissue	   sample	  with	   significant	   variations	   in	   the	  numbers	  depending	  on	  
the	   respective	   tissue(Wagner	   et	   al.,	   2011).	   Proteasomal	   inhibition	   can	   result	   in	   an	  
increase	   in	  the	  number	  of	   identified	  sites	  several	   folds,	  but	  the	  majority	  of	   these	  sites	  
appear	   in	   a	   protein-­‐synthesis	   dependent	  manner	   and	  might	   represent	   a	   perturbation	  
bias	  rather	  than	  true	  endogenous	  ubiquitinylation	  events(Harper	  and	  Tan,	  2012;	  Kim	  et	  
al.,	  2011;	  Wagner	  et	  al.,	  2011).	  This	  is	  the	  context	  in	  which	  my	  experiment	  needs	  to	  be	  
seen:	   Given	   that	   my	   study	   encompasses	   2	   biological	   replicates	   and	   no	   proteasomal	  
inhibition,	   I	   consider	   the	   number	   of	   identified	   sites	   to	   be	   average	   to	   above	   average.	  
However,	   the	   implication	   of	   a	   less	   than	   complete	   in-­‐depth	   coverage	   of	   the	   global	  
ubiquitinome	  automatically	  means	  that	  any	  differentially	  modified	  sites	  in	  a	  protein	  with	  
relatively	  low	  expression	  levels	  will	  be	  missed.	  
Quantitative	  Di-­‐Glycine	  capture	  has	  been	  used	  in	  the	  setting	  of	  identifying	  substrates	  of	  
the	  PD	  disease	   gene	  PARKIN	   in	   response	   to	  mitochondrial	   depolarization(Sarraf	   et	   al.,	  
2013).	  PARKIN	   is	  a	  RING-­‐HECT	  hybrid	  E3	  ubiquitin	   ligase	  and	  mutations	   in	  PARKIN	  are	  
the	   most	   frequent	   cause	   of	   familial	   early	   onset	   Parkinsonism(Singleton	   et	   al.,	   2013;	  
Wenzel	  et	  al.,	  2011).	   It	  has	  been	  shown	  that	   the	  activity	  of	  PARKIN	   is	   regulated	  by	  an	  
interaction	   between	   its	   N-­‐terminal	   UBL	   domain	   and	   its	   C-­‐terminal,	   which	   results	   in	  
autoinhibition	  of	  the	  E3	   ligase	  activity	  of	  PARKIN(Chaugule	  et	  al.,	  2011).	   Is,	  however,	  a	  
highly	   conserved	   residue	   within	   the	   UBL	   domain	   of	   PARKIN	   phosphorylated	   by	   the	  
protein	  product	  of	  yet	  another	  PD	  associated	  gene	  –	  PINK1	  –	  a	  conformational	  change	  
occurs	  resulting	  in	  PARKIN	  activation(Burchell	  et	  al.,	  2012;	  Kondapalli	  et	  al.,	  2012).	  These	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observations	   have	   been	  made	   in	   vitro	   and	   require	   conditions	   of	  mitochondrial	   stress.	  
PARKIN	   activation	   is	   also	   accompanied	   by	   its	   recruitment	   to	   the	   outer	  mitochondrial	  
membrane,	  where	  most	   of	   the	   so	   far	   identified	   ubiquitinylation	   substrates	   of	   PARKIN	  
reside(Chan	   et	   al.,	   2011;	   Glauser	   et	   al.,	   2011;	   Narendra	   et	   al.,	   2012;	   Narendra	   et	   al.,	  
2010;	   Wang	   et	   al.,	   2011).	   The	   aforementioned	   quantitative	   Di-­‐Glycine	   capture	  
experiment	   aimed	   to	   identify	   the	   PARKIN-­‐dependent	   ubiquitinome	   in	   a	   site-­‐specific	  
manner	   and	   in	   response	   to	   mitochondrial	   stress(Sarraf	   et	   al.,	   2013).	   In	   this	   study,	  
HCT116	   and	  HeLa	   cells	  with	   and	  without	   overexpression	   of	   tagged-­‐PARKIN	   as	  well	   as	  
untransfected	  SH-­‐SY5	  neuronal	   cells	  were	  used	   in	  a	   total	  of	  73	  proteomic	  control	  and	  
quantitative	   Di-­‐Glycine	   capture	   experiments.	   In	   some	   experiments	   proteasomal	  
inhibition	  was	  used.	  In	  total,	  4772	  non-­‐redundant	  ubiquitinylation	  sites	  in	  1654	  proteins	  
were	   identified.	   The	   rational	   of	   the	   experiment	   is	   that	   overexpressing	   PARKIN	   in	  
combination	  with	  mitochondrial	  stress	  –	  a	  condition	  that	  has	  been	  shown	  to	  activate	  the	  
E3	   ligase	   activity	   of	   PARKIN	   –	   yields	   an	   increase	   in	   the	   likelihood	   of	   detecting	   signal-­‐
dependent	   (PARKIN-­‐dependent)	   and	   mechanistically	   relevant	   ubiquitinylation	   events.	  
Additionally,	  tag	  affinity	  purification	  mass-­‐spectrometry	  was	  used	  to	  identify	  interacting	  
partners	  of	  overexpressed	  PARKIN.	  Overall,	  this	  study	  has	  led	  to	  the	  discovery	  of	  many	  
new	  ubiquitinylation	  targets	  as	  well	  as	  interacting	  partners	  of	  PARKIN	  including	  proteins	  
involved	   in	   metabolism,	   mitochondrial	   fusion	   and	   trafficking,	   autophagy,	   and	   the	  
proteasome	  /	  ubiquitin	  receptors	  and	  also	  mitochondrial	  pore	  proteins	  –	  namely	  VDAC	  
proteins(Sarraf	   et	   al.,	   2013).	   VDAC	   proteins	   were	   identified	   to	   interact	   with	  
overexpressed	   PARKIN	   in	   response	   to	   mitochondrial	   stress	   and	   also	   to	   be	  
ubiquitinylated	  at	   the	   following	   sites:	  VDAC	  1	   (K53,	   109,	   and	  274);	  VDAC	  2	   (K135	  and	  
300);	  and	  VDAC3	  (K53,	  109,	  163,	  266,	  274).	  	  
In	  contrast,	  my	  experiment	  aims	  to	  identify	  specific	  ubiquitinylation	  sites	  /	  targets	  that	  
differ	   between	   the	   wild-­‐type	   SCFFbxo7	   and	   the	   R379G	   mutant	   SCFFbxo7	   R379G	   complex.	  
Rather	   than	   using	   tagged	   overexpression	   in	   different	   tumour	   cell	   lines,	   I	   am	   using	  
material	  derived	   from	   littermate	  wild-­‐type	  and	  homozygous	  R379G	  Fbxo7	  KI	  embryos,	  
which	  allows	  me	  to	  observe	  differences	  in	  the	  ubiquitinylation	  status	  of	  target	  proteins	  
on	   the	   endogenous	   level.	   I	   have	   also	   not	   used	  mitochondrial	   stress	   in	   order	   to	   avoid	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potential	  artefacts.	  Amongst	  the	  differentially	  ubiquitinylated	  proteins	   in	  my	  study	  are	  
also	  all	  3	  VDAC	  isoforms:	  For	  each	  VDAC	  protein,	  several	  different	  peptides	  carrying	  the	  
unequivocal	   Di-­‐Glycine	   remnant	   signature	   of	   site-­‐specific	   ubiquitinylation	   at	   protein	  
level	   have	   been	   identified.	   The	   peptides	   in	   Table	   5-­‐3	   show	   all	   Di-­‐Glycine	   remnant	  
peptides	   for	   which	   an	   Xpress	   ratio	   of	   >	   2	   has	   been	   identified	   suggesting	   that	   the	  
particular	  peptide	  was	  x-­‐fold	  more	  often	  identified	  in	  the	  SILAC	  light-­‐labelled	  wild-­‐type	  
than	  in	  the	  SILAC	  heavy	  labelled	  homozygous	  R379G	  Fbxo7	  KI	  MEFs.	  In	  fact	  some	  of	  the	  
specific	  ubiquitinylation	  sites	  have	  been	  identified	  to	  be	  more	  than	  20-­‐fold	  more	  often	  
in	   case	  of	   the	  wild-­‐type	  background	   (for	  VDAC	  1:	   K122).	   Interestingly,	   all	   unique	   sites	  
converge	  onto	  exactly	  2	  lysine	  residues	  that	  are	  conserved	  between	  VDAC	  1,	  2,	  and	  3	  as	  
well	   as	   between	   the	   mouse	   and	   human	   homologues	   (Figure	   69).	   Additionally,	  
differential	  ubiquitinylation	  of	  VDAC	  proteins	  was	   robustly	  demonstrated	  across	   the	  2	  
biological	  replicates.	  This	  is	  very	  unlikely	  due	  to	  an	  artefact;	  the	  protein	  concentration	  of	  
the	   input	   lysates	   for	   both	   genotypes	   had	   been	   carefully	   quantified	   and	   differential	  
proteomic	  analysis	  of	  the	  digested	  wild-­‐type	  and	  homozygous	  R379G	  Fbxo7	  KI	  peptide	  
mix	   prior	   to	   the	   Di-­‐Glycine	   enrichment	   step	   confirmed	   that	   there	   was	   no	   significant	  
difference	  in	  the	  abundance	  for	  VDAC	  1,2,	  and	  3	  between	  the	  2	  genotypes.	  The	  fact	  that	  
the	  identified	  ubiquitinylation	  sites	  are	  in	  all	  likelihood	  facing	  the	  cytosolic	  compartment	  
rather	   than	   towards	   the	   inner	   mitochondrial	   membrane	   or	   being	   buried	   within	   the	  
many	   transmembrane	   domains	   of	   VDAC	   1,2,	   and	   3	   corroborates	   the	   validity	   of	   the	  
experiments	   with	   regards	   to	   the	   VDAC	   proteins	   (Figure	   69).	   Furthermore,	   the	   in	   my	  
experiment	   as	   differentially	   modified	   VDAC	   sites	   have	   been	   reported	   before	   as	  
endogenous	  ubiquitinylation	  sites	  for	  both	  human	  and	  mouse	  homologous(Chen	  et	  al.,	  
2014):	   In	   the	  one	  study	   that	   identified	  as	  many	  as	  20000	  endogenous	  ubiquitinylation	  
sites	   in	   different	   mouse	   tissues,	   the	   authors	   were	   also	   particularly	   interested	   in	   the	  
divergent	   pattern	   of	   ubiquitinylation	   sites	   depending	   on	   tissue	   type(Wagner	   et	   al.,	  
2011).	   This	   allowed	   cross-­‐referencing	   whether	   the	   2	   conserved	   and	   differentially	  
ubiquitinylated	  VDAC	  sites	  identified	  in	  my	  experiment	  in	  MEFs	  had	  also	  been	  identified	  
in	  brain:	  While	   the	   first	  ubiquitinylation	   site	   in	  my	  experiment	   (VDAC	  1:	  K66;	  VDAC	  2:	  
K64;	  VDAC	  3:	  K53)	  was	  only	  detected	   for	  VDAC	  1	   in	  mouse	  brain	  samples,	   the	  second	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conserved	  ubiquitinylation	  site	  was	  found	  in	  all	  3	  VDAC	  proteins	  in	  brain.	  Overall,	  I	  have	  
high	  confidence	  for	  having	  identified	  2	  conserved	  lysine	  residues	  in	  all	  3	  VDAC	  proteins	  
that	  are	  not	  only	   functional	  ubiquitinylation	  sites	   in	  vivo,	  but	  also	  highly	   suggestive	  of	  
being	  instrumental	   in	  the	  difference	  between	  wild-­‐type	  and	  homozygous	  R379G	  Fbxo7	  
KI	  and	  the	  pathogenicity	  of	  the	  latter.	  
Of	  course,	  my	  findings	  only	  allow	  the	  conclusion	  that	  VDAC	  1,	  2,	  and	  3	  are	  differential	  
ubiquitinylated	  dependent	  on	  the	  Fbxo7	  wild-­‐type	  or	  R379G	  mutant	  genotype	  in	  MEFs.	  
The	  set	  up	  of	  my	  experiment	  does	  not	  all	  the	  conclusion	  that	  VDAC	  proteins	  are	  actually	  
direct	  ubiquitinylation	  targets	  of	  Fbxo7.	  So	  which	  E3	  ligases	  have	  been	  implemented	  in	  
the	   ubiquitinylation	   of	   VDAC	   proteins	   in	   general?	   So	   far,	   only	   PARKIN	   has	   been	   put	  
forward	   to	   be	   involved	   in	   VDAC	   ubiquitinylation:	   As	   mentioned	   before,	   PARKIN	  
overexpression	   in	   combination	   with	   mitochondrial	   stress	   leads	   to	   increased	  
ubiquitinylation	  of	  all	  3	  VDAC	  proteins	  at	  specific	  sites	  in	  HeLa	  and	  HCT116	  cells(Sarraf	  et	  
al.,	  2013).	  Overexpression	  of	  functional	  PARKIN	  in	  neuronal	  (inducible	  SH-­‐SY5SY	  cells)	  as	  
well	   as	   non-­‐neuronal	   cell	   types	   in	   combination	   with	   mitochondrial	   stress	   has	   been	  
shown	  to	  result	  in	  the	  identification	  of	  higher	  molecular	  weight	  species	  of	  VDAC	  1	  while	  
overexpression	  of	  several	  different	  pathogenic	  PARKIN	  mutants	   fail	   to	  do	  so(Geisler	  et	  
al.,	  2010).	  	  
It	   is	   intriguing	   that	   3	   different	   autosomal	   recessive	   PARK	   gene	   products	   –	   wild-­‐type	  
PARKIN(Sarraf	  et	  al.,	  2013),	  functional	  PINK	  /	  PARKIN(Geisler	  et	  al.,	  2010)	  as	  well	  as	  wild-­‐
type	   FBXO7	   (my	   study)	   -­‐	   have	   all	   been	   implicated	   in	   the	   ubiquitinylation	   of	   VDAC	  
proteins,	  while	  another	  recent	  study	  suggests	  that	  PINK1,	  PARKIN	  and	  FBXO7	  not	  only	  
physically	  interact,	  but	  also	  map	  to	  the	  same	  pathway	  converging	  on	  the	  mitochondria	  
and	   possibly	  mitophagy	   (degradation	   of	  mitochondria	   by	   the	   autophagy	   system).	   It	   is	  
therefore	  highly	  desirable	  to	  set	  up	  in	  vitro	  ubiquitinylation	  experiments	  with	  FBXO7	  as	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 Quantitative	   global	   proteomics	   to	   identify	   differences	   in	   expression	   levels	  5.5.2
across	  the	  whole	  proteome	  of	  wild-­‐type	  and	  hom	  R379G	  Fbxo7	  KI	  brain	  lysates	  
There	   is	   uncertainty	   about	   the	   number	   of	   proteins	   that	   constitute	   the	   mammalian	  
proteome.	   One	   general	   approach	   is	   to	   apply	   the	   one-­‐gene-­‐one	   protein	   rule,	   and	  
accordingly	   the	   human	   (as	   well	   as	   mouse)	   proteome	   comprises	   about	   20000	  
proteins(Clamp	  et	  al.,	  2007;	  Cox	  and	  Mann,	  2011).	  Up	  to	  10000	  non-­‐redundant	  proteins	  
have	   been	   identified	   in	   a	   single	   human	   cell	   line	   and	   about	   8000	   proteins	   have	   been	  
found	   in	   the	  whole	  mouse	  proteome(Cox	  and	  Mann,	  2011;	  Wang	  et	  al.,	   2006).	   In	  our	  
study,	  we	   identified	   a	   total	   of	   just	   under	   7000	  proteins	   in	  RapiGest	   brain	   lysates	  of	   3	  
biological	  replicate	  pairs	  of	  wild-­‐type	  and	  homozygous	  R379G	  Fbxo7	  KI	  animals.	  Of	  these	  
7000	   proteins,	   less	   than	   1.5%	   (107	   proteins)	   changed	   their	   expression	   levels	   by	  more	  
than	   1.5,	   and	   this	   number	  was	   further	   diminished	   to	   0.2%	   (15	   proteins)	   if	   only	   those	  
proteins	  were	   included	  whose	   expression	   level	   changed	   reliably	   (p	   value	   of	   less	   than	  
0.5).	  The	  total	  number	  of	  proteins	  identified	  in	  this	  study	  is	  significantly	  smaller	  than	  the	  
expected	  number	  based	  on	  the	  one-­‐gene-­‐one	  protein	  rule,	  but	  comparable	  to	  what	  has	  
been	  published	  in	  the	  literature(Wang	  et	  al.,	  2006).	  In	  contrast,	  the	  number	  of	  proteins	  
whose	   expression	   level	   differed	   reliably	   dependent	   on	   either	   the	  wild-­‐type	   or	   R379G	  
Fbxo7	   KI	   genotype	   was	   negligibly	   small.	   In	   fact,	   the	   rate	   of	   false	   positive	   discovery,	  
which	   conventionally	   is	   in	   the	   magnitude	   of	   1%,	   is	   significantly	   higher(Higdon	   et	   al.,	  
2011;	   Y,	   1995).	   Subsequent	   immunoblotting	   indeed	   failed	   to	   validate	   any	   of	   the	   as	  
differentially	   expressed	   hits	   by	   the	   proteomic	   analysis	   and	   a	   p-­‐value	   of	   <	   0.5.	   For	  
example,	  Integrin-­‐β5	  and	  Neurogenic	  differentiation	  factor	  2	  are	  each	  at	  the	  end	  of	  the	  
magnitude	  spectrum	  of	  differential	  expression	  between	  the	  wild-­‐type	  and	  homozygous	  
R379G	  Fbxo7	  KI	  genotypes:	  While	  the	  proteomic	  analysis	  of	  Integrin-­‐β5	  determined	  it	  to	  
be	   100-­‐fold	  more	   abundant	   in	   the	   wild-­‐type	   background,	   the	   expression	   level	   of	   the	  
latter	   was	   measured	   to	   be	   11	   times	   higher	   in	   the	   homozygous	   R379G	   Fbxo7	   KI	  
background.	   Immunoblotting	   for	   the	   2	   proteins	   reveals	   greater	   inter-­‐individual	  
differences	  than	  any	  discernable	  difference	  based	  on	  genotype.	  I	  have	  aimed	  to	  validate	  
as	  mainly	   of	   the	   15	   proteins	   that	  were	   identified	   in	   this	   study	   as	   long	   as	   commercial	  
antibodies	  were	  available,	   the	   change	   in	  expression	   level	  was	  more	   than	  2-­‐fold	  and	   if	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more	  than	  2	  peptides	  were	  identified	  by	  the	  proteomic	  analysis.	  Although	  this	  precluded	  
some	   of	   the	   potential	   hits	   from	   being	   validated	   –	   such	   as	   Glycosyltransferase-­‐like	  
domain	  containing	  protein	  1,	  Lactrophilin-­‐2,	  60s	  ribosomal	  protein	  L36a,	  Protein	  Pcdhb	  
20,	   Protein	   KTI22	   homolog,	   and	   Glycosylphosphatidylinositol	   anchor	   attachment	   1	  
protein	   –	   I	   decided	   to	   conclude	   the	   experiment	   at	   this	   stage.	   This	   was	   based	   on	   the	  
negative	   validation	   of	   the	   proteins	   that	   I	   actually	   examined	   –	   amongst	   them	   the	   2	  
proteins	   that	  were	   accordingly	   differently	   expressed	   either	   10	   or	   100	   –	   fold,	   but	   also	  
because	   I	   consider	   this	   approach	   retrospectively	   not	   as	   the	   most	   suitable	   for	   many	  
reasons:	   Ultimately,	   it	   is	   not	   clear	   as	   yet	   whether	   FBXO7	   functions	   as	   an	   E3	   ligase	  
component	  with	   an	   effect	   on	   the	   proteasome	   and	  whether	   the	   disease	  mutants	   –	   in	  
particular	  the	  one	  for	  which	  I	  have	  the	  R379G	  Fbxo7	  KI	  mouse	  model	  –	  differ	  from	  the	  
wild-­‐type	   only	   in	   their	   substrate	   specificity	   /	   incompatibility.	   Even	   if	   a	   difference	   in	  
substrate	  specificity	  was	  the	  underlying	  pathomechanism	  of	  the	  FBXO7	  disease	  mutants,	  
a	  differential	  ubiquitinylation	  activity	  upon	  substrate	  proteins,	  does	  not	  necessary	  affect	  
total	   protein	   expression	   levels.	   In	   fact,	   it	   is	   usually	   only	   a	   small	   pool	   of	   a	   particular	  
protein	   that	   is	   being	   post-­‐transnationally	   modified	   by	   ubiquitin.	   Another	   argument	  
against	  this	  approach	  is	  the	  high	  complexity	  of	  the	  mammalian	  brain	   in	  contrast	  to	  for	  
example	  a	  single	  cell	  line.	  It	  could	  also	  be	  that	  FBXO7	  might	  exert	  its	  specific	  function	  in	  
one	  particular	  part	  of	  the	  brain	  –	  for	  example	  within	  the	  basal	  ganglia	  –	  and	  any	  possible	  
effect	   on	   protein	   expression	   levels	   in	   this	   particular	   region	   is	   being	   diluted	   out	   by	  
analysing	  whole	  brain	  lysates	  rather	  than	  specific	  compartments	  or	  regions	  of	  functional	  
neuronal	   networks.	   There	   are	   many	   publications	   that	   address	   the	   various	   different	  
strategies	   for	   the	   identification	   of	   SCF	   substrates	   by	   the	   means	   of	   proteomics,	   but	  
employing	   a	   difference	   in	   protein	   abundance	   on	   the	   endogenous	   level	   to	   identify	  
substrates	  that	  differ	  between	  the	  wild-­‐type	  and	  a	  mutant	  form	  of	  an	  F-­‐box	  protein	  or	  
any	  other	  SCF	  component	  is	  not	  amongst	  them(Harper	  and	  Tan,	  2012;	  Vertegaal,	  2011).	  
In	   terms	   of	   using	   a	   genetic	   approach	   in	   combination	  with	   global	   protein	   expression	   /	  
stability	   levels	   as	   a	   read-­‐out,	   there	   is	   only	   one	   successful	   and	   established	   approach:	  
Global	  Protein	  Stability	   (GPS)	  profiling(Yen	  and	  Elledge,	  2008;	  Yen	  et	  al.,	  2008).	  GPS	   is	  
based	   on	   a	   dual	   fluorescence	   reporter	   system	   that	   uses	   fluorescence-­‐activated	   cell	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sorting	   with	   DNA	   microarray	   deconvolution	   to	   detect	   changes	   in	   protein	   expression	  
levels	  in	  live	  cells,	  but	  is	  far	  from	  my	  aim	  which	  is	  studying	  the	  effect	  of	  a	  particular	  F-­‐
box	   protein	   mutation	   on	   the	   endogenous	   level	   in	   vivo.	   To	   conclude,	   the	   depth	   and	  
coverage	   of	   this	   experiment	   in	   terms	   of	   total	   proteome,	   the	   low	   number	   of	   proteins	  
with	   a	   differential	   expression	   pattern	   between	   the	   2	   genotypes	   –	   which	   was	   in	   fact	  
lower	  than	  the	  accepted	  number	  of	  false	  positives	   in	  any	  given	  proteomic	  experiment,	  
the	  complexity	  of	  the	  sample,	  and	  possibly	  a	  false	  hypothesis	  that	  the	  Fbxo7-­‐dependent	  
ubiquitinylation	  of	  a	  potential	   substrate	  automatically	   results	   in	  a	   reduction	   in	  protein	  
expression	   level	   thereof.	   The	   problem	   of	   inter-­‐individual	   differences	   between	   the	  
individual	   animals	   could	   possibly	   have	   been	   overcome	   by	   pooling	   brain	   tissue	   from	  
animals	  of	  the	  same	  genotypes	  together	  prior	  to	  tissue	   lysis	  and	  analysis	  and	  could	  be	  
considered	  in	  future	  experiments.	  	  
 Steps	  towards	  establishing	  an	  in	  vitro	  FBXO7	  dependent	  ubiquitinylation	  assay	  5.5.3
A	   big	   step	   towards	   setting	   up	   functional	   in	   vitro	   FBXO7	   assays	   was	   the	   recombinant	  
expression	   of	   the	   various	   SCFFBXO7	   complex	   components.	   The	   original	   protocol	   was	  
developed	   for	   the	   biochemical	   and	   structural	   analysis	   of	   recombinant	   SCFSKP2	   and	  
SCFβTRCP1	   complexes(Li	  et	  al.,	  2005).	  Recombinant	  baculovirus	  production	   in	   insect	   cells	  
allows	   efficient	   production,	   while	   the	   use	   of	   a	   dual	   or	   multi-­‐expression	   baculoviral	  
vector	   allows	   protein-­‐protein	   interactions	   between	   direct	   binding	   partners	   and	  
subsequent	   intermolecular	   hydrophobic	   packing	   to	   occur.	   Initially,	  we	   focused	   on	   the	  
recombinant	  expression	  of	  the	  FBXO7	  wild-­‐type	  and	  the	  R378G	  KI	  disease	  mutant,	  which	  
forms	  the	  basis	  of	  the	  R379G	  Fbxo7	  KI	  mouse	  model	   in	  my	  thesis.	   It	  emerged	  early	  on	  
that	  despite	  co-­‐expression	  of	  untagged	  SKP1	  and	  the	  DAC-­‐tagged	  R378G	  FBXO7	  mutant	  
the	   interaction	   between	   the	   2	   proteins	   was	   impaired.	   As	   SKP1	   is	   co-­‐purified	   with	   its	  
respectively	   co-­‐expressed	  FBXO7	  binding	  partner	   via	  DAC-­‐tag	  purification,	   significantly	  
lower	   amounts	   of	   SKP1	   were	   repeatedly	   co-­‐purified	   with	   the	   R378G	   mutant	   in	  
comparison	   to	   the	   wild-­‐type	   FBXO7	   protein	   (Figure	   78).	   Re-­‐sequencing	   of	   baculoviral	  
expression	   cassette	   excluded	   simple	   cloning	  mistakes	   as	   the	   underlying	   cause.	   It	   was	  
therefore	  decided	  to	  also	  include	  the	  only	  other	  homozygous	  FBXO7	  mutation	  –	  R498X	  –	  
into	  the	  analysis	  for	  comparison.	  Figure	  80	  (A)	  shows	  that	  the	  truncating	  R498X	  mutant	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was	   indeed	   capable	   of	   SKP1	   binding.	   My	   conclusion	   is	   that	   the	   failure	   of	   the	   R378G	  
mutant	  to	  efficiently	  bind	  SKP1	  is	  an	  intrinsic	  property	  of	  this	  particular	  mutant	  protein	  
and	   possibly	   explained	   by	   the	   close	   proximity	   of	   the	   mutated	   residue	   to	   the	   SKP1-­‐
binding	  F-­‐box	  domain	  of	  FBXO7.	  In	  fact,	  this	  is	  an	  observation	  that	  was	  already	  made	  in	  
a	   different	   recombinant	   expression	   system:	   Bi-­‐cistronic	   expression	   vectors	   expressing	  
recombinant	  GST-­‐tagged	  FBXO7	  wild-­‐type	  as	  well	   as	   the	  R378G	  mutant	   together	  with	  
SKP1	  demonstrated	  impaired	  SKP1	  binding	  of	  the	  R378G	  mutant.	  	  
The	   next	   step	   was	   to	   demonstrate	   that	   all	   components	   of	   the	   SCFFBXO7	   complex	   –	  
individually	  or	  co-­‐expressed	  were	   in	  principle	  able	  to	  assemble	   into	  a	  SCF	  complex.	  As	  
the	  functional	  association	  between	  FBXO7	  and	  PI31	  is	  not	  as	  yet	  clarified	  and	  PI31	  could	  
potentially	   be	   a	   regulatory	   component	   of	   the	   SCFFBXO7	   complex	   as	   is	   the	   case	   in	  
Drosophila	  melanogaster,	  I	  investigated	  tetrameric	  (without	  PI31)	  and	  pentameric	  (with	  
PI31)	   SCF	   complex	   formation.	   5.3.2	   shows	   that	   DAC-­‐purification	   of	   the	   SCFFBXO7	  
complex	  with	  and	  without	  PI31	  is	  successfully	  achieved	  in	  the	  FBXO7	  wild-­‐type	  as	  well	  as	  
R498X	  mutant	   setting,	  while	   not	   possible	   in	   case	  of	   the	  R378G	   FBXO7	  mutant.	   It	  was	  
therefore	   also	   no	   surprise	   that	   the	   R378G	   mutant	   was	   incapable	   of	   mounting	   an	  
ubiquitin	  free	  chain	  formation	  response	  in	  the	  SCFFBXO7	  E3	  ligase	  activity	  assays	  (5.3.3).	  
Based	   on	   these	   in	   vitro	   findings	   alone	   it	   could	   have	   been	   easy	   to	   speculate	   that	   the	  
pathogenicity	   of	   the	   R378G	   FBXO7	   disease	   mutant	   is	   explained	   by	   its	   inability	   to	  
assemble	  into	  a	  functional	  SCFFBXO7	  R378G	  E3	  ubiquitin	  ligase	  complex.	  This	  is	  of	  course	  not	  
the	   case	   given	  my	   contradicting	   in	   vivo	   findings:	   the	   human	   R378G	   FBXO7	  mutant	   as	  
well	   as	   its	   mouse	   R379G	   homologue	   are	   very	   well	   capable	   to	   SCFFBXO7	   complex	  
formation	   as	   convincingly	   shown	   in	   the	  overexpression	   systemFigure	   14,	   as	  well	   as	   in	  
the	   endogenous	   human	   and	   mouse	   system	   in	   Figure	   38	   and	   Figure	   40.	   One	   of	   my	  
seminal	  findings	  in	  the	  R379G	  Fbxo7	  KI	  mouse	  has	  been	  that	  the	  expression	  level	  of	  the	  
homozygous	  mutant	  protein	   is	   significantly	   lower	   it	   is	   for	   the	  wild-­‐type	  Fbxo7	  protein	  
(Figure	   36	   and	   Figure	   34).	   I	   am	  demonstrating	   in	   Figure	   83	   that	   the	   relative	   ability	   of	  
SKP1	  biding	  of	  the	  mutant	  in	  comparison	  to	  the	  wild-­‐type	  protein	  is	  about	  the	  same.	  In	  
the	  in	  vivo	  system	  additional	  SCFFBXO7	  binding	  /	  complex	  partners	  might	  compensate	  for	  
the	   perturbed	   SKP1	   binding	   ability	   of	   the	   R378/9G	   FBXO7	  mutant.	   One	   possibility	   of	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following	   this	   up	   is	   to	  perform	  a	   size	   exclusion	   chromatography	  of	   the	   in	   vivo	   affinity	  
purified	   SCFFBXO7	   wild-­‐type	   and	   R379G	  mutant	   complex	   in	   comparison	   to	   the	   in	   vitro	  
complex	   and	   possibly	   subsequent	   mass-­‐spectrometry	   analysis	   of	   the	   relevant	   in	   vivo	  
fractions.	  	  	  
The	  most	  important	  application	  of	  the	  in	  vitro	  SCFFBXO7	  E3	  ligase	  assay	  will	  be	  to	  validate	  
potential	  FBXO7	  ubiquitinylation	  substrates	  –	  such	  as	  HURP,	  cIAP1	  and	  TRAF2	  as	  well	  as	  
to	   differentiate	   between	   physical	   interacting	   partners	   and	   ubiquitinylation	   targets	   as	  
identified	  in	  my	  affinity	  purification	  mass-­‐spectrometry	  experiments(Chang	  et	  al.,	  2006;	  
Kirk	   et	   al.,	  2008; Kuiken	   et	   al.,	   2012).	   So	   far,	   we	   are	   in	   the	   process	   of	   recombinant	  
expression	   and	   purification	   of	   some	   of	   my	   potential	   ubiquitinylation	   targets	   (for	  
example	   Reticulon	   B).	   Another	   crucial	   implication	   of	   the	   in	   vitro	   FBXO7	   assay	   is	   the	  
validation	  of	  VDAC	  proteins.	  
 Preliminary	   data	   towards	   the	   validation	   of	   VDAC	   proteins	   as	   SCFFBXO7	  5.5.4
ubiquitinylation	  targets	  
One	  of	   the	  most	   exciting	   findings	  during	  my	  PhD	  has	  been	   the	   identification	  of	  VDAC	  
proteins	   as	   differential	   ubiquitinylation	   targets	   of	   endogenous	   FBXO7	   wild-­‐type	   and	  
homozygous	  R379G	  MEFs.	  Of	  course,	   I	  will	  not	  be	  able	  to	  demonstrate	  a	  difference	   in	  
ubiquitinylation	   efficiency	   between	   the	   FBXO7	   wild-­‐type	   and	   R378G	   mutant	   towards	  
VDACs	  as	  the	  R378G	  mutant	  does	  not	  assemble	  into	  a	  SCF	  complex	   in	  vitro	   in	  the	  first	  
place.	   However,	   I	   would	   potentially	   be	   able	   to	   demonstrate	   that	   VDACs	   are	   direct	  
ubiquitinylation	  targets	  of	  FBXO7	  and	  shed	  light	  on	  at	  least	  the	  question	  of	  whether	  it	  is	  
FBXO7	  or	  PARKIN	  that	  is	  responsible	  for	  VDAC	  ubiquitinylation.	  As	  these	  results	  are	  very	  
recent,	  we	   are	   still	   developing	   tools	   for	   the	   adequate	   assessment	   and	   study	   of	   VDAC	  
proteins:	   in	   house	   DSTT-­‐production	   of	   VDAC	   1,2	   and	   3	   antibodies	   and	   recombinant	  
production	   and	   micellar	   refolding	   of	   VDAC	   proteins.	   I	   am	   currently	   performing	  
experiments	  with	  intact	  mitochondrial	  preparations	  with	  and	  without	  CCCP	  stimulation	  
as	  substrates	  in	  the	  SCFFBXO7	   in	  vitro	  assays.	  Due	  to	  the	  lack	  of	  efficient	  and	  sensitive	  
VDAC	   antibodies	   I	   have	   developed	   SCFFBXO7	   in	   vitro	   substrate	   assays	   with	   intact	  
mitochondria	  and	  FLAG-­‐tagged	  ubiquitin	  in	  combination	  with	  denaturing	  post-­‐assay	  lysis	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and	   FLAF	   affinity	   purification	   mass-­‐spectrometry.	   Preliminary	   data	   shows	   the	  
identification	   peptides	   mapping	   to	   VDAC	   as	   well	   as	   ubiquitin	   proteins	   as	   well	   as	   Di-­‐
Glycine	   remnant	  peptides	  suggestive	  of	  ubiquitinylation	  events.	   I	  will	  have	   to	  scale	  up	  
and	   refine	   the	   procedure	   in	   order	   to	   reliably	   detect	   in	   vitro	   FBXO7	   dependent	  
ubiquitinylation	  events	  of	  VDAC	  proteins	  in	  situ	  in	  the	  outer	  mitochondrial	  membrane	  of	  
intact	  mitochondria.	  This	  could	  involve	  differential	  Di-­‐Glycine	  affinity	  purification	  mass-­‐
spectrometry:	   for	   example	   using	   intact	   mitochondrial	   preparations	   from	   “heavy”	  
isotope	  (K8R10)	   labelled	  HEK293	  cells	   in	  combination	  with	  Di-­‐Glycine	  enrichment	  after	  
the	   in	   vitro	   SCFFBXO7	   assay	   (using	   “light”	   labelled	   ubiquitin),	   I	   would	   be	   able	   to	  
unequivocally	   identify	   site-­‐specific	   ubiquitinylation	   events	   of	   VDAC	   or	   other	  
mitochondrial	   membrane	   proteins	   as	   dependent	   on	   the	   FBXO7	   in	   vitro	   assay.	   Until	  
reliable	   VCDA	   antibodies	   are	   available	   I	   am	   also	   planning	   to	   perform	   in	   vitro	   FBXO7	  
assays	  using	  the	   inducible,	  stable	  expressing	  VDAC	  1-­‐C-­‐terminal	  FLAG	  Flp-­‐In	  T-­‐REx	  HEK	  
293	  cell	  (in	  combination	  with	  untagged	  ubiquitin)	  and	  use	  FLAG	  immunoblotting	  of	  the	  
assay	  product	   for	   higher	  molecular	  weight	   species	   as	   a	   functional	   read	  out.	   Figure	  86	  
shows	   that	   the	  VDAC	  1-­‐C-­‐terminal	  FLAG	   is	  actually	  expressed	   in	   the	  mitochondria	  and	  
hence	  suitable	  for	  this	  kind	  of	  assay.	  	  
 Summary	  of	  chapter	  5	  5.5.5
In	  summary,	  this	  chapter	  has	  focused	  on	  trying	  to	  dissect	  the	  differences	  between	  the	  
wild-­‐type	  and	  the	  homozygous	  R379G	  Fbxo7	  KI	  mutant	  by	  comparing	  protein	  expression	  
levels	  across	  the	  entire	  proteome	  as	  well	  as	  differences	  in	  the	  site-­‐specific	  modification	  
of	   the	  entire	  ubiquitinome.	  Caveats	  as	   in	  any	  other	  comparable	  proteomic	  studies	  are	  
the	   incomplete	   sequencing	   depth	   of	   the	   proteome	   and	   incomplete	   capture	   of	   the	  
ubiquitinome.	   While	   I	   discovered	   no	   discernable	   difference	   in	   terms	   of	   protein	  
expression	   /	   abundance	   in	   as	   many	   as	   7000	   proteins	   between	   the	   wild-­‐type	   and	  
homozygous	  R379G	  Fbxo7	  KI	  genotype	  in	  mouse	  brain	  lysates,	  I	  have	  made	  a	  significant	  
discovery	   by	   identifying	   2	   conserved	   ubiquitinylation	   sites	   in	   each	   of	   the	   3	   VDAC	  
proteins	  that	  are	  preferentially	  ubiquitinylated	  in	  the	  Fbxo7	  wild-­‐type	  in	  comparison	  to	  
the	   homozygous	   R379G	   genotype	   in	   MEFs	   using	   SILAC	   based	   Fbxo7-­‐dependent	   Di-­‐
Glycine	   capture	  proteomics.	  One	  of	   the	  big	   advantages	  of	  my	   study	   is	   that	   they	  have	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been	   performed	   in	   the	   endogenous	   system	   either	   with	   differential	   ex-­‐vivo	   chemical	  
labelling	  of	  mouse	  brain	  lysates	  or	  in	  vivo	  SILAC	  labelling	  of	  MEF	  lysates.	  I	  have	  used	  the	  
in	   the	   previous	   chapter	   characterized	   Fbxo7	   mouse	   model	   with	   knock-­‐in	   of	   the	  
corresponding	   R378G	   FBXO7	   disease	   mutants	   at	   the	   endogenous	   locus	   for	   these	  
experiments.	   Furthermore,	   I	   have	   set	   up	   functional	   assays	   for	   monitoring	   the	   FBXO7	  
dependent	  SCF	  E3	  ligase	  activity	   in	  vitro.	  The	  compromised	  SKP1	  binding	  of	  the	  R378G	  
FBXO7	   mutant	   explains	   why	   it	   is	   unable	   to	   form	   a	   tetrameric	   or	   even	   pentameric	  
complex	  with	   Cullin1,	   SKP1,	   RBX1	   and	   PI31,	  which	   is	   a	   necessary	   prerequisite	   for	   any	  
functional	  enzymatic	  activity.	   In	   contrast,	   the	  only	  other	   so	   far	  described	  homozygous	  
FBXO7	  disease	  mutant	  is	  able	  of	  SCFFBXO7	  R498X	  E3	  ligase	  complex	  formation	  and	  as	  a	  read	  
out	  for	  functional	  activity	  also	  capable	  of	  free	  ubiquitin	  chain	  formation.	  At	  least	  in	  vitro,	  
this	  would	  suggest	  a	  different	  pathogenic	  mechanism	  for	  the	  truncating	  R498X	  disease	  
mutant	   in	   comparison	   to	   the	   R378G	   mutant.	   The	   substrate-­‐binding	   region	   of	   F-­‐box	  
proteins	  has	  often	  been	  described	  to	  reside	  in	  their	  C-­‐terminal	  domains;	  hence	  binding	  
of	  a	  physiological	  FBXO7	  substrate	  could	  be	  impaired	  in	  the	  R498X	  disease	  mutant	  as	  it	  
is	  devoid	  of	  the	  C-­‐terminal	  22	  amino	  acids(Ho	  et	  al.,	  2006;	  Jin	  et	  al.,	  2004;	  Skaar	  et	  al.,	  
2013).	   In	  contradiction	  to	  my	   in	  vitro	   findings,	   I	  have	  unequivocally	  demonstrated	  that	  
the	  human	  R378G	  FBXO7	  and	  corresponding	  mouse	  R379G	  Fbxo7	  mutant	  proteins	  are	  
able	  to	  assemble	  into	  the	  SCFFBXO7	  E3	  ubiquitin	  ligase	  complex.	  I	  am	  proposing	  that	  there	  
additional	   binding	   /	   interacting	   partners	   or	   co-­‐factors	   that	   compensate	   the	   impaired	  
binding	   between	   this	   particular	   mutant	   and	   SKP1.	   Given	   the	   juxtaposition	   of	   the	  
mutated	  R378G	  /	  R379G	  residue	  and	  the	  F-­‐box	  domain	  of	  FBXO7	  compromised	  binding	  
is	   likely.	   Usually	   binding	   of	   2	   proteins	   –	   such	   as	   for	   example	   FBXO7	   and	   SKP1	   –	  
strengthens	   their	   intermolecular	  hydrophobic	  packing	  and	  hence	  stability	  which	  might	  
explain,	  why	  I	  observe	  reduced	  Fbxo7	  expression	  levels	  in	  the	  homozygous	  R379G	  Fbxo7	  
KI	  mouse.	   It	  would	  be	   interesting	  to	  examine	  and	  compare	  FBXO7	  expression	   levels	   in	  
human	   brain	   or	   other	   tissue	   between	   the	   wild-­‐type	   and	   R378G	   disease	   mutant.	   If	   a	  
reduction	  in	  expression	  level	  of	  the	  R378G	  mutant	  in	  its	  homozygous	  compared	  to	  the	  
wild-­‐type	  state	  could	  be	  reproduced	  in	  humans,	  it	  could	  be	  argued	  that	  not	  a	  difference	  
in	   actual	   ubiquitinylation	   targets	   but	   a	   threshold	   effect	   of	   the	   R378G	   FBXO7	   disease	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mutant	  is	  the	  basis	  for	  its	  pathogenicity.	  Nevertheless,	  FBXO7	  is	  an	  important	  player	  in	  
genes	   and	   proteins	   that	   map	   into	   signalling	   pathways	   involved	   in	   Parkinson’	   disease	  
associated	  neurodegeneration.	  There	  are	  only	  a	  handful	  of	  patients	  worldwide	  affected	  
by	   FBXO7	   associated	   disease,	   but	   unravelling	   the	   signalling	   pathway	   of	   FBXO7	   and	  
further	   exploring	   its	   entanglement	   with	   PINK,	   PARKIN	   and	   VDAC	   proteins	   as	   well	   as	  
other	  PARK	  genes	  is	  an	  exciting	  avenue	  for	  appreciating	  the	  relevance	  of	  FBXO7	  in	  the	  
bigger	   picture	   of	   neurodegeneration.	   In	   the	   end,	   it	   is	   about	   identifying	   new,	   targeted	  
means	  for	  developing	  causal	  treatment	  for	  patients	  with	  Parkinson’s	  Disease.	  
6 Summary	  of	  all	  result	  chapters	  and	  outlook	  
	  
My	  first	   result	  chapter	  shows	  that	  FBXO7	  does	  assemble	   into	  the	  SCFFBXO7	  E3	  ubiquitin	  
ligase	  complex	  and	  that	  this	   is	   true	  for	  the	  FBXO7	  widtype	  protein	  as	  well	  as	   for	  all	  of	  
the	  3	  known	  diease	  mutants	  -­‐	  T22M,	  R378G	  and	  R498X.	  These	  findings	  suggest	  that	  SCF	  
complex	  disruption	  is	  an	  unlikely	  mechanism	  by	  which	  the	  FBXO7	  disease	  mutants	  exert	  
their	   pathogenicity.	   The	   Alanine	   mutant	   screen	   of	   single	   residues	   within	   the	   F-­‐box	  
domain	  of	  FBXO7	  gives	  some	  insight	  into	  the	  interaction	  between	  FBXO7	  and	  SKP1:	  the	  
employed	   single	  mutants	   in	   this	   study	  are	  on	   its	  own	  unable	   to	  abolish	   SKP1	  binding,	  
and	  based	  on	  what	  we	  know	  so	  far	  complete	  SCF	  complex	  disruption	  is	  only	  achieved	  by	  
the	  simultaneous	  deletion	  of	  several	  residues	  (>	  4	  amino	  acid	  residues).	  The	  non-­‐SKP1	  
binding	   mutants	   also	   demonstrate	   that	   there	   is	   no	   dimerization	   between	   the	  
endogenous	  SCFFBXO7	   wt	   E3	  ubiquitin	   ligase	   complex	  and	   the	  overexpressed	  mutants.	   If	  
this	  was	  the	  case	  one	  would	  have	  expected	  to	  see	  a	  signal	  for	  SKP1	  in	  the	  immunoblot	  of	  
the	   affinity	   purified	   Flag-­‐immunocomplexes	   as	   Western	   blotting	   does	   not	   allow	  
discrimination	   based	   on	   the	   source	   of	   SKP1	   –either	   bound	   to	   endogenous	   or	  mutant	  
FBXO7.	   Retained	  binding	   of	   the	   tag-­‐immunocomplexes	   to	   PI31,	  which	   is	  mediated	   via	  
the	   FP-­‐domain	   upstream	   of	   the	   F-­‐box	   domain	   of	   FBXO7,	   shows	   that	   the	   mutations	  
introduced	   in	   the	   non-­‐SKP1	   binding	   mutants	   does	   not	   cause	   disarray	   of	   the	   protein	  
structure	   to	   such	  an	  extend	   that	  binding	  via	  other	  domains	  would	  be	  affected	   (Figure	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21).	   Whether	   this	   allows	   any	   conclusion	   on	   towards	   whether	   FBXO7	   (or	   SCFFBXO7	   wt)	  
forms	  homodimers	  is	  an	  open	  question.	  
The	   second	   result	   chapter	   is	   dedicated	   to	   the	   characterization	   of	   the	   Fbxo7	   knock-­‐in	  
mouse	  model	   of	   one	  of	   the	  pathogenic	  FBXO7	  mutations	   (R378G	   in	  humans)	   and	   the	  
endogenous	  study	  of	  Fbxo7	  in	  brain	  comparing	  the	  wild-­‐type	  to	  the	  homozygous	  Fbxo7	  
KI	  genotype.	  A	  first	  finding	  is	  that	  Fbxo7	  is	  widely	  expressed	  in	  different	  tissues	  and	  that	  
the	   R379G	   Fbxo7	   KI	   mouse	   displays	   a	   hypomorphic	   expression	   pattern	   in	   the	  
homozygous	  state.	  In	  brain	  lysates,	  the	  difference	  amounts	  to	  a	  reduction	  by	  half.	  If	  this	  
is	  not	  an	  intrinsic	  artefact	  of	  the	  genetic	  mouse	  model,	  the	  reduction	  in	  protein	  levels	  of	  
the	  pathogenic	  mutant	  could	  amount	  to	  a	  pathomechanistic	  threshold	  effect.	  A	  second	  
important	  and	  novel	  finding	  is	  that	  endogenous	  Fbxo7	  assembles	  together	  with	  Cullin	  1,	  
Skp1,	   and	   Rbx1	   to	   form	   the	   SCFFbxo7	   E3	   ubiquitin	   ligase	   complex	   in	   vivo.	   The	  
demonstration	  that	  the	  homozygous	  R379G	  Fbxo7	  mutant	  is	  equally	  capable	  of	  SCF	  E3	  
ligase	   formation,	   a	   feature	   that	   is	   retained	   in	   human	   patient-­‐derived	   homogenous	  
R378G	  FBXO7	  fibroblast	  cell	  lines.	  This	  allows	  the	  conclusion	  that	  the	  pathogenic	  R378G	  
FBXO7	   mutant	   does	   not	   exert	   its	   pathogenicity	   via	   disruption	   of	   the	   SCF	   E3	   ligase	  
complex.	   Using	   endogenous	   Fbxo7	   affinity	   purification	   in	   combination	   with	   mass-­‐
spectrometry	   has	   confirmed	   PI31	   and	   Exportin	   1	   to	   not	   only	   interact	   with	   Fbxo7	   in	  
heterologous	  systems,	  but	  also	  on	   the	  endogenous	   level	   in	  brain	  samples	  of	  wild-­‐type	  
and	   homozygous	   R379G	   Fbxo7	   KI	   mice.	   I	   have	   identified	   potentially	   novel	   Fbxo7	  
interacting	   partners	   of	   which	   the	   RanBP2/ranGAP1*SUMO1/UBC9	   E3	   SUMO	   ligase	  
complex	   is	   one	   of	   the	   most	   exciting	   findings.	   This	   warrants	   further	   exploration	   as	   it	  
could	  be	  a	  further	  example	  of	  the	  crosstalk	  between	  the	  ubiquitylation	  and	  sumoylation	  
system.	   Last	   but	   not	   least,	   the	   preliminary	   phenotype	   analysis	   of	   the	  R379G	  Fbxo7	   KI	  
mouse	   line	   has	   revealed	   a	   significant	   motor	   deficit	   of	   the	   homozygous	   KI	   animals	   in	  
comparison	  to	  the	  wild-­‐type	  genotype.	  A	  neuropathological	  study	  to	  assess	  whether	  this	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The	   last	   result	   chapter	   focuses	   on	   trying	   to	   dissect	   the	  differences	   between	   the	  wild-­‐
type	   and	   the	   homozygous	   R379G	   Fbxo7	   KI	   mutant	   by	   comparing	   protein	   expression	  
levels	  across	  the	  entire	  proteome	  as	  well	  as	  differences	  in	  the	  site-­‐specific	  modification	  
of	   the	  entire	  ubiquitinome.	  Caveats	  as	   in	  any	  other	  comparable	  proteomic	  studies	  are	  
the	   incomplete	   sequencing	   depth	   of	   the	   proteome	   and	   incomplete	   capture	   of	   the	  
ubiquitinome.	   While	   I	   discovered	   no	   discernable	   difference	   in	   terms	   of	   protein	  
expression	   /	   abundance	   in	   as	   many	   as	   7000	   proteins	   between	   the	   wild-­‐type	   and	  
homozygous	  R379G	  Fbxo7	  KI	  genotype	  in	  mouse	  brain	  lysates,	  I	  have	  made	  a	  significant	  
discovery	   by	   identifying	   2	   conserved	   ubiquitinylation	   sites	   in	   each	   of	   the	   3	   VDAC	  
proteins	  that	  are	  preferentially	  ubiquitinylated	  in	  the	  Fbxo7	  wild-­‐type	  in	  comparison	  to	  
the	   homozygous	   R379G	   genotype	   in	   MEFs	   using	   SILAC	   based	   Fbxo7-­‐dependent	   Di-­‐
Glycine	   capture	  proteomics.	  One	  of	   the	  big	   advantages	  of	  my	   study	   is	   that	   they	  have	  
been	   performed	   in	   the	   endogenous	   system	   either	   with	   differential	   ex-­‐vivo	   chemical	  
labelling	  of	  mouse	  brain	  lysates	  or	  in	  vivo	  SILAC	  labelling	  of	  MEF	  lysates.	  I	  have	  used	  the	  
in	   the	   previous	   chapter	   characterized	   Fbxo7	   mouse	   model	   with	   knock-­‐in	   of	   the	  
corresponding	   R378G	   FBXO7	   disease	   mutants	   at	   the	   endogenous	   locus	   for	   these	  
experiments.	   Furthermore,	   I	   have	   set	   up	   functional	   assays	   for	   monitoring	   the	   FBXO7	  
dependent	  SCF	  E3	  ligase	  activity	   in	  vitro.	  The	  compromised	  SKP1	  binding	  of	  the	  R378G	  
FBXO7	   mutant	   explains	   why	   it	   is	   unable	   to	   form	   a	   tetrameric	   or	   even	   pentameric	  
complex	  with	   Cullin1,	   SKP1,	   RBX1	   and	   PI31,	  which	   is	   a	   necessary	   prerequisite	   for	   any	  
functional	  enzymatic	  activity.	   In	   contrast,	   the	  only	  other	   so	   far	  described	  homozygous	  
FBXO7	  disease	  mutant	  is	  able	  of	  SCFFBXO7	  R498X	  E3	  ligase	  complex	  formation	  and	  as	  a	  read	  
out	  for	  functional	  activity	  also	  capable	  of	  free	  ubiquitin	  chain	  formation.	  At	  least	  in	  vitro,	  
this	  would	  suggest	  a	  different	  pathogenic	  mechanism	  for	  the	  truncating	  R498X	  disease	  
mutant	   in	   comparison	   to	   the	   R378G	   mutant.	   The	   substrate-­‐binding	   region	   of	   F-­‐box	  
proteins	  has	  often	  been	  described	  to	  reside	  in	  their	  C-­‐terminal	  domains;	  hence	  binding	  
of	  a	  physiological	  FBXO7	  substrate	  could	  be	  impaired	  in	  the	  R498X	  disease	  mutant	  as	  it	  
is	  devoid	  of	  the	  C-­‐terminal	  22	  amino	  acids(Ho	  et	  al.,	  2006;	  Jin	  et	  al.,	  2004;	  Skaar	  et	  al.,	  
2013).	   In	  contradiction	  to	  my	   in	  vitro	   findings,	   I	  have	  unequivocally	  demonstrated	  that	  
the	  human	  R378G	  FBXO7	  and	  corresponding	  mouse	  R379G	  Fbxo7	  mutant	  proteins	  are	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able	  to	  assemble	  into	  the	  SCFFBXO7	  E3	  ubiquitin	  ligase	  complex.	  I	  am	  proposing	  that	  there	  
are	  additional	  binding	  /	  interacting	  partners	  or	  co-­‐factors	  that	  compensate	  the	  impaired	  
binding	   between	   this	   particular	   mutant	   and	   SKP1.	   Given	   the	   juxtaposition	   of	   the	  
mutated	  R378G	  /	  R379G	  residue	  and	  the	  F-­‐box	  domain	  of	  FBXO7	  compromised	  binding	  
is	   likely.	   Usually	   binding	   of	   2	   proteins	   –	   such	   as	   for	   example	   FBXO7	   and	   SKP1	   –	  
strengthens	   their	   intermolecular	  hydrophobic	  packing	  and	  hence	  stability	  which	  might	  
explain,	  why	  I	  observe	  reduced	  Fbxo7	  expression	  levels	  in	  the	  homozygous	  R379G	  Fbxo7	  
KI	  mouse.	   It	  would	  be	   interesting	  to	  examine	  and	  compare	  FBXO7	  expression	   levels	   in	  
human	   brain	   or	   other	   tissue	   between	   the	   wild-­‐type	   and	   R378G	   disease	   mutant.	   If	   a	  
reduction	  in	  expression	  level	  of	  the	  R378G	  mutant	  in	  its	  homozygous	  compared	  to	  the	  
wild-­‐type	  state	  could	  be	  reproduced	  in	  humans,	  it	  could	  be	  argued	  that	  not	  a	  difference	  
in	   actual	   ubiquitinylation	   targets	   but	   a	   threshold	   effect	   of	   the	   R378G	   FBXO7	   disease	  
mutant	  is	  the	  basis	  for	  its	  pathogenicity.	  Nevertheless,	  FBXO7	  is	  an	  important	  player	  in	  
genes	   and	   proteins	   that	   map	   into	   signalling	   pathways	   involved	   in	   Parkinson’	   disease	  
associated	  neurodegeneration.	  There	  are	  only	  a	  handful	  of	  patients	  worldwide	  affected	  
by	   FBXO7	   associated	   disease,	   but	   unravelling	   the	   signalling	   pathway	   of	   FBXO7	   and	  
further	   exploring	   its	   entanglement	   with	   PINK,	   PARKIN	   and	   VDAC	   proteins	   as	   well	   as	  
other	  PARK	  genes	  is	  an	  exciting	  avenue	  for	  appreciating	  the	  relevance	  of	  FBXO7	  in	  the	  
bigger	   picture	   of	   neurodegeneration.	   In	   the	   end,	   it	   is	   about	   identifying	   new,	   targeted	  
means	  for	  developing	  causal	  treatment	  for	  patients	  with	  Parkinson’s	  Disease.	  
In	  conclusion,	  my	  PhD	  work	  has	  mainly	  focused	  on	  the	  E3	  ligase	  dependent	  function	  of	  
FBXO7	   as	   the	   substrate	   recognizing	   subunit	   of	   the	   SCFFBXO7	   E3	   ubiquitin	   ligase	   and	   its	  
potential	  role	  in	  protein	  quality	  control	  in	  the	  central	  nervous	  system.	  However,	  it	  is	  well	  
known	  that	  F-­‐box	  proteins	  also	  have	  SCF	  independent	  functions	  and	  this	  also	  appears	  to	  
apply	  to	  FBXO7	  as	  reviewed	  in	  (Nelson	  et	  al.,	  2013).	  It	  is	  important	  to	  keep	  the	  possible	  
SCF	  independent	  roles	  of	  FBXO7	  in	  mind	  when	  putting	  the	  findings	  of	  my	  PhD	  work	  into	  
context	  of	  what	  is	  known	  about	  FBXO7.	  For	  example,	  it	  is	  very	  exciting	  that	  2	  conserved	  
lysine	   residues	   of	   the	   outer	   mitochondrial	   membrane	   proteins	   VDAC	   1,	   2	   and	   3	   are	  
differentially	   ubiquitinylated	   in	   an	   FBXO7	   genotype	   dependent	  manner.	   Based	   on	  my	  
results	  so	  far	  it	  is	  not	  possible	  to	  say	  whether	  VDAC	  proteins	  are	  direct	  ubiquitinylation	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substrates	  of	  FBXO7	  or	  whether	  the	  preferential	  ubiquitinylation	  of	  these	  proteins	  in	  the	  
FBXO7	  wildtype-­‐dependent	  background	   is	   a	   result	   of	   other	   regulatory	   factors.	   Factors	  
that	   might	   influence	   the	   ubiquitinylation	   efficacy	   of	   VDAC	   proteins	   could	   be	   the	  
reported	  interaction	  between	  FBXO7	  and	  for	  example	  PINK1	  or	  PARKIN(Burchell	  et	  al.,	  
2013)(Figure	  91).	  This	  and	  some	  of	  he	  other	  findings	  discussed	  in	  my	  PhD	  thesis	  are	  very	  
exciting	  avenues	  for	  further	  exploration.	  
	  
Figure	  91:	  Proposed	  model	  of	  how	  FBXO7,	  PINK1	  and	  PARKIN	  could	  interact	  
The	  PD	  disease	  gene	  products	  FBXO7,	  PARKIN	  and	  PINK1	  have	  been	  suggested	  to	  interact	  with	  each	  other	  
and	  could	  potentially	  function	  to	  maintain	  mitochondrial	  integrity.	  Impaired	  mitochondrial	  integrity	  is	  a	  
recognized	  pathomechanism	  of	  PD	  associated	  neurodegeneration	  in	  general	  and	  the	  outer	  mitochondrial	  
membrane	  proteins	  VDAC	  1,2	  and	  3	  have	  been	  suggested	  to	  play	  a	  central	  role	  in	  this.	  It	  may	  therefore	  be	  
that	  VDAC	  proteins	  are	  direct	  ubiquitinylation	  targets	  of	  FBXO7	  or	  alternatively,	  that	  their	  ubiquitinylation	  
status	  is	  dependent	  on	  the	  interplay	  between	  FBXO7,	  PINK1	  and	  PARKIN	  in	  an	  SCFFBXO7	  independent	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